<!DOCTYPE html> <html class=js style lang=en><!--
 Page saved with SingleFile 
 url: https://www.nature.com/articles/s41591-021-01643-9 
 saved date: Mon May 30 2022 19:20:54 GMT+0200 (Central European Summer Time)
--><meta charset=utf-8>
<title>A guide to immunotherapy for COVID-19 | Nature Medicine</title>
<meta http-equiv=X-UA-Compatible content="IE=edge">
<meta name=applicable-device content=pc,mobile>
<meta name=viewport content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<style>@media only print,only all and (prefers-color-scheme:no-preference),only all and (prefers-color-scheme:light),only all and (prefers-color-scheme:dark){html{box-sizing:border-box;font-family:sans-serif;font-size:100%;height:100%;line-height:1.15;overflow-y:scroll}body{color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;line-height:1.76;min-height:100%}article,aside,header,main,section{display:block}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}svg:not(:root){overflow:hidden}button,input{font-family:sans-serif;font-size:100%;line-height:1.15}button,input{overflow:visible}button{text-transform:none}[type=submit],button{-webkit-appearance:button}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{-webkit-font-smoothing:antialiased}h1{font-family:Harding,Palatino,serif;letter-spacing:-.0390625rem}.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}h2{font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem;margin-bottom:8px}.u-h3,h2{-webkit-font-smoothing:antialiased;font-weight:700}.u-h3{line-height:1.4rem}h3{font-family:Harding,Palatino,serif;font-size:1.25rem}h3,h4{-webkit-font-smoothing:antialiased;font-weight:700;letter-spacing:-.0117156rem;line-height:1.4rem}body,button,div,form,h1,h2,h3,input{margin:0;padding:0}p{padding:0}body{font-size:1.125rem}p{margin:0 0 28px}ol,ul{margin-bottom:28px;margin-top:0}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin-bottom:16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{margin-left:0}.c-article-author-list li{display:inline;padding-right:0}.c-article-author-list__item svg{margin-left:4px}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:0 0 16px}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;line-height:1.3;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-reading-companion{clear:both}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-header__menu--global .c-header__item svg{display:none}.c-reading-companion__panel{border-top:none;margin-top:0;padding-top:0}.c-reading-companion__panel--active{display:block}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{flex:1 1 0%;padding:13px 24px!important}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.c-breadcrumbs>li{display:inline}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}.c-skip-link:link{color:#fff}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}.c-breadcrumbs__chevron{fill:#888;margin:4px 4px 0}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:8px 0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__row--flush{padding:0}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin-right:24px}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px;padding:0 16px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;line-height:1.4;list-style:none;margin:0 -8px;padding:0}.c-header__menu--global{font-weight:400;justify-content:flex-end}@media only screen and (min-width:540px){.c-header__menu--global .c-header__item svg{display:block}}.c-header__menu--journal{font-size:.875rem}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}@media only screen and (max-width:1023px){.c-header__menu--tools{display:none}}.c-header__item{display:flex}@media only screen and (min-width:540px){.c-header__item:not(:first-child){margin-left:8px}}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}@media only screen and (max-width:767px){.c-header__item--nature-research{display:none}}.c-header__row--flush .c-header__item{padding-bottom:8px;padding-top:8px}.c-header__link{align-items:center;color:inherit;display:flex;padding:8px;white-space:nowrap}.c-header__link>svg{margin-left:2px;transition-duration:.2s}@media only screen and (min-width:540px){.c-header__link>svg{margin-left:4px}}.c-header__show-text{display:none}@media only screen and (min-width:540px){.c-header__show-text{display:inline}.c-header__item--dropdown-menu{position:relative}}.u-button svg{fill:currentcolor}.u-button{align-items:center;border-radius:2px;cursor:pointer;font-family:sans-serif;font-size:1rem;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-hide{display:none;visibility:hidden}.u-visually-hidden{clip:rect(0,0,0,0);border:0;height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media only screen and (min-width:768px){.u-show-at-md{display:block;visibility:visible}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-ma-0{margin:0}.u-mt-32{margin-top:32px}.u-mr-2{margin-right:2px}.u-mb-16{margin-bottom:16px}.u-mb-32{margin-bottom:32px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.u-lazy-ad-wrapper{background-color:#ccc;display:none;min-height:137px}@media only screen and (min-width:768px){.u-lazy-ad-wrapper{display:block}}}</style>
<style media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">@-webkit-keyframes transparent-to-yellow{0%,to{background:0 0}25%,75%{background:#ff9}}@keyframes transparent-to-yellow{0%,to{background:0 0}25%,75%{background:#ff9}}@-webkit-keyframes highlight{0%,60%{background-color:#ff9}to{background-color:#fff}}@keyframes highlight{0%,60%{background-color:#ff9}to{background-color:#fff}}@font-face{font-family:"Harding";src:url(data:application/font-woff2;base64,d09GMgABAAAAAQ2EAA0AAAAEcMgAAQ0pAAEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAG4rnXBy+DAZgAI82EQgKhYNshIQZC5JuAAE2AiQDpVgEIAWOQQfdb1ugJpQJmTJ27cM6gDGCJmrUOcQsUQdIXYvue+o75BrihxaiyM7OjhEOB0llX9QJppuOrzq5bUBFGcrcP0n2////////i5JJjOklD5d8HlAAABS1XZ222wZKo8GM0pzZYVEC0bSlQ1icYGgoeDqf2bdtiwHRjRNxwhlzLycsCJcRq0qqpEqqpL6pTRSCbGjabpbq1I2CxG6mXa4w50WMjoNwLAtu8AX5fm0eHBHIGkGNoEYwdZxAyo+C1Wfx+auqQpWgRqzii3frttbk0+FwcUzwEWVFlrNjd8V2E23bCRfbAwWOLIZL4kVe5fO39jKvyfuBHRRfm8pHVaRKUGOPO5XYyPl7wjOLC1/w93VSBm+0d/ItaVRHNKDohp6KzeqJ6b3mKa16zLhhf2FdhvgZe/GjblRJ2YvxKo4ii2TSH30VN4Wu7ky1CpoKJsTQya52r2lWaNReMD+X6KL8WAnhmc2aUYIYIjwCpcOSkcOUDDaNKV2tsz4kXmeVOiscVfurlTp5wqF9nr67TYnaLdTmtbanlA0fGrUv0FiPx1v+k9THf7DEuzRJGVVNCd/KGaYRrNPzRq3QqjhqldOP+jF9qv//mjwGBuMyD2hC6MKQNaW5ynaMm55wlK+3iaJv2hdZLUvWAoH3ARLc/TGyZwiW2+1r/7/t99G13//2//vqRQVjBdvYgAGjatBSEiUgUSoloNIlUSIGIQqKAg7R3G4/omSAtBKCTEoRx8iyiBFWQAsSEQKDSeaIUqRaRCJSQqJEskZRvx9kz9t3qADVCXf+HJAk9EA6RsfoGEtkdMpH58NHv6ancuND8N9ugKAEEj2PrxFRssrUuQrV+/329BscJUZAHcUqbudG5N+LABjm/N63/b+M/KklubYlnfNxig0btlRUtIMn+Frqsvw1PO/ajFHBcnGbqRwfm0l40++3wmX6pkCIdy2Ar7t8TPXNp1P/bpWet6AMdAIMSZZsxS7TSddEbchFGDv9afrDFETJdssmoAf/9u5vUfPQ4pZZwkncFkhqCZUAAQRB0PH/9gJNuqgE6OVk5eRkZWVkZWSkpSXSEolEIiUlJQVPMbn1B5JhQtyVzrRub3XSStaJX/eMegww1si2A1hRxWgn7J/0ND1B0QVVWuhGhyD8jQo7N7mJP+ALlaHGBfL+/OtWfy/oK+ck42vOjuhzeOMWy7ZS7s0J3NGIcYbtvtK3Jb/JL5CQIE4BBFGYBrYtzXH71xToq3sMUi0tT0ZGRlZWIpGVlS8hilzdfLrVz/xy8ujigzS68F2aBls5ZU/89d/Ylm2/4GE3JE4QiwF3jpzJ4E2xxKJAMdD+evdf06yqLMEvYXv3/iDfJ7ssbeS2xBgB1TTzQCWD3Mzcp01qqupa0waHtkiPliQIBxr2J936dtu/7ZlY7V5fdU3Dtkv7JWJ4xPCIQQgeg3kzx7bhTRiceEmkIPWKTFin3wD/AwGhhIv+E/UvT05WRkZGIpFIS0tJwYFubKF2Q4qinyDxv81gLKJg6JY6BtvKY3B+mzMcN5ftl18WcyopNACtSL4lljiE440O3Tr/a44Qb8t0k4hPzP5cP5Z2EzPc75HFE4TGwDxDKf9DhkKcrMNQ8XPgb2HMmjNnYp4pcQoAKVBM4ROgk+z9ErKj4sjG10P/czseJrFXWfhBPgsLC3HlSjTg4P+/pbPM+YooHuoikZxV4x2ztNkMfaALlURRusNpjNi4jaM2j5DgBATVstmbZZucVMiOQugsZUoLWYnXuJWPcSgFDiTl3xmkIxaA5/9NU9u5+PxnB8rjlOG8nV10w1WuKneuMf/Px+fHw98RBa1JLAjFTKWIAXZXA+wqUQ4KsTLZOYVKqZIrtS5VuffpU92IrGg3nZu6MPzzv1bv27tXv7teV3A6xDc4EwKf9YQK2BgVVXWr6/Wcqrlr0o+rK0Q1E6pwdxgsCx1ePh1gVGGhSIWVjZDRFv7/Qn5h9Ffu+/+p2WfaRXyOWT8r74PYcizlfJApVD6swsMluhrslfg5szv887kuknURHh4KhSaa4Mw3XGN8rEyKlBofpj7M0FWtc2i+HVkXSWEs/Z+pWjuDZb5EOuJcxZVkV3e5leRctG6vu6Ia/NnB7M7sYsFdggJ2SQi3UCJISyBAWjDogCUoeUFQfqQjpcuJduV3FUU60zF0F0PrKlaXctFe016XQnVldUVbH0/fLm1mgbIHhMXhygc8PP4h972z/e+oElYX5KpQHYTByuI6vewx+axG1CGEQ3f4flOv7/0PyYdMoPrrZApTMrlX1M7daT0hIXxCFCqxrhRqEqk5TcXJzOyTTH5C2xFiLEwIqRnJ3PzU4w7HnY5iergd9HCa/7XMrDs00uzq0iquLmdCVnvniMyg+r3f3dL0dI9SuhDziG2vMztswswiCxEbEBNmnqF5vv6e8dsDwVLzBFck1bAuS4aJB9j8CZoIgn/cpW2/qFJ9KkGWRJpIgElbQAFmFEggdOB+9+4tpZJmxrNfe21v3So3AbNGHzo0NITcfUl//VbStrtz27RWdEY/zIiGxTQFGqbjAB4ci03VPOOtvcfKo2MnG+WrKoNLnCy0YMNQHqj1QGtan/A5lce8O0iWZBDiI4oxwRgROnbqbejX/4mgvxiI17JNgsh8GUREZJAQwiPXsk2WcLb11ddk9+/O117noymKJBERCSQQESnW2j7/v1vlhnRDnI9BDiIijTSNiDQi817+3d1lbLUgLvB+ilUI0z/W1J5WQgrUriwjDsQNGc3STG3346c/w5k/qpPeti/aO6/EG4EECPIeEtY7iaqphGnYI313Z60x1hhttNFay0eUiCilRESJvv9XnRvJgOclyCTRw+9aW0TZFBUado8iO/O0WivhpXTwQM0sy5mYdHMoHqQJkMnzUDYGgj5GS94/FsAEiyMC0N0eusmB+PGbTwfut1ctDkowgK4L8F9DHCnEzu8QANp7Z8kj870HHI/cI4FnxCPrReSILkXYAhlBwcAhxL9FQp37fhMH8yDS7gllFZTViP1hbQIEsMn8ZRSgD4+OT04vLeUrbCTOvPCfT8Xt89tZJ90881MfOw/y9GX/V/vzPhxgQNTxSag8hcrVatSmx5A/VhxIAQwCw8LYMCVsP+wo7A7sKexfeACeAz+EGEQcRdyIl8b3x6+I3xL/dfwRpBUZQhYhVyGPouyoACqGykMNoCahlqEuoT6hy9Db0b8npCUcSkQkjkziJ41M+jXpddK7pA+YGswYzGLMesx+zDXMs2RYMj6Zm1yT3JE8kDwteXfypeQ3WAc2hG3FzsCewz7DJeL4OC3OjvPgQrgsXAGuCteCG4kbwM3CLcNtxu3HfY+7gLuFe4z7HW/HB/A5+EMEMaGOsJbwkMgmdhCPk4gkE6mI1E/aTNpNOkVtoXZQe6gPqS+pH2hsmpGWRgvQKmgjaffpWvog/RqDzJAy5jB2Mu4wnjMrmGOYq5hfMy8wrzE/sQKsAlYdq4U1ktXPmsSaw7rFRrPz2IPsW+yXcgj3wzEkYQ/NPdZkoLOkhzGW2GBHnVr60USeVurSiKZ0YLniu89t6ADL3puN8LsALdAKYoIxgo2CW0KIUCksEI4UzhcuFe4Wfi38V2QVNYiGRItFX4suiF6LMWKhWC8uEw+IV4jPSGAStaRJslFySQqRGqU10hXSMzKYDCPjyuwyj6xLtlC2RXZL9lKOlYvlRoVaMaTYrhyv/FU1pEaomzQD2knaZdqdui36RP0M/V39M/1rQ4VhjOGZUWosMR5KwadMS/lkMpt+Tc1LXZX63Cw2l1kwFqXFZdmWpk67lG5KX53+xiq0zrD+bsPbPLYCW6ttvm2b7YztdzvCzrT32C9lyDNuOUyOhY5VTphziyvL1eVa6i5xn3L/68nybPR88Ia8Td45Ppgv5qvzI/wdAX1gKPBvMC/4LEQN8UPa0ONwVbglPDJ8PzIpciGqjbbFymJTMo2ZV7LGZ/fnEHNu5Brz+Hlj8sn53PwZ+QsLfIXIQnwhs7Cn8GHhr0VDRb8W3yq5UiotvVFWVtZV9nXZs/LE8v7ybeXHy8+V36gQVqRVZFWsqnhaCamMVA5UDlUurrxVhamqqzpQda06Vj1UfaUGWWOv6ah5XAsM8LV5tdvrhHU1dZvr3tVb60vql9bvr//QQG+wNrQ0rG640ZjY2Na4ufFx4+9N7KaRTWea7ja9aY40T2le2nyhBdaS1tLUMtCysOXXYYnDLrQKbQ0QYYMOh+RwywopKz5ZiakTJ/UY8WhIFmIxxFEG4IejQZc3VVlWyaflq206XlHJsgi0op8tHkLFPqVe5eJn9AvGmopZwUguuV31OOEUzeIIGq73VL0rnV3t2c/2rqe70drNPd7q3r9id8yPD/rdzY/CeyKrVmrdmEu/GO1uiuWysOsBK8T43QlapC3RF/N1m2hTIL0ycnQWuq3dXeQl9CvWh+OgBiN4uGZXqI2QGxVujNw4tQm0KSqpJViUD2WErNL4OyZemHRl8rU53ea2LVKWFO35fmzosrFlU8f2OluZPZ23la8O9m1+nT5mB2Ml+zJ60dWGqsqyEX311+LN/5p4bdKNyUdTaW5lkbE4W2KiFRujNO1sVbRK/Qd/Gd4V5cZo3axPZra6dqftaJu803FVhjra7JHD9bc4YdTDJgiCTeQPpO4vafIhWR2KdWvZFBK2iUy8HR6OknY93LaGxlxzXuzeKFb3Kiz7eG5R8hcvTjB6bG+KrdTsbhIk/OiYjibCMCRmON2KrGkwUr1FMy866Kv3rqc2rLQ/PqyCIw2c9e/aENnR+A8FJIvKF6OXqU6WSgXgSsGVgWuQHBnwyIJH5UD14PHB0+M0lKTJGUZd2rJ6g10ZeN5B5wN0DMBjCx47cFBhaH25tYXj0OyirdUqU7npJoGbwjRWn34taVFotLLrR1c4s2bWV0IGX1ZQGgMOtJIoYqLEyCSLbHLIjQ0adIybK9m8odXQ1lKlyRcAgBFDHr2MYizPeG5+WRkk15PiwnYzVsTT+RZ6krCrzW7k3U5rl3pL/cmYfADrGZs8OqvyevdlpmtnzJCszcmWHL812pZtT/XLdPDGi8xJoSod4c9kSpdE4esNntEbxE38FeCwUeQJPcuHtbENlXVLFR3KDtdyUaF0JDvadiw7vlKU9FDzv/J2syk/qvKZSQNadLW+MqQxZo09msIORnnSiLCEcvaEXFdZ2Yddb4pMftsVdqxBZZoIS6lGvjon9dckO3hNciTMY4k+1O3G1kihljafIAhsKjHI8kA/pmIH8pLregpWrIaCpMxUARGlPezXu2H1yjh0y+Gu3B0KWUoZT8fkxFclWdbt971V5a0dcZBID1S612BlFyk1JlDSraRhmG8EhzhMXgrOacxSmdJAP1k6Y4iYpVK1pdQRY46yREFPWMVXPljpRrbdHNRM4UAdBlZyFPgRdcEpJIdH8tfu4b+RHduZSyan5Hq14A0PLO/R9qGvz53NX9Crwnq79fZrQtEfZf+ojqAmaECLDj2GxPi2T5BPiCcCo3k1hPqkYdxIgJtC08QSfYd7u7a4iVJ7LezWYBd46btZsy1JuzI6saEbpZJMPOTDdpO3mShKL2MDyHEcISSJ0TFsIsLBE7Vu9vz84ZT0aOTCElhK+zLQzhMQEawMaRLjwSxjnN7wurvK3CATwzyFxclyfj/wWgaMB9AtwnZT11wS7pUvJ2BkW7LwufiVVp5LfM+lyER7Z68eDZbZ0SbxmPW3410j94coiVpl7cDy8AHkV5rrf//CvpbXfq9v2mbEO8Sk5o5IestU643lcUgMABJY+VGICP85kJnCCXVwwhwC1JYUyCMDxJCe/HRsuzY6LLLXFZZSJDjCwSlFCg4+85p2+XA2cF/XYOuwmt46KySyU8KjIHaO9LUnzeheYyKuyOFjkR+hte8orvSaeDOIMBeY7DhewrcZpZu9KjRYx1+LIaP9g+H0MdJ88TCBRr2cQ8DqvQ7K0xtqTQiECq+aqSg4E+1nuX8pOv19UJ0MBaTOCx2oxNOHOu+Stoaj7jGYDGUfGkEIV4AjwpOFTRYHiavqR8NoBDNWYqnxLFz3WZAjHvtJoG8uZIcKWivz/7GwWGc/bV2Xf90YTCN/PTRaE3/Lx6mH64N5CAcDCKW3ayQlG9Gb+oxwh8cRjqIP+gA42dWpNKevdE801hfrhwEGGWKYEUYZY5xjd9K7U84454JLXZlrbrjljns9wCNPPPPCK2/uvXcffPKlb/ipf+H+AEKMBCky5ChQOlVO7TQxLTr0GDBiwozFWXtnw44DJy7cePDKh/xFQEERcuG6CFFixEm4pIyPn/4iS055KFCkRJmKAREYcBAgQYEGAxYceAgQITkyEAUqtJrZ0RgijDIGo/DbMWXgkiQlhGMP8EiRkFGlWZMr9Mw4QwYeLOXQ8zUNNOdGNUEzLWaYBLYbF2Rp196ZrijFsxtHxUTje+rMixY//1KJqvR4bTGUD4yL4duWf3Li2ted4vXhQkrFEVCCztKZ2zZPFtb0y7RdqqXclcYHRT8mjpV9XTTebJpFWUZ39kryajWhNDGbUoUu8L3zuhb2tHzYrtnljup1Tp2nWcy5/kagvzdPI5MtXwvgXCCHyM8CyAVALgRyvXxodlIxvpTAowqe5+B5DZ43VFWy1gAeWwJQ2RAXX+5Nw+JArK2dCLjoeqwNFUn21DwHGuKaRN+YEq3nRnuuC04D544HgGilN92tiLmzHcaeGPfsx3X9g7HE/MvYYS0Q7pkvy22KRPt5h+yJ/nGjHDTITLrwtYvQk7ZfqKODrjgrBEd4fKeAuJ6w5msy2yTtZm0mNPO5/3vtS/GvSxHWzfVuzjKgfqDkg/JF+XVN6WAGXi6pHfRiwBL0LLFR7U1s2cNEEa3pCE3pg5e1mOFNOxv3VRDum8uhmJQol2MigSLBoTGDIqIXK9ZZleSXO6ljItfndZ3IvvGt6nt1qfOuG69R0aE/wvgGiySbInN6o3e1Lr1pG3ACXfcZM3V6KqByUu6b5DI0OJlYrY3sppE2Xwod1CQ1bJa8m2fWT+Q1fvWIw09XbpV6459Tbh64rm0RcrZN2U0gOir0vK5mWPAeO3eazDDO14OiCuFyssab0Ol8dGOFQQYnlQOAA7CEzwDsLsdy3vCMM7c46X6dz1qrGu2BoFojYyyMaHK82WuY/bRpi306+MTn+6dr6PNmeROJz0klp4cifmi64SZFE8RJ+lPFI4tTMevZYbbp+O30IWA4JHCoAh0wmeCK5WE4YJMCUhhZwKdJhC5iy8cZtia70EBhTyhvKCypK81iYhssx+LeW69ZAG0g1UTQIQBHDCQCpaB2aHH0wOBo0VN3+KlPxlkwsplMmeo9IcEQebzNY8H6OA1GjIyiKGGpmtJBdTVGM1YT2jcpDK2URnFRryH2spb0hTMsFpWwDkZEJIPNxDZYLtvRS9mKFGwpaFmtx6hFtss0giiUDo+Je2ZDs1raD6hCbTw62QvuEUe0d9B/MqPbjCnurxnaUQDimgRNJs2FRa7F1Zvn3l//TKYOjJ+Rasxz35t36EOknurbQhwxTxPVu+c2+nYVLJmrbVLCD2DRefKh89Ionyw7v+g0h8gYDNBou6bS/HE52ItypfXKKjgYYYZTL0DyIJ+9zDWdX12Uu536BtABAczTyMvJW8OlKVPi1BJ1NNA02kNgMEKOZi9f0oTaZzQ2S4+6FJFiSc50IZnQvBgTutrC1ECa6ZTGAdc+BY3Jockjp6VYcide36S0Jmsy5GgUChlQoFkVjQ2VWapr4kCxldMjZMYzj5RUH2ZWJEW2CjLygIOEe8VaDdGrERf1gDjUo9iQNtpFyE8EBrVBIfV+uap6tQFVeoWupaaFVZez24mBAEWPwA5nuKri8idxmvXZCBS2K0UiR1IOTKzperlxtR0qVotyJh+uEziDAWxzNVMZi0zuNhZQ8b+x9rrFETaYuWPis38UMRihbxDZR82HkzbazDKS0MA0EDaTws4ZRygYkDGFo5xsKONrlOVoLjlkud2Ppt4RWGnIRlXARW/sWi8GoxzBKDMVa1zCYyJQ2pIqDpnMgYHdR/io0TSrzepIOumiu+5JvR03mIY1NjRVmhPzLA4vV6vFWrKuDbQJ+xzo8M2RjosTnVKfpfMvuhhc6kq6RjfWXYcX3vUJ3/pLibtOXphkBots1P5+AigIoTrayq9VEKWtygHMPVr5tl+ZYC/qVmgrdZhOuqa7nZltqTExp3ncYjrkVBeDO30W3/oD23Qs24+2NCFOTegVOHmHbjJmaAiERaNpfn5t/bSHjh6dfbp79e4ZdmMwxZzmV/VKWu1pzaxrY+ZQR5497iowZ4zrzl0XGQAAhmmNHMI172lFrJSRlvKioBIqo0qOgP/zaPBdEkKl1fJ5W1sdplNd3FZ3x0bMJOY8IiNix3FjXiI5Ehf+owOUJDsiqsnUZgdh1Siaaaj0L8Y2QrvFcJhyeWQhVhmbrEWce/DaSNzAK4/WA+cW4gxrDgCG1ViRNSSFJnBpFDJhR1XAWFaHvVhoe8CtkPeQSA6aI+UBHRVZxAbxk9o0yGQ6tdsNzkXyh/xr/hAolKFZi2P+q2kjL/RQhuYdnZUKq+uwlqyXzMifPj06oEUk+UOOA4bjuKh7Rh1P151gChF9pRgFPSgEZoYUS5i2OFEOrThT5pmho1MzgmVZPL/opZDvhYWylNK5BsAFIe2K98Dmm/uRf/xP3Fv5wuWOi0dodNVM3x606pNhXsgHLpNMMR8XYhKW8LljjaKUUBKLS5kr3IdHhyeF58FL5zW98R4/wj/+qu/ww+S3zZ8MkiBlU1ayqBDlRic6S9kY5QEqNnMS+v0eI5bQESwZPQl9JGtxLMQFl1ddI5rhc/Adfoo/oIGcAr9ydVYiHdi8ZavaboWdDLtD9qyp2B6vDpjNhnYPt2ni0M6V3+/RxF8EQniEyPvFMWMy1uq9X6HlzCdKO7WjzSEpY7JrUEpPrCi1yRn4vjFbEBHGEnRMVQdq20uKSZblg301UxuQEkIWJbhEICdkFJVuH8xs19kx8YpXfBx8XjRyN6qU4a12CxKsexi1dmC6nItG8rAjz4csrk6UGRcP8JqUIv6ta3mkuDDH3/JkA0a+M+oDpK5E2Vo4mqTqSngeCgjzeLtou5BICWzNd3VAWdo8AjvVbAQVaBWtSJ2xbANVpapql2XTmFIBvQ42DjpgAB0Is2RY9TGwpfroWzLHuFXhi+xsq9scnjL0lLQNFWOQ3L6zup88gJ0ahXmHD/gy5l31Cw3sSIJUZNry8eXCRW9uyfwajwqawvnwxnMmyqOYKMm7NL/0ApUiEHB/JXIIx+RD0iuI4Tbjw0Y+TDbIz1JEqUdLPFosEOJLHN9SXngoHsMTzijP8at+g+XLZFugNqWMtYm/UqbWfgzLgsdt73z2CsUVv9YYQjftuXl4IMaggTfHRUfJ267aHdFibLYmtiGnkfJZoGISItosJiwbt2hz3OLVMZe1w0ScrUbHQKB9UqPWG+3N3SJS3mzrWx2tiApAxDoQHjE8CThW9U1kv5p4OYBXmDpQQaUpkPMskG12zeCEHNS7th/3fXF82wmYPLQiKA3AqI5/inmlED5NzBtgGSmrj9JmQ05fIam2Zm1R7Pdk8r1AfoutO+4N98lTy1Qf7r1UdsIIxIBofBby2L2d+XkUdbMdjLuGYLkg1olQvl4YljskUS57mc2TiBGA6MG2EZ5vp7sdOW0WjUQj1k5v5SxH/XbH59M91fbtzOM9oPR/O2Q6nOTIU7C1fQttI/VOPv7X1GM6eHypMRjjzwSWqsDl8Xz2UlsqfFH6PIRzVkybrlHQ1TlW0Cug87r0i0PMEaHeMvGFrvxAG1X9rw6mu/Wt6skOY3mkLvbqZryOWS/tS7u0pqXdAGSsJt0Jgo/BO02vNllDMaO8ewWE8G5Nuor1oYpaZ535LyFtn1Oap+2utcwW670zF22MNxBkXmCK+uD1hMI9Qsbm6P0qRNKggJVIArm4N+2xI++eOYmINBz2Zste9oc6dzta11bX7q79B0W5K6S3YRonPEok60fa9b23jnXIAPPiLWtUzT88/HR0eEa/DejvjDBWjZQIU2nKATUmFUEDGg4gmg4LTYa3QkiBF/c+/frbvY1t6U0Ug2iGVDC1bGTm9oLN+AwXJB0jZzwvEOwm6TJkOhDztEBud4MyJrQVx4WDJYRDbvc0Yv1UDmJkraDpVnbk3ICr7XdUrYMRyf1tdF4hEEREjtBOdmwf95sb3Tcvp4B3gSB4KnsynvsgsUv2IcLOvUQL5K2jJOjqEqJoYExya1AZXU6dGwnWUkOQYJ6M7cTjole9P9qUOCuq1A1r9jDzg9/fI+HZgXb4N/Ov15nP8kzy0tzAEolWdtidMelCLdXWj7N2lt/FL1fzGiefU01T26RauRfnWmlXYud970ySYu7vTI0pi+SQS664thNCypSm6Bkb0OY+UxbmmRdeeePdXgCvIKaUYiFVcb+0v/xf61FDCIfB/1k+f3uvUiJopBhtjLXGIUKHCKQ+oiQ72uRjKFrKQo00FijpezKsZZxl6jhL5ZDzLZ/xKyiFSnCncIISIaYESqFMf495KEClroqaaKsPA3a0O7v94j7H9n6f5HGjYUzjg0nmWBbRkAqGcoyRymgA6LHgwCNfT8EkbwrHVIkpTAghMcW8OJBYVyeLYqjsYV+eAirmzGYCKaN6qib/06xFPAQRmpC6nQb0OlvMGrSmwpneYIcXMrMvONYjaiaFxuzGoUnm/Gj3SK4YgSlRIi1kjRfWqYJaGnDIbweLsFCIFLFu8YtR0ZT2WG3104AdmpVdRWZcm2TbLEClDwVBukaBg1hSG8YGlXiuCQzvNjns8tV1k8iL3JvQIFWm6AMM2HBKfIkuFw9ddlmxpawuEI7jchbrTjv0GYSdNFplT+9oHHh8X1ClDniyD6ViiENgVIJjiP8wMAwDALJhCTXPDUrcey1iFvrfTxa86cjI+Ix4fgLkISDsy7wvOkGZqAHogwGMfdNRY0vxxhk8A99eQlB6hx4B+VbBqs9BtQ7n5n59/cJ8TNOsACxF3pspOA77QoyQSFIltzptLlgTS8gKRBppH6o2Es8G7hHpdV9tkF44ST2ILyYjvlplzARqMCGCKUrRuSgsrzqEFjGQNaGAErwMQxmWM6s70AAmukyGpO0+VJSeJb/Ct/gbwfcvD/WCPYgfnaAUzdN8yHJH1BTqhBACcQM3fjxi//IT2ROYilKUgT3i77WLls2zgYNmYtvUbCTR+O5p6DGtDRF36yhHFilJmrSlOSVyWiDqUMh3LShLKZ0rDC6IWqXqmiI0qJvBO31dAEFf0RDzksjqyqwjQKHrEH4HNInMoPIu4OEFquuStI2OTcbsWend94HQFGHhHYtCEJqTNYeP1C4cHKGEEAKExAmGDh+nj+Fj2YUlw3T2Uhr73hv+TO77gnHl1arWKx0TijLvkedWAEBtk0qiyWFQ5hpeTByJUijjtp5GFMEHWpGDBP/i1TScC2q9Dj8t5Io+UOgXDKgg9oCB2h1RxI61SsUHOjoi70wmc2WUCFemx1X2Ep96p7eLGxw3DtUInUIL9WJD3WFeCDxRishJEFwrcSVg+eJCReMKBGJEVbXIYFlyNCogSTtiByVUOGKl/1Zeis0Yu5Qu3P68+JT7lug2XHVZxU6ktAIY0LeLCr6M8FxlXjQna4KaGVGTKp6PgcmtrIo9ehXZ4Va83omoOmNWHwKUWqmd2ocsCofyODzP1rEc0o3NtgBKh6Pl99WbDOzP1xedtVuxcpNh5dwNKjbQjSnYWzGhtFTcBlxum1+WK61u5eT8L9x3GJXUXaB5chjrHN6zHP44YHKXwDFCGxqxxuQf5dtUyz3nLu7zmCVjZ89CL7VJKyuiP1c64I26cuIgeUiD9pskV44G6rDVaeliWMPlGGUVzUc2cfpmsn+o6MbuIhVewbyct9JnAO5q1V4jGT6q82u6J8zsrRPTt3lbvH2jWjkT8gCqowN9Sbg8g2bTBioDLkeVB2lrI6/A3QQb5h70tC9yd2cpWXS7VDbgXeTKMbwGt7ZC5i4x0K3RzWxdw2mVwyDistANdT91agXffP3aj2G2k4Deyiywbpa6h7zVO3FbtcKSkRUoS6Sy8E/seEUqA2nWF7+s9i10E9JymEDXynML3yAoZxgX2vTMkMtc472PThTUWqbWOmGhrOLbvqPWb8JSV53Kyyuoy4FR1TxVmLpZNjzQVVM6Fr/M3iVdqf6Od4jSqlD36ngli7+ySAq/V+1JVCejh1k8ub61WxwTnstYaGAJqp2Dp55McSETLk3jYyFflBEUuyd7aXf1t0qSeGB97N0iT+Gpl76d/dHAH72ZNSN3sn6R5WK7bq1/Vpnup2T3c+rkuSHJE9TcB1LmF5cL9PHFcY1X1gD3lHBkSB43crZvY/OE47jiHXmqbq2zdnys7DZgnylcrGPwjRfAEsDjI0xNT6fxaTzxKuuyajtcjXhNKL7eeNuNF7T9om94pZxLggfD10rtmIMvqrj/1wZHW8PvpQTb9J1b4tZU2VLiB0Prz7Kt/ZD+Y8G0Rfy2SBepM3kipuPARWJQQEOpSkPxg1uG/CfRjbwFhEA53Kwzu3bRVOjUuQvmC3fXAYwGDRHZp1ILb4n6wg5jdtX/z0Q91NVFYNFgsR+Mihn43/9+wJRIbCl0QAG2VDZrnymLxILdEBoPT1PuZxyygaraI/fGBx8S3tDgZej/SkLMEAcJmCABUhICNAYmHDEpAjk5Mi0TCjMzNjc3jqAgrohcPBUqyDRrJjfccArt2il16aLSbYDaeBOZTTaZ1VRT2Uw3nd0cC2RYaimvFVbwWWUVvzXWCFhnnaCNNgoJ7bzye1pBBalXUlka/a45rcYaS7fJpnrWTIu9aLnN3nfQYcadd5EpSJpzoDOzViSkelBQ6kVHbxQmZn3YOPXjETaGgrLxhGgahJLeRHIymkWZp68eCRRKQ15h9NUUy1RTceyMKJ6D7hI46S2Ri76SuBldMg8DpfDhV5oAAWXAwpYpVERZYsSWJ19+35Qo6bs5fyuwaLEiK1Yqtma9Eps2K7Ntu3IHjqpw5rxql66qHbCixfzqYx+7vgSmqj+ppTdUwIIaLn3pjZW5zMZrXnMTrW+9STDQMo8esWmMyP3BgtYMCZZmSUlvjixf89Rotk6Lbv+98LJdb7xtnx7DDjlw7JQLl865ceuCN98u+Qs44Jzgg8MlUUcE96QdMTyUcSTwRM6RQtG3I4e3yo4K3ms/Gqd1Hrezeu62y+YO6ZG/h/bE4on6ycqJ+cXmSXhl52S8dXhy3js7eWeOCxdHEMw/4/Si39yb9g9Xz33NzfP7tH34gX0rR0drx8frJqfqZxcal1e6bm52393rcXDS6/lbf1AtDlR+KNel6n5KAjmHUBRVlQU/nwU81TW4KUUC2Lh2AuJ2CRbckbdP/RfJPVmYShGBfBgpg44xxfHwlI2OhaWcQRk0vb+Cotgdaq3VGryIdYoORtUJsvt8ULQq06eFmL7N35dlcxfi8wOe3lN2O4z5DORGKfFIrgvs2g3JYSJvP+iveXpFEvR7ArJZPAN5yic9wF8DbAx5m+Q4DoL+HCS7GGBJ5hWjcxb1hOFb6FzarZIrQhzcUz54Pn8Kg3UNuvcg/xSxeOII5nyB5V0tz/GQKsO/w/DHpML3LlA85zsoRcYATeBOUsaUXfUavTCTYLRwXPnDSmSLUZbhS5ePXnzTrNCenmXrX+DbyMI2S0M+erm8S3dYCQRuReEPYURpQNwQW/EKKKCxG2YRR5HkHs6Zaz/TTYhUZGFVjqbRI08Ne4UR4HoeKCWutxf2vtrPzd62Mp96w9N7ZeRqOiYnPZ/FuB/OF3VfWSAp8S238BhUrB2jgRJsvVCgmBAOWgxeQ+Mei863QcVifeH2EqnEPoQOwXLiwV4ckogxLIFEUdEFKvbR5ggDvSThn/YhoSBmJaqLv6xvaN+ZtOWBspbq4kS/EBHqgxkvgrMuED0RYD2ZNkFMjss0ULw5hwsS7pVWhXc/Pq//dN9pRRZO4MAiCk72B5djAmSYmuFqPFi5HIkt+u50f2KQh5WmkLN64RfBxCV36b5DehQQiFdiy51ZuANXtdqztuYVzJP8oKh2IlVUUtdamRM7vxlJblPMgZc5l8UrnPLhsJ6j1UlVMtZzPXDMFo8gTOjDhP/1gdVC1hwv/DQnE63LUAsa0aPIcWm6NEK1/Al1rVUyK3VBM5FhSS4NLDILDUIVM69om99hscielW7qJ4A6C9OfK4i8rZ33TzAiZfUxYVMWr+rkHPiu4ckpgeVeCGf3dU/7GYD7mhuISQrFCAKz40jwI8VW6CAqa0ncS8ulW0ag64WY3AU2MMEatzt0Zw/OFJ9ChCCPM3vldAxCzRBu7hzWk0pxYY+R3o64AeFB435126csmmlgVT34Fqf5EwWzUqRx3uULSMLXYEAndyTBLuRAjSTX7uN3p1QWkUNSrNfOBHc5C2dbjgkBK93A4V8cxkOb0dYNBfxwUtV6t0xIlHYmSKAbIFoycEeOw/qlSKYwy2RjZ33OqVrliML8BKGQyI+PF7fthHvURmTdF3ZFVHGQIFp36C5oOjO8BjIPHcUO6bzEHmVkb43Kg8aaJCCFdGA6uoAMOdlPLsewLxFDbGVcY1xY5N+ovSyJO85Ksn+T8DYXHWmr0XJE38AME54iu39hOIr6sigx2KFJlcsOd4TRQ/94fd0X9blMVqfpZDJJqcnOnbiBfii+PPgak3nGqAIN0bPD6OShecut02eBZQUZglyiWbJowPlH5LGyvLQ8w391QR5Zl3gz5MzEUykahga9rmUibu5MzHMlKqlPwvELduk6YWrK52rnYjqhwUZDLy025GdiwTkSNYYIS40S83mSSeTwZb9zabl5ReXWGMBuAgd4YTTtCVCHEL/iteAQ5084FsXcCvnGIdEEP3jgzOYTZiE3+MbbHcF8/04nyRsDrdtsdneyv79ccy9p8NWhINuJoLnVdmjyxR78tcR6wYHHvnMWXBryYdrTMWXW69yC8eHUjGVO5RfQ/gkHW6YOLL0qlJ9EWBQGTDQaeYRzRIrTZFr9rPH2BQEcTBv+YF1H3Hd4Jnn7guQSzQ6HhVwHYj+pkOyvMxusE434GmWt1oE8MexMSCAmTZCgBwY3HVMfzJ5UProQ0+KkYqz7nLvcOSIdZG1NM0E3Hv5z16i2MuEM9K5b+Bc8zStnTV+feS0aldEfx+BECfHGBHjgxrYr+JrkZ/J7qv24vHAUBtP7bvjG+LSXwV1SQLhLYz9XkhxN+qsJc1L3ybLcW4hAEIPcrpEWAP57yJ3EfZfhV36HGYHilhfCLmPflXLAWtzXoKIZaHiApVdbKYmAtNr8jYq8J+0cCqNMVZ6agMpf+sPrK+5UzwvdsoeVjbG5GT+JZtZ/Y9ASRzd9O89zkNHguZAT1sjU0wNxYOzSAil7zY1vP/+p56JC3mflntjXUJLEoa3bBq7w+1gCRGddD4LbRSQOiyZwz2nPnF9VfrvHo2XGM6GrHn1bdAGwrCAhtp2cROTOwzFxtNih+EDEIg9djKJJpYf7QZ/mrwGiZClBbNVOxkcbrKLsMVhP9LgMn8Y7ljO4JeWD7RP4nscrvp7sTy+K+HE47sFBPmLet0sUmQ0BeYAULilIyB1oz12jZMXCfihE1ZahOTT8lQXBA2nPjaN8fk4cNoDdLSR6+ibVNp+QYDww7Gry3AwXlfSGm1F0Aggd/JvTe5PI/w6Xv37MO6KD7wIEF8Jd43V202WZIL0bytH+SQXl0ym7Sg7SAztn+i8/VRv/8YrG5PhyEcGAqQTQN6HrjnsVP8qANz8B5PLgfk1vwZJFsdiZA7UKsyCpNHecwMUOXwRjzNmZw2EhWMNB/eQVJ/sDOIa2OPplhKvfKGW11h88UT0JF/HJqamqRN+5Ay3oMQFxn+C7kr9+yrU1N4A1PRQ6eAOmPcR8/HPKrC/lH/sw8PUpI10QtU7tNiyeHjaLEnxvIt7Vk/hwQKJlBSxeXf3fPMygXnanNCRAXB72mbaGvOdnhrgmj3KySd4IIbsLF/xjInU+Ba0+gEw9PdBm/dhfmTneNvGjh9xdMWZEWBhonwgqREujlFiu5l/vnWHK9oIKy2A/5h0n+hf4doolSUN5oYpfVPJkANX8DXbe9ds+7RT7Cv5qVhIJHSyhGFoDJwm5QV4xXcLWhb4T+lnghSmzcqK2bOLLKWh0qJg1YDUB8FgVliyAKdFIrB270BBiJ+fXPMUnzdriiraOfGqMu1z0jOCY1CVeFGP+f67Mgvl5dEnSVpFFtjnkmFPOueSaW+555Jlf2OJLL6PM8sqvoJJKK8OAgs4i3Qjd+gyYwJefAFihwoSLECNWicLeHPsUU061wQUNu/Q1bx0MQjQW6dxUqVGnQZMWHbpeeOmNt2w5cOTMhRtvPnz5+yJAmgyZsuXIk++b74qVKFWmQqUq1WrUqlPvpwa/NPqtSbMWrdq069Stx6Ahw0aMGjNuwqQp10pGKvGDEGOTpEVZtV0/2NF4Mp3NF8vVerPdH0/X25Onz56/gM/ItLCX0DQvyp9/+fW33/9gddv1wyik/vc/CEZxiuV4QVZM1wvCKE7m5RoJFUF+Fl34UNYkSZQ2balV9L7cLLLIJdtsw+eQQ/M55lhcTjnVk3POdeWSS7a55pp1brn1K/fcq8wjjz7mmWfh+eVXQtiwxRRffKqll555GWWUX2aZfSuvvB6VX37KFVRQaiWVZFJppQVXVlmuSEjpUVDCoqNHY2GJLV16PCOMyEy37l7r0xeOp4F0TeCTukG+OZrIrzemCGgBFrYOoULzEyasQOHCixQhokkxYqoRK7ZWJUoKtWlzXCS1Ym/wKQqVgARDFt1VQb7KKUjpYZVResseHSkUQeYeamiksIZjuLilKqpKpKYi6iqmoR80VUhLn+noO13FeqHfXuqpN3rsrVTYiggOihIO6RrkGu3ASaFbjAfdMUF8BiVokkRMloQpkvK5uK2Vtky9ki1LObKXJw/58vZNPr4rQLHylKhE6a6MmlVoWKVGVWlctf6o0axaPVMnRfXS8FNOGvTWLxlq1KLf+qRJnZrlqUX+WhWkTVHaNaVTmbpVq0dtBmVkSH8NK96Ieo2q25jsjMvGhBpNqtqU9Exrh6wo4LDPFzzfiDBkdBQEKjYaDiYBFiE2FXhU4VNDQDshnUT0ENNHwjAp48mYSM4kCqZQMvWp0KgBGiQtBh3TnoF+KURMJCxMlkY1K11s9LKTymCEAy4ncC6EvM716TzkwyOsHuOgju+K0jXlG1ooGKFkjIoJamZomAN4/h6lD2h+xFmPdwYsseJlwpct2B3Re6Z5qbvQDmLshbs3Bj7o+5KEohUABstDHCkcL0N5EUaFTJMaavGkuWR5fA14jycswjSDkAS3UhoW+jwyAIttXmQoJhUYgEAiQUHphJaAIxF+iIAgIppPR9eIgdWfjaMclwiHGHWSiEOqTjK1kvsiChrFdHLS+xIGRgop5fo92IzDIoObU4BREPmElCzst4jI0iS7g5Mj99U/TwGTQmUsylG6ChlVyqRKUdV+phoNbBqVoUlZmv1sLYbJ0apcw+XTJrd2WXTIpNO3GG9Q0BRVmuZXmmW2iDkqMFeFhlRgngotlN8iDbdYfksGDbfcCiErreL1+aGQ9YrZoBLbFbYzhQcfc6o3mcMgBXjYYhw9bT2bNtocetFeta9kMhDZz9p01HHvOuksjv7rIpsuwZwHkmY1WIaOhs5kO8NkWgo4hLSIiNWnqU4nMrJFRYsM58oHKHOiOnZEXPw6CCENEXWQEJs0eFtO8YtKEZGKOqipjDbspWeIKZCQieTMJJf2CxKzycjNIZiIkEiI7C+amZjsTOXIiVauvMzkK0hUoeIklChNVJmq1FWrSVOtpmQ0aw1juPa0dehKJ82aRBIZ36xoapRRmW2JGiPSNPYN0RpnfOIm+ZKeqYJCm+Fr+ik3oZNtUdZ8UYk/X9wSiUlbITlDK6Vm4HNpoWxXlJWdoqce1MTpob/ZenzQe0/I1k85mgHQ7FPR3K/+JXY9en/YTdJMfZArvm4Um9JuAU/c8HQbgXjQFhKB7qAtXsTiQ0l+gJV/o6QKaCBfIY1GC39k5lR/uq6cFqFUTFidLWklflVtHmqpdnVU53O7alhDIzWqqLGaQmu6ZjGbq1X81gRa6wFt1OZ3/q89hPZ7aCdE9w4AU0GgCOASD40HsiGhiUC1JCjWwPDAHwGNI0KNFF7blKEq0oXqMdA4JlZh14jHHb5kwgP9EyGZBA2TBrblo3BUCvFUSKZG1bRhL/0YYgpYyYTumdG9NLQviCphVKmvIVjDNKGv+QBrLaBvGNRrAxkhY4l0nCNtUo+8qXgKnaijbzq+y8WTp+nGTU88bSYjPS5RYnTaqI8MkqGQ0aCoSd1mIJSeIA2aaJs78BoYmTtLomwDIxcYeUhUgSR1qxJ24eEXhwlJ2gLq3J3lhnAXQc41HnBf//rtC6gqnR1GKQ5s4D2GVds0/v9wIxVvo+tXfjFG+6jPxyvHX/UcVXA7+kX3pDD9OJg7Lz5YkUTffAAjI319fezF5i3Z+xbMGh9jHr6drFeodE3kb++GP1rVfxhlcd1ftWnkbx58h+nheqZjp7Yob9YEe/90kWxD8t1eVib1PNSQ1KMW6Yl2mqfDi0V9zJkJRz9FohWb1UpgkWH25z6cRCRznY3W79SysC7nPtCQeIsZH26HPNgWMiUU1fkJ+hSZcsVmMHwNDdqdTLwgjQxIy0+mcTizlDaK9mHB+dgZRxBGRUuCB+PMgdXHm2NOTDXH+qqDn82oz2NSMhu56erN2l7et/aXnxjtKganKO9qjzmAxjgsXXu97TWBN5b72iRsLc8hYnYEJgthKgXQRgwtwzA+u3S69E5y1o+KeXv9Xr3ml8WtBg/yc8+YTPWsrtE7A/La3mVLW4ccOwXEh/nplQLbUboCjBkdnQQQoF5qPMpMLAJwx/se3yMNRNK4dV1egNdz22te8DzdsjYvwkI1GdRrjBmh6NITlfZedLAdy4+3Qg8blMqzneyVIf1yj776xLRmZhqm+pYjGwKp5MMXiezDIRrh8eLMBq10itutIqbrh1nNENn7y3YX6LHR8UL5LI4MuU32FoXkvd9mG34731yGv2ilh3CxDyXYF513t4OpMazZS4QVZs/wyNVVtZH4sBM05eS2+V2kbrzGzmfo6ev0Exqoa/fWpzlLp8V0Ydpvwh2tt/E+rFeuu9QgNSt/0HMPwRSoj++XQOrzw4SGhUdERkXHxMYdbtrrR51m8ettsN1OV1Oc1rpRzGIVt/glLFGJS1LSktX69miegOCRq++OMNlkcaaaKu7SB8BIhpUc9n0lUqyQ0JDQEsEkhjOSzkmuxlPiFE9JaV2ISbYdX5xM0OJaoAAlAUrCxq31TPD2aIK0J5cg7SXQM1DnpZDmpdDl6SjyUsjxUmhxNcw5ecyghotf2jnIFKEpcinnWg7iEuUqNJVOjuemxbWqYlehVYsO7Rw8QryqNalVpbUqvhWLGA0KHRwMRzz+GWFSPJOb8qzRtBo9rkSpkkp9WrM3a+ZhU5o6iXKmUKEp8tDkeDpCvBQqXA0zJ5c0wcpI8Mp4W9IYwJye/i5AfGcku9MPFFwizf3NWCwJIJXlmyWmuEhOvqQWCOWtVkXpJjfBrVWVVi06tPPwqt5V2XtBml2RI4vMatWRm2UuyVbJNdPAxCO+q2Ock9DfDeOdE5Lg6hvGPmPKSESI78qiY1HT4lUy0eHI8d1WkhcBRa5YQ+W0eKIkeNLEdxacdTT0990HvW6H1rLtpsURiyLu6mSxU5HaNUFsUFnxKMQl09lFiezUyeueEtapU9Wp09NlcdyRQJEceW8Kh7bhitLQomVRzxWQzjsyQrGQyeW3IyPSjIgy5ZbLm0egmHf2yHqijmOhQDFC+T75IMd/D2DACdc//AmGHZUXyZqtm83rutNJ3ebvf62Hw6Aa5hOJjo7WlmFTYcrD9veAOescQHlZAI0oCubDkITDPKFIQR2pTl9mG702LlP+eSziaKT6Q3IAxYqgeVpsWEqkg1Y26VEF5bSH6ujZKXjjvGeFsX6Eox+113yqsdtkZayaeHJs+DMiMLgEPiNJMbDIl5gCWgTatx2zkjnYMp87yu2u1S3+KKW8V+/HHlWChZUTkIe8RLPIHMgYnyPKpsHgDaURXKARA1JxPjBd+GbOy0VH0j4acRWfl9jYuU61TE2ivJhO2BV6SSlRgTUKDAtj/T47aw754AKbWljsE5ppq6OYy+3cHjQYJnBYkpuy8pQJYRUkL+xkJ0d70uimGITdSc3qJKSAd/BIlZaLq5riqVOHT4xKaid9b95v0o6Zkx7zUS6d9rlbjGoUdKeNawNLwTwZPxEyVmOb+JTx2VNsE3VtxXmkm7W6KxC34+00S/PIB5e4AW0NjcJ2zTzH+Bhzx9vBQpZld0ZoHRRcLgOuYIsvbShHc7aUUk22Bw0+2uFW+BpsGHba5SWbvldD0zh00KktUvCZZ1p+hQkGOQRpJoVwp0kweUz1mg1OPasy4aDP3eFjYBbdCorOEKbeMOV0WRHQ0IpYKr/msBIYzOmUClN905aR3Q662Df+Wr8nhzNZZkEObCdm9c7oHzRjQ+mT8c+WQvLAlQILnfthXW4Lr5jL+h7i3teSKiRUuccb/Uvj2urZd1OdLeYsfRC2Q+z0Iok1dqAjmswNZUe7s/U23lg4d0gPOFHCT2BS1H0bOVL+jUSKxUaSdm3VHT8RuMfkg7uQ/Fj4hVOrpwGSNPC2j0U+GlDaWuMAHnHGvyT+hJjc0ut5uUmn1ae5o8hpuWMsJwLG5h8VSnhEEmyLV8q52oVEINIMI2HI2Zy9Lm/ZzO+uRrienqYXvgXMJ0vn4EP5yAnNL3OKBdi3Ve+uPHmwBd/2gZxxhMvGH4ksZZAdnZyNrETS11f7Sr9R1pvV8ZwU+G2eUtww70Br3POOS6vnjjm+oUzS04OPhw9quy8n47olTD3Eb5+nMMj3UKXm6W0Z2s81Lbta2HCbsCNd+MnItHChPrjmaayQ62k8dK0RlgB33no6RtZ+l2trqeUiLytvPtW5jx+ta4NkJ1Amet5G39Vnwuih3RcHT0/uB55p82DnQQ/8bqemRvwcxJ1pKUspxRj7U0TVxWk3LfkRu8LE3EtEjHGLhZSC71WtoWRQg+GOtjZ2KF6IVFac/R7srz7a0k4g5zN6Y1wF36EF6vSkzdeD9lim84N7ufGxayKBxvk5VGady8vQXojxt2iOJbIKN+okYD0XLTCt84606XvKXJAkxSous+3YLnnbkCijSMnRbE2KQ8pDzJPENl/dAPV6AXPf+ZA11yAxlD08HWrFInRGNjdaVPJPaQblSnXB5o8tj1gipHkNPhlVKV0JQVCHEpq/zPzmbtfJOCgzx5Q5FJW1MnYoXb8Klniu4MfiLYMBYlPVKEzNyxZKQQbAKFgupPcDnVqqyzRXE4v00mc4Wa6lqGD1UI15q8NJa9SlG4Cnw8SgfMQJew0NjYinMIrZOn57F0fFXUNJ2YmpPSp+m1mqtvKl3cV+sal8yseJbx8DZQ7dZIfmaCd51AFKLShtX/XtSjM1Z651Wi34LnG35ojtmc0Xwaheb0urjpxALaU1gdpvyyOrJZPIAAyMkNVJpTk7+UXHqSht7Z+ni4yfrJz+GA4lrRYXTDIkvJFGzhNlQAHiDpC0S9KgRnEhi9za1OlzILbPtfLyss6fzVziAHQrlCV5LYjliC+zeLXtj0LpwmY8mHt6yTaYCj5wbFrOySJUI4F7hv9Gaau22pYrPwpqlUu8/Bt1tJ7DaVEBDH8qh6GCJNEUz4pGSWNT6iA9hIr+7SXBUMa74k8yisFyJhF682PdDAapJcu5BOmHdtC1Kk+EkKeNl97InJ9S4ajFjJ+nVI+Q7zp1CT7ijPo6/6nlQS1u+ICQcq2e6ccGt2Bqw8gq0PU9ctexIdMOUdXyytwhdj5LMYoYWqI/myfZqxUPK9Z0EJ0L3+sl7GPkVL74Zz9DJV/dcnZcq1ptIuOlNPHy0jMUkqcarV6dF1JnKtLMIRwqCWYVltodOkpfnYuf0YP6UGmKMiIJR03lGMW4EOm3MuhSwg79SMvNK7iugO6KSfaaWGGEmtIeUB9MdE0PHlZfnjS/DV+R1qFzpQYc8hPDb73tRO4y65dafhA27EDoDwVwthEoKfGDfcEHCbUDlW+0ftSi04prvjAXweTYVOfhkP988owl+1QH5qxnRwhDI59YzAIr5V8a5jo1iKkl82tdUEzGPw0yWBluVWFXMO9sNku+iXxs8rPG5bBZwy4c/fHVAeGkFBZKJMlL4sSlVD6t+N8qSqoytTj3NzcrIETDZNEIb1i4AQ3YqFwxge+kY5Vxs/WOlXtP5MjgSVlTTspjpQ+apiHg1QHqeUPUxpIjwnbEhoZsc4q8AZMTQVj5JllqKbUBaGQTVZuR76sowwN7J5UVNxmbjLD2IiUf9AAd/mPYMNr7IF7ZAas+dWoBrUuUFV5kr9RFo0s0TEQeaU7WZcy+ZaiSkYCOwoxaeU9dqvQtgYDu0wE18kBR4p/dgkOADE93lH8cHFRXizJlbq41BG/p09s04YlYoKRxV2VQZLOUgUWeE+rZAWmQLDzLOIxKdPIxgCQPRjaKU/Q5ObWYQM2gYQ8y8E8zweyowHhLTb0tevM6Ys04SuV4Cw0PfO0CE1TuayX23H7mr6/kOGaEIzj0sTl+oGhz1984v1LLeZ3VULq46/irkgYdhoOBi7K8M6mOW3Hhht1bhWyHy2LWDelsJQ6stzURyAmPVeXeCI2zry/+aTb/4RPKi7AvlFgxAw37E7NZfmK1xk+cpviJ1w7/eoLmJ5qkJUkj71V2GdaEgGmtviB1WE3I3CT+Lo4RaErOEWo67kE1M18z+KbIWI6V6AS3VJnTIRhOVw2j6W0DjDfNcUALiMhZhm4hwwm48S7AhCsCgm4EB6mJIgbpSXA6PryRg0RAgEUwfOjdjRqkS4ETVLp9fGBAgsoSOhaYwGF2zUi2xfD7JSYhTdbqHztGe38KDAryWG38I2vgn+xIcBAdu44lrrE3DtxwQ3hzQXLjagLC1vpG20I1AQBvghmuzb4TVrpVRClLbLZvQpe8a0Y+zo0vwhG4aSeuBcOcmfBnFtiZjWjmQJ+5QFs46BYBtEWCaFH3w39hiwFtsSCaJaBbPNCWQFJLRDTLwc4KKLMSdEstoh8VjAMHjgvmWmm5uEOIC1Ombk/fTntwnuqOn07F99wo/ir7hPjrlkXVR+3QBJmyDEUb84yioFsIgCeiDzAEL5l6fIM8/kEZdXgAHwL97/uB3EorPV/s2rNvr/1uL9ZtWG9Dp0EA7dtDy9yyhlFlxIhIWWOEbPWWJ57yxV2BHlSo7Yq1XYl4K5VgZRJoROhGWT/JHiPWXJgydZt/++3h1vBGIyOjKv21eNQOm4kmzJndwohReZwPy2TnXbUjRHHB/UZMwqpQowbn+1WW0XkdthUFXUcA/AGG4CX7jn9Q8Sa6t3aFmoVgALwFXUdAWhEjRaIPrSbU+jUh001aKyqtxHWisGOgxo4/betk6F4HkvM0RzyF5+ezMZ7VfDcSLa45R/WVr1tQWz1JEu7ObdWqfzb9OzaHI/VqcgjZvcRalEaZVjuulJlRZuYoe4A84I+ygWhGmRllChR1/xNcloyo9yuGTt2OzSi7fl0tBYzI5WJCvWGJGQf6uoROKWYa6trtUqkGpf4oVeryKF2HRvsT0QttfzxQCt5gfxV16sAaViix6fhjRd/T20knOiUoUiK/FWhrJadNQoTrZJPp0NJsJ/CjfByVcj+7TDKbRkdsSZEcpcxFMTwUx1MqvPWYr/L4tSf6JaIezcEIRImCpAXbkhOXRhWVpkpJUKklpWexYsRLSjURSfCUhodFK6N48Qge/iY9VgUqKbzYL2WxeqOVgp5vjLaJAmZmfswsFM6sFK1sdVNw4apoeyhn5a2egh9/2QLkuEnHD/peyRfoIy/GTOFZ9iXZZqOhIseUG5uSCm7bU2/MfPXNHPTPnA2srBVWeI8Vk3BhvsIJxSJkC7kLJhma0Tuzemtedhb03JKeWZGudaXbUJp/KrSpYlvKsK1MO/rfobRTnZ1pcqHSpWZX+h1B9jh7A+DUjSgYk1289VovsmsmbAdB3T2k714sexSM3Yd89yPbo0ndYzDtsUj2gF/b3xUtyEfeBAZ89IVPhgTGzqpUZ0xq2Lsc7BXSwn7TtNarCu1ZIf1LZ8SFKyCX4eFbiy4NHt7eihpBLVVR18Xslg7b49e07vI7L/AmgwsK5lKXtaJ7MBTe2pYF1emv9FEGT+Fxb9k82qjlnGAsKEkSy97Px6tSUDS3HVyPue3RhpzsU2AO3UbRhcLPzALvu5AtP+Q9TalRQ8HElJZCi8xlIOHQ6YTPzw6vi+MrPtSMLNMo3Bf6UCo8D9M1fZphW04YS0SarCpc+aPK4NNDfYxVHi6go9fbGYikln35bRS5pU4n9QWAN+CnarWGCNtZhEGx85E8bkVSoHU/8X3mVqlAhsA+nXD057QngMU6WlncW7YincTtqRCONXfWW2l11/hHrrLX+00wz12nY1fjtuGxFQr4ytz3jdH0m1epsDJejePLrDM8X0rdYBrrML8M+UfrPvIxEyIMb/CsU4TSgb+ZCLrdezXxkReYND1+vf33DrrTWXXNewT0q+LqFKZp0qlojhq0c976b0cMi67dMyBe+Yl4Ftlxbe+05r2g/gCcGIPeNdLcx3Ua5HXNdbCL3r2lQUT0W/D77yXrrvORGvNvVTcsL/nH8iQvcO4gn9+R7H2DzH1ARHsrW8nEPdRsV+t7Scv4hAxWfhM2Urd9RsKpVXQuWGronIgMgyzVjZrVCuebqnfB0z4x2XRWVEe1glEwoQeicQ9KWD4ENX/ukXkBlfs2+uCnWyStFKSrIncqmGtl3IAysKc71FYy1OnDm0C5ogbLBaebKmVVhd8hvNisrJRsvV0XCclpVz5gDYXClbRksD635scjm/Re6FEMVhPW0IlRyk40kAqMnlxMNtx+Fe3LE5TiQj6eHmeogQKsYb2kWQczFvBiZ1bhFsyaA9brIMAqNXwr1Qi5qxNyyZNwDAz0uvzrJ+HrPg6U7hYTvIVz2TcTrGT0/nResCf1VEDdboGHxYTilr7Etj9PoWJ6jX5K0gtrbieesXR814JZzwlUi0o9jL4O1qMyK8cwxEaLs/rmI4LTDb62tWJ3hesUjR90pSixlFQ91XEffT4oDjUe2JIHVR8hctBcEmjgeUEatJ5YtKNUMsTTytZdeUgIFYb4VxkSZnt1rtM8zApudHk2wWE7MNSQlDb1SNapUyD4NLgeRDDdKVsh55SNYyZO4YtI2niVWgJmS8oouRaUGyjLeJdoQhg5vWdswmNS48Hs87iKgYXu7ol2+lQX53yCWiys/SbuY8oZLG7nretdd49zx1CGXt2jZuPsDS3gsdOFS/H+tJ9d6x8AjhOMlm3bKxdfrc/FRRMGJcjvulv9ib1nk3KaV/B+wnnuXBxXbc3JnXy4mp2d7jNUKeKHsQY2L3RF9YzEOimb6QrIsHnjdXeZAkAhz5N4XfMmQ92WdPDQVY/GXMzVy3PcR5qbSNenh2tR11GgfIdUmZwJYJ3/rRGgr1dVGUxgH4DVOT7NutmbOp/Qq/Dxr8RHmELtLswCIumSPeTOykPZD5fOqr4Rcdo5Dz6d6wKaqyF5DLQ9alVpEvHvzeay6wsASdQn+RaiDDQnC0FrBnkzPxLBaCzh0eTozyUDlCHG6K7odYVIcQ8Ku9ybmtVUqiMq4jSaNgvYLqZ+APsuDEmAfkNiUyXoKqKr4Th8WvdwZw31qjBW1Q1AyAJ21ZEEPCS9yhBle4ro/Gx1+8SBqiP/yo4whcm5b/KUeS2XvZ23kqQ7htJHUtQ1P69nY0pJgpSPQu9Rlg6K5qT10UnuqdiljZWCpS9B3ziqbZIphkPPGGiu1W+qNml8km4cHgyBtZzXxuq9elQVmfExqaLhG82iQvoL6RgyOYIWegbN9cEUtow7VXTNQ+5YOVqUNDFpaSBZl5S/8Uq4eZrr+vxW0IT2qRohDyqY4t36r18sjZGwcSqxqt3+RHPhxWDliGDcA67Iyb8qJ2EKtTu8uRwY5kQUJakwST1+m7t7FdRZoNqgsmu5+UZrZHLFLHfcIUPPEVRBKb6OiSEg+4K6KJorVUmZaGu5hsTYDsm2BMkLV7SU2OVkv0p6pugKtPCY87vnBdeiU2y8GvaNDbN+EaFYeG6g1gHPgnvQummDrqbKs6IqeQqKC39rAyT0falS6HbZLtmkeg2NqfSoXng6yYOoHo6mswTkJ292SBKRYuwxJx1fPMNY1HPgwPuCrjrLv/KsQLsDg7GLf6JYoJyMacHFptYpv4UPHY+goJfEqWYTExhrmeUT8MFDk8PW8q6g60vQjJlSJpqK1WMPVG0bF5ubiX1xPjm4LlZPAzXQtcJpxUya6rTKSFZ9wJUaDV4KwPBJ8XirrsgYc8x9ANuru6edHsfxObDYFkpVeNbrTvpuEbjxv8Ec3GJk86bxjT3cQeHgZeV9J20t6o8pvK/Z9/BlFqucSYywt6R/17MKpTwX0t41LzmWBOCdFA6xgOT8+3DYURTXVCf52RnytpMABkJI2Vb/hSbC1e/kYQ1flEHiEcoBquatqtgjqhGNe5nMNmChANYybpygM9knNbtiPWb3tZbI9qTxcgXHiGpLd+WWweS/3Dh3tQYks0VlM5HtbzIGIbsx5+TUGW1HFW5ONFEQmwexs1v2tNmABW0mja1q1aVovvxmBdYkr0Mua3Jnf9XaE1StGsncdMZ4phCDLKuxk6bkuYDgN4Od4bFp7hMbjWTcc1kEMzIjrsWPaznViqYptGa6qA8ErApvTP8Mudct3isAfoQdIidcZbAzNwibJKjJhu8pvCpR/StFDbmrE3KrrwVEaoDx8zfo03wX/I8YJWE3fIrnaT4expOU+rRCsOt15X+7SEEpK5vwtKqMajIqezDiLrbwH9lg+FW1KofbsQDzEBhRc3S6QQOu8NW7ytdlSJ24kZIZeYykg9uDVvrwFmTYIIig2HCNZWU07n2hOnCgtPt5ewPhByi9/pfIJOc7FwBZXTvhLFR8b+fTjmPrtPQz9LLNKetnN81/wUWJ+pWja5JECVp25fknaG7LcZsOuBxwWuzeaF7bKtRRyEjWra62rUDGtKsonQn21hOQ7Dwe2SnimYBYaXQQwDmXoNqvIB1kz1tHkwK1ni1mRWe40nO9PuQi3II3rnoc5AfuLb5x0nlsoggWrAt1e/zNE3732dvXv/S3liTqeIDcc3J1ecAtLvOZvvmBmflLvrLPzL3NJ7XuP0J/dkuoHGQ5LIgZq2rB3pRaq/l6N960nDHyLhvEORjCXkCrq5YHz4Tptzz9avYZ1tuWXPUv/4z7RzpeO8Puk65ZnHHNHPhi/h4yvOHnGWlysMFkLPYMauy9bZnVE13GGmCf/Ek+vXTfao+DuTfX0rLp+me6zmpppMqNutiar8MtitW+GBiJ2b8SJk830ok32BHurNjL9wWOIgUD+TXkuhrOXC113duzk4lveMPHi9ypRHAZgbfdwDq9OOCzObmdbjzk4CPPgbS8cdX/dqD8X0vaa/nxvMkqW1AnrkoQtRxmqYT4myA4cGAuLVV81dr/I4BRS7/oMhPpC/JYfMUJxgqcTlS7hTlf6dfHbfs5tbFaRfW/yo21PejIFVCFkP0JHzOMHadaReLDoAFlJWXgWdsh2nGsQYh73nqWDA68T7+peFoezgzlQG2s98JEJQjhejUlwLYD6H1+1mNnkLJcLgv4zpdWfR6J4ia4sm9kmhYNxCcI7TNGlNobuIfrlTSVfYrFFw6kN4ILuyHH9GorkbMeJO3peEkIAYxV02omfMWj85X7alQTVtEYl8ecCQ645wUHY0tEd3ghnXfNcE3kA2Nh22wvd0V4xaxQGkKcGLHAVQ5t13f7pQxcMfbwCEV+WHgUCQgcYCYxLCkNIZ1ySpVaFWvTqXGEE2N+TOgNH71k6oaYQ7XxvEybkkmXL85R68EfxDEn0+Zh3OLh8bgf/3/6U3nX2+tim+aPctrkv1qqPcw1UpO5WXO1Fq7aaAC2XoMqGIJzY0C6fEwoV+AG5hWyZnOv2LG/N5w43TuuXO89d173gR+/MxAIe4bw0s9Elqz7JFfumSlQdObKlZ9PBysQK0Ag4aCg6CRKhJUEx4iAIB4RDQodHRQDQwImJgwWDhQuESwxMSIpKQoZGTg5ORoFjVQ6OhZ6eiwGRlwpUgiYmBilSoVlZmZkkUHFwUHMyUXKzU3GI8AqKMgmJEQuLEwlIotCtmx2OXIo5colk6eASqEyauXKiVWqpFWlikO1ak41Grg0auQ+sbAO4eXLP3gMKzXX2ep2PBNw5yqfe+bQevo/Gj9ZJ+JXm0i9uJ+h/Bn0bB1hoGBRwNGksuAShA0u2KCn6ggVbRCXk+p+SqR5Upaet8eshVIjPwFHKooL+/X1lez6cEmnoqbl4OTi4csfzifxT0cqyD6gCzvntvdXBAdbb6Ho3R6y/u7kQ3wPVP0Le/9B2Qeo+gh7nzJlXKCADjK2Cib9Ke7favj1TTVBt8t3ZB9Y5RLRu2OoarwmIdDFMKoKZgj0thpSRRo2HuEp5S8B/hwZf1LAxlCREn04ky2ZzoCDYUaAMCNXmP4HR52ghyVVHiN6CoQZB/JMzBhjmfAbBz/RICUylktoGrSPpleG8eNX2t6KaNr0RcgQB9IrD00WM3HAXy8JhO1MJs/6XF3cnwKoy2W90GOCN5IUnjDD9fjiEEtCwqWY7P3bJRlNQgkP4BKKiVzcf7mP3r/3qwMD/8MbJTBiGH8Q1XRJi9h/+BtnMjnZYagDLAeylWIuY1d5vJEN1Pa2jRVcGG3sHvhxhYrdgJAT9ujOBtajALAZkCZ6NG5RnSneFy9t0Ud+mgAqZeTMkb/OUTUQUKOegZ43aZHiKv6mAlAW/vCkMIUOZCp5a/khf7GTqTdljmnq6DtjCQfI+0pikAG197I2IuSVBy8tDyq1WYCJVOdAkbTojiR8Ygv8G8jGCSEC2SwwGC2Bf+HeQkudH2fLkEt6jrAo0wNgO4RM+DRJ82ngpORKoRb8A7x9064nAPmbMvO+sjeK3ni+r0boHZYK3N3qA2Ok4TsBeEF2/FWAOUC2Vp8bCEyGWmD+9f/vg+Rrpp+TA3vpTjFU6lv6pkz6b7pH4dIZRTtM0DFr2KB9BNf0n3kfzyMYMcGUkX4Hmh+F/xE+6S6kyGNuuTN0Jm1cAl1ZdTZIZtOpn9tImt2IWc4HQQZsZgBsmgGArRSrg0OzGbl+8nZhHfqboUgz5L4P1sJK3jTPFYDtBkdyxK3TYi+UXze8m7culz2sOm7LTO/6GJSkduuzi/jlRxvdiU2R+0GqT5/78ImaeoJGUqQiufWYmG3iEpX+s8Y/eqocpaJZoPvs5ft8APQNAQDAxOyzlaNTkauHt0+WXzaP4MeH53n+79wNjNLMfS3tkJtuXrYOFm/IYLNC6JAs5RSU4fUrAKwB0AFAGwAtAADApxYWA5CekfKXtenYm/6AX3x6a/xxGu+SqdwnNfIihTlD5qOcd3H1bC9ekGux2+667wH1xM2Xfc9PETymi2UexxfgRlTisrOuevFaYZ7Utx9/IGIS0rJ9pDTL/1GQMbGwc/Pw8gt4L/fm14dPwVK20lIycr5yOsZyVq5yegpffIsYHQ0KAQ4VRTKS6eV+P2oeWwTN3CiCATNfJEsjrM/6uFcD+QjzT5m6uceLyizYRFc4x1+wgncOD0MOQsLv5Y837P9lX/v3wavncilVfdRE6Q83DeeCHd6L19P0+MFFVcbhZPitoqiLaSl21838qPjeuNvsolT2wlB58GkroPNso6zVxl/UyyZPvOHNhStsrugsJMUp8tohKzuw5r0I0FsLd8+FnFn49ONYtE2+kHjhAIdepxu+ZLMRmkphZOdz8sISZXWoTLNHydTD8Ght2L5017pyGYvGyQ9dBcqepGZRukBW1BVxqpy7CAZiYnOx92ixPnq1TWpPUm++9mbSpLsXquzkV/jxrhb3Upe9M6mMu5izjddSnes0CJEOY0obQ2fiWHXWVSAAnSlJuod4C1b//LrruqDFLrjQM4JtAYU6WIVljwlZHyArIyZNqMk251KDJ/nsLqG4pLJFrEGlkV9IVcrOJJ/hxwXCxqc2FB/mxxzEgqcz3PI/dqh8XOJB48Nt80cUoGVjCyjcO60TAUvdFCL4Uo0w49MIlc76JK9w/v8o0Beo77+pFM/FkvEbRs7tK/GhEMjOZOgrBs/MyhgjBWlCC2RolBksoYank1Fl6wm9IRGV0pV1uMLUvTMO+94pMT3t6F21lmGvZFLH9Jz4jaDy67zWuOzdmW2RdLC8Rm91n/rT8b/kRIpPOWmIxaretaWflWFTefIpckcfgicbjxqKFtiBl24sVhxOp8AnhmH3A0S0mmulhaIgSaUwemikV+QpSi33rWWHWidbxgosR/ByJqo44VFEAe7YU4dDtj0J6Yp2lf6hwiBU3Q2qZefBBSWHs7t4y7dyHcmlbGTEhCkz5o4DkZz5ADx/M+KTTDbISI1yiGoSXMs6KLIB6vwDohkhrpkA1kwzxACdhrwJCsRzEKQotATDEfCH4xIZTqLhZAqR+9kUNMbSCmZ5srDqwYPf10i+OEGxisSNQGu4cWTY8RXLXjAn+lzZlVODT8K5MyyzBlFl3iCaLy/6nOgTvAzkzVsoU2FMhfHjz49/3bzWLc3neIDPQ1P3GsQwweYGfjg4tyDxSJBkUNTwDJdGxEIU4QktHowUqxBIYOzZQOUQyR54tiINyrUmMuRsWrm2ZDHdKRpvVhGKPDTj2IllL5gT/XJq8Ek4d2Zl3iCaPjv2SDgJF+x69AabdTscI80S4wgFG8dhZhkQpYeengfcCPgqhC2cO2mLR0vSPcasUbSJDDDLha9p0CaYYLIpJteUBos0YvPN3dFl6fkaTeFHrMUeOjJf4JGOgWTTIe3wlE7+GUUWMWMvvFEFIpgOmUeCg8cGAzqSO3JsYsPGpnLM2LSPFpvYILFpHyGWS44SJagK0NGIEIGONFpSJClBkCAeG6zL24FhaUR56FQk8XycMng5JLJHOtgpMmgiGHHjIkwI57/wl4kDTEjxsOP/9Sz7qWlNez2ExyBkYOUVU4iBz7uMNslszdCncdAImESMbHwyFanWYoQxJpuTCVoxPVY5US8bRl7T3ktAxCKWws4vS7Eaw4w01hRz2y+mg0pEwiahYpIhIFuJWq26DZhqKHIcJgkZh5RaKoegHKXqDNdjnGnm2XE4DAouGQ0zp5BcZeq16TXedPPtOEIyKh45LQuXsDzlGrQbZYIZFtjxeFg0fAo6adwi8lVo1KHPoJkW2g0Zv0MnoKSXziOqQKUmnfpNNMsiJI6t1Y+ohU7p5lhslY222+/I/UTqaxt6wTV3PPTM7974Z36qa2sfDoNBwyJj4pNSPxoxu2tYmhL9ljngTv3bcPpMa21urIaXqNKgVZdRBkyaM1rba1vhQxZbYa3Nc3tb9/Au+F4HHHXCOVfccn8+HdHc1gD/1Wvv6kMjIJAwiJM+YnhtB4JLTEnPzM4jNLNGjNDqEAXK1GjSZqR+49eUrUfMMt9SIK+y3hY77V+HNipx3CkXXHPHQ8/8vt5skcQ/9aljGDQsMib+km50rGaUxsEnIkfRqtiicZ0WHXqMMWiaOXPhpVb1JhFejgKlqjVomV2XXbAvbwZMmLdmp076LUAm+9k0gEJF6/ODXmh8mZLi3l89SChoCRIlwUiGhRtvbn7wICCogCCKE+AJPJGn8iyeyTN4Ds/muTRpbyGjhDclspSo0WKkzXb62lEdBkyYt2bHP4kFMpppqLiktMw8IvKUqdNqpDEmwYmWLEuB8kgBUDLdj7BcQgNV/bjNZJTxgoSLh5enWLVGHQZMmLdmB/lOFoCMQjRFLW5JBb51wQ5xvxYZiIMjsUShPam9cLSt19Lr6Y3U+d5AZuyHPmFKdZjyx/zEEqLbPb4MrOOhgW0JouToWEUAEy6IOyIuHgtYeSZV3gVfyr8amjjDdk5zn7f4Vv7f0KRldnGa27zGR/yo639TYPI8m9jPaa5zl8e8yWfyn4amzLOLCzznc3l8aOomrWeBiuuHZySOMcP3rWb16qlXnenbF+ynLYsG6fuSZdarr7pZy5ZyAefUiCuI/VXeyy/g/RrehSDY+hsiBlxWITfI+3G1lIHW8t63ky7wC/wxY9aceX8tWLT0vx3qjFVrnt7wz6b/tv7XQ91m174DaxyNnM/v4Arh6WGYWLYj6no+TOGcEDhfhQoTLkKkqDMLUP3548RLkChJshSp0mAEix26+rm9+vQbMGjPsRNnLt24SYmoZTTTMzUdZETEeh9BQapyD6P3GESC28fpcZEEZ3VfeY7ohUUwajuu559Ze5Kiuj6Cq2e9uvmyn87X259//f2PjkAIYZcT/8OjTqAZI0ElSkqCp1N1w7RcP4AS/N5plhdl1bRdP4zqAu3kh8mfunt0vZY7veDi2gJVbt5wcEE1LeSCV7q+bkp/th0vrKs8JdCCz3jBQRh3o7K92/t92MfpTX8GM5zRPs9itrOfw5zmPJe5zm3u85jnvGY3x8lNKDivnUmB+U/2Noj/b76c5S5v+fu27ytY8UpWuqrVrHZ1q9/PNa9lHeta93rWu76NbGzjm9r0/mxu8/u7hS1uaWtb38b+b39HO97JTncGBgwEGGBBFjwEDFY2dhkcFChSokyFqoceeeyJp3Q985yhIAxp81C8On8V77z3wUd69Bkw9Hk/Vriila18Fatc9Rr2a437vaa1rm3t61z/Bja4oQ1vdBOb3Mxmt7yVre7fNre17e1sd3s72OHOd7HLXY0wABwQdDCBwAYHJLjwiEjIA+0n0T7n6JhYl5SQnDnvahKMUkR8biUlI0/OCRW1v5KEiP7pjVKYpDKzSJOu5ABdn65Yn53VC5XhCHlhsmA2h8vjIwKhSCxBpTK5QulzQPO/PulHqwggVr1G6aqnf5XSH05HN6zntxwWhycQSWQKFQgJ3tNZL95gstgcLo8vCObYQaRhY7Y9MGygd7sg6DdBm2/z9g7O/WjnFLQ2ce2tOEgYbGJqJnY+MXlKVGnQqsuoTkAFOTqd1w13uG6ks3WzO183p6M6t2OQ5sQBSL8LdcJudyJddrK76uS4M5G7AvsVkPkfMZcVsHINoxHFgYXFxTbZcv4jgFQLyiKHKCBKiAq6BlFDCIimcIW3EaSqUXoTYSCBIAgOEUHEEAlECpGBiSaZbIqpphX/RYEUHrzeLMtltayXDYi4I6cBEOPtjYsconNFD1KAW49W3DwUHulXpWGL6wfHEFNIpmVA+iFGSWPhv/t0Dk4Mbh4sQREc2fIJFCokVa6GTKMWGq1aGXTpYtRtQIrxpsuw1CpBq62WZa21sq23QY5NNsmzxRH5knCsscywsRuGi18rIVHtJKR1UtA2gp6pPhbpDRgwLh8+/PMTILBAWMFhhYosRLS4wiVJKVqatOJ89714hUpKUKWqFCNGSrVpszTbdjnbrF5BFWQdiHjdBgD3mAltuz0Sfes7dG4ax9TOlKAuS1nQQSSDMAMuNyDVRDM5zTFPyGobxGyyVZ5vfeeVG8a9dy9Sqvqe775tLosas50dP9TbZeFkuS4vtyuzMj0AgRtvGuAxS6CssUaSdTbA2GQzHAhoddUw0K4aZ+jejR5DAggIEhrgD/bAxYHoGRlxoElu/T1bcaBJan09G3GQuiNsCCmttyPdrvScxYkTFAciKCIOBFMuCIhuA4DXWA8NAiZOHOByA+JMNE1CsZcAThy4uAvZTk2EHgWM41CxzRXkk0grvhdjAUlEEJzuQPyfE5rs1oJZ0XGSbEQg9TMoIES3EInUSpivLs4230ruKyWQmtV8cfgAaa5vtawBzpiLHyKj3zyaWHy0XHG45HNwA2T95lCEImff18ruZONl/aZIfPHRMsVh6g4mWtZvHI8rPlq6OHS9Lx0r6z0EtvhoqeJQ9T5UpKzvwjFFTr6vlTxDxsl6F4YuPlqiOETdIqJk/WNQVNS2mhevp3iMqH8UggzbfHV1gUWIejcO5jN0ioeDJLXblN12rVUEPEThu5ne1Y058XnzbFKBLY8jd8mgDOlDPt6lgvH0wMrRwBTeMn2o8W/MhGjiHrTjBrPxq0sf+pAP5UKSmz6M44fjQ1FCH6bxwwuhqeGA5pEYsMsHlFp902rjLkh3vMI48ccfCQ4rjU+ZJjBoeHT81oDauGCwzPmiQwiGH8Jh2ZF060hZ7l1eQcAkwytzytxHzsvwfdzOOaNJVKovwkquMk7WccuouZlaSLhWXpKyaLZJACWC78BH2ne1tzYRGuq8du4xbNWm/D8JElWrb9F60t9SDU+eT9uvDaYNigDipMNh7NRm8WsfNhqvYWFLkaYCgWLRCrhAO6NOXUzZ0sfc6Nx151mq3l9u8hV/BW5K/CWI+HwOmsPCwYF6XwUD7pt3Ot/3wL+mFb8EvPHN8f21KHd97HkHB/Df4T2dFNwJNrEMeBag5tYVwDKJgCZd19KwRl4HKs7+4gEbCQfcZzyERMBkGhYDttmbWAaKrBuVWidrpgW04IZr6a1vye2VfRh3FhkKVDANRkzZcIk1LniCBUeBrssa6EnvFaV6Na5o/BH+VP4MF4y7nvvWejayuWMcV2sd265xfqw9tTRxaek/fs8JwWRcWmlW225/EplfzJVaJ2qi+beghmuhLXOJd2UPxp1JhhwlSCTjhPWy7XHFm+CFH/VG4WjB6bACZ4t/tKHN0FN2Lc2BTOun6w8AlSYZYTQnrBWiyeUzLPnvN295Swg2f1h6Y/KJw5pHLk3A4g6YXyynzHgxhuSL8zMw9+53wOwNmD0TsJaA2S25kWdq2PTVsdUYM+tj+Vf8yOdBiPK7AK9JMJ4wSxuo7wDU92qlNoD6XaNrTWMLQLtgbMfR0LKdB/gGdMlP0/AU2inztZO04eA+hmK12ab71gxfmEV0p0a11HYrjLfc+q8lqt122WOtzSDbU3TlxSMgIrlkYGJh41ouISUjp6Clo2eQYrINpviel5MkVqjoyhsUEhZxmSNXnnyF07dCpSrVajRq0qxFq6k2meYHE9Id9TtNmvLdFhcMs7PY167pNaaI4LvCnfDdNpd7DkZaEj7pybAO9HrX1CThbvfTIRkFFS0iDh4+ASFRu6RSUlHThIExGC5NOisbuwxtXLx8/AKiYjJlZadAkWIlSpXZqV2tOvUassjeMPci435kUZMH5HpIvr8UWqDYIqWWKCPrbplKK1Rb9bA1j1r3uA1P+udpm9Q8sNx/6ih62qLRNs12YNql1V7WqHrbp+2htQ7oeGS9Q7poRqHr68gzj2107Ll+DKM78aJTLzvzKvE6O/faE/+68KZLb7vyLoI5ICeC5GTQnIJpDFhOBc9pEDldfM6AzJlQOQs6Z0vOBYnA6YDXiaBLXE7ywlbd9TfQUD11aNGMg4CYTCqWmdhx8bzCRUhEQkpBSUVNQ0vPwCiFiUWadK/xMxvviyA48by0MjJ/skDy4OS7cSKztVCslkmNOEk8rZDiqwRREqWizDkSc66knAcLbu2/ki+fn2DafWaZL5kw7ulE8T2tdjpnc+WbKh2s2OGqU+Or6nPgtqkcdgRRFAAQ4LueUvuecI5Sq6LmrWKocjAzSxIk4xDRSJfGys4mg4uPdzoZYqLC2MWKBLFL1QlT+8yNWOf45kvs4a5NmlFt+lQxSXXYDnvtcxzwbgcd0OWIEUYisHlbss4aXzvkpkrAE5b43C1wCEKmB04wWGFRrWPaCTiX0UbfibaokvGSaJv5FpgJDgsGB7NSKJFXCV5gORV1YIfTL4Pgyu7JPqjDkC5AuqYC9N4BMDwPaB8AjvoRXPjdAcz/IQIz/jUV/fZsrLJ9gXvpwmqYxsDCthMyztx/OEak1dZSO+9au9aqbo2ojCx8tlOC+SkebzglldJjCSc+I9BQAmAhOiLObkR5EIYkjSou1Ab+I4abHl9HcVmiGiL23hOwX2KmLypPj5XlHVD4jK5UPy1ZwYn7lZwH0xgf5TKBMaBjxg7sQEnZaSl11TyEmO5elfCVFausCJF1hUK1s+0gisqUBIfInTpcLlbg1r46taVpRrY8cNDOHL/XWlOpa9ZUbAka5zimVlTIkbYmo0oIxsEaLBdqUKupKyonalOtysY/VMp9JW4ztCLDtd8CupQKXANCohbcSJ0pJF1hoRlbNhlGXTfq+SaDqNok3MsE6JAV7plvdjg4kAz3n12aeN1lGED2egCf79qzSMeCDaHXlFPrJ61ZWURkFXbs3M6GZtmnJ6cDsNFcpP6iUbU7eWUHczDQjM3XToRetuFwMjatpyP9apKAjlKzBNZajoCIo4N6PM7RnwRBHhFCSISU3u5feEgEih3ARwGFCJzBuZ9O5QB4cAaHOZDan+EOgpfxHPeCvPYR9xkmCTrjKDdsAjB7KcTWvf1eQxMGQCGJ7z5fEDKD2CFWLK0RNs9vz03oFcJYY673EDHMAghz0ym1+z3kxuYAVq7UxZgjMc1iom102wfvu2fadc16WX6p8RKdTRfw4vnacQiZACGMgMfnhhGA4wLcGK4IjHoMaAVkD7kcrZl7rnAmkFtiXWdLXHP25rHhiw8pG+8d8uzM+UX/lgv13f/m+v+7/8iN+tvczxhEzVo9bnOlOilz38RZHALI5jTicE6DyOGRxMkMmdAA/tEgMAxw2KvHfe77I6nzQGHy5RoQgbx9OoEW4qUrVu7p97KNxng4qMe2DP2JDkga7aNIoFgPF8Rfv2PsNJ6NR1md+UEyCHblGGDDGjThDhU46Rt6o0juO5aT5913rDV7irkvAeepiK0xuz46hoh+EgDmplFqi0HUbdRjG+RJMg8BHwY0xCJ7ZfuBu0QEQgctyEvdF38N+kU0pwJAuAOEtUOeVTRmocTGp8Rd+wO2ySdNMa9NiKgx4CqPWk9txyLxhsZLXXsDfwQh1H34fECovdJrDqaOivGgpyPVhqc1XCa9ct14bvM32Q1TL5bJbID7cYIBVptEa2VilC+ezm84vbFAXBmK5BrPaaPdCbjFriCX61ocQOQRSwAmmJqYOuS21/SwiL4lsiOBBxFKzSoFgdbr4fNEBmbo8rfDWQYRArHVymEV97d4WHIQBSsEJl0cQx+A6Dq7DC8S6BPojtzHlPmXxZTdr9Lw0yiaiPIw9UOXJNSrZSV8jSkPAQHNRQOid212tSKbcJaCAQZZ5iSni50jTozwovGrb4RUnwk5EIXtx2ZLnzrdtRZt/l6DiOCPOysIGGDzw+hrOzPENQGlG9N2xLoAv19ir08b9R3tp9DQhvQFCeOn6LyQX0EejjNAfGSmFYojp8/Bhkicg7gTh0m3/QY8zqKFodQK1n9KODoEb4tOa1kpfAtVqHxkp5UnQTx9kjDBhMxuCbi/vKB5CpJT2KBhsi57cE38cO9m5HZ0ZfHGQrYUy7UIHdyiaR7LdiVKnq1JeRWQnz/LbkNLPN3sHuK/G9iSf+QqhcXz3A5uO8x3BkXjteBNHn5H5E8lTqA/NwkCRP+RgUjAR5JTKmrlvy//A7RRnScxXEeTIXo5LQJVfM9MdWRZPIZcs8nZaOGsRjk9ljgKcxDz1XZrWzk1kQJti09Pk7FmPsoULoMqqUvi2AxMMylkC3ol4PmLhgg74NnINN5fpKv3LJFiSxAwfokmBcPUDbJXoPL6yFV6gMpVYd02K2QoNWq1L919j2KBbpC7evsMwpiU3VT+pRLu6LfYwthMhJ/Bycx6v4c6qxxQ82v7IlpzU/oJ2mILQg3E9NM0tzKP2YVAFJrcBhTU0cpToRtvG68AcHj+YnJQEiCEsj1GHk5d+YO4GyFPZity1gkJvwxzsRXsY+Bvf8mzSUvnBl25RMNitthjRpovwJuMVdIO9Qov2x12gTLeicmXmP9k5G2DSq+WR274GctNiAodVoRxMKAyMuNUe5JT+uPFh7DDpModDng2oN4bbo4NJushTBTnMo46B/wNldIB+4HKRwyiNwAFJMibxQsUUMlUI6wn9XcNupbnJXipr9egm/J8B+uYIRJrYK41bAQ5H5YGXD75Sf9b98JL9Pj3oVpwJ7NAKZrNZVuBBaUlzmfYfdwAy4ugGxN+CAwOtio8XeCETVBos8xswE6yifTig7RA4Yp3uM5GC0mJ+6PuGGOzmhVyA/KQ1dfknq5iyeMe6EIzPfae0H6e/DkmAGDtLjYAFVRw2aOj1noGrrTGNldY+iOzYueKync94ezO62TOx0Azybl05HNe7EpTb3mTjkraNOIab2c60Sh8Y3jARDESdBeNHF9lCmNr6fFL16MElGbIc9QGIBdXsHxgJXSKR/cBpDXnm97udAC07zraMmdgOXSc5xhDl9HdeH9/ZkF3vPxQLNwmwyPlXSaB0zD5oLb2/ePiGE1oMULC/FrwO/waAwq6vaK8u5XvIbcciPYiYrJHNKaIrMGakO1gDa3wPq8wsyEXooQzoPoyVHEMKUwiEFuGgcnoLCUsD3cktS2MoayaLA2IZj3NEKozSmGBbjLevhXCYOiEmU7pUUrcuTg+IZi6Ah7SSR85XM8wxTuO7fvR1ONq2Zoz8GzuUbkKdnk77o3gaQyf3vH7IO2483RwhWcE6kmKZaoNkXXmT2bNdV37IxW76YNpOIPycd9D6BJie47ZDlLUttzDNN7l3DAwF5d+61r48+l2voojzdvsZ/QofR3qrEWoV8Tbauc39x1z+8ondLOF0bhsCs93Gx5QdxIiqQh1oRWrbcu9AqBXqW0R6SSMhOP3DRgWbtG5tG76NW/2KGqA0+KgxEAIHeRFYbcLIzX3WOW34qkaw5+tyfuws+PlFjW6jfureS+xitIFnA4sOkpU7zjW1C7h6cukwVPmrZ1uaRyZ9s4YMcuDY/uM0Mb/GJ9X2n7yeiFtRH4frV7RPVHeRymv9Efwbxgp66cDdd+OMte0CfS60yd2BnmLCRRwmRmqiTZeTJp0VFrzuu8qXZRmEkcgLieVErtc3GhV+o3g4rbLWQE5ZBFCgfb9nvfc0aKCPSH8I1x9xr1AhEgfefs/hqURVeMHDbMRoYb66tRKmcs+RdvjepuXHWO+Zld9oxdthaOaBWeIu8GDf1jHfN7PfYfIVUIOmTvbPM0ZbAnm5ED8oS2gZH1GZ5pCBup7/xA7kPs87My5qd3wLnUy281w3p35zNBjnf0A07lfURrkEflrcQR/peputwl6MzEVmvMNu4gjyHZGAq5TXOX7JXTbw9P+4l1jF7gqZ6tZnEWXlYq4flEQKwXd/ZbvAVlWkfptYH6FfXtEjx+cJIBUY3zTN4QXkUTxqj0vwcm7+XpiAvyAUVXzu1GRxI/alrN/IoZ6qfldeoop4Z9V3aCxNooc9i7G15xVE4Gw/F3zWSdsVu8Sf7uMb4JCgbZ/t/9dadOCtKK0i2tDuV1oOfLCYDSkXUQN+rUo9qQq6XCNNhup55oIGyuk0pFHzu0SIisoqAqpG2ts8WupTTubAp3+oSmaEkxOGmqlg7e+fXz1wDf2mSdaORu1w1RBY6ul/Fhti+o749G1giu3QooESQMFCUMehbmigMfkj4QVpGk8DJiSXR2LH6C9xan9ldHCEL5rFNatzoz0xSQnorMf1p7zobYJTKpSfQJUqDv/m73EciSIQlB3h6FLfnS/438h93/83wf3/fNhC38FSyaIcF4ebd9kj+QGtWuVIlZiGQgD3174jD0We+Uu80TSSmWvpCKvyuUheE0ifH85wkMlk9+akMVKQ+78IwY9LU9G92PUN+BCl6SxgjZMtgUP3nZA/PEsc6xggsMVRNaTarLZzmNZ0Sbyq0pwF6mdgltk7I64tbI5Xx7HobeznZOpyCrzQHv2M1TQ0KplFo2veamabjyNLZ8mg/8eqhNO410vCU+iXIwEOvNm76CSq1zdw3fnXW5KeBVvYV1hwIFjjVjo+ImLXGf5zv+g8zrT2ALEjmCi54Vwm83nGHKdHf8fLfQscPmP2RTs7yBgnz/faUQ+A9qPP5NvjUUIOL6eUycUyGAdTYANXOP6P3qQ91oxE7EqCDm1aByziL3PmqwgFl9lm0JSS9sUD+4fqiBwPa3QBqzRIWndjGQWdZPm99jHlJa6koOs4JSxcMnz3EWqGdg2ko234zrznXbseVJSrOgH65OJzonygqJXKRu1guZH2ZNGrcRaTu/j5Q9M3blTFsMqT0R3kddVGyE7bBB0L5d5DmIR93F963TdsOPhN8kdXGzpwcCMBPNzD9uDPzZPKfLibNh+vg/snm4m9s8vnMUNfiGxkvyVHkIFw7g/EVwzNpAXsT2bKYjUuGkr6QufdW6oC8gLpf5dQftytNTssW78cPmm04lSr0mMjqWAFbAmgzbuv40I9JuKkhCNNQWHisdYWix3LXmkQGFC6h37pcifzGPYwaXuOIJNtZPlFksvY5jfrngZaH/uYUsPkPIm0QlpSpQY6LLMI/PqhKbwQiEy3alvQfV7jIUGkKbQEtOEctLI+z6+rl0pBMBE7vXihatPzv0M2bENvklW06kLyem6JYuxPCYvLlr+H3cx5DT3nsv/+YOMXi3L+JyWpDw5rTwm0uV+uXzzry+jiWPnnGcDkksYhVHi2HKOTxJOGzPvTLV9nTpG3ky38hqblG3Kfq0ocJgI9Ohx4oWAH1TdJklv2u+PD5j0PxPb7VYtw0ug0iu0Npzno/iM0WJJ093LoKhxPtnpdUXCSZb3nKE29JTBovuWEInm3mjlkmAV2OEpCFTfJyjQ6OdAPVo2uKJCQbRkgLP6CqWZitMCy1i9hxTVySbSMl0RjmWBOU9DHH4HbptHiYQnLl58CszBtDRVOj6pArlGBaxp/+zBHdaG0YhO5fY5ugs0dsxbkWnW3ggWW/YwTpCOPNN8YMasQtJwe/dvQOLSpRlr+yYNzAOPNJ6IVKjggN0MzEp/Kd337GzXAKx5klCX/vIOo29thHXSoSCts8GbLZHznCSbalRflf/JGaeVA8rETR5aRFCdfHDdOWVti0ShO3i78vQeMGTCoQtYwjffDUcO7el3WSL0FTRLjq+Fb30hHClcxLCr2jE4+bBAqD8Xz1sh2rtCfzBTGFHqT2VEiPqeiEWzSHrAZ+E/2WoAn9cDmrvKRUNCQ9XE/HMmfaAHex7uNFYqOtSh1UktYY3qYsa6uInu/gfWAsgPFNhXTBmYL1DBuPwk3k3KGiNgYdJlaF3xuUODGypv9zMFCpSxnQFJhCWHkraDdZmjGxfz5G+utVf99G2dLXpRXCNUjAWqm6xIjQqwR8f9h9Qjiiaxwihynhzk1EJMj4lHMjIFJrCqOUl6IFInYIaGxQ052mfCCv5vAsYx27in/y0bL+YcMDcHPnuEB8b3I8yGsYOlZ2tO9GbFT9zw/PfDPcje4FTc1JlE/+QwwlzRoo7B+dn2E9ccr+dbQCNBvMX1iUlWF5k0DYcSEHNHmMMm5wz2BWJCVvdhycmQvzVUMDAM5rHa0Zp8A2r08R4jMQdozs7jZk0BuraABpLqM1K60HLoE8+8+WVOnvATbz1RsKIOdUdoY0q1kYe8LsljX3dU+Ik9FanA3xc6XO/Ahz02qy/v5IuQxz1F4QUHNh3CP5NbjHNLjKJBYsLcrW36sCI9u7/wNW/t8GqXbnuxyYxvLT6rxxud8iNapFYEH7KhMsiWUTxPZmKGym4Z2tCSnHwvEGwvABrOms2fV9vlDcxuOG3MLMTsfSbyCj3tHCqF++W/Hq5Az8B/pL6lxoEwcA8YM1lW6gtgKMJ8RTzSP/2RSgAaufWypuqZPAc77FM3f7nGXm6VbtkYhvlSiL2gbB3+nAJ1046+R1GHwgTGeQ3p42s+8BDWr+AnPiGaO8hWQCjrdF1VBYFZVoZIHGXpPIb05FQSQF0LS84qgsoTohlkRhkRo8sdj9sHud0BN1vOHHSi28JnwaZY6AeGYQK2mbIQQa2jzVOTKtx9/vakb3UNxnprAoh5sMtO72ca+zpYfSuavL8/G+LE0OjZJjtuJVnnU65eXtoceE8XRkFa2Vovi2JHWa9OHok9XEQqSNIF0AkUXyuO4g113Ay/vlFSA0ezSmJ7CfFxo8aeS84E2Y6Mp7ue75NK9Y5hg/44lF0lznD+zEhixvqAWiu/Y63z5U/A7D+tGlerci0eQt3Pw4qasHEr6TazQhNEyAk8SjDHHxV+Ex+iM4dcTUSQweUf97yv0MyAVFnMmBYmgEVon/TqxO+YM11Xx2tOdFzxE8MFtEKNaA/zL2pPPnXdxltw8Ffwx7NTVwnBSwiD4jqzJD0k5IOGeJgMZU8JY3fVyQU7KaYVZiaNhC03ZnJsfpr8BjMyiQmaMoH0pMbXtzegvda2egb+xfdMtiukcb1SfkYsr9xMhKwD+fyOBmE9Vyh+jRQWt4EexIEh9p+X3hxiB8av4CxbBxay/1abgoEeMtJNg0jbNh+aX/i7qWuknavtmPO4wOcEGHA4P7rQpnF7EAdqD3Dlvmk8IndvGR+Hi7LmbrCR+taf8UmMls7DZ/QNBQhDKRF+eOwZMC+YDZF0dw9xZqC7aAniCd9IEY2d1TI8L42qxTNnOj+Hvx7g+YeEbh/nQ0yT+QeNBAziOwOQFA/nw78yuvHIMfth0vgQo0FM0EOL6hGZxAGwdGNGMjFNmkks1WsQNSB3JPT/XDKoCj7mq33/OMDth7ammadWgp9bXCg98o71xY0064FY0eBl6InlZxtMD1YR3zH7J8+8tYMhOsO5g3clnBFkfZ9duc6QGf7hBABwcyMaAc8KX8xtQH56u7myrUWGadOr6qczOXC5fmlf+h+TGLevy9xpiO19uwuHPfQgcMY0u6pBIkUxCIBOD0BOJqBr6tNGBFFJOJH90QuJAxzYHhiRIOyda5zJRW4eN0M6sfK37PJH+0s+3hkZNvlkMLG6qvjbvD3oWElZDHcgoTPNioW4EZNGhwA9HInZj+5+2Tm31goZ/A9lE2ETIJV713mSbRKXFXQ9pXMt9eFJc6W4+Gk7mLUL4VewpScxgWnElCM9ckMz0GbDH5a74a5gevoGvTX5Npj65BOWWQNOF1S+gfElL3CzYy4+sH/SO6fTlKcWtOCiDGkOIuaoFDbAEQFp1jBxbDlJ5mC5LxHbOBu3thvPqyTuPlpieNVOTLyxc8mjtYsD0M5BTw9XKTx2m8/+STWe2MzZhgp27tJbseZPnGXypRwfT7AQCw5B7Hss1MKljnJu/TAPvf6tKNgzohnku5Pch1iOhzj0ZG/LIRTem9Rc112BaQgOq9syMi7mfNtydbrUjKdjrDltcmjN1eqDVec3nOmrDb5PzFDyfe9GBnnhJOZgjaulvkPzfSd5fbuI4iO/S6ZctezVmHAwsLLYXu2GEYaK75493qlpFZURSOW5oBmiYC7eX31TaMkVPUOTX+HAS5cz8qMZXqmRLUzTaXU1mRaafSn8Yl9HwENDpA9rp4YdEzJIH1moi79SoqHqrTAi80nNNtC/r1ccRXNiqzF0C98TuB8or/YytcC73FrzX1g7lTTQlZNrzuXBNXQFS/ctiSf5+ky0p1bwYXo4/7HzVzv/8e2tDr7TfAJcHgnRD45/XHzi5zugvs2asYv4Kn3QdOSg5HSPTMj/rA+k3aQP/EP4rsYVFrW1CuF7qrvDfJoLQzmT1NFNZQaFYWkhvyvSLb97Wodc0esAt6+RbVpNwdGqx87T+c4e3DPnrNXK3xc3cuKA9d44CudyXU5FHjX6kEAf9hmz7E5wHzuPn2OhsW48AegGyym5+yQYV52iEp8bzJhn87ya1+36Wty2/fJJ8ulMZm59EwCDunzReRqZxuNhsJ1CALmb/UgY5Q06FY7K9XWH//WcDlAxZUKmlIMvhNDRGn3dViVVS5HIk63tp2FcEBlnI/acIMbm3iHSvKal2BlE3FsjITGUN3hLTgtD0+pVXKGQc63ZE/EvVBxxmGnQWkK/Z1mhcB2vvjuNfkGOu3kWSeiIAJ2RKXJTn7aEc318DZwwWrcnxBL/8jb8ykiTbtCLnY1BHrGnXo5mJHa0T3k4s/2wLAvHcgM0BmJcDopxHFB7C9dLVbagNS3G+sjqFYXLom/5ZjwGdQu3MFmtq1ZiPE6s5TlljC7HeQ+tLk+4LPyGXQhWuk5b6HxVM+oUfgrSa9y6eWn71zV+a3rBJGiMRrsuHF7AJMLv27vvHeKlsz/YgRcS7yKFEyOB/6kMSekuZopBUjlNaHeM7xQzQ5KcVM8OkYpVB8sH8rjhD/xCsOsuc2wzhVF7hbKiB9RxVp65EPW6qnb/KzZ2v6yg2V2VMRZFPOq5ZQecuaX9QCfJ5Ux65E8Ne48JH8vyaUbXaVN9iLiDMbwCOXqnnNhN3Eyyg+3WrDitrnywhEjVvcrn0qNG6mz8puPlFUqJt9qr4lxyLN2kGD73zhxjElNXK5ruXjS51j6HOaLkKva3df3jyu9xlWrNfhSBWpOxf+YiNIXvwOYz83UiVs8KfMQllC7Zrxm8bIV6Se+8sYlcG3avrTm+GSWidRrNT/bbCqjbAAMibsWBdG/L9qSt6pwq7s41UO3xYPnj1txHrpeLm67Qy/azEluho7dAEOMVFB+gSGic4+IA4jwgB+hl+hidr7vmCjyxPVBsIZZGp7J7vZrY9HviRQeuJGuO2c5PwVQrUmKfxCRMpeECVSqBjk5GGkAvsg/SDiVNDCpZGd8cUViobimFOChB83jWdaBntpAlVN265x6YOkTC+AyWAHXYHVXQPoXagyXHvjtQOzVYR7Q8ubYKFK5MGy3ADu1DMcaJBiRo4mFvvT5rQpOdZ6DFCfub/wbG/vnqMHCdQWW5EgipkDuBO6APVDFDTGTUYeXicj2TcEKIFa9F6VsUdMm/1NOQQGFfLT3M0UkhP2bZK9fRZAW5iLx2sOGqRC8bmhansqyDNZy4ZIOogHe/WBdwN2UOn1WmCuxRi7bvbDQaWjTY8eoy20NMnEf8yBSJ/42TcemH4yVGYlbSn+/u7WiTWKuzwlpszf3iPs9mFmnIOe6UjZ1oc8jaOAH2CDsofiVsqIVzueb5WWk3lS0QgHomaXHsk7X4QDwdo/DiDKp6/PJ4EswhOH6CTd2SY3EktODm6+/e9zqVuDF/sZwbuhpJnvqEKS7uXEY3Xy8Pu93wCxbD8DW+mOn1lr9jl8klwXm0tjbxoIb4NJBkXcoPFx648GJ9IrKoDkvkmvnbNpm4leYGyQ6P4DkwFzL2apjCzQlLeEZXXv8piV4KxQbpWnrdp8YgOnwOay6lqkIpJeUZ/rAZCa28LqdKyXVn2sEEWzzbLS2RVCoYcnt5USqN73vNPcDL+qrGpx2DJ43XkZJaZ0VlP9oVY3346pdeYt0REXJJdV07xLFx40nC2CTrFmP/stD2DxtDrvz5dyKsJ8Na0nYm6Iy0kVWBxmBT104XSzZ51DvmZ787b6vPqaVOrjjzq1CKVb/VcG4ETPf/MT/a+MFMenpLk6hPWl8cqyY06yXMbedJecQdyJ5KbGyPMwquTiIcsRnSmXQwPLccN4jB5K3bxek5Z/PO76K4kn4jU3vHm5CRonOaknjfU5QR63eykM8SdKQbMl4MAKOLduZ79UrFau5JzaIasRAuwlbgkBQXGNL6R3L5TgriJy9uBtc2+/a+cLo2XK6/6DgNKj3btBpnXOFdc2n2qRrlyZB8ffsYhuXqHr5w33sgxrEJv8v78bnNBS9+ui3YXTebyjSxC3l8AkYdzAimKfO1fXgNn4VfrFaWPkqoYZHhapnDQkWuvJAQ5CJ/JgDU6Cv84uflpwN2+58pP1VbC1Ty+ytbK1t3BJb4Ib6nvW75nJd/0L8keqEfPKyLK8wsQ9SiFaiBWMUxmfSikGzaqbjk5j26dEkWJJU49kGzxTZcdYyh7/nXoF4zAIltWRxr3R1diIi3QoeljN67wKcZDZ9ACUeDJxA6Y8OPyWttbR0iWOBHRjjQ0hSZsS8hMp2E2HtNEt8P73VW4KTk08jlfKKBLMvxTci9jW8NmQGIi4ElMuenM4ddPOJL99Lrles6bUE9EstUJGJQf+gYxFvCHSPG9ZJKN0cNrWr+Bb/mV5D1ED5mtAH5839gxTZNslXnjzvDnd0UuqpjwuG70QY1zNe4UJArDYXdSmg9IbUW7UntkpAUg4ZJimlAvhNrpa54iVVcCz/2i+CuukvtXjne8OiafNLuCysdcVFMUDoJwRNKYvWtG/+0JwARG+3j8l6612rfzvP/C8X71CxKf/v5I0tBM/PxzW3F1DmanTweedAXNE/ihbfMSLelPCV9JTGOeH133P6p3F8uMTTc2mjZOiv9eIU8cPyZy+CUhxTE7RxGZqtlxjHMgdmFhHprF8XS26H0rZZUzp97BtPdRmxnB5FtGCXuPBv1PzglDOvMdEsOhhYiztEP+nHrD5s2uSI718C3RxwNnp8fACg2/pd8swRMYqyPIQECY2QY2WBwM0mnaSYc+o3vKtNwhkDO2bYYbFbC+EIEgzWKl2E93pQPyGWBhddKxn7jlSCI+KIcvE/nJINmVMqRkQID9pKzvOHgCI4t8ZnpRM9Endo1if1KZlAfVNFdEtCib7291z9gNyMOFBAiGDO2mpZqTEAfmI7Y6q3vNC9u6WsDN8B0w4wWDQwHyJQShHDGVOXFCbvBKbSV6FaLCj6tcPIZEtJKxztiB0OrC42CrSFdTb8n2FlFRD9mhGQSNNsIyUPAQqyFXTMzKlM2FvSLZng2NDCgIBrZW9yp55eYGtFgOzhriiCYTOXRKdqAGxw+ZF3tlsK9d377bHkXsDGkBQk5YafEVkQ9k5moAW9AfsLwIqnhBpo5/Tcz/31LihulvDVaC85uVCVH6lWswU/2U/mlQC6nSAsJiXVnys/1yOQKFNnWCKhy4UpwDZ1/TX+rj+P9+Mhy4+NgOLUx9YwzYKfDRfswo5fT80IDaY5l+9t/MnGC1dLcDnZZK6Vsp+Qx0GYzpob7RLjfJ4FLTySKbkEQTOOeQ+YKv4TF2iepUzHLsEaJRHD5QR7O+1OKaVqCx4GUqx9xIrgg9n70nxOFV4Ds9nMV9CbDLkcA3FlcfdTwkgRVR3lEbRT4I+qLdHm70ncuiDzTaTNO1y7ssQfUhzF2OXRLnje8Hlt4qSXIVhErzeiWdhF1o/KGCo6fUvZ7fy8qyEU0D5yoFnvC2iRgGJepKpK71cA8XwTKhTM53gunh96TmdeVApVgbD7S6VIQf1LmzN4XJf7Xo+FzBMlXZSuEnGZZ0Y7lnUNfk+kqDbuhmvF3hFp/u/gsuZXs9PnJeYtfYlmmpLoDg0NB8XmqSSy8XXjxIKUZFS19gTOPxgb86+V24/gI9dHFi6KILqYRBqyh/KIT1LeD2lHGAhajKh3wxbh3JKnf1aoGt07pL/ooFhVNWhpYwchyvOEFukiywAQ7CgfKAeaXfwD+jmMUafKj5GkWHSeWkFPoUqAC0WFFgOQYj1R522/jWzhowCsIwUAWdNbwH6wzf+2UQG9UNLjHnogtDLsE0qOE9/ijlAfLF4ueHhQcLKLe0eSMNC5TCiNZ4CQeUTfJFbArmoXOh1yBYy88aEGQfj54H0+53+Vy61UXU206rY7mfYjhVcGV/yBrg5LKG06rg8qsz0ZzVXPHBxE0LRYT5LK6qkxZVX4yjIl772pqN0YJBqT7BXDOKTGLRz0ezMuvXYYkxuNIwEhyBNTb7Bk0WaRBhYEsy426MpfCUUUHeGOm61FJVLTs7We8hNaypB9hQzwm3K53ocvTe1hpptftVIC0NOFEqUa0U+lschmkie6eTuP9JAYaGOXjiG/UpI1Y+cGOBkyEXAvwKcDYjU8Tp3xpg39TriXy6mr9FfzYJxAuA0dlrWtF16wYSqCLSpuHspx1qpeEDDluVhqm25OFYvMdmeX1SrwBRMF1m3KaBFqCBP1GRxDqawKuOFD+J9rHOLpHYvWsqeJgm+C+0/BaSVjuwZt08TTd/SKwfRWBvDYhPUGLmNNkThGU8bhE2T+jedGN1tyTgLntCeQFeZjOLWVPtQspnByHHq0Xp6wRWSCNdR2HyQFkRgS6NF7ch8tlaMs3wm43eYVaANiBX4JkX+54qirMtPFT5Gz6PaFGUncIcv8dHxxc4l4/Z/NwZuqVMpVWpqs3Juwss05zb3SLmcxhlhvUxcENFlCi8kDjiQQyOClVD0PIol90Hnf0p1bCpcinD1sKoqMxXrF7yzYEZyWn6ewysFAfpCTY9l8OSL/c1u0usRAhyx5iSs5pjqzQ5Oqm53Rg8SGLaPkZTKIFKrvv+ns+PSVCeVdJb/vW9NSWzNRWoYtU2zIW5imJgBXEOvF0pv2Rl2unZKeh63y7DwA2JR0u3JCwdKymoMgJ1DNwpbcqnbA/aqE6VpEWY/pFb+tc0E/Qq+F0/Wvqm4NsnSAz6O0OmwdUwQqSY/QAZ6/EYK2lCwbfcWrAUFYTjgIj338WK19rBBJG8Se/6WCDm+jGb0is+9NggB+BgNL9aAtO9ObZh41Z/BbJpSKBfybk2MBPL1+trE9jN8oe7XPxSUzc9QWlSdhBtzypuEnATdlbXxPw/vKbSWo9Fdk2gTK8F9fig/l1tLAOfyOlHWlfhUioLcdM5rvcx351W0wV5EOqHiMQu3snj/C55XgU5BzODqMDoFAtKdEi5AfRjz+c7qEHcETiMalQSBkgZcRJkK5IwyWnx6moUIFmce1R6QKFE3UfYU4ROKtFkIRu0s+7Z6QLsLK0hwR/KDTM4D4qBuHQU2yGrqepQKEbfZekKUHTYtpalLbVQeZTiVrsycQ819kLLwzm7LQrQfjniXcLMSCfC5FviTfustKNCLIEOY9gKxt3qnoURm3rrhKM4APhqpcKer8Nli2+oMAaidA1s904veNFNgNpaG+bdmVSKLNZ59RXa2tHj+VAk3skc/s324vZYttm27+Ag2RtCcaznKRC2yukJebOCQ7Drlxsl4MhVirlxmk2IHknSNIKKA+Z7LLazqGkQAtnq8PLzBL5BOh0wyG68waKmLkR2QeyOI0Y+b/2ootwgS6FsVquu5l+bfeVxWUPlZbUQeVm/R3spNQzmcksmEgtyeSGvG7FilIw761Cyoh7on3s5A8ZtcKwevc3Ius0r7aEtOJIQrGpeAYKlNpx1AG6QuVlW+KY52Ut0D79AzoVfqtIWO+3czi7S51fPgn4bepPbIUzef4ZxhXbVQL1Dr9+Rur8lHnjfCSKx7TYtDRlPtn5izQ35cywPHTLu8+PHGcJUNxlUxBA4XTNjMYxH2+iG5UlSnTjzbtjJmdVWt3Ry9AIvqSkayrKG3M7QiKgNJN4zLqGTHckHHZHMwFWpXBRU+bAUKjR77vEWZGx+pJK3YzCYsuMqoqxOre1i5ySOBF9qsbmq+/4fH6MPcqcnSkHBSQw5ikuxoaEbfmu6XX1rmnt+YsietG2EWe2laq6I+56mjmtMi21nh51rxsDWa+m0EZo0bxGjCoHmsPNi3+LKriVGS+ISHyMv56PNWPLQF+dMqFxySbR6PdAy9dUEawF8BJuLvItsuA5PJTnrgXuTt10RWG4X19QqZlRWJw+o6ZiQOe2jqAYEZPh/T+q5wnqu1fNX9m2sVLlQe8ok6PLf1i1CF0uN+23aUkC+c/OmO0VJzcO7iXbGBtPtl6SsQQMli4B23jz6/hkruTG+K9v0rQqAe9Jl9cIX6XKa7yhYoUaodVyhp83CERFBgc3gZX7Lj5Wh3Kn7cuKHps0/+DrbG9k1GZs+VogK5NOSjgcoofx9rcBM7YaJP3jh1fxzfUbK0dXLq4386Vkfs5Q3rqnnPDL3M89HTl6coyiy+nwbMobn6OjTIb95AMumWOD8Bp59pjKjbYjKUL3CpE7C1EwOTm9bUvu6Nxlbelk0HfX1acqK0mdUlJunVNZ1aNLn3csJdVadypD/JQIuzc/P7Y2hcN8JaICkOeTGk4PPMZgT8ZMaKqp4QmOyamUh6O2cChkC0aByz2tRzgo6XGW5tkvhvE/tpCy8uvfTFGPUtfKDne5rdpsRqPdKltn3YWaEA4iACYwSjyv5fSF5rcxU+qrfYFKN0nIgIti7+jcTS51TJOjzvHllUmyY65wOOzyxADjDF/c9/EZogd+rsqUZhnUUq/pdn+fGZC6WE6VnBk9WylwjyrWxk+Dyz6N+J7j85pNrA9Cne6nqHQCx6WVcTzHChhguGNL7/OJf8lZAWQ1fuhoI+FHwsOHR/GJ1WuKiHr+fWDczTU6JgkQu7TCb6/mpFkaGTGrutIjos9fKoGJFkB7cQqpk/g7zasDuWuR/b1kXP70Hqu0On05PZNbxq/lVbGLdsV2M4u41bxadjkjc9Zqkb3khwMSqH5JP+Cqg64nOVaQoEVZ15PqPuu2cyr/m4kMro6Hr48PDSZ2PH1B37SbKKGUl4DhBLsolDEi8uuGr+X9O0YdVt4/dQK+8RqHozt7THjEYqnvRpcZ/f4/evWc8vlKuVvp/pKyRqEtEPnay+cAG9jTfdRc+K36nI6n29ktW9/sbz4HL9l5kunqAncPN71kTffd0YAbu2TcNmJKS2UAWYcfOoon5K5dMuUA2dNk88eXgsL2OpZN3wVqh78U3dklUQg33Ps6cnuy3jrCM8U343btpIEn0KJ5NRhVODHMzYx/iyq9GUYKPDQ74+mp4WZs2cxF/4QXCQKLqCCUfroYHbXPqqbsBNOLg+LVhesKrS3osozZQA/b4y4NS9f330Ku9eIbiKJHU35CEqpF74W5Kor/kcJPaBZJnix1kMFa/2RFc2HGYFG5Z2Zb6SyVfz+0aF49RhWChrDZtZ43yILnkXiBR2JnPL011owrm5fKSWeiMWYx1JElTa3g+AKSkfl58hFefylbB9p6ic9pDOU4P1ZUmZmVdZ6UnNGa08VRYmATVknucVyRECquZoZ2sSGQ+kHDPlFesyL5hXirSAxfsr5ceKwMFJ6Ft7GR3/JKmiYO2jnDnJn1ar9jGO2USUl0g1BNN3wp4HLYdnsZEwt2D6+zVwdxRerjzWDcvvfeEydZbigUONzCmoyAsjUUrBDqlZeHEwmsI0zaeHtyzmkXjjNsMiWiG17aGDFGObOwQM0lOofOUlE9IErd7WBp7lgTfDNHx2XC/gqZHPIY1+YU1rjCmrZwoEywai7DoTbbYk0NqeTcqWUc2ff7wbrLdK7HS1JqCrgup6TW7RQMy4gUylNaa8eNy0s006KXHCQxv6zrxIwreqaMTGTkITwuII6ClnI9qmLdgpzWzGQSOwP5RGHkxHIDdJnVqRJQt5CIk5uzj+J4WGvhhAR3Nxv8b1E2pL6/jiNsoFM7hyZQ3QGbVaXwZ+o7GV57IX7cJhKZn7C3G3ZshfceUbzzX9hiQ8ik5Pt2RekKgQuzerWmscaZsMvQzVfyfbtjDKVTa3aEXXanWm1zh5xOx2G/2CnzpubiZu8jiZv4ZHecB9I5tFAJIOWk5MzWnKF18AL9BeUPWtGfjX/p4QXr5ua0ZiSTNquIbhCq7oatXA01lhrsOc5A1nUwo5Gdx2Lmszn5TFZeQyNAA4eUFB+IkHfDKEnxiLvm1CCskSPD5LAVOe+2gnAEbkF7CrVY5wgKdcr5PNIAjaURogpQ/FVm4HDJtU1JdmCHxHJxrJ0w5828gpEfWiAVdYNf7kt3cuefoShAnRIoWgYbFH4gipGZHudOFT+3QRhqyDMQdCVB8mGD+NttHNe5ebB5/NvtrGx7IOs6+J67teJvGmBI+L1bv5nrIMfQII5NRFCh1l4pS3tfgX0cPaQYNqj/ZS4n2xnMujZym/Zpw2DboSngjjK1Suz3S+vsLlmTL1AqMcxDH8cpa/YFSdLf20PDOkbkdGcMjNb2APCTjhy4MAhDnpUx2+vjcqBtF79o5ykjnFQHp9plZrc4cuv0Plty9v+urdm+3uEn5+Hk/y9oBvgw9E3QiGyQDqrHq22PBCoEatKS2HczEb1vrKgEGQ+AlfB391Yz2aFcUsSQSs5pKGHL/lgAfm6G14/GXWehnjpRw+CT5UR6zdzTTCsMiOJ182L6/4gQuR48upXiwlhgjYjHv6gEMQHui437k5JmL+zgcmOPwiyTKheHh/ehrqbMPsZkeS4hndu//gX7mMntfN6Sf5xkUJvLYIS2zNMuWBLwo7Zs6W6Zn+Ce4lQ8ERhAqI+PjK0ehx2pX2JQOaS//MNHxnaOx07hKLKHRUcDLWjbmhkTRMpT5ckO6Q2wkczBBn4p+AmW/7x6Uz4/0tUqtFhHLh5QLZ/MZnv4S0E6WZkQ/MZ2G9bXou1vgVkv5ow2i1StD3iFf3R26cY3wQaadL1jX7EijxaCilHP1Fdq3k6oaL9aPL540pnaz+dvvsaSXmgtVn47qun1jrnzr6gN99T/6K5WzXvI61qsj9grgMYs9rmkZcnMqn1T897ACv65Fe8Id77g+409VuPMhqk+HptK/oKU+NeJ9UiyMUx2Ai4v5ZEqdT3RllAytFz7XZ++gpSZWAbOHTk5absrqh2NC4IypivZRRMpIgfiR6NWj5UKqCmOmokNocR9zy8IXJTSYaSshqZKFnLMaZyWys+7nc3SavzUf7rBU3WZ+Rc1+0S0ayaV+JzK/JHjwopMMYkUuigs1zVVtMHaHEY4JbR9r1jAdE2ZgZ/+GuYiKZ2N9iOw9GJnBq92MIuVUZ5bmhy+wpq+/eXtywL1PLdgZ514lZig2MvijSpIqsSCWHrO1n1PRDsC5NZj868VLgj88ue/j08kGI+LwZ46HrJutiwjPKyj5uS3RYk1z792M11GqBUo8YfFPJTmMrHHL6qzu8RNrkCxRO+rT7sO/b7Mam+tHDcuk3+Jt3aZd69IzcYZ+OlYoYektFZbr0OuV1p9723uYR0jwt0Zdldr+4hQtzPFEYrP+hEO7fUawMr7xQYtvHDd3Jz2DAxRvH6nJaFk3VcIlLcZ1mqWY7oXkraxOC3jwOPWRAcW2+o5R7Hkarvptp4YioKErpsllv4OseUxSzgS3kYWt3pq3CSVmrK5oqhuWQA0fuXt//G7WHLkbCB74twpEEm+tZVAKvrC7dU4xKIDbm8yULlrb1CHyqRTi8tVs6OVdVqTrUETLJPxYFZ8a7Wpu0WTxFF8f0EBoVccHBKJJoqiBPQjYWgIRDcdKl3SB5OG0L1yQRukTJWvQQRjdSkFYIzB6RpT09FR9XQp5+30s62MwcNv3K5RfcUjjR3paXaPm3WgABpf/v2c2QG6KiXKIlICwPVRxm9pGtcn3pXb6/j6W8Y0t3p667ySkJsiq6zOyWRrEDvGQHNhJcUej6oyaqtjppqKiNz4Gs7srw6TC4vzgfql8O4hVGQyUEuoWLRmX0IFUMPtYUn53/HAmTuhUDBHMOZpizKbkJ2q57bthtZOIDSx+1zJHcpsuyonxSYp9zrKeSmcp302KqqBd/HnT6Clqk4/awmt/fcoN0XsJ3fxstJMoiJnRjHfYCjje3zSZn++f35Hz/R8FwV1g4+OMB1yieC/+/eFcgXpMlP071IlyAYSplU7sxZ7xj9vyahDBui9X/4VWLisMe9IF2BtUghCjtQSrllbRPaqZR41s3lwGn3263ChSCX2/q+VKDRZhM0sBSO7SXvHefPYQE8OY8vxgo/movskijeU7mb/8QEhXsDt2fTsjqiWn8Rg/egNCPe706MggFanm7WY1nkmyjOIA7TJ/CyzSVTotBbzDIYyrsctbfQX+Rfr/VkGiZBHfBCmaHkDB0fgo0P3JRLBv/fOA5R9Y0YjQH86mnMUWE0OGQ8BaZMyYxngwQ1lFzu6xLNyI+IZjp7sqqG9nmD2ncn5lKmy1tSCv54Dnt1fqQWyVurU/MnZdzzB9auzqzJ6xDMiueJZGV3ZxasB8XXoX8LZCNkQwvgasPkY5yFkcxDCvyYDV/tPUzs+I1Pqp7Zx8XnRfAi3Osz8GGCT35H+T04nDLK6WNzk15R/KGzv+zCtmgvNDmXhuVXTmygqjXclGFFcqfaqKE19VVx8Vigb+pCP9t7LpvxDeQ1Y2PwE/v+pd2R24GOYiUPyo3lWbuutp5A/6+j9CQaS/uD4CZMgfjB/ex83AnRG6rPAo4PYBpt33Kuze/XwJYGzq/lUvp4uefEjBR7ALncFuiblhrk957GVSl//p/ub9Kol4HM7/ZpY0lCBirvsqa1kp1xJdQ9IGQt9uMmpn6Ht/122jV4oZEWCIbZPKOSFg/Onfh4Tdemk0lPJ/VGefuMNkWV7C9vfSgpbUMJYhznStqL8tUL+hhkQPJhZPqAhLsiYvRgDs7a/lmEW35v31baBtq6P1G5ooCURQnMtq7p0BVBJk+htUH9DAoTqWFp+6TEYdTZSdx2eNANUAsZm8rck6C7DgdWBlv+bz3TNC+DN85xfLwUR81xz6BfKIh9OzuzfpFRvkLTTP8/xx7nQLmYl9Vb0v9NnYENsN/rbaDtyQfFUTvM3RETuHhrtQDX14LfzQe+nsZskaAHYe4Tu+yoYbEQ2ke+j0b3CAQFXOJbuPwR4ztdUquBtxQN4RM4OCs3DGwt8E/gzOeyZfP5MNmcmQFpgal4ifKKeJBLDf2Hd68c+7yEd3gpJVdoQbzk7LedFsOxTqrkObA5ORTaG6VEHPRpGNk7NvieYyWLNEAhmsFgzwfhMaja1bIVQnJb5s99CJ6q2/06ALHdd6/OWHSxDhkHwU1tkBYV6mE7dn+DFEH7hj/YZ+/k8crpMaIBYOzkAVCcQc3th/C4GMDbDDqf/1wFev/B0eEBBSJ4jcPmlrcGgoDcrb4K6vHKTbWxvcOeIQs2c0vpJ5lyg1J5UycyVjZ6xrUTRyByJ8dastY/syFhe0Z19bN7MU+qjjpyu+jpTO66gZJTWL0dhMQI77Daz+glT7/LFXOr+rIrhZgf9Q3I6wh//M9ZBxLkVZffe0MWPVFFauYK5gDgKQ13FnpQHKGaO/cEpU5s8pYJpVL9QwnT8deaPekaYI6I6//Awlco9ua9ZjDVn25P/3zv6HkYoLir4muKYPHPPMJvbtDzGZXozQuPkKVME4gNtW7mhMf0C1VX9aqNX71E70xlncncCLRTiyaErfGSNXUB6nfz6qbhvZjbHaAj9VKPlTfvlRGK8h0A0IX6aKBenCUgP7736Szy1P4tjMIZPXLlN521N9NBkxlWhdb6hi5yla+nkx3EC09ADmpb5TPIbwO1upy4OCHPeuv3/lUPPI6cIW3FPO8Tyoy7yEjb4t3l+ltYszvWYyxmpVjnmNVNx2C6gBsCDLsOO/4vJ/AtvZ8xIgU31gefBZfvl+577HSmwvbzguXDZdvm85zzcgD8V2Z7ZAGOIKaTTBEymgEYXYqLP7M/enDGNAdL259bng8+lngO5mOnmDdfUHfVeuIGAzC3bzXyKoBVj3S7CdXJjmQBzWuSzmXhrGrIZguGvxAVeawqns6eazQ9B9KeDgYSeTln8Jyi44J++KTzhTysle6av8Ztp3cEnlf/S2UVLfGAn0317tO0IoMqu0q7K7mrLsFVVNVe4dWOzq1osFiYnDqbC5nyECSj87KlLSZRlFElMZXVV6KylzEnH6fWrGkVeRgQT5VsadHSpp0DgoAWToqK0MaBbSIluXLKuOUWmnLLfzNqUoE5o3LTe3+vO1J3gDuEkR7eZTvUf3vewFkEJBDPTnzQxuxLwu03X7AJGcP+2zBJh6lrHkHBttxMQt9KPzswnELq3vmawiQU+Hs+XT2QzXm+rwzx1s46y2ubYAtVWgchh/PPNX2LB1g0KwdM/Hz8VcpcrVcvBAaOCle/30cXX3oCiklzIuWjGMQni49xXsgoCXrok3RU4le67HuCwW5WroGCvU0YK/BMR5SIyVBFVBqLGRwv8yaLfodLW1Ee2iPkLXJIHc+SCVZcUeJOuETXH6cSxD6ajWyTavPbgtLXv1q/zSggMV36RcdyR+JNtCWd5E8O3b7wDE/b1B9ctyUYSOL40C+2HiNTkYpdaMoS11kCm4iuUiOPWGOKHdpUTWjVOPBM0iux5yE1IQz53VnBJfkodD7Xkf9cWsC7NPDTau++YSBF6Y2LrZd8xvhPvQnrFokRi1U4szOWUUagJSycurze5MRZSHhzyg1D466UktxReqcLRhx59hHmPPeLLoeDbM1rG0T+qIht9KWhU1aKV+9BVaDsdxOusYNVrJh1nigEaspTdfOGUSZf19HNN8czLVaXfwQv2iJNHjYw/0DfsVOFefj5ItFPMDCCCJB2RMS2FFXbmhbJ4FBI9YnEmw64v4vqd+qojeMcfoSFsciIKg0EnYbnHokezcIlOc03QXcBTsa8FPvwN70G920M9xHbn1SYNT8nOF+aw1KmJdAwmIZENLimO7vtn8Ci6IU7GGQfYdHGQFadaNTJ8MCzDEN7OuFmud8rxxSEZ2P6Xo8px7lH1MGGHuAjsDDiZ/yY6p121G7n42Uaai730ql/34O9vPQX9PdMNZNMZ3QXgNDaEdzRjPF6jRuMzYjx9eAdQOIi7uOxkK1mGRzy/icFdnn6y1DKnOgHepxFYO3nUIG08icUyyFFTHtKYYGkF/RGF8oTOeEKhPNrEACaDbhZ4b8bOYzDy2ex8BiMPxOyjQL9KJxDSv4JSqA5YgXWum0uht5FIbXR6O4nUDgTJqA647LVA6ROaiEWTBqBPuJzVZNxaCvKSQ1gLqF1ucFibCMkFezsXwvHWc3KS9/9XSgqUJjHL1Lq66WnZ2VEQBDy8GE92VN2tHVVQ2mv0+1nAAt6o26PtNe2i11RNLb/WtBwOC7DcJK06zMhjRbR6QXhdmC4VOhJD8RHEqvGytPS8WG5GCeA40fFyDmXzdboc/iFujk7HzT2U40A2FS93pVZODxA9LIXCy4JNPnIFMmBelodFtN+7aKw3Fox5sWOwnmiFys2nj1j86/23ftKowC+W3yk9JQxKHoOSQwHHj+geX8HqlMNUfEDqwg3hJuIvxXWZm2gUIX8YBDbDetdaNpxdSS/0FVY8hBY+LHuZ1G1ck+93o1bC6iAAKSTZ/uJEKHz+YrtEvP33NaHwn9+300WmBxrNK5PxlUbzACyamNvqwzYVCZzsW1zXr2LaLRJxgxS/g8jcEaWt6Csbbopiyssbwvp8Fnkxgejy2L5JIH+MFIr/HUlx7LsoXaJ2YZcbiYzXTDozGMgSqBzpResmIrvhFi/IkGAsm5YWv52dA86PrQtuVf6i1M1AuyQX2GADgddSk5LKle+0Fo5NcHeywYfrj6qrxiWzNhEwDXsnLHxLC9tPMGNJDRW5HwaC999mjNqGgZspuNWrH8nDAsce8afg6KsfYmCerNdMBm7Kpl4XmsgVlSep5u6+x/j2TEnKIrWaSwgOBd+j00ldLlkBXjVS834Y7b/0SoHfZfKDEjN2aOjSffux41w+ljZ0WT7d8ZBBx/H3jvGC3bK+XPcsefYONNt5Ztn94eaf+8dckF0w350x89lI8x/rnFetxMDEgCfKcfFO7ioA4sS/rK+0U6m8YqsjR6CDDu1cDeG03B/PJznPvyM5Wrq6pMHRVz9qu9Uoueh3aXRR3d2b/JgvvuQq6nd/YtX8QpKl/L5fSpsDTOqHkhIpgSluJOFULeubvaic5SZK4h+Cv3Yhc/c8hf+RBBIWuXAjsRLUq7+VeElngk5b5NwMyB6chQAsukPVWHMuESpV+lHjsosBv4O8BmiljBd40D/AyvDJfANsF7T42xu6vPaR0p6ZMG4XB5J04BJnczxz+8vNJxV3433Arrk5DC1a04hRDexKvKY6RICamf5EjcEGotN/egKEBzucmqbc8AilC07uc66O9Zu98C5Zjl9Zk+F6FXZi4ulLsLeYfbARh7euw29h5CI87IUJ8QndifEJBfF17WpFYnxiCbKmdeTQCen9MAXNOeU5RUGkWplY++OWg4m1SnUUGSsua1eiGnvXnaRsVHZZZIVBax1/Dw1T+f2+p4hK2tU6bjBdUmjtUiY0nlzXi2pUAnPcxdydi8+SXfwj9aRWFu0qshv/1TIZFepvntnyEfhhOEz3+rxko0q0VIzJ2II6RaPnk+mLqOzfU5zSyDhi1lZ8zqiu+v2LNxeUViChQ19Qt/a33Pwbdhjpe7za5OWPmQXSzozs/ZEAOUxF7ZqH8Vd0gTciJBLfLKGzYKrzoi328yTykNS6RHUQKBQcfYhFClIfUkimz1E6Mch9HBX6vdJau1PU4PaViEys5BcIosqxjRyspUb8l4Lnypz0Y8sKRCvOvZpooadWmK+P82YZKljDrCiPbJgvXCpNf+V1N3Z05XRk2ENN7SMi7aCIrkfj4PQ+P8jYY7boB5shC9QGY11oyUzusqiXJXu1Tuz8uQ1ZksUE2a4sLdOfmndvvro7XSDAYid4vZAfXEFKhnLRPNRcTwm9V/S1h535EFcsbtxBOyboSDOWMfRI3nusmpu2HOY3YWa7btGOT96a0zHhDtWKDlNQdqttYB4DJTuy6qh0QN5424+x6jH9fgVdnNwP0a4xhVas96eAuuwryEzOOU8gd1gA0y81wZ1a8BvYrlvS4ZgRZwJCqILF0BBR9Iu9njZz1e9CRS1rlxc2HB7x0zBj1aqpQ0xXSsWBxrMb58xvuJ7N0qyf8n78x40YIpo4gnT9HVv9PA7kzOaEcmPWlKjSEKRWGgKi4RmBfKFG2L3peekZgy5Wq+6Lxdre1DODAqactD3GkY8+wDiRjst+M5kioNI8LNFoZkxiNrUwwucXq4VXcDaHrVOHKKHDovRA/mewHA/LwA6o0iSlnowyntF9OLzoHPesfdL/0r7Yt9mSEbKnKHyGtLTMAJC+L0bnrVu4IT6TizVRB4Tj5aM0PeVEpDGPfA3BUO17nkwL0/JppStgRslwe65m2Ewc5RKdDuNiBr9bKGdFbcs5URwOCxy3re81DGkG9dexQdlsXnaKSVzp8ZfKUuxVCrdPUKLVsoosnmxpCvREz/HDHIl4bRQr1/hxHycT0s2aAdY1C8UebKhQE6P+Sh6HYcAHVKrjXwnQyOCE+9xK/t89UaJa4kUX/MSgHqXpg4Q+uXGYiuqhbiXDq8ZnOzKyqsd3IMm/1E9iUmsbFUxTtfQSty8z10dSKDMxx81yZtWiRTwYkI3g7qcTbkMv//tr3YQBcdgyLXdEeYnN46xFFtGH1Wy+Y9GZ3a0Z69WoQo/+8xJnBnkk5NX2MICx+opGcTEDGhHIAnR2iWMHvjveJFrsqinVpBDt+0lYos73pc+HLEmALLHOd28LWdaC7MS4jdY14Fcn6xQJ0z2JtL2Nk9Ke8YkN44iN8/LB0tadK+msNNL2IQ57y775d9VHn3yoLkMdpthjMxIxMGHJlV9FIz/MePyuFQRP/RFyotrusr3EsWNY1c4HksME1Pc1JKmPyf3ur5zZS9FjZlISuhaQvlzOoWlmxTeWZcHA7Xjf8WWEFduIlMtMOoGbPPH6QcWsAqUHSeRfmuHFv4FgTMb3rokxlFof4VIhKd2srUgLaK1Ouy8QNqFW76x2uKs6dw0heQs2LZPQ/z6UVxAJE88W8xT24NdH2j+xAgeW/v5+0j25mOp75+Edh9XPLROBL5kaZMxRhU/YmOEq4OrTy0R2D7cqzcxqzsip0/vp5+dkatfzMn0dPV2hFrsto7ITZN+6SYMlcV3SJm+gRGxwNJoir/d7SgU6SVLuUtp4BqyCHLX4F0/jtnBzl4WUXVsEOL1YlQzFUAIjbUu2LNXsyShlJ8L8adcx1VsS3KtB5aWnKUGLqp0RQBZIDCTFqiiFdpfB19Un13tSSG2Gstw029nbG5VkHwiTdidgIbxEkJzQmNWTB/dISa4dDrrSlCMzh1j1ViO32hsdrotAktjojoQhJ3kgzXK/T1RpUeJzBAH6k3qn0TCIS3W5+IGkkLLdPEEl+tsEvmelV/7M4EKwBnmGk5GvnVxicjYLmO1H993nQmauHpc8fnFALXMkh4WGuUmdYW2f+8PL7MU22tJpjem5VRZfAgEEyFcT+H5cptxAq9ZG/GoV5YvCn4/AjvwsNp2i9ys1AXKlQYnL4wUVkHrqSbozIaLu0DZJ6S/+dRA2D8N8RXD8+4JOgHckRs01GZN3tX0vYRys4FyaR3HEfCS+pLjA/90Ecsnjj+tNJ9af+GECPINOMBGp2x4/fglev7BOtdZEewHXz82Jvs8qabimvxkJoQMTZPnRzjFklE56u3Wz9XgOvXlbL4t2VWyRVFbMj1n8d5UNbjODlsjeD3cZAbws0dPhSRrRwWYB9jK2x7KY7Ozg+8uGUjxyIFW1P7ODVs/2PfVwlr1ZBcjYsv47+M2lDvPpAxfrWO+Bgvm30/vvnbMY71n3Tn31O0jxOZVR1bH+YzjiYLZ1JyiO3HPBflN4cfrre2i/TOCwLsIusi9CL7LduXIHzDT/PW9gJ9s6tbQ0Y2Zd2WiNVVvFPo94YSu4wZ7PsU8rKs6YUVsxWmfTVrPO0fQ21PqAZDi56oksRpXqqsXRmKYbP01fLYmM/rGA9Bw+NR/kXHEt0aYD2wz53ejU9KG9QP1Xto9J97HZPjrTd2Vz8GUwVoSpczKF5WxfIxAvA0yiUIxJF8vTL7saIXjPnluf10V5Q2sdn4R+8i3FtB1pjbtvOwFAee2EcG0F77XcRrjmRoPtCd5JuqaKjBnFxY7pjRUTdR73JH1zJfgVFmaQEZUTDR5T2nBpXpa+Jxo19uRnospiaZUOMgMBA8g6/95Reuq66/op66kbrhun8lI1Jq/eVHe2dM3mNV8snRFfeOPBs7QlriX89CnpoKjO9mskNi0aO2SxbIuOAgx1jcBhQ576c2auTEuL5BeaNeW+Wn0/xTgyAmDgxObG3fxoHP0PCuUNnf4Yxn50y9hzg6n3rFu2yhodTlj1eFZzz4ieZtYeZlPP7HCm2ZyaaQnLjq4SyMlSGUkOXHxfBSU9e8BQUKWcXlConZ5d2aJPz6hT+PNFY7PZp8+/7LRks+KPn58Cf61Nr7AzHdPKNy3OkYHJwYCEgSNcu/sAFAcYOEnA/AApwdJB3qWzfzk7VGD05g7nXxCGFy8CY4MCgqAIANWB2IT5XlNQq45q5MtLQJ3BcGHcpLGPvmQ82jp2/MSLlIiZGLvzu3D/YkWMrUhAmOnXmhF/LvyJpdn6fu3I3wScP1gjHwUHv1+tv5HwbFhVMAOM+TwgQb0lHDt6//+X8PixB6kBCZjyecB8nwlCyse/M6okgdQHXzJAwWjyeB9EeUYjEh8mjkaTy/vIMRiEeR8NQwUnX9JdcjnD9fIkn3/zPmMQxf2bvL9ZjUxmI2s0N4DbH6ut1Z2mzsw6Fx/B8Ms9nsqG46Zsp11g5D2k0y/xjAK7w5T9XYOn0iNn+BFufl1mp2n2fk79tH6RaPRn9WzCPhtN1b+0Hkh9mWKfsta0NndhMBnEydTo4KnV7xyj4WSWBoSLcteajvPVogAfTFrsLR2mjvaFQVGpdjiaZTpHaTiZw4Kihe0dptk3Ul9d6S26K2vvt6LL2TwmI/lP9rF1D0O15daVUzB/TmPQFo4ZY7mO3ApjxdfrAzy58MqN5VIV1zsbyWPUp4XSEkUfh3McEib1dimRqWtoVcCBfjQWNE3+dta31hgw2RTkjPgBd5vFGtSxnHkpHE6Kx8nSwxSX3p71wxeTapTgW7HkiEBwQSK+CH5I7C5cG2J0cvza9pPXiydQiidcb2+XdC/ofFQ52MnKK9ULJoujjNZy/J0hxvzCkbqRLSkt3eD95ZmjRzdVVPDNdnQQKzQ2OJfzfZWFnkik0FMJuh4cGtlyZGFQNIwT04Jv0XPI+m97hx3asJuSkNciw3IZ5uVW6pIYJfQ2ZSx8TNWv1BjOsSOxi4K0jBKUHXyIbnxzPt2o2TmABmn7v6dzcKpRzFB48XfgwKYVs8Kidm/Aw/dL039RmR3ORIc0wHUwbwhEz87Olcl5AYsjy3yb/rfj7+YFlZsAH1FAOSzkreBHAMKJUVjFReKXbkJfKl+NddW8XqDfHP8QYAZ7gTAZdLuHlHSkwihHbDhjAITMS9JnVJZ1a9JcoxSlRaaJRUpyniJqd/TSePn4ysT+h+OPCpFq3zgtDnGEWOXM445I9Qe5MkWQnxJid+dZiGXiTLMnc3ebvAQIQ/2VfjyftuA+b4iQDbQ6tNnhPI9nCr2VdYqYXL9Q7R2/BmTCyrMYl9nE/3fANHpUjZFjHthiejmm//mXT1i2Plkb3f/yf9z6k9XRfS9tr0eP/nk/cHRwSgmNgvBQiCIxuamwI1G2Kt0lE1AOkCQXXD/ieMD6YnyCeyRbjzz9GuzIYbeAaXj81psS5pICG9+xM7OL2uJlIP7I5yrVLswyA3zZBzXIqL9QhFfu+wcDPOaTTWR2jthe0uak+k6M2hg2e+iwi9kchexemZfZDScn2sLeGSinCoWJH23zSnfNQlpC2yQKfcO07XYMffEPxw+i4h/L3MwGS9cFpc5f3MxpUPucLRHoSGDqNsmndK/4JTQ1fNVH5dL8iyppYjiGrWEo0Iw1KfdM8WOtXA1EDATHKEb8ZANbj0quTniZRQp4ayPSUFBMsXaROVRWBnHeWM44GIW19drBOY/Tg0jRBVLg/B2xCYlB0NOgd3Oxoj+3lhCH7KsF7Aen3yAc8bSjuNyHIO2agQbZDucsWSdUXHwlo/3pj8LPVjCL0qyc0govR8Sh6VhZeSwkh6gpHYkxszkxPMdN1erKO2bf861ygxyPQcv5PwtYvQUMawzDu8LRGpySPwCmWCaPODwha3w1eV3B3wvwVeatv2pG04I8r1CwSim634pKjrpdIW8IEEVJJouxG3+obFn8Kw2J0yUQHUIhHoSsaS53qkHC1UJ3/6NSfvT78BLBh2FwT+1xTloDWB6xUqqaCrXLi8aMmpm8f+VR1h1jt4NopupXHQU+5GOUWa7doGRBu+l+vO/XKLPpJ770MMpBEiqVy+KDU7wikPHbySkvw3m0b7hMTnaeSLjl9phA8O4j06Ox6Cozw1WmT7u01CrqL1QFRm35UqD8TQgc4YktB6T+SXIv7Dq+ULpdXdXwc+roAuAyyBp8qkCS8i58PM/GP9kRKEQ+Hf0TlX3kYhrbW2Aw83OHk86Dwzjk9cFRMyYylTC1dAMTL//eoDvLxdNTpZgPNpBPcHLKS7FezmMuk1dTJxR+cXNUIHibwPSo03TVmZEq00tCtgUjICf9TqdiKJXk51QFE8RZO8JF1hHimXkR8QxrT7jKsff7+2XCYcQ+Vz5lqni4rmDBc4B5sUBXIB5OmZrvIvYJhunKvt/rCFdZg8jMyhPPtI4IFzkAEYpzX9ALl/fD9XcA3kjfD5dTL4L7k4FxyU+9BOnlU6Vc4eoCzBds0juyM3qQ3cVEqMv5JUDT8a7oZbB/yWrvCtDxfgXSvxyZ/gpPF6D9AqnOzEH2fDSLfkeqjxcBpo57JUU1KV4dE3678iL68mb4X/EHAMNwr+HI1vNcVzeT38I3AR7roewix41Lg+eYP04Cw+GfjBd/wuHEpJSESG5ZnTEiu4ggDCAHhqUijQxDCPnsgs6XEjeSnQfJCaIzBFjW8PttaksNhEe88gnoov/rUUSKqrfBqY1kLAKKjgDTddalMfWUV7wygNAZnx1Jt2ZPvYkO/f7SdoQn0xpI9ssZDPePGcgYPdA/IQwQmVHxnJXNOV+W/Uan/9b6ZU7fyjmAPqoKd3TZyVaGHJ9qpmBwl2ecKrXJ8H4zAiAyPQT2Tiw1RhtPZrOIPm481vGQToYygDLeUKl/MphPOvzxNuZj/AmT8afsTXwPaDoAxvFSeQB5cxX5j8UMPJ6x+A/yhCyJYskfc0n0WTTaLPo6nEGyJjWOar6I2qL/Ui5eJ4kS+z+fK1kvBWPNhDaMO2Gr6TjYO0ODdPSPm4FyaP6PAKswlxGJsXlXAOGlsUBsD/PbghHxSEcsT6LmYTsy4lYgaowOXlH78AuP/ePH5Jqxbpu9d3bevKsar/6r8lLU9tZe/wXsqzyGTl9eb6J6xyfEzM76LbDT9YD/z6hJ3+wpl8z2VJZoDb2TDyzILNNyR6mgftvLccn1UoGAG03unzZXIJz4FSghqb5fDQAjsGAp95aHxTwNZT4OK4uSp7+1FG4E1Xl0rba8GpGUQ7fXbwI1BYDhpSFfbFvGqnIkKoNeZyxXEjaKrZaL/pcWO3sP73en23bH2KRLjx/+nlCl1qWlK0P7kyvvnGaxGOFf/pRT9etpULQ7ur9Ok6lp2h+1jYIKA6he4VEfrFj6AXSWG83VuUWV0bGTGJ6fS/ZSeqYcDaiviZQri9XKNKv66aLwlwbyO6nKTT07DFgeNGakEOl//3YhraOXIb1rVOdXWlAlMX9WqcNDo7yaXgyNQTKj5lRR1KktJOvkRdjDiKK7gUmz8CGPH8hqBKv6471diejIwMLtqEjis7V/8J+t+gk857b+ncHtmlbG92B8CA6jxuBB8LrIhSvq+AG9zKsxCKNPsxnKFF/yx/jSF6P3ngO/16n4wflRhkKRSb8pzE/3O/rrq/t8g6+eCHp6mbEhB57Le5rIctup7BXj57JTdNF0/yotVRXT8sEYQ27BnOAoa8Py3cY8OIXaNuqKZdQcfnR1I9jPFv3/eRZdJ40k7w3KKTbTq80t/Vc4XAl9SpAgKWx2esgS8M2ou2qzx4Wj1o5OOc3KFhsvWlM+55VZg7YMx2kZre7wbx/J8BVvwLa939FfV9PnG7z0RNDby8wausrN+wvNdmvU/MDaCEOhiNFvCvM9GP92DYOVmSVkb50wh83IW7ALHNumeQIp5dwur4PbmVLtiaYNznTtafUS2nhFKt/KDQB6u1Ll4xcR2rytrj0zB9M80ZRqbqfDy+1KKfcE0kCw9xJzJHxhD0x5HoBR2QNbOBLOvPQEdMItQTEh1u6lJ0fiH85nPXJQJrFp+PO/nUik17yh/1FHTzzx4gKRypzgID1iz39BFEym+6sdBHEzHaxDopvFBEe1n54chL2Yz77sJHUqqcQLH08k0kc+or+poSee+O88nqYe6aRcZs1/SBpJpnvbYwSxxQIFkUVGb8gj8JPWUWh7YEK+wEdal4k0rs40NOQwS9KtBSxjj3UKN5W2Gybky8jXUsPwdWQEK5ye7mOZekaAmCJDFpnhe8gIHP0chDL6WCniGLLUjzQvb3kiybSHdf8hmKXp6QVqTfpUHTN7kfOZDUzkCZTjHKzvIGayW2yG4H84uoVKWUohj6n0QX94rJ0wzS1g14+aQYCYJW6yGfLHwIw6CmUygdxS6n6ae2xExpotPRIkI37j1rzSW93SozfOPt0F+g1cdSriH9AEil1kI2aiqjsqjOzsdJfQh9SmS2UQrQb5EktdRiWXy4hqLCIHKfPTvNjRHnnmANxTrs8GEIlGUnVspTKIMqJrpnv7975r1jAJ4PLjo3wCBD2mcyBftTUeH4Y90LBZnvr9WFiYiyFlDXGtE3RMViJwPoqhjN+JTel0MqVwZGRg/nZUBK7FkKqGsHrCagoZI7O9IQXhWoov2rT+UwL94tIEUcGWwchqmG/h/2szh1/pcPIXBhYS82EYO/6raJOBT8cYascurmm8jpWUkOsO6jWffxWPrHZ6KYa8sS3EBszDIYP2aCIampAARycdrTJ2cDB7NVnvAgyxbtUKWF388dF7ZFSTO4IulGEoHTu5qeN5LCWKlJBIQhPAfalIijMxM/fvE7VMSx6XtB+PryWxVyRThGbi2FZvlRKVmJWX71K8ouNzcTiOM30qGntdXK+3Ne7mCznVeBQFyb28IJfPJ3DN6Y3t5Ya4YORlLSJS2Z8yOWVgHDyiHZoHk+ahpygJFdAGpR9cMTh9Yxrbu6uebuW+7Tv7A2Pi5T23a2xf5UjzLzmCBcOWmOaNYW3/MswxZbI8NNKMJx4TaLMsL3l//HMMuD7LSHNqNuOlpW6q/mGZOews08tZ0BJoRTm4qIhaGxgWU+MVWMd5GY8hlRUWgo+XInuWosKz75JB2yOSyE/LwJ93wjmBXMkFj6FdlovPMuVzwJxOwix2tzu5V1Zk1een2xTlAUcVz2TLJTqQONe+kqiBZMEkKfTYS3kGQwXX75Y3+i38Rmt5Zlaxs0J38UmpcmgJv/ZtDlUuDlLXC3ImsQWJwU9+qYCe9EKYH4jZeG7CPkMq6HE0DdtVvDg48OxORq1nM0Yfx3dUV/3Ax9usEIVc5vInZk0xwauU+4ysqasXo89zQsVStdjrVOdT1PocwqYkObOqr/LXzGfHqI4JOdxzj+8kFPe+EtNcwbSA22sTbo4UR2KSiTVqOu+eN8jbU7RNGAF321XFvv0Tm//ZWYXIpCrFIeo6YU7aglk4g5AfjNkETsJ6g5nETwx98ksE8qQXIA7nCBdbf7ah9ZIbtIKFHmibTsnvXuHPBfQ+vxcm64dhVB8emKwXxr9XQLsWkEB27lWdHO0TYD4tarnuKhekQHR5KQyCGWnjH7apleSQKSjusT+CEC6xkiuorrGS+WjbX5etoz8TMiJ+PxP3MTfsC3D9ZY64UBZqQEJ3CZmxMK8oWMg/F5TfNfSyEVIznV/ABLx1GBpwxJTSkakuKpPCJUCEGj/X36qkhO96Lkh9RsvY+dVYZ3TV5JU/5J1Rdmosw3xuw4WvTTjndys0wZnHcouOwnN2Du6eUGvoil/WXPp1/l6Bd9hJYQFrcNwEz5a5Zyg93BsTl/vM3C0J7pM+SPXitvZ29UVZqD+CTM5cEZ/k+DPE1VNbR9ah6+PCDA7NIeaTHX+Gudktu9266ERu3KIRnRKxSxvJY//RU9sBvqRolI7eFGrWlDr06l6lQ5PF+H1rK8MNR9AoiA6u9KCfoU9wX+7qK2cluHyMg1JuIePD1jaGG4FAIhA4kAJHJMuOvErFiD25I7D08yjLiJKXzrNngcO0TSjiwM9zQ1+uM8kvlhCI9I0UcnfIm85VfJaeeS7BfZStyDXszSsdrVIb8s86+HGdX6G2oEznM48WITHe4sgPCSWi/QiUdwD+Nr2HOdE3a1iiKx0W1ow4hfxbMNzXqmuQuG7nunUtGAAX47K5LB4vEg+NV/L4SkwiVyWKvK+qjEc6ByfAsvOhv4hC3xUlKTdzk6nXA0aG++DXB0gObeAFJZm7WZnUlI8E9Z9Lk/KPbXnU8kmxsqS8R1uOPVTIsOD6j7SE7AlL1qCz0zzlMOH7et5OHyQmSQLKkbkxaYkwczCSokyJdmUKS6SxcdEUJdhO94YfwxT+gKjaksKt8cSG6UNQQPpk+zjscm/cMHkwKKpJS+HWemPD9RHIFpyBmLfize5Tii5hOClyyNKYNToPcYLvEIUSI6Dsr6xAXRH65+0NNLMIHazPGlCSfOCrtDsBQICqSMvIt7sa5GEYNuKgNTYEa5QnBupav98azHOmD5RXysvJYXGuB+z3eBMrN62/SVnpXdINk/rRPXJBBbRMle/e4+rHMPoKOk4KzJ3M5p6F4axUk3h+yTquyrpz9pEv2rtNJaNlBz6Ty1OkUr0cFB45QHLcS/BOn7EC9end9CRZh7JH0W30482KUcp+Ra/pGs8LPdBcyc+NfduxdHnYhKlEgL3c3N68lvtrUL2WdlF5a34wa3dm6eaooC+jAUv6NbO12sY++cNmdurHd9kZbVbb8AyQKefn7oBfQiJbFpRzPc5mWSgm6wiEdJ3Z0RaJWV+Gv4TuQNmydZbcwnE9Y8umgIc7ts6oCV+7+jilPlN7dpapo8w3iuP62iJl/9Qgv3x/JlGl/lmtyiTtXzUGKE+mUCfQ5BYnSL3nvCwP/Ad45KQDznX8ZqPkmn6NT8oC1Z9L0fkTlol2PxJo+zk17gtuAxFH5IQDwbWPBUyidzpFkYwGWSAm6QiEDJ250WE+6kF0wYW5n31i5pZZ8oIpEYEk7Bcjgzvmzm2HLzbcz7IJ6DxZ6/vWwRu7zYwR70eAwoy+FB6W4x2WoYnXOEq9HCwvpdmBgUBjhzTsvCZo1opzX0T5EjhWy6oew2ew70psJG30oq2XJbp6Kz8FmroWnzqdg19x6+bYpLi5TlE6kZVC8Zh/i0/KA9rf34CTWBlls4vb1ybmW36Wo4t3L9u1FbZu6+JBdLEcsvUdXDYZoGlhX90AODX9FRiOpREFCdZ7INCu511dhV8Ge0DU5851tGXNzeUTge2luV4YDanbQlH9yKzMOomOgAhVxTEzVivRawRbV5CrvF5K1YqtAsHylZQh4q3LIQW7YDY8PycnGmgJsF86rWibDWkFtle6gDpZ6dzKlJBXH51dVIU7Gi6qHC6qE+bwt3o4BVMa7cBMoHXaRsG2HaRvLcDBtH/ZrCs3y5Ierf64ets55mMdHz+TxaZrnPRfXdZSqzXfCl69Mj/aCm+AT8pS6lQ3RfjDB9AOx7FvukVCisOZzbIYCgi5iBHwp1N+5KR3FJKPH/rivpaD98sisehMMEAG6a7QztQYy+Dn4bTIop3BOM6p5KwsByaxiBvAyehjwWgUkZ87N6sjiwk5Y+TG9uXS9foCikMvykx9LkPj4Zb4qdKSOyBwhfxZIPdMNByffk5OiFuJfF+VhBQc5rTmsA5tkXqwlf9f9o+09Z2AJyy+SvYhwT++zcjNBAYkByPGymdmU31To71UPz2blU+PkZy1JE7ItY2vVE2oBxfZkElf2MZ9AfWgtqGzVw8n0aOXu7YEJqyCTloVbNnWcvD64uAGrobn9YLKAeSDn5ooC6qq3lXPrF729+KucY+WbVtsz6hOL7MjdzRD96zd95N6Z+bon0Up/D+XXkH6vrCUBNqB4udSVIGmb1nvrfVqRtrFjUnGhjODuevhgaEUkr3tB23AX/NNJWB38CHG43745Vw8smSnP44jGudLnEu4dvMAIj4bGI9+Dl/loozx6zfzqMK5B0OxhtsntaWW1rTOsXGnJoxZHZfJzUmQmq+aWW9PILJObuAaHmkpBvKZeExWFm3vVx84jk9jfgV/6DIH4yAOfGoPhlw1hLVjV1dRMD0LSziqb3lt58sbe40jsiphAv57A6xxMcSn6z+YRgJMvRgfeiD17SwWbl1BqfK2bv3du77mY+PyX71ybHvwpWivmQede3XzY3Ob1FBnVVWXN1tGmRDESBv/Pl1GKv4KzjRbLcB7K4mc1fHadNx0EUN0jAdoMJ5MTrrYYGapW1Thjz+E0obd/KYJPvNQ8Q8Wy+h/vkJ8VmzZd6TkZhW7bMoISBvki7pXEubDbqb+LC0zIvIxZPBOLat8tp3Bj+ODqvQOfpE/ZVgwauksC48UpvXFZXILEiTmc2aWk9On0HWu4TctxS2+E4/JKtQzecS4pH844qBIHqT2c8q9Xl55k58iaTqANmGBEEPOWo2NYYeqKBj2LgY/vwWdjga4qrSYhCLtRSxl7OIzJ+Cgjgk6JnNBl+i3LzFfE8BrQ2NZSGuXkzKP9tPEEt+Qf86DB+kSPKpz7cIJ8JApnwimjt0F28PbGcuPquI3/jjC8xIONVcIcmONFgTo/KvMxWh8+AX7t8CRHY8CgNtSEAV/ISd7cx0k92nS5Sd750FzRq9R5SVp6hRcnyFQHa8zd7EzXjo+CxuD93/T6748LckZ+3osYJXcOwNoaosSpGWzrxW8nodft38ZIrFbg7mk3YcTQL4qVVrgs1ULJ+JqbEOjivdU8bxpopyUVIlViWjsVYJJhpVDimrBnmq+D2KXnK4hucc0QlBxSD0Kj/IiMos+vR2fbfQjovlVGpKntQmPxKNAUWEww7fxFR86a8MSQjTn1QmbP1AkQ+RVL1yDypOVafi+VwUMPjEp/OXGe9fCRFcB7RXPpyuTIfPWLKxG5MmanjUandXWqrqEf2+z2WdfAKx5t8En3WC5xFMLE7pQjbyjPmhMkiSJBrM1IrAIOMbqzKKy1v2matwMwzf60pSaGn+5jEtjNqlHfGU3hHfPpGondWs6SK/Va9TiVz8eUWQXMSRMhbo+I4guCfuzcr0ZNMS3xSGoHxoNmFPFMYc+n6KVR7Dn4/NPh+SigNsLrjvQ7TDcdOajtb9xPVz2AOwQWDZlsJyyAoEL60HAmXcYt5B8VoXYbRB5FAZ+dG8MgtEnUu68Q1p7Lx25DXin5ki7ukmFkzfJed/9SndpVNzgyDBDoYgyv+AXpvtsfZWVPZ7B297ssbVVbIanfj7L36I0TZaA1erc2GzXKHPjyrXGPEQ8ubX5StqoAbF7eRNoyxQ+GMh0aTeE32AWk1XUS5tDw66y2WJUr5colnmTcbsFCpfrj3sci8GCJ2WHyWfvq4WmnWZdNq80JejOsPXKKTXbX+jPPQ3qKDmSzh5Scd0XUt71DwyXSsUNdIWU00PfxC9ID1j7q6qBirTJf1bJWAfY2JLZY6rakWOsmwdO8nYDdz7zM+wDvA68suenuaE7b2/eIjAsfxbGSDXtP8ajkfBjcZWdLDSoAX2VKyu7kJVfWQGDa2tXSfqrgEN5DGi+SfQ2iL/xvwUy9vmSnBKgumvx7h4BzfVT+S2Ei/ClUfP6BLKMv6RZjcz3k2B2Mswfn98ZLOam0OkpXK6303jBl+KBnOtXyYo741WADEi2RuZXg7pirYf0fQ6T+2B/xpHL9Njn/QfOfWFLTuV8x49lM7v8wWKyWicv1Rpq2RnI2SM1WH7FzkjB5oACXZvcKZtV7CWGorJYNziY9APr6uMWx3bSmfPpr9+MOeYAxcZ5STki63FyfTtiYB5y/NAx9+NDNI0pl/4Y++YSvXxtUoxkzT++dgWXMZYwRenBtPv0rPkDYRqAhCKDL+wVBsh7yAZ/2Cf0i9cVIk2bM01NYWar3dbLTO2zb5bn0Y7DxQKhn7yOUor6iMTkgShjI4vZb7f35iBDEfQLD4h/reI9KXnKIDO+n8ls0d8ITpzsSY8zAMYs6bELASINliuW7gcOg9OQaXAZgMfJdzGD3EJrGqvK6WkRxbJm6ppqrEMVfsmIUM5wpQ9IvE3Ionh5cLdfs0kzImeqvrokZVysyr2qf8TmjPpVmxcudUqbguFaqVU0n45m0yHT/1HJ+x2pknpPtFSdQl5+d/hE2rVD12jYLNoXc4gsaSYxLFCep+DfraU6QenWvsPfhAXytBgjKcThdffzVrKjNE7BtE3i4HktpdCtPrQxWFt5CFkUmmcMuz83B7cVPKHnoxauEchfsNj4ilLaxzd7WYL3H9fndSTd9n7oBioo+Jz7SNEkBvb01KahY7sEGUNxvmb2PBKzqnMETyl/Bi+Ar/xPwO2kYzf3Fn9+mcCgMOQX3dt3k1id69fzlb+nzkmypv7mEuEOfLbtsrT/LjWNhDvwxTbgXYZMghvYy3OXsw0mTLwJySIZ2JlcRYCewXLJ1FzP7BhFnSBKGE8RrpMUbP6wIMO+y/k5KK3tJjiq7Pxp/cjI/FB4EBu3eIbdZj07+xdvRG12ng32JrKMFBuszsl7RgtrBsCtIjGoVgvxC3/Cxs+g0QCekjzavTJtCHeZPgcMlNYZKQ6fi9axxJH9g4y8GQSoJ//CV6WZrUwda969ezd9BC287p56Lid/SjeP1zMlj8Ot6+n5k6vKl0jzVap8qSQfuKR7UiyJmbnxJ3KZaR4uaSPhI4Vss7BkI0+9t1iBSmI5Ff+/H9biuNXpS1C4H0xA1nJD78E/yEiLP4yY0EAFUoGgriMrUiPWp9YLIn7VsICA4LUZ4ygsD/b3hGGJ3CoJPu/SmeN3k2Opbmr5F9N5guXLyZVuNSbEcpy4vbpcEAONn3/fyaJqnEysEwiRWT7LXETYs2RUV/+1ry7YX+MVCcqFZe8vcEvC33MKvjw1t2I1es3IUd1Jv15Jh4MksqvaVbR3BrKxMm0i3TNWF5YZMiSPlsel//Lhn40y7Q9a7UWt9ORxu/6oVntUD6hPmN9SvzyMQOQ7ItTUlELuS16xJV1a7LYVstXyYNJsZDHiiluidvvqymrDLUBuNUeSZaYaWihVWZSREUOFzDU00zLi1pJmbLEwgv86sELROJHQgf2PEQR3LYIwU+44F0LxtKu11JGT7N15dNXXcsLuDUXX0U6QiuMqGvcPiqWCwf1ZjmmtkTZyZLTbQ9dVgzrn5FKWw5DHPcIttqTLi72B8YeSxsJLYRfdShi6iL0tdsaUf8yslum9xf0sjT6D/W0rbv6p/MH7xjZLS06VAKRqijuNfoNmyTeK74gN+RbaDXqa2yi5AwJwfSe0lF8D4CRct/Y/Luw1lxpL20Gij+DYSFp137QZByvr3vNe5Rb1fz7vct3E7Y/0E+EmYbXrMpWcsGdD8fUEN2CyWDUCdkeV4JlaPhXtUe3jI/3LB+dEoYPRcaNnX/6prd+YwTFtdLgX0IUjQN1wx9/DYddU6FJsCSrldjJTZv/6a+J9Beg2rLSo3lYWrQ9IsQBpqc5l/SsqTLPJyp32HI5UtWaJi9JBKVk2R3aA+TYZH041xQ6an5jMn4aIOT8BUq0tLHbJGSt2F+qeHJJr27TaVq3mm7CGFj4w7U7tu8wkod13qIiZzXLTi6f5hwEtF2gkAwcfKYBm7t1WWO7MUH88fzI/t+vq9rdnx1+QG7Zb9+BrvW6VVrtUB05ZqlnNsGyY1SGQCmIszJS6urv30Dw5m2XY6KJocu7DyqDzIhp5sQe3JZ/Y/9KSFeakl3gAGYB4ZILFSjLTizmH8FfvpG2iuYAeyn/uCI+kBFMu0UgD3bbyrFGslG9Hu0lymY8QeKnc/0zpXlb6D5i9/A//HWSlfJUB/iZFRJ/vXtpX9mHHdQduibCBX7nMmZ1KdlI9lYTYb58pFqjJlOJsMMIEbYkZGmPQ1Etd8Y6+0pdlG8tz7I0+WIvPXpC7xfJhRlA/AiQgr048VPi4TCY/FhueOeq7zDTL4Uk9YaQuqPYjVvUW71g30VacUf3dgW9O9k/Y+jNG5THnAUQ8rMFl8Q8X/pov595ahm2dTZzzwT0Blt758YyprHVactbCEGCzqI7/rB5jbAxdRwSzV1PfjEat6sLm5puvIapuX6eiveePiK1K0qybI00ki0WP0CIm4Q4T8qFhIx6Hwbx9HIEtxIJuZL01td+O/mVczZGpPV9+/SplNX1Uzls4cE867UkQpyXzUyjXEKXzxrPKWQ/nXb2iIQRx7oOkAijEbRpYFMthh9FnkFe72MmqY/kmaBuwpj/+IKbHpw/lUSWgP1vtcpwLoniBzo0zD41kRxIOoKvmOVm3qpddAWZvBdc9lMm8yg4pRstasJBM+hy2Q67geubFmI9j9aNpJRx/bJzb1SGH24NIjP8zHoOos3svHR+m62SrKyKCP9k9Pz4pHiSusZCfHuSOWzUe4zgIe2fxcRHu0MAMpJsbEp0Q+4jzmVunzty0lbnGRxR+LQ6pyhoIIb47A7HB5BocfsxIBcM7yTSZZesrjmcjoSceyFUOCYR9sZ4rF95jEzm6rZCF1K0UyrPylslbVoDAbyGWOkwfOT2YWygh+X7ysXWljzoZv24dzs6FljdsGoPTK0NexxgV6fFy8JiVaUc+YAtPnpsr07B9GhdVYE+ny+T8MOE2UZLqsftf6XkEQAcXj6iN63XMhK2dbLcpnqOUdNVW4aEb/1Sy8pdRHUodNxB91lhCG8YXa10ur9EvoeUNB8+p64OpNv4PP9IdCgXNd+xHYdhTkPME4f3XoE6/O+/BrfHOWTDmeBCN5A30dPXZWF/L4YvofDfuElU5nILjJiernWm9KGaKN68jsh9UwpJ3X5MkJGDw2Orx1Vi1WMZ+2BHFaQrCMiYTPIPjWQz6HwXQ8zoBe/ZQFpuOTm/mhHa9f/2ZhDVnqIp9ni3RyJtYrGaNfEp/D2WZJhAU08gDlORHl7Pjr/iBHYJl62vrkfIm6y2UMS9W8Mw97X1RFpnx25bhbDekZhj09GW55bhhJvjMoJwmEc9QKGeIpNOx6QWJGMv4sLWd5YajkxIQM1nRPvAJgTuBtx1LRMxc2PR+xmMog0LeSRqGTKA84yQkkLr5QGfRF2VRGe+3DGfnwlAYJuJhXmlTsiOvVtywLb9T2trQOW6bmWXrAyiphUj0j1va1EkMhChEGQdR1FUH0BQTFfbNU37Vl1WQ209llvkGbUxtazDzJtOnsimZ9yDxc3nSntYeKs/l9t3QGS8+AxFveQzYN06h3HLZOINl62vvkfImMTayNL9/lm20YMRB5KKwWS65nOnhvBesaKzokh10qU+scgfCuoBUohx61AZA1DhuWW/nMwCz+cHhLB4cMmm9km1srlQKSd4bXp5G8kvqUg3FoAh7nHdVxA0zAIs0ZMMbBStv5tztKcpMB5nL7t4J7zk+kpfJz4lsHNXLl2gdLp/BI6HltoDQNbCMT72fiAiXDpEFy+nBCOTsMn64p7OvnDWWkbh1GIsH1r8TnnoH9cG8W7gkHgndlnS+qKn2m//J5F+AW8zd2grNRaz4bM9vNILnlMRO1t2iopyvX5M1QQuIE6LSJINLBM31l7SI8aPcobrxpSeZ72gcoAuktU+pR79hD3HoU7avplVOqUP/J+urqSRBFjXqbJ+MM4H3K/iqbSnToSnTl03oyl9zqr7xvaD5w4PyE73A45UQJZoIzXwsyXoMFY0ZXejMWtC3OvpGmvsUlvtUlvlutXtRJ3BlbS+eEtiO+PPpyrSs9DzracKISsNOY8NOrCPWgJLp3RpP5MLwESOXxWObgGz4xSd7eomLtpsWQsxLppvdBXvGPc46LarwFeqoi3BYXTJq3cSJ8GTtdcCzyDvNsbP8Sf3xTkb1OUFM4MRMRzrAnLqugleVKX7+q3Nk5rIPLFarh37S3u0aGHjfEFr1rOX7scUrCtcPeDHJizAxPZ92GwgZYh1yUVkGm6+l+x58xdNPQOZEK4hZPwk7uEHxYAMVfwPTk0/lXlyxe4x4nX1WMukP1EFmwdo6qgsEfiz+ebpbOGrjAoErYjGIKXMha54Ix9jiA+/fCmUdxg+VpKJO47rGseCzTHCAI1ArwM9YZkNv1ygPJVGQnEnJYkS+bbuKQXznxGzPJHIl265ztZyCXZi7RwlzuxOwBQRCEYngGuGSVmejYWgwbyr4lcWHD9+saBwpEBz+9J9I7ma+mMnhBFunCyGetmsqIm3E1BK2yyOny2S80dhD4v3iC1arKiiXKtyWdHUABPqv/cpU5aQ4LDEOH2siiMX0TprbzL7IQuZ0KMdXJyT/MPYZFvtuNgIv+Ltevj5kzGA3b5zEFO1+BAcz3QfE2ERH0lbfSrtTrxMWpPpvLZCqPPCfcNF34/cFgsYwK1PFfnHHf79mFpmx5jWwGeBFejtG2VlIvUX18SD07Niqe2ph6RSwb1yiyihacAm385ObXq12vBQVFY4bN6eFVy99CkFJXPX6uCpRqXSvml/fsj5umLAWRDMJDgz+RlLDEppomXIdI3FrB8tNxlKBhqs/Dod7h+lZQqP8Ob5khqECEO3zGmbilrZq6xjGQMTyqoo4jrxan8/iAEak/gSgvc66O+9vW8EALV7gTN41l6TYvr8pb5CB+x5Tv5AqRH6efg0GeiFFewXFmJuE8xHxjSSSe1H1Xf5h8FxK6KptplkARcMYM76G67nHJOYTBWmEdgrXIlHd5cdjua9huglrEuUXtYIJpwPVI2aRGLsefj/NiEu0Jx5oLFivCjBpiU+eXYFY6PXSZGJvG/YDN9DT3gd10Q7rW28gncIJsGw/5CcRC/sO0+2hipYpwaQdVN/3arr77PeCnJLyKE+KE16uFhf4x3zQS9LLvNGw0iER94WAQPNlmV+iZLj/P1lqEIoYOfMd//yyemw59sexl0Wlzw1ilSMcYoPbdMSrBBYaSZN0NXLFq+R3SQSrGOVRj28BIXRNRMCMRnponN23TohYnItIefoP2iUVJociXykC3nqYtq94JNrV4dIGcs+Z7C6nZOtcgkvCb38T5majvnly1KqgtdWhNH3NN6H53PxDP8AWdo1jhXgxFlXHA576mSTB4GMclHALGYn/KvlyyQxpVikdjQZqVU8deqWH+fMFivPqP7BknJ5IvYpE+8RinHuKS/Q3BqS8qtFWp/JxDp6K+22MuFi5AibnEz9NU/c8vJqbbYvcp37jotmIfNTY79mOTU603usUu6R5VTnnH6ZY6Pg8osCMvUsUVaSOkwwUfacahuN70wZFh6gpVQkxszkhPGCgajQ/URFM1gP0W/YZORKiJG+p459qCPurWlZZDBrgfQd6fpOpIm5P1Pp3kzIbk4rA4awdtQUFfJ9rRbYYjZOlJxIIAl5kZj5us2HtQ2Xw58iFh2nx90MZZCGjSTIhE+KIc1h9d78X+nFSgT/RTg3fF1dpaBhrE4Ab26m1TWXaZU1jR83gHF55gnXv4B7QkKWV62ipD8L00WlXf6dmQurpFd6e3+fQvyKLpC9kLpJQsW0ZIngArg2BKInwm/dvBQIHUcn2aMzGqpxoXeqnL+6+LxtutdGZ3K5uCIE6zvQPVdGqsRwVE2eiWXJQPzx30sgDUt+Qwgu/Tiw2vvGup/ZxRsWRWPN/UiTJuL8z7/Hwf14s8lGhwE3nXHh5kRuYWCbBpLHQ+4jDBMZfE3oPbGDLn+jlT5hEzbcGI4NLVKSaMFvvgUVfazBpzC8P3P1Y1m5jM5iOrski4el/3gr4TiKT7Y5PtFwSk1rQLAVGLb1AwGuxdTEQ8lAJVF3KLBMsA/0d10YpQvQSs4FerIiMvZ75wDQ7PzW5kOEtLOwEzJX+6etQcmFqvmn2RbnrY5URerHBTC9RhkZdA9bArcQKKKoKKtwMEE3CaiiqEkrcFgZvq5fc40hOLbKREr3HZzlpWbmJT4nJC46nokj/ZROzPxJRn38XjSU8QWdlUyfVUEj2EnMy5+MoEFI77SMn2VxiJ1FqJlGrHegnBOzC79JQxI/ZxOz/SKhVx6OSiU8T3VU056zjKokkW1FqMufFEgiwUTmAnrtaT6KMIGvn5XaaKNzkSIluMy4zCG/k9qCdai1vPpykqc7FyykjyPp5ufMMJF/vDqbeuWnqCCW10Td14LNIekk0NvYETBelFGF/QaqXbc9AtDXOZNH/xTX5snzNuF9Q2q2Fc+IRw3tnqWW/YBv8wGMuyTOACY7G4UcFCKMmYkJjcGQ3K58Oxu/KGIuxpHyG+dF9EnRvZ2TRxjMyHYMr5Tj8g3XGYdL6cBnUTKDfTXtFJr+i0f8nk/8HNRW1xFJjKZruYOwave0CzkVIgKRDg8fyylPwyv/VCO8dGtSYmaC0oQThziCcMeLPZMLdLba7+bZE4is6c2R78Hlbpj9DReuxbTaPwiauLU7doqSyrV+lMqxOCkvvEeHxHgI/LJY/pT0gEh/Q6Hfk4EKg8W7IAB42/RgyNqGA0hJ9th780XqbOzkDmyHMH+CwE0m0ji8SJssFuo/D+rBan8Uk/GI9zAtL7WHRfyUlTuRdjcxu3vKKga9/JeFSU5X/M0XFiO7r7499cxOenLTILZqD2vXNs0UcZoFbBDKqAPiCl+r1eKlSRVyyEmAppFQ7XbB+40iecPGTPfGPbDSgE5jBBTVm+n0K+T6d/pJMeQlEVkK9VKoXCg3UkwGEGvKGnWRZbZtPcrafBFLwNmyWfNaQbmi2fDYYB1KN5CE5eJs0SzFrom7ibMXsSbrDYGxIAR42ET/D45YSiUtx+M++0Yfl4Q3TDywc7jMRkAAzbHfPyJ6PPb018bESLH4vunvJGCBaH5FHciOyCBB/JXNMV6PbIUADHo5Vaud0WSNIOVrslCNb4VSAx4IbLkfhUoCZJ4f+EZNHl6XjKTMXVvz0TkQqjZQSyTM2iCZdJZkrn/xN/tliYNVpyNkg/zal0MBkJfKR+pxNsqPpVUY4oRUBE4hu5v9yLehel8FrtAQjUrnL581Q8bIGgkIZ7vkXUOZuz3US5mCoCovF6bCsFfKS/FHTA7zZr77i15AEc1mCLy+4gkiKoAsIRq9GwjHSojSrothtzWXLuC781e2Rq7YgjcyWFVrS5IFjy+PKeNPhys5x38FwKpq36HdDVSWd56DqOaGv/uM7aHxOSK+ieZp+M74Cyyw8pKd/YAbSw6u47nZf2dzmXeHvee/35YA9YnXLuFaCUH3rfvv5/4ZWBuslVA45WMjq8yTw0cY48uZNcbeyYu/w2VrQiOM3Tv9siUjuUarcctHUBW8UyPOOmbneKuZWKnVNQcEOKnUrg0GZUOD7nEI8y2SeBd8Uy4L1XLrqBQ3nTGZOSOtPIH2u4F2UpefrmMqXVJwLy5iXPj2BOEQDvEua7OMOKnXHRxmNKkVPLaSHKYJpHM5SAW8JhzMV9LHzv7pTIBJtu1PF5311tkAoWn62SkId+l/NYqmShyiU1f+rWCz1/6vJ20jbCMStJNJWImEb6LnH9qpd5Gv/NGoTT70nea96GYWx63XLNwhcYhbzy6I/tRGAtFi9/fCRfSeJb1XAmqmPgNgrTVrktGaxZaoc5nNRnsVsrS8jUmb1owqHjnLwMN6tdaZxF5QphKDqKr0NKBmhlKCm6u+ZYZarGryYwaSQzm769iqw+zESb6H7JANqBHs8l9FzW5UcLMGRjH2X1LOEZt8BM19zHiQkfd0EZXDhzt6vva73WbCL/zqNFOzLWqFf3cfKe7xIfBWJbw1mxyu2Q4KMgQD6JbTnHOy5U6UBfCjyc4llbl4pXNQR2ZtSFMQNetvgESlJNC5DAPNiUrEKVnQlkPpCT7mKE0LBIyk+Bw/zrGa/aVAipvG75qp+vIGhKQdorhrcZZD7q0VMINGkkDDXkoL9SFGOL7OiNybDaQ4xluPa/6D2PCjy+jbT6exY6/l3re8/duC/4LSDvwZPv30YRPk2eoq5sH1zdMe7Bto7T7+rPW8kpQY74mP0MA+nfGVmIyjca1/G0JSlsLBYH7IH+qCm3z4zVPM9rCmWw/YtwZat6QDoWYmHwU/W//5dYTv/l1GtiPvws1AeoQSwMAx0yxnAmUu9PaPg0cs/YWANy31WmCUV9LA9WQ2olTtdDwEIGQ4VNybzuV3JeBO7E5e56mROzltPAyOHVHhnNNHuqVDhHgNDUfQ7VymjJ4uDCK0ntTghZuJkz/TBU26DnHhDGa2fAA1JJeokMde+b1lOqmdhJgCmAuEwKiKxRPSkuFyLtP9ItEDdZegtKRBLdAnz2sx0PucBc5DxK9yJ7cVw02CsHbiH0S4fRQ3vO5SlQixKUtZnWZ6ZtEz1ZzPPocGfhzoihMx2lv6f5LTrXYUitmbFKoKJoGC0V68HW7K4twL7s25oxavoQgn5rbFA+21uW9TLdQZ+kQwWi0NPK3RQTiniJ5CyJ7YHgi30vR2QoFoCjPo9A6zeNOAf4aLvxrvlgp36R5WdXxmkpTO9AxAggGvukZYP/Q0iAeTAT1/TY75M8agiOgn0o8TIcC9J490xeaY83qiKbO/Arjn12FiHKiKTbnSuB00nXK43fjJj5U8OLlAPxmu70/v/E7vTs+tgeXYuPxZBZzFG6verhcXRPbZLGdEnTp5WZi56Ph+o39czJYUaaXOfGCjPwsUUHv+N7dkJ5bn9YM/eB5Hqyuv7GWtPP55zXXxsGS7mVnN4c75xlsn56vgBFObzO8Th86c9dUqq5FqOxzePne5eSOSqPO02dBqLX5/9y28OdfKJ82z1lVI14Qvexo2pUpuqPLe1OudXhNrZZfJS/9ShYRHDWGy6P3ZaiNuV5gZqooS2jC7klhzfSi32ilmnPdnLrUV8HVr3Lk5CGABSKxAjLbayI1Eg94MXPf+/K7vn6fvXMv8Gqrl/rDJuu+IJ1QTT2iQDHD5NhQI947V+mt/mtxstE1K3XXjcSVCYC2vgGy7R6/owdGFaKICkvPJenf8EyQJgxCcSGwvFOwoO3QZS8HEQKW4Ig8wZkjNKH4gUF0OwgqCP4LhVBxh07Fdg57rTS+nDcYFh5AsajBgqHek7q7G2G3yk0La97CbTXJcY59ahADLNAmRPrkSSYmsfQIfU1NcXDOL5UKDbRqScrFmTchnvdanH1oYAVh6+a7990SeDAYxw7f+1DgGCEURwIiJiIiFSIHsdCRhP6hxMwFaDaq0WyrrUPYaUdfWjLMJIDGS90Lce8eOtTaR+ZLOSa5/8ih5qNh3E+b2G4BmIFJJUlWUOJb/IR57B8ovg5IqzAMSVp131X7X93HaKp5kdoB9+FC6pSl57St0Fkx492ffr4902bmB/L7fNo28ePxZABpB3u92HfMgXsA8jK2Rv790+7XQ4HdwFjTOV8F2BNdE7pUiJzgvUBUOvAVEslWKb7X1B8Dg2BmBs8RXURL9MIg6fzxPKIQ7hEb88tTY7u7fOUf2DedPOZmwzTqOYoxcGShEpKsUlmlB+YZvb+1WyPeIihnashiV6r4B1sT3dJA0DT0KPIKvqhhmpxoj5H9UwHGt0F0JNdLyGVkN1Quy0odOAb7nZEaClEt43oIbaB8SgwwpvA119oTeFYc+qNWKXfltgTfStUkSiCeVQfFciiqXSiJy5L483O/b1fNL41egk5tz3a7qF2T1Pd5Dl83TH2YpzZiea40c4p3cLZ01kVylaovMlCvb+DXlDlKnyhgpGpv9hM7vxP3vCvw/naYMfFsaH/zPIXMzSN4G0z0EHoNCAE8ojq3TET/BI7xEoRaVIDb17DbVnKZ6v7t940KDPUvbWLwrIa+CR85q3uaGodUTGPImMcfk/Xl2x7LRCS9qvQ81YKjw6YrMyjwgjde4kSVW9+2Pt7MGIt2HG7sFF/f8Hd2hzzH7JVp8lbJmd7QrKsV7CrapWYvH9yRpArklOeAsr+LUdVEfw0Rh7UMitCBmv2Vt9d9/bxbGqOPUO03pOj31BSVwLZt/CyRo6aKImcmJ6SQ9Omjn7sSztvsovpvnpe7A0ljJjMD5Y+h2c3tocANyIYy18ndl0PHVPgX6z1tF8Nu/sYXNSyTtXcOfBkxc/Qc85EXg9kHvMRx42bNmx58CRE2cuXLlx58GTF28+fPnx90WAQEEJ+w4rcOxhOaXwexeAC+07iRLLs1082yVCkBSB0uBLOmSUTMiSLUduyYP88g2+K/BDoSLFSpQqU65CpSrVatSqU++nBr80+q1Jsxat2rTr0KlLtx69+vQbSIMNw0aMGjJm3IRJU6b9MWPWshWr1qzb8M+m/7Zsp92GPfsOHDpy7MSpM+cuXLrKhFcicICBwBEhRoIUGXIUKFG5hhoCDdpE18HSqO+er0OQya2ZOnjyhAZAb8tgHhqQZf+S1O1PfzYNRySX4Plf2n/6J9935ANA/vEHwI2/mIiGj+EAaN35+/o9QE/2gz/rDiSEG7+P/drbUw1HBA8Ag78BtvxxzNOhpZt93vb+qAToAXXnQgkPx/W7Ooqhyqqz7ID8t1sD/Jgr9tVwFZrLBdzc/3/bfMPf0dGukX1Sjw1HsYO6jxrhzzHmyhQxFcBvdoUE6pRLER/ZWodwajUPf9kYiIfKRHERc7XRrdBp6zAE4E9aUAAye8OVAVmy4eKArD6xsji7VokvhagFp+cYG5YadBU43TwsuRPIyU9B1yPfQcTFcZBxx1i4JlvF9PCXrXR9doY4Gn5XsoN7bjrBaXlR9/CmkqqjU5MUoCdpUqjqGqRiSrqx7qHmXiW4V6OtJoIqTHC741/a2d7LSl1avA2cnM4OqBeykQdV2GAT2B7/8g7FRXrNYZHD0wYXgRLuueFv123dcJJmFmmJstoo+v7AWA7x5+6kw08jkpHU8P/ZO+z/nZupEHqEdFhVG1w0tNItnTQkGLGXyAjeoJZ3Nia9hT4teajS6ShtQLLqzl7A0araYFu3zwaUXV3I8IsI7c1uCMUsPoY+uw9sYCddWf6+Xhw3jZL3dnpc5+t6dtlYzY7wYkhD2KWE/85g2ZVa1tHe+1Qash77OKNf1NWmzbXE3OUZtR3SHiekOLZmuh6kJSw15LRXqZVYy7q3R8+rIqCb3aVNn5ugHP/36tLehwkv2onYYfMor8h9WP2u0aaHCdrN015J7PiLlwx24sVuUgJqTmvsdgBZt1bFAZlQO8HvaaNL3t1wfHk6GSCzWiElIBeN2uvhMIQr2PQFE0ONCggDcl0nZVdr3wR3ySmowBVz1UIrkY5hA08+8NM4V0JYhU1fMLFmY4DK8D9MscF0Z03V6d0iDnurJRxi9jQ+lQ7I12E3m1dUu5spUM7fO2rC4iwVMyN/Iy6DAe7tOdoAWHv3i6kBwm93IGb0ub63zN8P46vh3liuEoCVOnR39EdCNy4A6G2uu43LGZGb/26sEQOkWnkxtIh1xZknQwFJWOh4cOatX/rggMPyfJ/RAboivZAonWHvaY/Vh/YpfLuzMbFNJf+CNDe40ahrl7g6+mjokpsUuVe2Enoje3whb83vFDEfvVmTSJL5LN4KQ9C+hYjS44Iv905N4JOvBEuu1DTeae/SpPw1Gsmmdk4TgKgJe9Rxwv/1RsJbo4vSidg0fOHd0iK1HZPS5fD5MWLPY91NXBDg9zWDtwOrOmOoi7gtVPmRwmKWLsklJ2rSwksVqpbMCQvvgEemo5uXZ8bFGxUSo++BJltoiqMM2j7s5wstEMOY56spl6kRQyrMXCzOdEinquvIC2xPHlh4NE1B1oIihUKlfi7cnCHcQfI4dGfTh++tXF3fHB8W5wsG50DifK7GCRO13qgqCYB/HCMGIP0j6pbd4sbbLbhlDSLMuNWNvjurhlCf99/N9EaHNX4/FoYa4FsNAdCAnLxQoHFnDk/pzpkryVU/cuFwuawKFdwb/0GH4v8v0KGeBdNtcKDWNEYQL9EThEoH1QdFV3X8H3xDNFRRQK9RR+twRuIlxOV8DIDa5sHyzjESL0IH7UOmg0Isxr8iTOSTfIS/8ZLoIqIFkdrSUsAmiwM47Q0Y9oPcHTx6IrdZ9WG67RsdBQ+6NVMRhB/Tzy2YxVukE29UPezNa+1Gbxm7mm7t1RhheS39AmiN9q05ukJV+2FrNUY0+fB3ZAldwGtQy/s6hq+FFpGJk+q0Acnqnql21L3GCMtroQX0y6sPli4oYZ+qiCMghfMuirGAdqeG6tLyXgyGvDK/hUWM724+AUAdONunp59OdE9fxFzfrjLs61kr3hC55K9E8s7a4URqqnRGjhSD9gxiTbfuOQcrSTZYQ9/xfo5sGMHwNXV9B8KafDshsqe0ch7CnGnQ1uZhgBa3ovbb0cVfr28AkM2bIsPQLZTWpDRhE0gVvLWF4shoYRjdRdoVa+paNzkmmECp4mMWGDfy5XyTY9Co+ikjAQzslL9gd2OFjyFNMSNmEigVFpqG0dFNV3tAXXnyDJ1BtRRPOGbS05oEvZztYhyJgZ2la+aRr0vCIDEzqqjKEhAGau1u7hNvztvo6RR3hzGkOmOClPiaGhOdVGqaVFHdhUVNkEAplFuNn6CVFNbo6iYlmfaelmx19wj6gOv24O5Vaid0ghboX2xFlN0RLuMLmTZf2q5ET7ORRRUcpqsWhdaglsMOg7Xuk9YEr7h60Vqp8Qi4pmRd+dJmYgbew/T+fmw86a6OMz6vPiEKWCGeWZ87ujqtDcvjK6lAaj7nE4VY4OmtiQ5vSdw7JaqC4CAeb98K6GBi2FJJQMhRo01wOM7EXEz0jJPReoNrQR0ih52m+PAiJf/ZsXyap8NsfotUe0iwK7w0xOCT1CZuVXUUtzMmRj0u02T+SGIjfotGz4pIrlqqylLwb1EltzQldcPQR9LdnEg02PclnC/u+XCFunHcfQbvMWLC0lVL0OKrhviqs8fHPMvPaBTdJagUYVQ86F5M7O5TRgKaSpE2tryrfKBLJEZzJo3aSy9n5Sg+KCUoyEwreEgrrcbmfzkWxxv3E1dlUgra0zHUVxWxJtzt838O/oRHcuB4rzmVJQlMa8IVBSxX8oWdW5ExsVPuFxY5PZ8fH6KwTDYbH98uRPFKe27pvv50UxPQaRFz49hhqU7Gr14sRsa1/TLAJwZdFtGNaaqtD66JXZzPO87sr5jWfuafv+M0qLxbVPAn1JLCupsRhiSwH3pzFDEJnjS2I+mo2JvgfG63fPy0Qu3V+bg49u8MVA9bM3vTPxXvNlI7Z+ksfTUqWy0OEIq/yQfQB4T033Hk8DWAb2/PGQD49sULvQSRjugRs0bAEAQgQPtcxwv0PnQb1C3FefqZ9d6RA8CbAPUg2OtOrdjLoFDnuC5OcEONOzNzlHwswDaaqDs985H8Hb6wkv65V9VLxgM/oqhk2IHXd81N3CfkOpkwsIX53P88RSFkConTG6KfH2jtIZfNQfKKaE+9wPaE+GD2gTwqgHxc9TCSlVgalDJSHSCMIuou2X26pFjIZKA8H7LU7w78GbH01/mbsf/IdP4k10liaUrleSkBotZgiuMnMHIEHiK76BljHIeM1/KVukjiYlBUx9YdozBaEwljhO8GXqoSc4KUOm3UgCcV8tTJ1bkjBZkSY2ucTVMuOb4fZX9z6erQisHNBrFCkiOAO9wR1EuQRzg8QDMKxxA0HiEagigPnTzEbtO5TexndMdRnESVBIhLCe4chvE8V6xEUUF0hjC24ml5S58SiO5OxL+U3hJ2daQSAHfWOEJAVGO6xMnu0iGSCAqqFEwksVIjQwLjb9HDXiJBKJTKCTS42jgo3MRPEDlTkp5jmiXFVBIPTHFnmvvCqjk70E0ZI6hiP4vZYlb6B6uCAGersOaTONkV+erP2RUjZQyAz7yntuEtGyy8v9rdLkkJLKU4kyW7IXUOnI+8l2qvLnh/zaNBDc5n3mueA9+5ipgOSz1bdpLwqbJouVcZrkFa+XvPDuorWMBaCdQWJzts/eiMRmeGP7I0wodKd7g6NjqDDepLveeg+tnXxaIUuvycCaQn7u1xtqmQrYbs5uD1JxK8H5S+N+rkf00DrICL3Y7Cj+IuEufJMhShfQ6vs1cK8L9EDQZaA1gFGWuZD6y3xOliZkuenuS6SaUnpbpAXXOL6ZDpBqtzqDsQ5UOCFKvT6QOg6qpVbRFwp4PkqZBNxlB5l2J59+8oD2P2o7FJKhhAZI/U5shT2syInYFbshO86ninreIgUdujKVdDcbuqG+Zv48GIfhszG0fPo911svQi9cvj8yeldiA5qFQSwCEOx/+1u3p2KClMxzhXzhNhaUsO2xBLVjAr6Ye5lHvLimT34MaogICjUlVS5+FBPK2cDxs7ry74Za9uijGGJLZS9ilMEwI8SIylEUbcItH76cyKCnxIVa9wfRzC5n4wSObLEQ+sTkriSj8mB6SdMqCjmKURY0jdI5/tdFZefjJuZ2TZkLEPUO+TXCEYZ/Fq4qJHo/IGesa+fV7txNv39HXbS6gEsVgk/fCMh84HRGPw/YRQYnHj0EpKEaokObgDzJrhgeMU3+8ZZPc9i6kzJVCr0sTeHRsiSXKzXbDiTvdAtifmeR4YWs/lPneF8ldPCuiilH35il14NG9J4tHFT2bFY0+9pLWdcPPuUtJNBkFUeLFQisvZRADxreChF5rSXUgN7ot6/cYZp4TthHxrlLnAHwQEAmAbC3EUBNolohMFqVBJQRLycpVKQZCAGxLMYUr1DLdGAuGgO8ToX5slkIuZdLwEyCIVEcJvh7ZIHjtWfEjng/gcIx+Mo+xXjuHGIQH3oDQ3IsIyC8xwZnaWArb8Xd+SmFgpQIMSyRmeT4poHXCOGde2j4KR6Dvh2P6HEgIPK52FIRGiDO8ZSofjoKvatIgymDNU7TsKiIMYiIIiyEQVGYgJP5aUCIM9kOlvaNtrf4GNSvIg0rjPEFZBMqD6DuODAZ4oAX1kkLLyvKSqV2ZJ7TpifScMFw1kucSAMewRaBlI1uhPAe6JO1AlrGcG7WdwHz5r4kMS6Wrqe32jAwy+NiXSr+xwUuJ+Kw4H13nDCDgFYb2frWID72MQGbjfI/z60hP1SeMysrxYp7IzPQK78GwENpF7P1kOFI4j20/gGmQyEF0mtBjB9RJyGUNZaeksU4IvLgJ5yUUS8hiHh+hG7552dK8BabDDUMno0SCkhHsfD1zRboNPnGFRzs+EU8VIG99SrGgw7SMyC8sJpBCAw2NUHQjTIJKEMJDw/HD1GjtukQ1Noq52vDGJYeZLSHjXUaTZvdGH6AN1UxKOJV7NjAXvXUriafed6bSe1UnVe4JF6IKVYnmMnuO3T8TtK6T+o+w46gpD6hKaDklIMUrXWuRjJHALaRArg9xwAsW59lHJlp+PWsk6S1G81NH1Bp9PuvLJagjRWG2KWVlsffiwRsTWyxjMCZHXhOx8dzr9+4K63dmQo7c7NnanrNwV15jKRpBAeo0tMa+6GPafHHzzk3NJ5LkuWu3dNC2KfCI2m+LRHmleiq3d+HDs1sZtfdw9KTPzGJOj+npiOElPfTsGa9DeQWk1sRsrsqREy1Qi2yF6L1BIwYU4QjxGZJxwLxM0q/veHx0A5Vh6m4y75rchx9E6GAOEebLrwXJj6lQCnY397rGux9nz0HJjFt/tszsj3p1ytZO0xebg43QiATBjbY+R9NjvN4kjhRpiSFxdDtxbBaRYyfi8WId1jI/9nuvdsDAmP8UuqZsgFN/q+C2P/djNQZ3/64/FPYf/6WHetZ6ZwT+V2xhoQN//J7777ockDui9Q7t4neBf85It3rm8+Sm8g3aqgWVXS7yY2qjkqz1Ug+qIJMvUPrJN6oDbYXUUKaAO4SOpE9GSqJNwc6iTGatSp+C1MDpNlzL9zqDieuQAuK4KqHG0S6dCYEpPhSpZViqMY3WqcPRBqQjKEajxpoymiiSf6yqKcP5XE+i3QE3k2M/UJE07RsVw7UsVi3siI4rDJ5yGOfFh0G9aAWtO/ZGV/ga88IFgeQ3zeXZe9BKqlNLHoWexjdx5kMrFaMYr6XU0bINf7zdgxQJVfPPWnCYMkv3s492DsAXwhOn8avZ7YdXoNDC333CMJN4DINsvNR80AF9fiOv+fDejb7zi23XQ0Ma4W7OhfhaySW5YyuFqui810BLI+CsJ6HwDH/7emVeM8icU7d89xH4XjS/RwZDrdRu6XoMP9Ufw9PD4NQgajCUM/hj1lWMzzyW5rvxLgEV9dwfg7Gugk8oyeGFunM7JzZ3FZDQNQ1xA5fNL9DMyXhlR5bpdGWhQdWtuOl7yzY4SV9/kupNBs21J00G9mxTg8e7B1MHLUq7x1XYTkKGkgUltxhYd15R2NdAbG/OF5ndtArKt5c6hJv0W32jEKK4XnTPb5MaDf5dev7m/r2mjlvHOMwMtZ2PcM+MsUdKHZr40ZehIUN0BdlWcLiJrZ4Kzq+4VWqQl3GPuy1ziuejSVhWPrWmu63dZ5e5nG/VLivBDqnWri7SbfM7wmcYbkzwlC7AvIvw8toswiOkddfdm+Ar13gFohL50WrtCNWqJiNWRkDrLyCldn8rJM6p0kcNLiUL0Q1+JBnpXDRhUpJGBUQqTVGY3jBhlymIWMg4CzM45d/Jo0fxohmvVxsunnV9Ap443cUuP320kw4c5hh5QtlFy9Osz2lhjZD1GgWsWGWfAeBNYQ0/kgHLTrbbGTSWWW2kVy4dxiBjN5wfVBWu3PRIksnOoUAUB6QQKcPt9Za99vteqwbe+sEWSQcfRSsbCthXMOnxr4WU4pJIAypQ1vpv/vzEW+BoXB89Ci2wy13pLLfOZDeZbId4kky0OAk7VZnN7YMJf0yZNCXXXjFnzQswwy0Qbwxc8vYykrzLIaIb+jyITdbRMzpRMzTQ4+P5xHREJGQW1f7GgY2BiYePg4uETEPZfS3iISUjJyD1DeV2/iYaO07PW+09Uar6lx66h/0VWNnYZHJxc3Dy8fPwCgkLCIqJiMmXJliNXnnwFChUpVqJUmXIVXfmgCsjJatSqU69BY6dMNWsxTKvh2rTr0KnLCCN169FrlL4uWuZqtDHGGjDOeBjRkYkvfNvkHpTBVttoCyz3wvnaopFIfJgoyYWNlyBR0gSl+sKJZKS/iDq6evoGZAqVRmcwWWxDI+O+3n7npmbmHC6P3wgTisQdxTyjMQAWhycQSWQKlUZn9KBisTlcHl8gFIklUpkcsSlv8xpSWAlHIlJZpOISklLSMp5rYU76tRYUlZQV2pUvTYSn/YkdYcSRRh5l1NFG97KRls2Y2f5o6mmmnW76GWZcykxLnXmWpS19Vg3bzfQd7RTNbd1vBHK/kfFMZrpPM5u5Q47Qaq+b7ewwcl2O/Xre85nv/Oa/L5rKjd4ydsESt84YhdvXGH7py3gzWcuWXBHMymCuYLPKq0B0VRZa3W1ei9Eq7wDaVVkVl4/YHdu41iolXr3JzGaRV8S2Ms4rI7dq/8/uB/AVB1y9UgP2aHcFGIir3FJky3H2I3SoDHScE36uWj5nEHQ03a/bM2IMvto0vx9hAZRr3LjXGEmvcfmeC1Zv3878gvime2nRXn5Ko/i6LpsRlYx7Tr69r7Uxjl7j6j0XqN7+n0stfIfj3DQmrdnTJCgN4uvCN/st+PZu2b/yVb6qV/1qXu2re/Xv52t4v17j+/2aXj8yUVFVu6dfvc7W9vSXefbsdp9Z/5aCBhvVIuEgfEcFY68FX86YibZxPjN+WmNVhm3DwvI4gWpRKAGgGxYJ9xVKuyeRVNeZWbDZcVbQJyU+KT9Q4ewS1oGwsOfSxS8NRune70ufS742RIC8byE8yg6U6LIMg2WEEcQdF5tLH1+/JlCs6xOXki5+ogoSBfoDgu5U9oWWc6Co0jK7mL0I3mNW6H822UpI2FN3RTQWUH7Plqv7H6UKPFsD6ILv2V2VJ+T7nAwgSwx34FpqF1DbAXbkPPc1PxODMHGeoNCnp1yLZz5Kl/MJvWrtky8S9n5ixsFgcAwmftZq+1uFg9ZAujjjAy5eXfy65KKIpY1q8dSluZ9LIFPEVcSynzAlGIoqIGkOrjbzN0wBp8l4/fUgk1sVyvbij9qSYms9sW2DmKg7tl5fqdkiiCe+jQpOHLnsRCd7HGjAgQY54owzChQkUY5K3HBDJdWIGtGocacdd9hHd9rlGc945rO84hVvfFvO/a55anjP8z/iBFrtTLUdOHHfZz2AdBOcsfe3qeYk2I4qmKlM9wnRUGZQfFuRfDnfdlfNj3DQeujevp3UCW6YYQceGWDCWYlrF0xSysW0YVBa4z7ja99reSntQoD3vORxZuU0wYSQB+qslYer/7Zc9+VRgLELHujT0p85Ej2Mfur0e7uRjpj2gw+vmXB4oLtW3vu8Il+s/+B6/bC9kKHsGTM++ebJSOJhMQsTrv35wP0R6BGz7OsIctnhD9xl2Kb6kdSp2eJoFjGtCNApDxSuQ9H59Zwga26NvzqylZuPutcCWRRYmL6EwKvOiKDFdTUcX7mhXmo7MvbuprqT5sIOd3/Glkdfmem8OD7/S2psr9GWte/EaEoFcoXphwmeur2bWq1lIZL4WXG0bz48+jubGM3g4sU3AkkjQZHkE3/3amIY5jar+JshzP0VytV4tr4jeelyK/yB3iARPka7MqTN/sM6LyRCFoaP/sM6R8O+eVJV1EK0DfqS3VfB3YKD+Jid/0cq8KAi9w1ldCWo8SgoVh1c731VgQid6PgJPv7gzfqocVzGNT5GjQvEbmeHqvrfWC0xkp8km9k0Ajcad3Lvdb/PfE6MqyZpD85112qt7UEHbbDyi/5f80xtf4q2ozSNZj6NaXQHpG/jrwkU7XibeOmOv+Xe+y1KOk4G9FOd2X/Brus2Bt1PyXt0XcknD2Sa3J8pURdSJNd6nPU418dZjxMUQAIACAAEQACEa2EF4T5x748KQ7zy3JWEmDqkJPZ3X5l1hlbMgXwZnD5tnP/xf3b6ZZWWTf9vB5bhvYb7A/qBqhZ5peIFt1lxu4Ajj+MFX78+Uu4sbbSouHmWiw9kPCtbMHBCK9XvYoXt5UrkPfSjIliRd/HfluHca6Gd6eYMNC9rAlOeVBFZPkozbenYCxme5DHlkR3AIz5WljAFwVWLUMruQwoydR6giLNbEFX1dutchMxOf5y5F7oMwrIll7n3xkl8giHCpDg0kLZKCIlXsdgecHLTs0H91Nxty2TOMnHIJB6YgDCZCxNJMIEya6q5Y2imqU5+6XeyJD/Fmd4DhpD7vgpLVCvFen5VBymnsuML5koFb0NF9UHfaqVUELvPlxVSGdTPjvWzIwhAAAAAkAAAAgABEAEuiAWoZyndUaAKDb0q1LAo1LgqFNw6UmhIwOJKt4IFhViL69lAruXWouhM3DW96ujCvYuU0eG1Rm67SQTg4C8eZFm3fgfkLTP17t15hySRdwlRoExrKdYeKCJAGVsoIcO7Pw6mUysnpyspamgNraNNqrZnRDph2j47q1b50bfVaPRaH9H8pqZwE8jscfWh2XZsgz9524S+2YCrBy3LGkTAL1fiJhi1jAW5ahCYve6KRTzYi8WcF7iNvFWHjlAWXKbI0FKRAiUERxWqWoW6nEKNq0Ln1cppkuYJUyMtDgxKlz5ypx7lywTAwzNsYuBanDEQf3KFGIFmZX3Sw9U4qWHtmqBOB9ffaiCuFuJxfn5zxrczJj5SziDXGUVZY7M0wBSZYjP142d8dOtRUIc0VwSI+iLaFanpEQtTVMRnpQnXgtzLyMzZmjVmDmoynljWGmHpDmurOIMRd9lRN8Vd8LuYhVssdsZ+OG/OfaVxqcyuyyee8+f45dG4xlHfkRqyCEqQMPC6zSRCA0gi7d+CxQIewZuELqqJdNBI4i4uGWJuZxh/4viNxkLTF9M/koBMUk2SvdCOLqZSSw+ebiylQD3lPiOUy2spZX/2F0kfWSk2qyZTxGcsGbNxzt9cUU2haaYwxakljgmkTOVxKffBVFJ6XnRJ8LLOSXSOjcfzGyzSuYQrLaW04CnIlI3YwzY42NzajPxZiXwXrSUXGvhQZMlGjjQRhKmFTDX2QQQb4K2tnGqw8dIS2oIG1/xHfWEjGpQHXUtERKEpEDFhA3JjQ+0Jr0apP5XLjl1NUWgfhLAzOCsjrhmxoRC8spGGtoDYFtrdbTwqG+OKsTZIr84wc4lziYPGXmGvcC5x0Dho7BWOPI4X3GbF7QKOPC4WzOCdr1UZLgtpOPGIeRiuvLFzc2Px6R9uMdaLw7wr6HC/dMkME2kftNjz1XjF5spmiBT80vc06B3ZsWW4wawhJfS2h+iSFXYVdoLGCnPx6xVudTiX2Cucm86zAfq3Meui6PtWaHfMVkcCfDO3md8kiv7aocp5Fuai29s2BDrSfEAQm7VAK+40ongeMRwhL0wWzOZweXxEIBSJJahUJlccJXpvKo1FUdcT8GpyQnQWRdVyWiEZqRAQDEIvDnpCsGRelBbGFR/shOgsetPAqb19UTQWfSCQNAR+HsyLorLAo5FLsJFKrcG1Or3BaDJbCNLq1UbRdidnF9cPltusaj2rYes5Val7mubtsqjAV31b45GrToNOMAfxuqxqlGGNm6qocY/rzF23pjOt1GDv99cDQK47a9TooZtuavTQQw2At41BcIQIdFmxMNjpGiiL5bel78Y7eCdwl6pGwLOeJSOl/ir9qAb7jkQHjeYwzBVrDz28A0hKNc2c7SNXR9BFs7UtVxcIQiwBeFe7MtQSQH5XxG/9MRiKM31/ER1p4ydIOz9ArqJ7eAe9vJ0euulB9EWAFftrqPXEoSsBsveXvAjGfu09JJSf8XR/KrH1kZ5P81kDy7MdtE/KN1WdJ6wX7zpUMMi/MPgzlcRfrvOMO4V6e5zhzpnXeyTtxkxvK3rOhVhY26Oq/Tp/xBf/o3FoxcHd8RRREhoyFSe04uCOp4hS3vxre+U7InyGlRhAjzV7jEIjaVRazX4A4DQqZs9VYxWbVRBI/+YAAAA=) format("woff2")}@font-face{font-family:"Harding";src:url(data:application/font-woff2;base64,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) format("woff2");font-weight:700}@font-face{font-family:"Harding";src:url(data:application/font-woff2;base64,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) format("woff2");font-style:italic}html{font-family:sans-serif;line-height:1.15;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;height:100%;overflow-y:scroll;font-size:100%;box-sizing:border-box}body{min-height:100%;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;line-height:1.76;color:#222}article,aside,figcaption,figure,footer,header,main,section{display:block}figure{margin:0}a,sub,sup{vertical-align:baseline}a{background-color:transparent;-webkit-text-decoration-skip:objects;color:#069;word-wrap:break-word;overflow-wrap:break-word;word-break:break-word;text-decoration:underline;text-decoration-thickness:.0625rem;text-underline-offset:.08em}a:active,a:hover{outline-width:0}abbr[title]{border-bottom:none;-webkit-text-decoration:underline dotted}b{font-weight:bolder}sub,sup{font-size:75%;line-height:0;position:relative}sub{bottom:-.25em}sup{top:-.5em}img{border:0;max-width:100%;height:auto;vertical-align:middle}svg:not(:root){overflow:hidden}button,input{font-family:sans-serif;font-size:100%;line-height:1.15}button,input{overflow:visible}button{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}[type=checkbox]{box-sizing:border-box;padding:0}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}.c-article-box__controls button:focus,.c-article-box__controls button:hover,.c-pan-zoom-controls button:focus,.c-pan-zoom-controls button:hover,a:focus,a:hover{text-decoration:underline}button{cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;border-radius:0}abbr[title]{text-decoration:none}b:focus,dd:focus,div:focus,dl:focus,dt:focus,em:focus,h1:focus,h2:focus,h3:focus,h4:focus,h5:focus,i:focus,li:focus,ol:focus,p:focus,span:focus,strong:focus,ul:focus{outline:0}h1{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}h1{font-family:Harding,Palatino,serif;letter-spacing:min(max(-.011715625rem,4vw),-.0390625rem)}.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.011715625rem}h2{font-size:min(max(1.25rem,3.5vw),1.5rem);line-height:min(max(1.4rem,3.5vw),1.6rem)}.u-h3{font-size:min(max(1.125rem,3vw),1.25rem)}.u-h3,h2{font-weight:700;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.u-h3{line-height:1.4rem}h3{font-size:min(max(1.125rem,3vw),1.25rem)}h3,h4{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;letter-spacing:-.011715625rem;line-height:1.4rem}[contenteditable]:focus,[tabindex="0"]:focus,a:focus,button:focus,input:focus,select:focus{outline:3px solid #fece3e;will-change:transform}body,button,div,form,h1,h2,h3,h4,input{margin:0;padding:0}p{padding:0}a:hover{-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:active,button:active{outline:0}nav ol{list-style-image:none}body{font-size:1.125rem}p{margin:0 0 28px}ol,ul{margin-top:0;margin-bottom:28px}p:empty{display:none}.article-page{background:#fff}.composite-layer{transform:translateZ(0)}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;margin-bottom:40px}.c-article-identifiers{list-style:none;font-size:1rem;line-height:1.3;display:flex;flex-wrap:wrap;color:#6f6f6f;padding:0;margin:0 0 8px}.c-article-identifiers__item{border-right:1px solid #6f6f6f;margin-right:8px;padding-right:8px;list-style:none}.c-article-identifiers__item:last-child{margin-right:0;padding-right:0;border-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin-bottom:16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{font-size:1rem;display:inline;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{margin-left:0}.c-article-author-list li{display:inline;padding-right:0}.c-article-author-list__item svg{margin-left:4px}@media only screen and (max-width:539px){.js .js-smaller-author-etal{display:none;visibility:hidden}}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-button-author-list svg{margin:1px 4px 0 0}.c-article-metrics-bar{display:flex;flex-wrap:wrap;line-height:1.3;font-size:1rem}.c-article-metrics-bar__wrapper{margin:0 0 16px}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-weight:400;font-style:normal;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-author-affiliation__list,.c-article-references{list-style:none;padding:0}.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;line-height:1.3;padding-bottom:8px;margin:0}@media only screen and (min-width:768px){.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-section{clear:both}.c-article-section__content{padding-top:8px;margin-bottom:40px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article__pill-button{padding:8px 16px 8px 20px;background-color:#fff;border:4px solid #bcd2dc;border-radius:20px;font-size:.875rem;line-height:1.4;font-weight:700;margin-bottom:10px;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;text-decoration:none;display:inline-block}.c-article__pill-button:hover{background-color:#069;color:#fff;text-decoration:none}.c-article__pill-button:focus{outline:0;box-shadow:0 0 0 3px #fece3e;text-decoration:none}.c-article__pill-button:active,.c-article__pill-button:hover{box-shadow:0 0 0 0}.c-article__pill-button svg{width:auto;height:100%}.c-article__sub-heading{font-size:1.125rem;font-weight:400;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;font-style:normal;line-height:1.3;color:#222;margin:0 0 8px}@media only screen and (min-width:768px){.c-article__sub-heading{font-size:1.5rem;line-height:1.24}}.c-article__sub-heading--small{font-size:1.125rem;font-weight:700}.c-article-references__item{display:flex;flex-wrap:wrap;border-bottom:1px solid #d5d5d5;padding-bottom:16px;margin-bottom:16px}.c-article-references__item::before{content:attr(data-counter);font-size:1.5rem;line-height:1.4;text-align:right}@media only screen and (max-width:1023px){.c-article-references__item::before{font-size:1.125rem;line-height:inherit}}.c-article-references__item>p.c-article-references__text{flex:1;padding-left:8px}.c-article-references__text{margin-bottom:8px}.c-article-references__links{display:flex;flex-basis:100%;justify-content:flex-end;flex-wrap:wrap;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;font-size:1rem;font-weight:700;margin:0;padding:0;list-style:none}.c-article-references__links>a{padding-left:8px}.c-article-references__links>a:first-child{padding-left:0}.c-article-references__download{text-align:right}.c-article-references__download>a{font-size:1rem;font-weight:700;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}.c-article-references__download svg,.c-bibliographic-information__download-citation svg{margin-left:4px}.c-article-author-affiliation__address{color:inherit;font-weight:700;margin:0}.c-article-author-affiliation__authors-list{padding:0;list-style:none;margin-bottom:16px;margin-top:0}.c-article-subject-list{font-size:1rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;list-style:none;display:flex;flex-wrap:wrap;padding:0;margin:0 0 24px}.c-article-subject-list__subject{background-color:#dae5ea;border-radius:20px;padding:4px 10px;font-weight:700;margin-right:15px;margin-bottom:16px;flex:0 1 auto}.c-bibliographic-information{display:flex;padding-top:8px}@media only screen and (max-width:1023px){.c-bibliographic-information{padding-top:0;display:block}}.c-bibliographic-information__value{font-size:1rem;display:block}.c-bibliographic-information__column:first-child{width:81px;flex:0 0 81px}@media only screen and (max-width:1023px){.c-bibliographic-information__column:first-child{width:100%}}.c-bibliographic-information__column:last-child{flex:1}.c-bibliographic-information__column--border{border-right:1px solid #d5d5d5;margin-right:24px}@media only screen and (max-width:1023px){.c-bibliographic-information__column--border{border-bottom:1px solid #d5d5d5;padding-bottom:8px;margin-bottom:8px;border-right:0;margin-right:0}}.c-bibliographic-information__list{list-style:none;margin:0;padding:0;display:flex;justify-content:flex-start;flex-wrap:wrap}.c-bibliographic-information__list-item{flex:0 0 33%;box-sizing:border-box;padding-right:8px;margin-bottom:16px;font-size:1rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}@media only screen and (max-width:1023px){.c-bibliographic-information__list-item{flex:0 0 100%}}.c-bibliographic-information__list-item p{margin-bottom:0}.c-bibliographic-information__list-item:last-child{padding-right:0}.c-bibliographic-information__list-item--doi{flex:0 0 100%}.c-bibliographic-information__citation,.c-bibliographic-information__download-citation{font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;font-size:1rem;margin-bottom:8px}.c-bibliographic-information__download-citation{margin-bottom:24px}.c-article-box{border:2px solid #dae5ea;margin:0 0 24px;padding:0}.c-article-box__container{margin:0;overflow:hidden;padding:20px 20px 30px}.c-article-box__container-title{margin-bottom:8px;font-weight:700}.c-article-box__content>*{margin-bottom:0}.c-article-box__controls{position:relative;margin-top:-56px}.c-article-box__controls button{display:block;font-weight:700;font-size:.875rem;background-color:#dae5ea;color:#069;border:0;padding:10px 20px 6px;width:100%;cursor:pointer}.c-article-box__button-text:after{content:"";width:20px;height:10px;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%20width%3D'12'%20height%3D'7'%20viewBox%3D'0%200%2012%207'%3E%3Cpath%20fill%3D'%23006699'%20d%3D'M9.6%200l-3.6%204.3-3.6-4.3h-2.4l6%207%206-7h-2.4z'%2F%3E%3C%2Fsvg%3E");background-repeat:no-repeat;background-position:50% 50%;display:inline-block}.c-article-box__fade{height:56px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0,rgba(255,255,255,.38) 25%,rgba(255,255,255,.75) 50%,rgba(255,255,255,.85) 75%,#fff 100%)}.c-article-share-box{font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}.c-article-share-box__description{font-size:1rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;margin-bottom:8px}.c-article-share-box__additional-info{color:#626262;font-size:.813rem;margin-bottom:24px}.c-article-share-box__button{background:#fff;border:1px solid #069;box-sizing:content-box;color:#069;font-size:1rem;line-height:1.5;margin-bottom:8px;padding:8px 20px;text-align:center}@supports ((-webkit-backdrop-filter:blur(10px)) or (backdrop-filter:blur(10px))){.c-context-bar--sticky:after{background:linear-gradient(to top,rgba(255,255,255,.75) 50%,#fff);-webkit-backdrop-filter:blur(10px);backdrop-filter:blur(10px)}}.c-reading-companion{clear:both}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{overflow-x:hidden;overflow-y:auto;margin:0;min-height:200px}.c-reading-companion__tabs{font-size:1rem;list-style:none;display:flex;flex-direction:row;flex-wrap:nowrap;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{color:#069;border:solid #d5d5d5;border-width:1px 1px 1px 0;background-color:#eee;padding:8px 8px 8px 15px;text-align:left;font-size:1rem;width:100%}.c-reading-companion__tab:focus{text-decoration:none;outline-offset:-4px}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{color:#222;background-color:#fff;border-bottom:1px solid #fff;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;padding:8px 0 8px 16px;line-height:1.5;overflow:hidden;white-space:nowrap;text-overflow:ellipsis}.c-reading-companion__section-item--active a{white-space:normal;border-left:4px solid #d5d5d5;padding-left:12px;color:#222}.c-header__menu--global .c-header__item svg{display:none}.c-reading-companion__panel{border-top:none;margin-top:0;padding-top:0}.c-reading-companion__panel--active{display:block}.c-article-section__figure{border:2px solid #d5d5d5;padding:20px 10px;max-width:100%;margin-bottom:24px;clear:both}.c-article-section__figure-caption{margin-bottom:8px;display:block;word-break:break-word}.c-article-section__figure-content{margin-bottom:16px}.c-article-section__figure-item{max-width:100%}.c-article-section__figure-link{max-width:100%;display:block;margin:0 0 16px;padding:0}.c-article-section__figure-item img{display:block;margin:0 auto}.c-article-section__figure-description{font-size:1rem}.c-article-section__figure-description>*{margin-bottom:0}.c-article-table{border:2px solid #d5d5d5;clear:both;padding:20px 10px;margin-bottom:24px}.c-article-table__figcaption{line-height:1.4;margin-bottom:16px;word-break:break-word}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{flex:1;padding:13px 24px!important}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}@supports (display:grid) and (grid-auto-rows:auto){.c-article-metrics__legend ul{display:grid;grid-column-gap:8px;grid-auto-rows:auto;grid-template-columns:repeat(auto-fill,minmax(120px,1fr))}@media only screen and (min-width:540px){.c-article-metrics__legend ul{padding-left:16px;grid-template-columns:repeat(2,50%)}}@media only screen and (min-width:1024px){.c-article-metrics__legend ul{grid-template-columns:repeat(3,33%)}}.c-article-metrics__legend ul li{font-size:.875rem}}a:hover{text-decoration:underline;text-decoration-thickness:.3875rem;text-underline-offset:.08em}p{word-wrap:break-word;overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{display:none;background-color:#ccc}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 4px + 90px)}@media only screen and (min-width:768px){.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad--300x250{display:none;background-color:transparent;padding:0}.c-ad--300x250 .c-ad__inner{min-height:calc(1.5em + 4px + 250px)}@media only screen and (min-width:320px){.js .c-ad--300x250{display:block}}.c-ad__label{font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}.c-ad__label{font-size:.875rem;font-weight:400;margin-bottom:4px;color:#333;line-height:1.5}.c-breadcrumbs>li{display:inline}.c-meta{list-style:none;padding:0;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;font-size:.875rem;color:inherit;line-height:1.4}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;padding-right:4px;margin-right:4px}.c-skip-link{background:#069;color:#fff;font-size:.875rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;text-align:center;padding:8px;position:absolute;inset:0;bottom:auto;z-index:9999;transform:translateY(-100%)}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out}}.c-skip-link:active,.c-skip-link:hover,.c-skip-link:link,.c-skip-link:visited{color:#fff}.c-skip-link:focus{transform:translateY(0)}.c-breadcrumbs{list-style:none;margin:0;padding:0;font-size:1rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;color:#000}.c-breadcrumbs__link,.c-breadcrumbs__link:hover,.c-breadcrumbs__link:visited{color:#666}.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0;aspect-ratio:var(--card--image-aspect-ratio, 16/9)}}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{width:100%;height:100%;transform:unset;-o-object-fit:cover;object-fit:cover}}.c-corporate-footer{background-color:#222;border-top:none;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;padding-top:16px;padding-bottom:24px}.c-corporate-footer__legal{color:#a2a2a2;font-size:.813rem;margin-bottom:0;padding-top:4px}.c-menu{list-style:none;margin:0;padding:0;font-size:1rem;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;display:flex;line-height:1.3}.c-menu__item:not(:last-child){margin-right:16px}.c-menu__link{display:inline-block}.c-menu__link:active,.c-menu__link:visited{color:inherit}.c-menu__link:hover{text-decoration:underline}.c-menu--inherit .c-menu__link,.c-menu--inherit .c-menu__link:hover,.c-menu--inherit .c-menu__link:visited{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;margin-bottom:16px;line-height:1.4}.c-header__row{position:relative;padding:8px 0}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__row--flush{padding:0}.c-header__split{display:flex;align-items:center;justify-content:space-between}.c-header__logo-container{flex:1 1 0;margin-right:24px;line-height:0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px;padding:0 16px}.c-header__menu{list-style:none;padding:0;display:flex;align-items:center;flex-wrap:wrap;flex:0 1 auto;font-weight:700;line-height:1.4;margin:0 -8px}.c-header__menu--global{font-weight:400;justify-content:flex-end}@media only screen and (min-width:540px){.c-header__menu--global .c-header__item svg{display:block}}.c-header__menu--journal{font-size:.875rem}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}@media only screen and (max-width:1023px){.c-header__menu--tools{display:none}}.c-header__item{display:flex}@media only screen and (min-width:540px){.c-header__item:not(:first-child){margin-left:8px}}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}@media only screen and (max-width:767px){.c-header__item--nature-research{display:none}}.c-header__row--flush .c-header__item{padding-top:8px;padding-bottom:8px}.c-header__link{color:inherit;padding:8px;display:flex;align-items:center;white-space:nowrap}.c-header-expander a,.c-header-expander a.hover,.c-header-expander a.visited,.c-header-expander a:hover,.c-header-expander a:visited,.c-header__link.hover,.c-header__link.visited,.c-header__link:hover,.c-header__link:visited{color:inherit}.c-header__link ::first-letter{text-transform:capitalize}.c-header__link>svg{margin-left:2px;transition-duration:.2s}@media only screen and (min-width:540px){.c-header__link>svg{margin-left:4px}}.c-header__show-text{display:none}@media only screen and (min-width:540px){.c-header__show-text{display:inline}}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}.c-footer a,.c-footer a:hover,.c-footer a:visited{color:inherit}.c-footer{background-color:#2f2f2f;color:#d5d5d5;line-height:1.4;padding:24px 0;font-size:.875rem}.c-footer a{vertical-align:middle}.c-footer__header{margin-bottom:24px;padding-bottom:24px;border-bottom:1px solid #555}@media only screen and (min-width:768px){.c-footer__header{display:flex;align-items:center}}@media only screen and (max-width:767px){.c-footer__header>:not(:last-child){margin-bottom:16px}}@media only screen and (min-width:768px){.c-footer__logo{flex:1}}.c-footer__list{list-style:none;margin:0;padding:0}.c-footer__grid{display:flex;flex-wrap:wrap}@supports (display:grid){.c-footer__grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(250px,1fr));grid-column-gap:16px;grid-row-gap:32px}}.c-footer__group{flex:1 1 50%;max-width:50%;padding-right:16px;margin-bottom:16px}@media only screen and (min-width:1024px){.c-footer__group{flex-basis:25%;max-width:25%}}@supports (display:grid){.c-footer__group{padding-right:0;max-width:none;margin-bottom:0}}.c-footer__heading{color:#eee;margin-bottom:16px;font-weight:700;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}.c-footer__item:not(:last-child){margin-bottom:4px}.u-button svg{fill:currentColor}.u-button{text-decoration:none}.u-button{align-items:center;cursor:pointer;margin:0;position:relative;font-family:sans-serif;font-size:1rem;line-height:1.3;padding:8px;transition:.25s ease,color .25s ease,border-color .25s ease;border-radius:2px}.u-button,.u-button:visited{color:#069}.u-button,.u-button:hover{border:1px solid #069}.u-button:focus{border:1px solid #069}.u-button:focus,.u-button:hover{color:#fff;background-color:#069;background-image:none}.u-button--primary{color:#fff;background-color:#069;background-image:none}.u-button--primary:visited{color:#fff}.u-button--primary,.u-button--primary:hover{border:1px solid #069}.u-button--primary:focus{border:1px solid #069}.u-button--primary:focus,.u-button--primary:hover{color:#069;background-color:#fff;background-image:none}.u-button--disabled,.u-button:disabled{color:#222;background-color:transparent;background-image:none;border:1px solid #eee;opacity:.7;cursor:default}.u-button--disabled svg,.u-button:disabled svg{fill:currentColor}.u-button--disabled:visited,.u-button:disabled:visited{color:#222}.u-button--disabled:hover,.u-button:disabled:hover{border:1px solid #eee;text-decoration:none}.u-button--disabled:focus,.u-button:disabled:focus{border:1px solid #eee;text-decoration:none}.u-button--disabled:focus,.u-button--disabled:hover,.u-button:disabled:focus,.u-button:disabled:hover{color:#222;background-color:transparent;background-image:none}.u-button--full-width{display:flex;width:100%}.u-hide{display:none;visibility:hidden}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media only screen and (min-width:768px){.u-show-at-md{display:block;visibility:visible}}.u-clearfix::after,.u-clearfix::before{content:"";display:table}.u-clearfix::after{clear:both}.u-float-left{float:left}.u-icon{fill:currentColor;transform:translate(0,0);display:inline-block;vertical-align:text-top;width:1em;height:1em}.u-list-reset{list-style:none;margin:0;padding:0}.u-text-right{text-align:right}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-display-inline{display:inline}.u-display-flex{display:flex;width:100%}.u-flex-wrap{flex-wrap:wrap}.u-justify-content-space-between{justify-content:space-between}.u-flex-shrink{flex:0 1 auto}.u-ma-0{margin:0}.u-mt-16{margin-top:16px}.u-mt-32{margin-top:32px}.u-mr-2{margin-right:2px}.u-mr-32{margin-right:32px}.u-mb-16{margin-bottom:16px}.u-mb-32{margin-bottom:32px}html *,html ::after,html ::before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-footer a,.c-header__link{text-decoration:inherit}.c-footer a:hover,.c-header__link:hover,.c-site-messages .c-site-messages__close:hover,.nature-briefing-banner__checkbox-label a:hover{text-decoration:underline}.c-site-messages .c-site-messages__close{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'21'%20height%3D'21'%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%20aria-labelledby%3D'close'%20role%3D'img'%3E%3Ctitle%20id%3D'title'%3EClose%20button%20icon%3C%2Ftitle%3E%3Cpath%20d%3D'M10.5%2012.621l2.727%202.727%201.06%201.06%202.122-2.12-1.06-1.061L12.62%2010.5l2.727-2.727%201.06-1.06-2.12-2.122-1.061%201.06L10.5%208.38l-2.69-2.69-1.06-1.06L4.629%206.75l1.06%201.06%202.69%202.69-2.69%202.69-1.06%201.06%202.121%202.121%201.06-1.06%202.69-2.69zm0%208.379C4.701%2021%200%2016.299%200%2010.5S4.701%200%2010.5%200%2021%204.701%2021%2010.5%2016.299%2021%2010.5%2021z'%20fill%3D'%23fff'%20fill-rule%3D'evenodd'%2F%3E%3C%2Fsvg%3E"),none;background-position:100% 50%;background-repeat:no-repeat;background-size:16px}.c-site-messages--nature-briefing-email-variant{padding-top:15px;padding-bottom:15px;box-sizing:border-box}.c-site-messages--nature-briefing-email-variant .visually-hidden{width:1px;height:1px;position:absolute!important;clip:rect(1px,1px,1px,1px)}.c-site-messages--nature-briefing-email-variant .sans-serif,.c-site-messages--nature-briefing-email-variant.sans-serif{font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif}.c-site-messages--nature-briefing-email-variant .box-sizing{box-sizing:border-box}.c-site-messages--nature-briefing-email-variant .text13{font-size:.8125rem}.c-site-messages--nature-briefing-email-variant .block{display:block}.c-site-messages--nature-briefing-email-variant .tighten-line-height{line-height:1.4}.c-site-messages--nature-briefing-email-variant .extra-tight-line-height{line-height:1.3}.c-site-messages--nature-briefing-email-variant .grid{float:left;padding-left:0!important;padding-right:0!important}.c-site-messages--nature-briefing-email-variant .grid{margin-right:3.2%}.c-site-messages--nature-briefing-email-variant .last{margin-right:0}.c-site-messages--nature-briefing-email-variant .grid-4{width:31.2%}.c-site-messages--nature-briefing-email-variant .grid-8{width:65.6%}.c-site-messages--nature-briefing-email-variant .grid-12{width:100%}.c-site-messages--nature-briefing{position:fixed;bottom:0;left:0;right:0;width:100%;box-shadow:0 0 10px 0 rgba(51,51,51,.2);transform:translateY(100%);border-bottom:none}.c-site-messages--nature-briefing .c-site-messages__close{border:0;padding-right:0}.c-site-messages--nature-briefing .c-site-messages__close-container{text-align:right;display:inline-block}.c-site-messages--nature-briefing .c-site-messages__close-container svg{width:25px;height:25px}.c-site-messages--nature-briefing.c-site-messages .c-site-messages__close{background:0 0}@media only screen and (min-width:960px){.c-site-messages--nature-briefing-email-variant.c-site-messages .c-site-messages__banner-large .c-site-messages__close{margin-top:0}}.c-site-messages__banner-large .c-site-messages__close-container{float:right;margin-top:-5px}.c-site-messages__banner-large .c-site-messages__form-container{float:none;width:100%}@media only screen and (min-width:768px){.c-site-messages__banner-large .c-site-messages__close-container{width:30px}.c-site-messages__banner-large .c-site-messages__form-container{float:left;width:calc(100% - 30px)}}.c-site-messages--nature-briefing .c-site-messages__close{vertical-align:top}.c-site-messages--is-visible .icon--inline path,.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages__close-container:hover .c-site-messages__close svg path{fill:#069}.c-site-messages--nature-briefing .c-site-messages__close{color:#069}.nature-briefing-banner__email-input{border-color:#222}.nature-briefing-banner__checkbox-label{cursor:pointer;position:relative;padding-left:33px;max-width:467px}.nature-briefing-banner__checkbox-label:before{content:"";position:absolute;top:6px;left:0;width:24px;height:24px;border:1px solid currentColor;border-radius:0;background:#fff}.nature-briefing-banner__checkbox-label:after{content:"";position:absolute;top:12px;left:5px;width:14px;height:7px;transform:rotate(-45deg);border:solid;border-width:0 0 2px 2px;border-top-color:transparent;opacity:0;background:0 0}.nature-briefing-banner__checkbox-checkbox{font-size:20px;cursor:pointer;position:absolute;z-index:1;top:4px;left:-2px;width:28px;height:28px;margin:0;opacity:0}.nature-briefing-banner__checkbox-checkbox:checked+.nature-briefing-banner__checkbox-label:after{opacity:1}.nature-briefing-banner__checkbox-checkbox:focus+.nature-briefing-banner__checkbox-label:before,.nature-briefing-banner__submit-button:focus{outline:3px solid #fece3e}.nature-briefing-banner__submit-button{background:#069;color:#fff;text-align:center}.nature-briefing-banner__submit-button:disabled{background-color:#777;color:#fff}.nature-briefing-banner__checkbox-label a{transition:color 1s ease-in-out 1s}.c-site-messages__banner-large{margin:0 auto;padding-left:16px;padding-right:16px}.c-site-messages__banner-large{display:none;max-width:1280px}.c-site-messages__banner-large:after,.c-site-messages__banner-large:before{content:" ";display:table}.c-site-messages__banner-large:after{clear:both}@media only screen and (min-width:641px){.c-site-messages__banner-large{display:block}}.c-site-messages.c-site-messages--nature-briefing-redesign-2020{color:#fff;background-color:#29303b;background-repeat:no-repeat;background-position:right top;background-image:url(data:image/png;base64,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);transition:transform .6s ease-in-out;padding-right:120px}@media only screen and (max-width:1040px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020{background-position:666px 0}}@media only screen and (max-width:870px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020{background-position:calc(85% + 374px - 120px) 0;padding-right:15%}}@media only screen and (max-width:640px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020{background-position:calc(100% + 374px - 200px) 0;padding-right:100px}}@media only screen and (max-width:480px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020{background-image:none;padding-right:0}}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages__close-container{width:25px;height:25px;position:absolute;right:10px;top:10px;background:#29303b;border-radius:12.5px;border:0}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages__close-container:hover{background:#fff}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages--nature-briefing__strapline{margin-top:10px;margin-bottom:0;font-size:.875rem}@media only screen and (min-width:1040px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages--nature-briefing__strapline{font-size:1rem}}@media only screen and (min-width:1200px){.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .c-site-messages--nature-briefing__strapline{font-size:1.125rem}}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__checkbox-label:before{border-color:transparent;border-radius:2px}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__checkbox-label:after{border-color:transparent #222 #222}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__checkbox-label a{font-weight:400;text-decoration:underline;color:#fff}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__email-label{display:block;padding-left:0}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__email-wrapper{margin-bottom:10px}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__email-input{display:inline-block;float:none;width:70%;max-width:500px;border:1px solid #fff;border-radius:2px;padding:8px 10px 7px;font-size:.9375rem;line-height:.9375rem;vertical-align:top;margin-right:1%}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__submit-button{display:inline-block;float:none;transition:none;background-color:#29303b;border-radius:2px;border:1px solid #fff;padding:8px 2%;font-size:.9375rem;line-height:.9375rem;vertical-align:top;width:15%;min-width:75px;max-width:90px}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__submit-button:hover,.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing__link:hover{color:#29303b;background-color:#fff}.c-site-messages.c-site-messages--nature-briefing-redesign-2020 .nature-briefing-banner__checkbox-wrapper{position:relative}.grade-c-hide{display:block}.c-site-messages--nature-briefing{z-index:100001}.u-lazy-ad-wrapper{min-height:137px;display:none;background-color:#ccc}@media only screen and (min-width:768px){.u-lazy-ad-wrapper{display:block}}</style>
<noscript>
                    <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-74406d1986.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
                </noscript>
<meta name=msapplication-TileColor content=#000000>
<meta name=msapplication-config content=/static/browserconfig.xml>
<meta name=theme-color content=#000000>
<meta name=application-name content=Nature>
<meta name=robots content=noarchive>
<meta name=access content=Yes>
<link rel=search href=http://www.nature.com/search>
<link rel=search href=http://www.nature.com/opensearch/opensearch.xml type=application/opensearchdescription+xml title=nature.com>
<link rel=search href=http://www.nature.com/opensearch/request type=application/sru+xml title=nature.com>
<script type=application/ld+json>{"mainEntity":{"headline":"A guide to immunotherapy for COVID-19","description":"Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections. This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.","datePublished":"2022-01-21","dateModified":"2022-01-21","pageStart":"39","pageEnd":"50","sameAs":"https://doi.org/10.1038/s41591-021-01643-9","keywords":"Immunology,Immunotherapy,Biomedicine,general,Cancer Research,Metabolic Diseases,Infectious Diseases,Molecular Medicine,Neurosciences","image":"https://static-content.springer.com/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig1_HTML.png","isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"van de Veerdonk, Frank L.","url":"http://orcid.org/0000-0002-1121-4894","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"email":"frank.vandeveerdonk@radboudumc.nl","@type":"Person"},{"name":"Giamarellos-Bourboulis, Evangelos","url":"http://orcid.org/0000-0003-4713-3911","affiliation":[{"name":"Attikon Hospital, University of Athens","address":{"name":"Department of Infectious Diseases, Attikon Hospital, University of Athens, Athens, Greece","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Pickkers, Peter","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Intensive Care Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Derde, Lennie","url":"http://orcid.org/0000-0002-3577-5629","affiliation":[{"name":"University Medical Center Utrecht","address":{"name":"Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands","@type":"PostalAddress"},"@type":"Organization"},{"name":"Julius Center for Health Sciences and Primary Care","address":{"name":"Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Leavis, Helen","affiliation":[{"name":"University Medical Center Utrecht","address":{"name":"Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"van Crevel, Reinout","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Engel, Job J.","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Wiersinga, W. Joost","affiliation":[{"name":"University of Amsterdam","address":{"name":"Division of Infectious Diseases, Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Vlaar, Alexander P. J.","affiliation":[{"name":"University of Amsterdam","address":{"name":"Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care Medicine and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shankar-Hari, Manu","url":"http://orcid.org/0000-0002-5338-2538","affiliation":[{"name":"School of Immunobiology and Microbial Sciences, King’s College London","address":{"name":"School of Immunobiology and Microbial Sciences, King’s College London, London, UK","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"van der Poll, Tom","url":"http://orcid.org/0000-0002-9199-5079","affiliation":[{"name":"University of Amsterdam","address":{"name":"Division of Infectious Diseases, Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bonten, Marc","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care","address":{"name":"Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Angus, Derek C.","affiliation":[{"name":"UPMC and University of Pittsburgh","address":{"name":"UPMC and University of Pittsburgh, Pittsburgh, PA, United States","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"van der Meer, Jos W. M.","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Netea, Mihai G.","url":"http://orcid.org/0000-0003-2421-6052","affiliation":[{"name":"Radboud University Medical Center","address":{"name":"Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Bonn","address":{"name":"Department of Immunology and Metabolism, Life & Medical Sciences Institute, University of Bonn, Bonn, Germany","@type":"PostalAddress"},"@type":"Organization"}],"email":"mihai.netea@radboudumc.nl","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>
<link rel=canonical href=https://www.nature.com/articles/s41591-021-01643-9>
<meta name=journal_id content=41591>
<meta name=dc.title content="A guide to immunotherapy for COVID-19">
<meta name=dc.source content="Nature Medicine 2022 28:1">
<meta name=dc.format content=text/html>
<meta name=dc.publisher content="Nature Publishing Group">
<meta name=dc.date content=2022-01-21>
<meta name=dc.type content=ReviewPaper>
<meta name=dc.language content=En>
<meta name=dc.copyright content="2022 Springer Nature America, Inc.">
<meta name=dc.rights content="2022 Springer Nature America, Inc.">
<meta name=dc.rightsAgent content=journalpermissions@springernature.com>
<meta name=dc.description content="Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections. This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.">
<meta name=prism.issn content=1546-170X>
<meta name=prism.publicationName content="Nature Medicine">
<meta name=prism.publicationDate content=2022-01-21>
<meta name=prism.volume content=28>
<meta name=prism.number content=1>
<meta name=prism.section content=ReviewPaper>
<meta name=prism.startingPage content=39>
<meta name=prism.endingPage content=50>
<meta name=prism.copyright content="2022 Springer Nature America, Inc.">
<meta name=prism.rightsAgent content=journalpermissions@springernature.com>
<meta name=prism.url content=https://www.nature.com/articles/s41591-021-01643-9>
<meta name=prism.doi content=doi:10.1038/s41591-021-01643-9>
<meta name=citation_pdf_url content=https://www.nature.com/articles/s41591-021-01643-9.pdf>
<meta name=citation_fulltext_html_url content=https://www.nature.com/articles/s41591-021-01643-9>
<meta name=citation_journal_title content="Nature Medicine">
<meta name=citation_journal_abbrev content="Nat Med">
<meta name=citation_publisher content="Nature Publishing Group">
<meta name=citation_issn content=1546-170X>
<meta name=citation_title content="A guide to immunotherapy for COVID-19">
<meta name=citation_volume content=28>
<meta name=citation_issue content=1>
<meta name=citation_publication_date content=2022/01>
<meta name=citation_online_date content=2022/01/21>
<meta name=citation_firstpage content=39>
<meta name=citation_lastpage content=50>
<meta name=citation_article_type content="Review Article">
<meta name=citation_fulltext_world_readable content>
<meta name=citation_language content=en>
<meta name=dc.identifier content=doi:10.1038/s41591-021-01643-9>
<meta name=DOI content=10.1038/s41591-021-01643-9>
<meta name=citation_doi content=10.1038/s41591-021-01643-9>
<meta name=citation_springer_api_url content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-021-01643-9&amp;api_key=">
<meta name=description content="Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections. This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.">
<meta name=dc.creator content="van de Veerdonk, Frank L.">
<meta name=dc.creator content="Giamarellos-Bourboulis, Evangelos">
<meta name=dc.creator content="Pickkers, Peter">
<meta name=dc.creator content="Derde, Lennie">
<meta name=dc.creator content="Leavis, Helen">
<meta name=dc.creator content="van Crevel, Reinout">
<meta name=dc.creator content="Engel, Job J.">
<meta name=dc.creator content="Wiersinga, W. Joost">
<meta name=dc.creator content="Vlaar, Alexander P. J.">
<meta name=dc.creator content="Shankar-Hari, Manu">
<meta name=dc.creator content="van der Poll, Tom">
<meta name=dc.creator content="Bonten, Marc">
<meta name=dc.creator content="Angus, Derek C.">
<meta name=dc.creator content="van der Meer, Jos W. M.">
<meta name=dc.creator content="Netea, Mihai G.">
<meta name=dc.subject content=Immunology>
<meta name=dc.subject content=Immunotherapy>
<meta name=citation_reference content="citation_journal_title=Cell; citation_title=Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein; citation_author=AC Walls; citation_volume=181; citation_publication_date=2020; citation_pages=281-292.e6; citation_id=CR1">
<meta name=citation_reference content="Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).">
<meta name=citation_reference content="citation_journal_title=Cell; citation_title=SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract; citation_author=YJ Hou; citation_volume=182; citation_publication_date=2020; citation_pages=429-446.e14; citation_id=CR3">
<meta name=citation_reference content="citation_journal_title=Crit. Care; citation_title=Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS; citation_author=Y Jouan, T Baranek, M Si-Tahar, C Paget, A Guillon; citation_volume=25; citation_publication_date=2021; citation_id=CR4">
<meta name=citation_reference content="citation_journal_title=Cell Host Microbe; citation_title=Complex immune dysregulation in COVID-19 patients with severe respiratory failure; citation_author=EJ Giamarellos-Bourboulis; citation_volume=27; citation_publication_date=2020; citation_pages=992-1000.e3; citation_id=CR5">
<meta name=citation_reference content="citation_journal_title=Clin. Infect. Dis.; citation_title=Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019; citation_author=X Chen; citation_volume=71; citation_publication_date=2020; citation_pages=1937-1942; citation_id=CR6">
<meta name=citation_reference content="citation_journal_title=J. Clin. Invest.; citation_title=Clinical and immunological features of severe and moderate coronavirus disease 2019; citation_author=G Chen; citation_volume=130; citation_publication_date=2020; citation_pages=2620-2629; citation_id=CR7">
<meta name=citation_reference content="citation_journal_title=Front. Immunol.; citation_title=A longitudinal study of immune cells in severe COVID-19 patients; citation_author=D Payen; citation_volume=11; citation_publication_date=2020; citation_pages=580250; citation_id=CR8">
<meta name=citation_reference content="citation_journal_title=J. Intensive Care; citation_title=Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis; citation_author=I Huang, R Pranata; citation_volume=8; citation_publication_date=2020; citation_pages=1-10; citation_id=CR9">
<meta name=citation_reference content="citation_journal_title=Physiol. Rev.; citation_title=Sepsis: multiple abnormalities, heteroge-neous responses, and evolving understanding; citation_author=KN Iskander; citation_volume=93; citation_publication_date=2013; citation_pages=1247-1288; citation_id=CR10">
<meta name=citation_reference content="Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: a prospective cohort study. Eur. Respir. J. 55, 2000524 (2020).">
<meta name=citation_reference content="citation_journal_title=J. Infect. Dis.; citation_title=Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19; citation_author=NAF Janssen; citation_volume=223; citation_publication_date=2021; citation_pages=1322-1333; citation_id=CR12">
<meta name=citation_reference content="citation_journal_title=Nat. Med.; citation_title=A dynamic COVID-19 immune signature includes associations with poor prognosis; citation_author=AG Laing; citation_volume=26; citation_publication_date=2020; citation_pages=1623-1635; citation_id=CR13">
<meta name=citation_reference content="citation_journal_title=Immunity; citation_title=Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia; citation_author=S Kreutmair; citation_volume=54; citation_publication_date=2021; citation_pages=1578-1593.e5; citation_id=CR14">
<meta name=citation_reference content="citation_journal_title=Nat. Commun.; citation_title=Deciphering the state of immune silence in fatal COVID-19 patients; citation_author=P Bost; citation_volume=12; citation_publication_date=2021; citation_pages=1-15; citation_id=CR15">
<meta name=citation_reference content="citation_journal_title=J. Vasc. Surg. Venous Lymphat. Disord.; citation_title=Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection; citation_author=AT Obi, GD Barnes, LM Napolitano, PK Henke, TW Wakefield; citation_volume=9; citation_publication_date=2021; citation_pages=23-35; citation_id=CR16">
<meta name=citation_reference content="citation_journal_title=Lancet; citation_title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study; citation_author=F Zhou; citation_volume=395; citation_publication_date=2020; citation_pages=1054-1062; citation_id=CR17">
<meta name=citation_reference content="citation_journal_title=Brit. Med. J.; citation_title=Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study; citation_author=T Chen; citation_volume=368; citation_publication_date=2020; citation_pages=m1295; citation_id=CR18">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Clinical Characteristics of Covid-19 in New York City; citation_author=P Goyal; citation_volume=382; citation_publication_date=2020; citation_pages=2372-2374; citation_id=CR19">
<meta name=citation_reference content="Mandal, S. et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76, 396–398 (2021).">
<meta name=citation_reference content="citation_journal_title=J. Clin. Invest.; citation_title=Deployment of convalescent plasma for the prevention and treatment of COVID-19; citation_author=EM Bloch; citation_volume=130; citation_publication_date=2020; citation_pages=2757-2765; citation_id=CR21">
<meta name=citation_reference content="Shankar-Hari, M., Spencer, J., Sewell, W. A., Rowan, K. M. &amp; Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis — biological plausibility from a critical care perspective. Crit. Care 16, 206 (2012).">
<meta name=citation_reference content="Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).">
<meta name=citation_reference content="citation_journal_title=Nat. Rev. Immunol.; citation_title=The role of IgG Fc receptors in antibody-dependent enhancement; citation_author=S Bournazos, A Gupta, JV Ravetch; citation_volume=20; citation_publication_date=2020; citation_pages=633-643; citation_id=CR24">
<meta name=citation_reference content="Zinsser H., Batchelder A. P. Studies on Mexican typhus fever. I. J. Exp. Med. 51, 847–858 (1930).">
<meta name=citation_reference content="citation_journal_title=J. Clin. Invest.; citation_title=A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19; citation_author=MR O’Donnell; citation_volume=131; citation_publication_date=2021; citation_pages=e150646; citation_id=CR26">
<meta name=citation_reference content="Arnold Egloff, S. A. et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J. Clin. Invest. 131, e151788 (2021).">
<meta name=citation_reference content="citation_journal_title=Transfusion; citation_title=Use of convalescent plasma in COVID-19 patients with immunosuppression; citation_author=JW Senefeld; citation_volume=61; citation_publication_date=2021; citation_pages=2503-2511; citation_id=CR28">
<meta name=citation_reference content="citation_journal_title=Cochrane Database Syst. Rev.; citation_title=Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review; citation_author=V Piechotta; citation_volume=7; citation_publication_date=2020; citation_pages=1-293; citation_id=CR29">
<meta name=citation_reference content="citation_journal_title=Lancet; citation_title=Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial; citation_author=O Abani; citation_volume=397; citation_publication_date=2021; citation_pages=2049-2059; citation_id=CR30">
<meta name=citation_reference content="Writing Committee for the REMAP-CAP Investigators et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 326, 1690–1702 (2021).">
<meta name=citation_reference content="citation_journal_title=Front. Immunol.; citation_title=Immunosenescence and Its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention; citation_author=A Aiello; citation_volume=10; citation_publication_date=2019; citation_pages=2247; citation_id=CR32">
<meta name=citation_reference content="Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021).">
<meta name=citation_reference content="Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 325, 632–644 (2021).">
<meta name=citation_reference content="RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Preprint at medRxiv 
                  https://doi.org/10.1101/2021.06.15.21258542
                  
                 (2021).">
<meta name=citation_reference content="citation_journal_title=Science; citation_title=Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications; citation_author=D Mathew; citation_volume=369; citation_publication_date=2020; citation_pages=eabc8511; citation_id=CR36">
<meta name=citation_reference content="Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern. Med. 180, 934–943 (2020).">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Dexamethasone in hospitalized patients with COVID-19; citation_author=P Horby; citation_volume=384; citation_publication_date=2021; citation_pages=693-704; citation_id=CR38">
<meta name=citation_reference content="citation_journal_title=JAMA; citation_title=Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19; citation_author=DC Angus; citation_volume=324; citation_publication_date=2020; citation_pages=1330-41; citation_id=CR39">
<meta name=citation_reference content="Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 324, 1307–1316 (2020).">
<meta name=citation_reference content="Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 324, 1330–1341 (2020).">
<meta name=citation_reference content="Rochwerg, B. et al. A living WHO guideline on drugs for COVID-19. Brit. Med. J. 370, m3379 (2020).">
<meta name=citation_reference content="citation_journal_title=Nat. Rev. Drug Discov.; citation_title=Kinase inhibitors: the road ahead; citation_author=FM Ferguson, NS Gray; citation_volume=17; citation_publication_date=2018; citation_pages=353-377; citation_id=CR43">
<meta name=citation_reference content="Jacobs, C. F., Eldering, E. &amp; Kater, A. P. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 5, 913–925 (2021).">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Baricitinib plus remdesivir for hospitalized adults with COVID-19; citation_author=AC Kalil; citation_volume=384; citation_publication_date=2021; citation_pages=795-807; citation_id=CR45">
<meta name=citation_reference content="citation_journal_title=Lancet Respir. Med.; citation_title=Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial; citation_author=VC Marconi; citation_volume=19; citation_publication_date=2021; citation_pages=1-12; citation_id=CR46">
<meta name=citation_reference content="Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir. Med. 9, 957–968 (2021).">
<meta name=citation_reference content="Guimarães, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406–415 (2021).">
<meta name=citation_reference content="Tharaux, P.-L. et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 9, 295–304 (2021).">
<meta name=citation_reference content="The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. Preprint at medRxiv 
                  https://doi.org/10.1101/2021.06.18.21259133
                  
                 (2021).">
<meta name=citation_reference content="Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care 24, 187 (2020).">
<meta name=citation_reference content="citation_journal_title=J. Am. Soc. Nephrol.; citation_title=Soluble urokinase receptor (SuPAR) in COVID-19-related AKI; citation_author=TU Azam; citation_volume=31; citation_publication_date=2020; citation_pages=2725-2735; citation_id=CR52">
<meta name=citation_reference content="Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10, e66125 (2021).">
<meta name=citation_reference content="Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021).">
<meta name=citation_reference content="Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. JAMA 326, 230–239 (2021).">
<meta name=citation_reference content="citation_journal_title=Lancet; citation_title=Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial; citation_author=O Abani; citation_volume=397; citation_publication_date=2021; citation_pages=1637-1645; citation_id=CR56">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Interleukin-6 receptor antagonists in critically ill patients with COVID-19; citation_author=AC Gordon; citation_volume=384; citation_publication_date=2021; citation_pages=1491-1502; citation_id=CR57">
<meta name=citation_reference content="Domingo, P. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA 326, 499–518 (2021).">
<meta name=citation_reference content="Patel, J. et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). Preprint at medRxiv 
                  https://doi.org/10.1101/2021.04.14.21255475
                  
                 (2021).">
<meta name=citation_reference content="citation_journal_title=Nat. Commun.; citation_title=Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection; citation_author=B Diao; citation_volume=12; citation_publication_date=2021; citation_id=CR60">
<meta name=citation_reference content="citation_journal_title=Lancet Microbe; citation_title=Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study; citation_author=B Schurink; citation_volume=1; citation_publication_date=2020; citation_pages=e290-e299; citation_id=CR61">
<meta name=citation_reference content="citation_journal_title=Blood; citation_title=Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies; citation_author=SV Seshan; citation_volume=114; citation_publication_date=2009; citation_pages=1675-1683; citation_id=CR62">
<meta name=citation_reference content="Kambas, K. et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J. Immunol. 180, 7368–7375 (2008).">
<meta name=citation_reference content="citation_journal_title=J. Immunol.; citation_title=A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways; citation_author=K Ritis; citation_volume=177; citation_publication_date=2006; citation_pages=4794-4802; citation_id=CR64">
<meta name=citation_reference content="citation_journal_title=EBioMedicine; citation_title=Clinical features and prognostic factors in COVID-19: a prospective cohort study; citation_author=S Bruin; citation_volume=67; citation_publication_date=2021; citation_pages=103378; citation_id=CR65">
<meta name=citation_reference content="Vlaar, A. P. J. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 
                  https://doi.org/10.1016/S2665-9913(20)30341-6
                  
                 (2020).">
<meta name=citation_reference content="Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293–294 (2003).">
<meta name=citation_reference content="Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, e764–e773 (2021).">
<meta name=citation_reference content="citation_journal_title=Lancet; citation_title=Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial; citation_author=IFN Hung; citation_volume=395; citation_publication_date=2020; citation_pages=1695-1704; citation_id=CR69">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Repurposed antiviral drugs for COVID-19 — interim WHO Solidarity Trial results; citation_author=H Pan; citation_volume=384; citation_publication_date=2021; citation_pages=497-511; citation_id=CR70">
<meta name=citation_reference content="van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med (N Y.) 2, 1163–1170 (2021).">
<meta name=citation_reference content="citation_journal_title=Intensive Care Med.; citation_title=Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis; citation_author=LS Nguyen, Z Ait Hamou, N Gastli, N Chapuis, F Pène; citation_volume=47; citation_publication_date=2021; citation_pages=619-621; citation_id=CR72">
<meta name=citation_reference content="citation_journal_title=JAMA Netw. Open; citation_title=Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19); citation_author=PF Laterre; citation_volume=3; citation_publication_date=2020; citation_pages=3-7; citation_id=CR73">
<meta name=citation_reference content="citation_journal_title=Res. Pract. Thromb. Haemost.; citation_title=The contact activation system as a potential therapeutic target in patients with COVID‐19; citation_author=JJ Shatzel; citation_volume=4; citation_publication_date=2020; citation_pages=500-505; citation_id=CR74">
<meta name=citation_reference content="citation_journal_title=eLife; citation_title=Kallikrein–kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome; citation_author=FL Veerdonk; citation_volume=9; citation_publication_date=2020; citation_pages=57555; citation_id=CR75">
<meta name=citation_reference content="citation_journal_title=JAMA Netw. Open; citation_title=Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19; citation_author=FL Veerdonk; citation_volume=3; citation_publication_date=2020; citation_pages=e2017708; citation_id=CR76">
<meta name=citation_reference content="citation_journal_title=Trials; citation_title=Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial; citation_author=E Mansour; citation_volume=22; citation_publication_date=2021; citation_pages=1-13; citation_id=CR77">
<meta name=citation_reference content="citation_journal_title=Nat. Rev. Immunol.; citation_title=Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19; citation_author=A Bonaventura; citation_volume=21; citation_publication_date=2021; citation_pages=319-329; citation_id=CR78">
<meta name=citation_reference content="citation_journal_title=J. Am. Coll. Cardiol.; citation_title=Recent randomized trials of antithrombotic therapy for patients with COVID-19; citation_author=AH Talasaz; citation_volume=77; citation_publication_date=2021; citation_pages=1903-1921; citation_id=CR79">
<meta name=citation_reference content="citation_journal_title=Thromb. Res.; citation_title=Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: a retrospective study; citation_author=N Muñoz-Rivas; citation_volume=199; citation_publication_date=2021; citation_pages=132-142; citation_id=CR80">
<meta name=citation_reference content="Mazloomzadeh, S. et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. JAMA 325, 1620–1630 (2021).">
<meta name=citation_reference content="Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021).">
<meta name=citation_reference content="ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N. Engl. J. Med. 385, 790–802 (2021).">
<meta name=citation_reference content="REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N. Engl. J. Med. 385, 777–789 (2021).">
<meta name=citation_reference content="Bendib, I. et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. Crit. Care 25, 23 (2021).">
<meta name=citation_reference content="Richeldi, L. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079–1087 (2011).">
<meta name=citation_reference content="Richeldi, L. et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm. Med. 20, 3 (2020).">
<meta name=citation_reference content="Menshawey, R., Menshawey, E., Alserr, A. H. K. &amp; Abdelmassih, A. F. JAK out of the box; the rationale behind Janus kinase inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovasc. Endocrinol. Metab. 10, 80–88 (2021).">
<meta name=citation_reference content="Henderson, L. A. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV‐2 and hyperinflammation in pediatric COVID‐19: version 1. Arthritis Rheumatol. 72, 1791–1805 (2020).">
<meta name=citation_reference content="Pouletty, M. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 79, 999–1006 (2020).">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Multisystem inflammatory syndrome in U.S. children and adolescents; citation_author=LR Feldstein; citation_volume=383; citation_publication_date=2020; citation_pages=334-346; citation_id=CR91">
<meta name=citation_reference content="Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. Brit. Med. J. 369, m2094 (2020).">
<meta name=citation_reference content="citation_journal_title=JAMA; citation_title=Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City; citation_author=EW Cheung; citation_volume=324; citation_publication_date=2020; citation_pages=294; citation_id=CR93">
<meta name=citation_reference content="Ramcharan, T. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr. Cardiol. 41, 1391–1401 (2020).">
<meta name=citation_reference content="Nakra, N., Blumberg, D., Herrera-Guerra, A. &amp; Lakshminrusimha, S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children 7, 69 (2020).">
<meta name=citation_reference content="citation_journal_title=J. Clin. Invest.; citation_title=Distinct clinical and immunological features of SARS-CoV-2–induced multisystem inflammatory syndrome in children; citation_author=PY Lee; citation_volume=130; citation_publication_date=2020; citation_pages=5942-5950; citation_id=CR96">
<meta name=citation_reference content="Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259–269 (2020).">
<meta name=citation_reference content="citation_journal_title=J. Med. Virol.; citation_title=Multisystem inflammatory syndrome in children related to COVID‐19: A New York City experience; citation_author=M Riollano‐Cruz; citation_volume=93; citation_publication_date=2021; citation_pages=424-433; citation_id=CR98">
<meta name=citation_reference content="Ruscitti, P. et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front. Immunol. 11, 1130 (2020).">
<meta name=citation_reference content="Morris, S. B. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. MMWR. Morb. Mortal. Wkly. Rep. 69, 1450–1456 (2020).">
<meta name=citation_reference content="Bastug, A. et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol. Int. 41, 993–1008 (2021).">
<meta name=citation_reference content="Uwaydah, A. K., Hassan, N. M. M., Abu Ghoush, M. S. &amp; Shahin, K. M. M. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 14, e242060 (2021).">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Multisystem inflammatory syndrome in children — initial therapy and outcomes; citation_author=MBF Son; citation_volume=385; citation_publication_date=2021; citation_pages=11-22; citation_id=CR103">
<meta name=citation_reference content="citation_journal_title=N. Engl. J. Med.; citation_title=Treatment of multisystem inflammatory syndrome in children; citation_author=AJ McArdle; citation_volume=385; citation_publication_date=2021; citation_pages=11-22; citation_id=CR104">
<meta name=citation_reference content="Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855–864 (2021).">
<meta name=citation_reference content="Döcke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678–681 (1997).">
<meta name=citation_author content="van de Veerdonk, Frank L.">
<meta name=citation_author_institution content="Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author content="Giamarellos-Bourboulis, Evangelos">
<meta name=citation_author_institution content="Department of Infectious Diseases, Attikon Hospital, University of Athens, Athens, Greece">
<meta name=citation_author content="Pickkers, Peter">
<meta name=citation_author_institution content="Department of Intensive Care Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author content="Derde, Lennie">
<meta name=citation_author_institution content="Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands">
<meta name=citation_author_institution content="Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands">
<meta name=citation_author content="Leavis, Helen">
<meta name=citation_author_institution content="Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands">
<meta name=citation_author content="van Crevel, Reinout">
<meta name=citation_author_institution content="Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author content="Engel, Job J.">
<meta name=citation_author_institution content="Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author content="Wiersinga, W. Joost">
<meta name=citation_author_institution content="Division of Infectious Diseases, Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands">
<meta name=citation_author content="Vlaar, Alexander P. J.">
<meta name=citation_author_institution content="Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care Medicine and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands">
<meta name=citation_author content="Shankar-Hari, Manu">
<meta name=citation_author_institution content="School of Immunobiology and Microbial Sciences, King’s College London, London, UK">
<meta name=citation_author content="van der Poll, Tom">
<meta name=citation_author_institution content="Division of Infectious Diseases, Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands">
<meta name=citation_author content="Bonten, Marc">
<meta name=citation_author_institution content="Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands">
<meta name=citation_author content="Angus, Derek C.">
<meta name=citation_author_institution content="UPMC and University of Pittsburgh, Pittsburgh, PA, United States">
<meta name=citation_author content="van der Meer, Jos W. M.">
<meta name=citation_author_institution content="Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author content="Netea, Mihai G.">
<meta name=citation_author_institution content="Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands">
<meta name=citation_author_institution content="Department of Immunology and Metabolism, Life &amp; Medical Sciences Institute, University of Bonn, Bonn, Germany">
<meta name=access_endpoint content=https://www.nature.com/platform/readcube-access>
<meta name=twitter:site content=@naturemedicine>
<meta name=twitter:card content=summary_large_image>
<meta name=twitter:image:alt content="Content cover image">
<meta name=twitter:title content="A guide to immunotherapy for COVID-19">
<meta name=twitter:description content="Nature Medicine - This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.">
<meta name=twitter:image content=https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig1_HTML.png>
<meta property=og:url content=https://www.nature.com/articles/s41591-021-01643-9>
<meta property=og:type content=article>
<meta property=og:site_name content=Nature>
<meta property=og:title content="A guide to immunotherapy for COVID-19 - Nature Medicine">
<meta property=og:description content="This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.">
<meta property=og:image content=https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig1_HTML.png>
<meta http-equiv=origin-trial content="AzoawhTRDevLR66Y6MROu167EDncFPBvcKOaQispTo9ouEt5LvcBjnRFqiAByRT+2cDHG1Yj4dXwpLeIhc98/gIAAACFeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv=origin-trial content="A6+nc62kbJgC46ypOwRsNW6RkDn2x7tgRh0wp7jb3DtFF7oEhu1hhm4rdZHZ6zXvnKZLlYcBlQUImC4d3kKihAcAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv=origin-trial content="A/9La288e7MDEU2ifusFnMg1C2Ij6uoa/Z/ylwJIXSsWfK37oESIPbxbt4IU86OGqDEPnNVruUiMjfKo65H/CQwAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta itemprop=position content=1 class=sf-hidden><meta itemprop=position content=2 class=sf-hidden><meta itemprop=position content=3 class=sf-hidden><meta itemprop=position content=4 class=sf-hidden><meta itemprop=publisher content="Springer Nature" class=sf-hidden><link rel=icon type=image/png sizes=32x32 href="data:image/png;base64,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"><style>.sf-hidden{display:none!important}</style><meta http-equiv=content-security-policy content="default-src 'none'; font-src 'self' data:; img-src 'self' data:; style-src 'unsafe-inline'; media-src 'self' data:; script-src 'unsafe-inline' data:;"></head>
<body class=article-page cz-shortcut-listen=true>
<noscript class=sf-hidden><iframe src="https://collect.nature.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<div class="position-relative cleared z-index-50 background-white" data-test=top-containers>
 <a class=c-skip-link href=#content>Skip to main content</a>
<div class="c-grade-c-banner u-hide sf-hidden">
 
</div>
 
 <div class=u-lazy-ad-wrapper>
 
 
 <div class="u-hide u-show-following-ad sf-hidden"></div>
 <aside class="c-ad c-ad--728x90">
 <div class=c-ad__inner data-container-type=banner-advert>
 <p class=c-ad__label>Advertisement</p>
 
 
 
 <div id=div-gpt-ad-top-1 class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type=top data-pa11y-ignore data-gpt data-gpt-unitpath=/285/medicine.nature.com/article data-gpt-sizes=728x90 data-gpt-targeting="type=article;pos=top;artid=s41591-021-01643-9;doi=10.1038/s41591-021-01643-9;subjmeta=250,251,631;kwrd=Immunology,Immunotherapy">
 <noscript class=sf-hidden>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-707403496&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01643-9%26doi%3D10.1038/s41591-021-01643-9%26subjmeta%3D250,251,631%26kwrd%3DImmunology,Immunotherapy">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-707403496&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01643-9%26doi%3D10.1038/s41591-021-01643-9%26subjmeta%3D250,251,631%26kwrd%3DImmunology,Immunotherapy"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
 </div>
 
 
 </div>
 </aside>
 </div>
 <header class=c-header id=header data-header data-track-component=nature-150-split-header style=border-color:#e40428>
 <div class="c-header__row c-header__row--flush">
 <div class=c-header__container>
 <div class=c-header__split>
 
 
 <div class=c-header__logo-container>
 
 <a href=https://www.nature.com/nm data-track=click data-track-action=home data-track-label=image>
 <picture class=c-header__logo>
 
 <img src="data:image/svg+xml;base64,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" alt="Nature Medicine" srcset sizes>
 </picture>
 </a>
 
 </div>
 
 <ul class="c-header__menu c-header__menu--global">
 <li class="c-header__item c-header__item--nature-research">
 <a class=c-header__link href=https://www.nature.com/siteindex data-test=siteindex-link data-track=click data-track-action="open nature research index" data-track-label=link>
 <span>View all journals</span>
 </a>
 </li>
 <li class="c-header__item c-header__item--pipe">
 <a class=c-header__link href=https://www.nature.com/articles/s41591-021-01643-9 data-header-expander data-test=search-link data-track=click data-track-action="open search tray" data-track-label=button role=button aria-haspopup=true aria-expanded=false>
 <span>Search</span><svg role=img aria-hidden=true focusable=false height=22 width=22 viewBox="0 0 18 18" xmlns=http://www.w3.org/2000/svg><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg>
 </a><div id=search-menu class="c-header-expander c-header-expander--tray u-hide-print has-tethered u-js-hide sf-hidden" data-track-component=nature-150-split-header hidden>
 
</div>
 </li>
 <li class=c-header__item>
 <a href=https://www.nature.com/nams/svc/myaccount id=my-account class="c-header__link placeholder" data-test=login-link data-track=click data-track-action="my account" data-track-category=nature-150-split-header data-track-label=link style=display:none>
 <svg role=img aria-hidden=true focusable=false height=22 width=22 viewBox="0 0 18 18" xmlns=http://www.w3.org/2000/svg><path d="M10.238 16.905a7.96 7.96 0 003.53-1.48c-.874-2.514-2.065-3.936-3.768-4.319V9.83a3.001 3.001 0 10-2 0v1.277c-1.703.383-2.894 1.805-3.767 4.319A7.96 7.96 0 009 17c.419 0 .832-.032 1.238-.095zm4.342-2.172a8 8 0 10-11.16 0c.757-2.017 1.84-3.608 3.49-4.322a4 4 0 114.182 0c1.649.714 2.731 2.305 3.488 4.322zM9 18A9 9 0 119 0a9 9 0 010 18z" fill=#333 fill-rule=evenodd></path></svg>
</a>
<a href="https://idp.nature.com/authorize/natureuser?client_id=grover&amp;redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-021-01643-9" id=login-button class="c-header__link placeholder" data-test=login-link data-track=click data-track-action=login data-track-category=nature-150-split-header data-track-label=link>
 <span>Login</span><svg role=img aria-hidden=true focusable=false height=22 width=22 viewBox="0 0 18 18" xmlns=http://www.w3.org/2000/svg><path d="M10.238 16.905a7.96 7.96 0 003.53-1.48c-.874-2.514-2.065-3.936-3.768-4.319V9.83a3.001 3.001 0 10-2 0v1.277c-1.703.383-2.894 1.805-3.767 4.319A7.96 7.96 0 009 17c.419 0 .832-.032 1.238-.095zm4.342-2.172a8 8 0 10-11.16 0c.757-2.017 1.84-3.608 3.49-4.322a4 4 0 114.182 0c1.649.714 2.731 2.305 3.488 4.322zM9 18A9 9 0 119 0a9 9 0 010 18z" fill=#333 fill-rule=evenodd></path></svg>
</a>
 </li>
 </ul>
 </div>
 </div>
 </div>
 
 <div class=c-header__row>
 <div class=c-header__container data-test=navigation-row>
 <div class=c-header__split>
 <div class=c-header__split>
 <ul class="c-header__menu c-header__menu--journal">
 
 <li class="c-header__item c-header__item--dropdown-menu" data-test=explore-content-button>
 <a href=https://www.nature.com/articles/s41591-021-01643-9 class="c-header__link c-header__link--chevron" data-header-expander data-test=menu-button--explore data-track=click data-track-action="open explore expander" data-track-label=button role=button aria-haspopup=true aria-expanded=false>
 <span><span class=c-header__show-text>Explore</span> content</span><svg role=img aria-hidden=true focusable=false height=16 viewBox="0 0 16 16" width=16 xmlns=http://www.w3.org/2000/svg><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
 </a><nav class="u-hide-print c-header-expander has-tethered u-js-hide sf-hidden" aria-labelledby=Explore-content data-test=Explore-content id=explore data-track-component=nature-150-split-header hidden>
 
 </nav>
 </li>
 
 
 <li class="c-header__item c-header__item--dropdown-menu">
 <a href=https://www.nature.com/articles/s41591-021-01643-9 class="c-header__link c-header__link--chevron" data-header-expander data-test=menu-button--about-the-journal data-track=click data-track-action="open about the journal expander" data-track-label=button role=button aria-haspopup=true aria-expanded=false>
 <span>About <span class=c-header__show-text>the journal</span></span><svg role=img aria-hidden=true focusable=false height=16 viewBox="0 0 16 16" width=16 xmlns=http://www.w3.org/2000/svg><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
 </a><nav class="u-hide-print c-header-expander has-tethered u-js-hide sf-hidden" aria-labelledby=About-the-journal id=about-the-journal data-test=about-the-journal data-track-component=nature-150-split-header hidden>
 
 </nav>
 </li>
 
 <li class="c-header__item c-header__item--dropdown-menu u-mr-2" data-test=publish-with-us-button>
 <a href=https://www.nature.com/articles/s41591-021-01643-9 class="c-header__link c-header__link--chevron c-header__link--dropdown-menu" data-header-expander data-test=menu-button--publish data-track=click data-track-action="open publish with us expander" data-track-label=button role=button aria-haspopup=true aria-expanded=false>
 <span>Publish <span class=c-header__show-text>with us</span></span><svg role=img aria-hidden=true focusable=false height=16 viewBox="0 0 16 16" width=16 xmlns=http://www.w3.org/2000/svg><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
 </a><nav class="u-hide-print c-header-expander has-tethered u-js-hide sf-hidden" aria-labelledby=Publish-with-us-label id=publish-with-us data-test=publish-with-us data-track-component=nature-150-split-header hidden>
 
 </nav>
 </li>
 
 
 </ul>
 
 </div>
 <ul class="c-header__menu c-header__menu--tools">
 
 <li class=c-header__item>
 <a class=c-header__link href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel=nofollow data-track=click data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external>
 <span>Sign up for alerts</span><svg role=img aria-hidden=true focusable=false height=18 viewBox="0 0 18 18" width=18 xmlns=http://www.w3.org/2000/svg><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill=#222></path></svg>
 </a>
 </li>
 
 
 <li class="c-header__item c-header__item--pipe">
 <a class=c-header__link href=http://feeds.nature.com/nm/rss/current data-track=click data-track-action="rss feed" data-track-label=link>
 <span>RSS feed</span>
 </a>
 </li>
 
 </ul>
 </div>
 </div>
 </div>
 
 </header>
 
 
 <nav class="u-mb-16 u-hide u-show-at-md" aria-label=breadcrumbs>
 <div class=u-container>
 <ol class=c-breadcrumbs itemscope itemtype=https://schema.org/BreadcrumbList>
 <li class=c-breadcrumbs__item id=breadcrumb0 itemprop=itemListElement itemscope itemtype=https://schema.org/ListItem><a class=c-breadcrumbs__link href=https://www.nature.com/ itemprop=item data-track=click data-track-action=breadcrumb data-track-category=header data-track-label=link:nature><span itemprop=name>nature</span></a>
 <svg class=c-breadcrumbs__chevron role=img aria-hidden=true focusable=false height=10 viewBox="0 0 10 10" width=10 xmlns=http://www.w3.org/2000/svg>
 <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill=#666 fill-rule=evenodd transform="matrix(0 -1 1 0 0 10)"></path>
 </svg>
 <li class=c-breadcrumbs__item id=breadcrumb1 itemprop=itemListElement itemscope itemtype=https://schema.org/ListItem><a class=c-breadcrumbs__link href=https://www.nature.com/nm itemprop=item data-track=click data-track-action=breadcrumb data-track-category=header data-track-label="link:nature medicine"><span itemprop=name>nature medicine</span></a>
 <svg class=c-breadcrumbs__chevron role=img aria-hidden=true focusable=false height=10 viewBox="0 0 10 10" width=10 xmlns=http://www.w3.org/2000/svg>
 <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill=#666 fill-rule=evenodd transform="matrix(0 -1 1 0 0 10)"></path>
 </svg>
 <li class=c-breadcrumbs__item id=breadcrumb2 itemprop=itemListElement itemscope itemtype=https://schema.org/ListItem><a class=c-breadcrumbs__link href="https://www.nature.com/nm/articles?type=review-article" itemprop=item data-track=click data-track-action=breadcrumb data-track-category=header data-track-label="link:review articles"><span itemprop=name>review articles</span></a>
 <svg class=c-breadcrumbs__chevron role=img aria-hidden=true focusable=false height=10 viewBox="0 0 10 10" width=10 xmlns=http://www.w3.org/2000/svg>
 <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill=#666 fill-rule=evenodd transform="matrix(0 -1 1 0 0 10)"></path>
 </svg>
 <li class=c-breadcrumbs__item id=breadcrumb3 itemprop=itemListElement itemscope itemtype=https://schema.org/ListItem>
 <span itemprop=name>article</span></li>
 </ol>
 </div>
 </nav>
 
 
</div>
<div class="u-container u-mt-32 u-mb-32 u-clearfix" id=content data-component=article-container data-container-type=article>
 <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
 
 <div class="c-context-bar u-hide sf-hidden" data-test=context-bar data-context-bar aria-hidden=true>
 
 </div>
 
 <article lang=en>
 
 <div class="c-pdf-button__container u-hide-at-lg js-context-bar-sticky-point-mobile sf-hidden">
 
 </div>
 
 <div class=c-article-header>
 <header>
 <ul class=c-article-identifiers data-test=article-identifier>
 
 
 <li class=c-article-identifiers__item data-test=article-category>Review Article</li>
 
 
 
 <li class=c-article-identifiers__item><a href=#article-info data-track=click data-track-action="publication date" data-track-label=link>Published: <time datetime=2022-01-21>21 January 2022</time></a></li>
 </ul>
 <h1 class=c-article-title data-test=article-title data-article-title>A guide to immunotherapy for COVID-19</h1>
 <ul class="c-article-author-list js-etal-collapsed js-no-scroll" data-etal=25 data-etal-small=3 data-test=authors-list data-component-authors-activator=authors-list><li class=c-article-author-list__item><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Frank_L_-Veerdonk aria-label="Read more about Frank L. van de Veerdonk" data-author-popup=auth-Frank_L_-Veerdonk data-corresp-id=c1>Frank L. van de Veerdonk<svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-email></use></svg></a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden"></sup>, <li class=c-article-author-list__item><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Evangelos-Giamarellos_Bourboulis aria-label="Read more about Evangelos Giamarellos-Bourboulis" data-author-popup=auth-Evangelos-Giamarellos_Bourboulis>Evangelos Giamarellos-Bourboulis</a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Peter-Pickkers aria-label="Read more about Peter Pickkers" data-author-popup=auth-Peter-Pickkers>Peter Pickkers</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Lennie-Derde aria-label="Read more about Lennie Derde" data-author-popup=auth-Lennie-Derde>Lennie Derde</a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden">,</sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Helen-Leavis aria-label="Read more about Helen Leavis" data-author-popup=auth-Helen-Leavis>Helen Leavis</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Reinout-Crevel aria-label="Read more about Reinout van Crevel" data-author-popup=auth-Reinout-Crevel>Reinout van Crevel</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Job_J_-Engel aria-label="Read more about Job J. Engel" data-author-popup=auth-Job_J_-Engel>Job J. Engel</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-W__Joost-Wiersinga aria-label="Read more about W. Joost Wiersinga" data-author-popup=auth-W__Joost-Wiersinga>W. Joost Wiersinga</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Alexander_P__J_-Vlaar aria-label="Read more about Alexander P. J. Vlaar" data-author-popup=auth-Alexander_P__J_-Vlaar>Alexander P. J. Vlaar</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Manu-Shankar_Hari aria-label="Read more about Manu Shankar-Hari" data-author-popup=auth-Manu-Shankar_Hari>Manu Shankar-Hari</a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Tom-Poll aria-label="Read more about Tom van der Poll" data-author-popup=auth-Tom-Poll>Tom van der Poll</a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Marc-Bonten aria-label="Read more about Marc Bonten" data-author-popup=auth-Marc-Bonten>Marc Bonten</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Derek_C_-Angus aria-label="Read more about Derek C. Angus" data-author-popup=auth-Derek_C_-Angus>Derek C. Angus</a><sup class="u-js-hide sf-hidden"></sup>, <li class="c-article-author-list__show-more u-js-hide js-small-screen-show-inline sf-hidden" aria-label="Show all 15 authors for this article" title="Show all 15 authors for this article">…<li class="c-article-author-list__item js-smaller-author-etal"><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Jos_W__M_-Meer aria-label="Read more about Jos W. M. van der Meer" data-author-popup=auth-Jos_W__M_-Meer>Jos W. M. van der Meer</a><sup class="u-js-hide sf-hidden"></sup> &amp; <li class=c-article-author-list__item><a data-test=author-name data-track=click data-track-action="open author" data-track-label=link href=#auth-Mihai_G_-Netea aria-label="Read more about Mihai G. Netea" data-author-popup=auth-Mihai_G_-Netea data-corresp-id=c2>Mihai G. Netea<svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-email></use></svg></a><span class="u-js-hide sf-hidden">&nbsp;
 </span><sup class="u-js-hide sf-hidden">,</sup>&nbsp;</ul><button aria-expanded=false class="c-button-author-list js-etal-show-more u-js-hide js-small-screen-show-inline sf-hidden"><svg aria-hidden=true width=16 height=16 focusable=false class=u-icon><use href=#icon-plus></use></svg></button>
 
 <p class=c-article-info-details data-container-section=info>
 
 <a data-test=journal-link href=https://www.nature.com/nm><i data-test=journal-title>Nature Medicine</i></a>
 <b data-test=journal-volume><span class=u-visually-hidden>volume</span>&nbsp;28</b>,&nbsp;<span class=u-visually-hidden>pages </span>39–50 (<span data-test=article-publication-year>2022</span>)<a href=#citeas class="c-article-info-details__cite-as u-hide-print" data-track=click data-track-action="cite this article" data-track-label=link>Cite this article</a>
 </p>
 
 <div class="c-article-metrics-bar__wrapper u-clear-both">
 <ul class="c-article-metrics-bar u-list-reset">
 
 <li class=c-article-metrics-bar__item>
 <p class=c-article-metrics-bar__count>24k <span class=c-article-metrics-bar__label>Accesses</span></p>
 </li>
 
 
 <li class=c-article-metrics-bar__item>
 <p class=c-article-metrics-bar__count>9 <span class=c-article-metrics-bar__label>Citations</span></p>
 </li>
 
 
 
 <li class=c-article-metrics-bar__item>
 <p class=c-article-metrics-bar__count>134 <span class=c-article-metrics-bar__label>Altmetric</span></p>
 </li>
 
 
 <li class=c-article-metrics-bar__item>
 <p class=c-article-metrics-bar__details><a href=https://www.nature.com/articles/s41591-021-01643-9/metrics data-track=click data-track-action="view metrics" data-track-label=link rel=nofollow>Metrics <span class=u-visually-hidden>details</span></a></p>
 </li>
 </ul>
 </div>
 
 </header>
 
 
 
 
 
 
 </div>
 <div class=c-article-body>
 <section aria-labelledby=Abs1 data-title=Abstract data-gtm-vis-polling-id-50443292_563=114 data-gtm-vis-polling-id-50443292_562=116 data-gtm-vis-recent-on-screen-50443292_563=621 data-gtm-vis-first-on-screen-50443292_563=621 data-gtm-vis-total-visible-time-50443292_563=6600 data-gtm-vis-recent-on-screen-50443292_562=621 data-gtm-vis-first-on-screen-50443292_562=621 data-gtm-vis-total-visible-time-50443292_562=6600 lang=en><div class=c-article-section id=Abs1-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Abs1>Abstract</h2><div class=c-article-section__content id=Abs1-content><p>Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections.</p></div></div></section>
 <noscript class=sf-hidden>
                
            </noscript>
 
 
 <section data-title=Main data-gtm-vis-polling-id-50443292_563=115 data-gtm-vis-polling-id-50443292_562=117 data-gtm-vis-recent-on-screen-50443292_563=621 data-gtm-vis-first-on-screen-50443292_563=621 data-gtm-vis-total-visible-time-50443292_563=6600 data-gtm-vis-recent-on-screen-50443292_562=621 data-gtm-vis-first-on-screen-50443292_562=621 data-gtm-vis-total-visible-time-50443292_562=6600><div class=c-article-section id=Sec1-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Sec1>Main</h2><div class=c-article-section__content id=Sec1-content><p>The COVID-19 pandemic forced the world to accelerate vaccine and drug development and evaluation at an unparalleled pace. At present, the COVID-19 treatment armamentarium is largely represented by antiviral agents (often administered in early stages of disease) and immunotherapeutic agents that modulate the host immune response (often administered in more advanced stages of disease)—with the rationale for immunotherapy being that dysregulation of host responses feature prominently in COVID-19 pathophysiology. Host-directed therapy is, however, a relatively complex approach, and several important aspects need to be considered.<p>First, apparently obvious choices based on knowledge extrapolated from analogous conditions may be inappropriate in the face of novel diseases with complex immunopathology. Indeed, the initial expert opinion to avoid corticosteroids as immunomodulatory treatment for COVID-19, while later on they became standard-of-care (SoC), underscores the importance of obtaining solid evidence based on robust clinical trials. Second, the host–pathogen response and resulting immunological milieu is very heterogenous, which indicates that not every patient will benefit from the same immunomodulatory treatment strategy. Furthermore, this heterogeneity may not be clinically evident at the bedside, potentially necessitating the evaluation and deployment of biomarkers to guide patient-specific immune therapy. Third, all of this complexity needs to be dissected, understood, and then re-packaged in updated treatment algorithms in a setting of constant change in available evidence.<p>Here, we attempt to provide guidance for immunotherapy of patients with COVID-19, on the basis of consideration of these three major points. We will provide an overview of evidence from the major clinical trials of host-directed therapy, discuss patient stratification, and propose an algorithm to guide the use of immunotherapy strategies.</p></div></div></section><section data-title="Immune pathophysiology of COVID-19"><div class=c-article-section id=Sec2-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Sec2>Immune pathophysiology of COVID-19</h2><div class=c-article-section__content id=Sec2-content><p>COVID-19 is a complex disease in which respiratory manifestations associated with viral replication are accompanied by systemic effects, indicating that SARS-CoV-2 infection is likely to generate a broadly dysregulated immune response. In the pathophysiology of COVID-19, we can identify disease triggers, mediators, and effector pathways (Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig1>1</a>), which can be targeted by immunotherapy.<div class="c-article-section__figure js-c-reading-companion-figures-item" data-test=figure data-container-section=figure id=figure-1 data-title="Pathophysiological factors targeted by immune-based therapies in COVID-19."><figure><figcaption><b id=Fig1 class=c-article-section__figure-caption data-test=figure-caption-text>Fig. 1: Pathophysiological factors targeted by immune-based therapies in COVID-19.</b></figcaption><div class=c-article-section__figure-content><div class=c-article-section__figure-item><a class=c-article-section__figure-link data-test=img-link data-track=click data-track-label=image data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/1 rel=nofollow><picture><img aria-describedby=Fig1 src="data:image/webp;base64,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" alt="figure 1" loading=lazy srcset sizes width=685 height=299></picture></a></div><div class=c-article-section__figure-description data-test=bottom-caption id=figure-1-desc><p>A summary of the pathophysiological factors targeted by immune-based therapies in COVID-19, which can be categorized as triggers of the infection (for example, SARS-CoV-2 virus and recognition receptors), mediators of the immune response (such as cytokines and complement), and immune effector mechanisms (the kallikrein–kinin system and thromboinflammation). ACE2, angiotensin converting enzyme 2; IL-1/6, interleukin 1/6; NET, neutrophil extracellular trap; ROS, reactive oxygen species; ssRNA, single-stranded RNA; TLRs, Toll-like receptors.</p></div></div><div class="u-text-right u-hide-print"><a class=c-article__pill-button data-test=article-link data-track=click data-track-label=button data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/1 data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel=nofollow><span>Full size image</span><svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-chevron-right></use></svg></a></div></figure></div><p>Although the disease trigger is infection with SARS-CoV-2, and the first steps of the infection are relatively similar in most patients, the heterogeneity of COVID-19 increases with severity of disease and is largely determined by variability of the host immune response at the level of mediators and effectors. Infection is initiated when the spike glycoprotein of SARS-CoV-2 binds to the human angiotensin-converting enzyme-2 (ACE-2) receptor on the epithelial cell surface, with the host transmembrane protease serine 2 (TMPRSS2) promoting the entry of the virus into the cell<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 1" title="Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020)." href=#ref-CR1 id=ref-link-section-d6748958e750>1</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 2" title="Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020)." href=#ref-CR2 id=ref-link-section-d6748958e753>2</a></sup>. ACE2 is highly expressed in the epithelial cells of the nasal cavity, providing a point of entry for SARS-CoV-2 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 3" title="Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429–446.e14 (2020)." href=#ref-CR3 id=ref-link-section-d6748958e757>3</a></sup>). The virus is also recognized by pattern-recognition receptors on immune cells, which are responsible for the initiation of the host defense mechanisms. The subsequent production of immune mediators such as cytokines and complement — produced locally in moderate amounts — is essential to fight the infection; however, these can be deleterious when produced in excess<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 4" title="Jouan, Y., Baranek, T., Si-Tahar, M., Paget, C. &amp; Guillon, A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. Crit. Care 25, 120 (2021)." href=#ref-CR4 id=ref-link-section-d6748958e761>4</a></sup>.<p>Several studies have shown that the IL-1–IL-6 axis is likely to represent one of the most biologically relevant signaling pathways in the SARS-CoV-2-induced hyperinflammatory reaction<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992–1000.e3 (2020)." href=#ref-CR5 id=ref-link-section-d6748958e768>5</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Chen, X. et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis. 71, 1937–1942 (2020)." href=#ref-CR6 id=ref-link-section-d6748958e768_1>6</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 7" title="Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020)." href=#ref-CR7 id=ref-link-section-d6748958e771>7</a></sup>. Interestingly, in patients with severe COVID-19, low HLA-DR expression on circulating monocytes (a marker of immunosuppression) was clearly evident, but the monocytes retained normal to high production of cytokines (in contrast to bacterial sepsis)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 5" title="Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992–1000.e3 (2020)." href=#ref-CR5 id=ref-link-section-d6748958e775>5</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 8" title="Payen, D. et al. A longitudinal study of immune cells in severe COVID-19 patients. Front. Immunol. 11, 580250 (2020)." href=#ref-CR8 id=ref-link-section-d6748958e778>8</a></sup>. At the cellular level, COVID-19 is associated with a marked decrease in circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 9" title="Huang, I. &amp; Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J. Intensive Care 8, 1–10 (2020)." href=#ref-CR9 id=ref-link-section-d6748958e786>9</a></sup>, reminiscent of sepsis-associated lymphopenia<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 10" title="Iskander, K. N. et al. Sepsis: multiple abnormalities, heteroge-neous responses, and evolving understanding. Physiol. Rev. 93, 1247–1288 (2013)." href=#ref-CR10 id=ref-link-section-d6748958e791>10</a></sup>, and this is associated with disease severity and poor outcome<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 11" title="Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: a prospective cohort study. Eur. Respir. J. 55, 2000524 (2020)." href=#ref-CR11 id=ref-link-section-d6748958e795>11</a></sup>. In addition to this reduction in lymphocyte numbers, their function and capacity to release type II interferons is also severely affected in patients with severe COVID-19 (refs. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Janssen, N. A. F. et al. Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. J. Infect. Dis. 223, 1322–1333 (2021)." href=#ref-CR12 id=ref-link-section-d6748958e799>12</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623–1635 (2020)." href=#ref-CR13 id=ref-link-section-d6748958e799_1>13</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Kreutmair, S. et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity 54, 1578–1593.e5 (2021)." href=#ref-CR14 id=ref-link-section-d6748958e799_2>14</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 15" title="Bost, P. et al. Deciphering the state of immune silence in fatal COVID-19 patients. Nat. Commun. 12, 1–15 (2021)." href=#ref-CR15 id=ref-link-section-d6748958e802>15</a></sup>).<p>Additional important pathophysiological processes in COVID-19 are induced at the level of effector pathways, such as the coagulation system. Thrombi occur when hypercoagulability, endothelial injury and blood stasis converge, and these conditions are frequently encountered in severe COVID-19. Subsequently, arterial and venous thromboembolisms have been frequently reported: studies show that between 21% and 69% of patients with severe COVID-19 develop thromboembolic complications<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 16" title="Obi, A. T., Barnes, G. D., Napolitano, L. M., Henke, P. K. &amp; Wakefield, T. W. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J. Vasc. Surg. Venous Lymphat. Disord. 9, 23–35 (2021)." href=#ref-CR16 id=ref-link-section-d6748958e809>16</a></sup>. It is believed that inflammatory processes have an important role in the induction of thromboembolic processes, leading to severe complications<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020)." href=#ref-CR17 id=ref-link-section-d6748958e813>17</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. Brit. Med. J. 368, m1295 (2020)." href=#ref-CR18 id=ref-link-section-d6748958e813_1>18</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 19" title="Goyal, P. et al. Clinical Characteristics of Covid-19 in New York City. N. Engl. J. Med. 382, 2372–2374 (2020)." href=#ref-CR19 id=ref-link-section-d6748958e816>19</a></sup>. In later phases, patients may develop pulmonary fibrosis, or they may enter a more chronic phase known as long COVID<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 20" title="Mandal, S. et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76, 396–398 (2021)." href=#ref-CR20 id=ref-link-section-d6748958e820>20</a></sup>.<p>All in all, the pathophysiology of COVID-19 is complex, comprising an interaction between hyperinflammation, defective lymphocyte function, endothelial dysfunction, thromboembolic complications and fibrotic processes in the lung. These processes are not only complex, but are also highly variable between patients, probably related to the heterogeneity of the host immune response. This warrants a stratified immunotherapy approach in clinical trials for COVID-19.</p></div></div></section><section data-title="Immunotherapy for COVID-19"><div class=c-article-section id=Sec3-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Sec3>Immunotherapy for COVID-19</h2><div class=c-article-section__content id=Sec3-content><p>From the start of the COVID-19 pandemic, it became clear that dysregulation of immune responses against SARS-CoV-2 is one of the main features of disease pathogenesis, especially in patients with severe disease, and studies aimed at rebalancing this using modulators of immune responses were initiated early on. Our aim is to provide an overview of the immunotherapies that target different components of COVID-19 pathophysiology, and to propose a practical approach for the use of host-directed strategies in clinical practice. Table <a data-track=click data-track-label=link data-track-action="table anchor" href=#Tab1>1</a> provides an overview of the most important clinical trials of immunotherapy in COVID-19.<div class=c-article-table data-test=inline-table data-container-section=table id=table-1><figure><figcaption class=c-article-table__figcaption><b id=Tab1 data-test=table-caption>Table 1 Overview of the relevant immunotherapeutic targets and respective trials discussed in this paper</b></figcaption><div class="u-text-right u-hide-print"><a class=c-article__pill-button data-test=table-link data-track=click data-track-action="view table" data-track-label=button rel=nofollow href=https://www.nature.com/articles/s41591-021-01643-9/tables/1 aria-label="Full size table 1"><span>Full size table</span><svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-chevron-right></use></svg></a></div></figure></div><h3 class=c-article__sub-heading id=Sec4>Anti-virus immunotherapies (anti-trigger)</h3><p>Eliminating the virus as early as possible is likely to prevent or limit the cascade of immune dysregulation and therefore severity of disease. One aspect that is important to mention is that new studies provided important information on antiviral therapy, such as remdesivir and molnupiravir in COVID-19. However, because these are not considered immunomodulatory drugs, we will not focus on their use, but on the studies using immunotherapeutic drugs. Immune-based virus elimination with either polyclonal convalescent plasma or human monoclonal antibodies to the SARS-CoV-2 spike protein might prevent infection in susceptible individuals at risk or might improve outcomes in those who have established COVID-19. The underpinning biology with immunoglobulin therapies is the provision of immediate antiviral humoral immunity that on the one hand reduces the viral load, and on the other hand may induce immunomodulation through Fc gamma receptors<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 21" title="Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. 130, 2757–2765 (2020)." href=#ref-CR21 id=ref-link-section-d6748958e2583>21</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 22" title="Shankar-Hari, M., Spencer, J., Sewell, W. A., Rowan, K. M. &amp; Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis — biological plausibility from a critical care perspective. Crit. Care 16, 206 (2012)." href=#ref-CR22 id=ref-link-section-d6748958e2586>22</a></sup>, with both mechanisms contributing to reduction of illness severity and improved outcomes. It must be noted, however, that the role of Fc gamma receptors remains controversial in COVID-19 pathogenesis, with some literature referring to its role as a disease-enhancing factor<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 23" title="Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019)." href=#ref-CR23 id=ref-link-section-d6748958e2590>23</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 24" title="Bournazos, S., Gupta, A. &amp; Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633–643 (2020)." href=#ref-CR24 id=ref-link-section-d6748958e2593>24</a></sup>.<p>There is relatively solid data for efficacy of convalescent plasa when high-titer plasma is used early in severe infection, with the first data on the use of convalescent plasma in infectious diseases going back to the 1930s<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 25" title="Zinsser H., Batchelder A. P. Studies on Mexican typhus fever. I. J. Exp. Med. 51, 847–858 (1930)." href=#ref-CR25 id=ref-link-section-d6748958e2600>25</a></sup>, and this treatment has been explored in COVID-19 from the very beginning of the pandemic<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="O’Donnell, M. R. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J. Clin. Invest. 131, e150646 (2021)." href=#ref-CR26 id=ref-link-section-d6748958e2604>26</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Arnold Egloff, S. A. et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J. Clin. Invest. 131, e151788 (2021)." href=#ref-CR27 id=ref-link-section-d6748958e2604_1>27</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 28" title="Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 61, 2503–2511 (2021)." href=#ref-CR28 id=ref-link-section-d6748958e2607>28</a></sup>. A living systematic review by the Cochrane Collaboration on SARS-CoV-2 convalescent plasma analyzed data from randomized clinical trials that had been conducted as of 20 May 2021 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 29" title="Piechotta, V. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst. Rev. 7, 1–293 (2020)." href=#ref-CR29 id=ref-link-section-d6748958e2611>29</a></sup>). There was no difference in all-cause 28-day mortality (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92–1.05; 7 randomized control trials (RCTs), 12,646 participants; high‐certainty evidence). Similarly, neither the United Kingdom RECOVERY<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 30" title="Abani, O. et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 397, 2049–2059 (2021)." href=#ref-CR30 id=ref-link-section-d6748958e2615>30</a></sup> trial that enrolled mainly ward patients, nor the global REMAP-CAP<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 31" title="Writing Committee for the REMAP-CAP Investigators et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 326, 1690–1702 (2021)." href=#ref-CR31 id=ref-link-section-d6748958e2619>31</a></sup> trial, in which most patients were mechanically ventilated, showed any benefit for treatment with convalescent plasma. However, in immunocompromised patients and older patients who may be immunosenescent<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 32" title="Aiello, A. et al. Immunosenescence and Its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol. 10, 2247 (2019)." href=#ref-CR32 id=ref-link-section-d6748958e2624>32</a></sup>, early administration of convalescent plasma seems to be potentially beneficial, although this is based on smaller trials with fewer patients included<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 33" title="Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021)." href=#ref-CR33 id=ref-link-section-d6748958e2628>33</a></sup>.<p>Another strategy is the use of monoclonal antibodies, which differ from convalescent plasma, because they act against one predefined target, such as the spike protein, with high neutralizing activity. In high-risk ambulatory patients, a combination of bamlanivimab and etesevimab reduced COVID-19-related hospitalizations, reduced viral load and illness duration, and decreased mortality<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 34" title="Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 325, 632–644 (2021)." href=#ref-CR34 id=ref-link-section-d6748958e2635>34</a></sup>. Another antibody preparation, a combination of the monoclonal antibodies casirivimab and imdevimab (REGEN-COV), reduced 28-day mortality among hospitalized patients who were seronegative at baseline<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 35" title="RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Preprint at medRxiv 
                  https://doi.org/10.1101/2021.06.15.21258542
                  
                 (2021)." href=#ref-CR35 id=ref-link-section-d6748958e2639>35</a></sup>. Antiviral immunotherapy is likely to exert therapeutic potential when given early, especially before the endogenous development of antibodies. Although this treatment may not be of benefit when endogenous antibody production is mounted in later stages of disease, it theoretically may benefit some patients, such as those who are immunocompromised and remain seronegative with persistent detectable viral loads<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 13" title="Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 26, 1623–1635 (2020)." href=#ref-CR13 id=ref-link-section-d6748958e2643>13</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 36" title="Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020)." href=#ref-CR36 id=ref-link-section-d6748958e2646>36</a></sup>.<h3 class=c-article__sub-heading id=Sec5>Immunotherapies targeting immune mediators of host defense</h3><p>The immune response can also be modulated by targeting the mediators that are triggered by the virus and which drive several effector mechanisms (Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig1>1</a>). These can be non-specific and broad, such as corticosteroids, or very targeted, such as inhibiting one specific cytokine.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec6>Corticosteroids</h4><p>In a retrospective cohort study of 201 patients admitted with confirmed COVID-19 pneumonia in Wuhan, China, in early 2020, treatment with methylprednisolone was associated with reduced risk of death (hazard ratio, 0.38; 95% CI, 0.20–0.72) among patients with acute respiratory distress syndrome (ARDS)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 37" title="Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern. Med. 180, 934–943 (2020)." href=#ref-CR37 id=ref-link-section-d6748958e2668>37</a></sup>. However, effectiveness of untargeted immune suppression needed to be demonstrated with high-quality evidence, ideally from randomized studies, to be accepted by the scientific community. To this end, the RECOVERY RCT (an adaptive platform design) was the first to report that dexamethasone (6 mg once daily for up to 10 days) reduced 28-day mortality in patients hospitalized with COVID-19 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 38" title="Horby, P. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 384, 693–704 (2021)." href=#ref-CR38 id=ref-link-section-d6748958e2672>38</a></sup>). In that study, 2,104 patients were assigned to receive dexamethasone and 4,321 to receive usual care. Overall, 28-day mortality was 22.9% in the dexamethasone group and 25.7% in the control group (age-adjusted rate ratio 0.83; 95% CI, 0.75–0.93). However, reduced incidence of death in the dexamethasone arm was found for those receiving invasive mechanical ventilation (rate ratio, 0.64; 95% CI, 0.51–0.81) and those receiving oxygen without invasive mechanical ventilation (rate ratio, 0.82; 95% CI, 0.72–0.94)—in other words, the patients who were sicker at the time of treatment seemed to benefit from corticosteroids. Similar protective effects of steroids in patients with severe COVID-19 were reported in REMAP-CAP, another adaptive platform study, in which 403 patients were included in a corticosteroid evaluation domain<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 39" title="Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA 324, 1330–1341 (2020)." href=#ref-CR39 id=ref-link-section-d6748958e2676>39</a></sup>. The median adjusted odds ratio and Bayesian probability of superiority for the primary endpoint (combined organ support-free days at 21 days and mortality) were 1.43 (95% credible interval (CrI), 0.91–2.27) and 93% for fixed-dose hydrocortisone, and 1.22 (95% CrI, 0.76–1.94) and 80% for shock-dependent hydrocortisone, compared with control. Two other large studies from Brazil and France also supported a benefit from corticosteroids in patients with severe COVID-19 (refs. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 40" title="Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 324, 1307–1316 (2020)." href=#ref-CR40 id=ref-link-section-d6748958e2680>40</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 41" title="Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 324, 1330–1341 (2020)." href=#ref-CR41 id=ref-link-section-d6748958e2683>41</a></sup>). After these results were released, similar corticosteroid trials terminated enrollment and combined their data in a prospective meta-analysis led by the World Health Organization (WHO)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 42" title="Rochwerg, B. et al. A living WHO guideline on drugs for COVID-19. Brit. Med. J. 370, m3379 (2020)." href=#ref-CR42 id=ref-link-section-d6748958e2687>42</a></sup>, which provides a high level of evidence for the effectiveness of corticosteroids in hospitalized patients with COVID-19 who need respiratory support.<p>The observation that the beneficial effects of steroids are significant in sicker patients could be explained by the pleiotropic effects of steroids that target different pathophysiological components of COVID-19 present in severe disease. Although this might explain why so many patients benefit, it also makes it challenging to define who needs to be treated with corticosteroids when progressing towards severe disease (Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig2>2</a>). Another important consideration is the possible over-use of corticosteroids, especially in the early phase of disease when such treatment might lead to detrimental effects, further supporting the need for guidance of immunotherapy.<div class="c-article-section__figure js-c-reading-companion-figures-item" data-test=figure data-container-section=figure id=figure-2 data-title="Treatment guide for moderate to severe COVID-19, without critical illness."><figure><figcaption><b id=Fig2 class=c-article-section__figure-caption data-test=figure-caption-text>Fig. 2: Treatment guide for moderate to severe COVID-19, without critical illness.</b></figcaption><div class=c-article-section__figure-content><div class=c-article-section__figure-item><a class=c-article-section__figure-link data-test=img-link data-track=click data-track-label=image data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/2 rel=nofollow><picture><img aria-describedby=Fig2 src="data:image/webp;base64,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" alt="figure 2" loading=lazy srcset sizes width=685 height=489></picture></a></div><div class=c-article-section__figure-description data-test=bottom-caption id=figure-2-desc><p>A decision-making chart for immunotherapy of patients with moderate to severe COVID-19, without critical illness. Igs, immunoglobulins; IL-6, interleukin-6; O<sub>2</sub>, supportive oxygen therapy; suPAR, soluble urokinase plasminogen activator receptor.</p></div></div><div class="u-text-right u-hide-print"><a class=c-article__pill-button data-test=article-link data-track=click data-track-label=button data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/2 data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel=nofollow><span>Full size image</span><svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-chevron-right></use></svg></a></div></figure></div><h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec7>Kinase inhibitors</h4><p>Tyrosine kinases also have pleiotropic effects and are seen as attractive targets in treating COVID-19, given their established druggability and the fact that most tyrosine kinase inhibitors have a well-known clinical safety profile<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 43" title="Ferguson, F. M. &amp; Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353–377 (2018)." href=#ref-CR43 id=ref-link-section-d6748958e2727>43</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 44" title="Jacobs, C. F., Eldering, E. &amp; Kater, A. P. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 5, 913–925 (2021)." href=#ref-CR44 id=ref-link-section-d6748958e2730>44</a></sup>. Tyrosine kinase inhibitors can block cytokine signaling pathways and many immune effector pathways.<p>A double-blind, randomized, placebo-controlled trial of 1,033 adults hospitalized with COVID-19 who were randomly assigned to receive oral baricitinib (a Janus tyrosine kinase (JAK) inhibitor) or placebo for up to 14 days demonstrated that patients receiving baricitinib had a shorter time to recovery than patients in the placebo group (median 7 versus 8 days)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 45" title="Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med. 384, 795–807 (2021)." href=#ref-CR45 id=ref-link-section-d6748958e2737>45</a></sup>. Importantly, the effect was more pronounced in the subgroup that required high-flow oxygen or noninvasive ventilation when compared with those who received placebo (10 versus 18 days). In a phase 3, double-blind, randomized, placebo-controlled trial with 1,525 participants, 764 received baricitinib and 76 received placebo<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 46" title="Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 19, 1–12 (2021)." href=#ref-CR46 id=ref-link-section-d6748958e2741>46</a></sup>. There was a 38.2% relative reduction in mortality, with the 28-day all-cause mortality being 8% for baricitinib and 13% for placebo with a hazard ratio of 0.57 (95% CI 0.41–0.78). This was an additional effect to standard treatment, including corticosteroids, since 79.3% of participants with available data received systemic corticosteroids at baseline. The FDA has recently authorized baracitinib for emergency use to treat COVID-19. A Dutch clinical trial of 400 hospitalized patients with COVID-19 found a beneficial effect of oral imatinib (a cytosolic multi-tyrosine kinase inhibitor) compared with placebo on duration of mechanical ventilation (7 days versus 12 days) and 28-day mortality (8% versus 14%)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 47" title="Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir. Med. 9, 957–968 (2021)." href=#ref-CR47 id=ref-link-section-d6748958e2745>47</a></sup>. It should be noted that the primary endpoint was not met, which was time to discontinuation of mechanical ventilation and supplemental oxygen for more than 48 consecutive hours while being alive during a 28-day period. However, the beneficial findings warrant follow-up trials to validate these outcomes and select which patients might benefit from treatment with imatinib. Other kinase inhibitors under investigation in RCTs in hospitalized patients with COVID-19 include those targeting Bruton’s tyrosine kinases (for example, ibrutinib, acalabrutinib and zanubrutinib), phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors (duvelisib and temsirolimus), and JAK inhibitors (such as ruxolitinib and tofacitinib)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 44" title="Jacobs, C. F., Eldering, E. &amp; Kater, A. P. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv. 5, 913–925 (2021)." href=#ref-CR44 id=ref-link-section-d6748958e2749>44</a></sup>. Recently, in a trial in Brazil, 289 patients hospitalized with COVID-19 were randomized to receive tofacitinib or placebo. They showed a cumulative incidence of death or respiratory failure of 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% CI 0.41–0.97; <i>P</i> = 0.04) at day 28 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 48" title="Guimarães, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 385, 406–415 (2021)." href=#ref-CR48 id=ref-link-section-d6748958e2757>48</a></sup>). Therefore, there is a good rationale to explore tyrosine kinase inhibitors as a COVID-19 therapy, and the results reported thus far encourage further exploration in larger trials.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec8>Targeted strategies: anti-cytokine treatment</h4><p>Both IL-1 and IL-6 induce local effects, such as macrophage activation, endothelial leakage and liquid extravasation, as well as systemic effects including fever, somnolence and synthesis of acute-phase proteins. Although moderate induction of inflammation is necessary for host defense, overabundant release of these mediators is deleterious. The CORIMUNO-ANA study randomized 116 patients with mild to moderate COVID-19 pneumonia to treatment with placebo or the IL-1 inhibitor anakinra, the only immunological criterion being a plasma C-reactive protein (CRP) level higher than 25 mg l<sup>−</sup><sup>1</sup>. No significant effect of blocking IL-1 with anakinra was observed on the proportion of patients who died or needed noninvasive or mechanical ventilation at day 4, or on survival without need for mechanical or noninvasive ventilation at day 14 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 49" title="Tharaux, P.-L. et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir. Med. 9, 295–304 (2021)." href=#ref-CR49 id=ref-link-section-d6748958e2772>49</a></sup>). In line with this, anakinra had no effect on survival or release from organ support in the REMAP-CAP trial, in which 378 patients with COVID-19 needing organ support (without further immunological stratification) in the intensive-care unit (ICU) were treated with anakinra and compared with 418 controls<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 50" title="The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. Preprint at medRxiv 
                  https://doi.org/10.1101/2021.06.18.21259133
                  
                 (2021)." href=#ref-CR50 id=ref-link-section-d6748958e2776>50</a></sup>.<p>By contrast, patient stratification based on immunological profiles did identify patients likely to benefit from IL-1 blockade. The soluble urokinase plasminogen receptor (suPAR) was found to be associated with the risk for progression into severe respiratory failure, and this formed the basis of a biomarker-driven immunotherapy trial<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 51" title="Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care 24, 187 (2020)." href=#ref-CR51 id=ref-link-section-d6748958e2783>51</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 52" title="Azam, T. U. et al. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. J. Am. Soc. Nephrol. 31, 2725–2735 (2020)." href=#ref-CR52 id=ref-link-section-d6748958e2786>52</a></sup> (Box <a data-track=click data-track-label=link data-track-action="section anchor" href=#Sec11>1</a>). In the open-label single-arm phase 2 SAVE study, 130 patients with COVID-19 pneumonia and plasma suPAR of 6 ng ml<sup>−1</sup> or more received SoC treatment and anakinra (100 mg subcutaneously), which blocks both IL-1α and IL-1β, daily for 10 days. The incidence of severe respiratory failure and/or death after 14 days was 22.3% compared with 59.2% of matched patients receiving SoC alone<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 53" title="Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. eLife 10, e66125 (2021)." href=#ref-CR53 id=ref-link-section-d6748958e2795>53</a></sup>.<p>These results provided the rationale for the double-blind randomized phase 3 SAVE-MORE trial, in which 594 patients with moderate to severe COVID-19 pneumonia (WHO scale 3–5) and suPAR of 6 ng ml<sup>−1</sup> or more were randomized to treatment with SoC and placebo (<i>n</i> = 189) or SoC and anakinra (<i>n</i> = 405). Anakinra treatment provided 2.78 times higher odds for clinical improvement based on the 11-point WHO Clinical Progression Scale towards both full resolution and critical illness or death after 28 days<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 54" title="Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021)." href=#ref-CR54 id=ref-link-section-d6748958e2810>54</a></sup>. The 28-day mortality was lower among patients allocated to anakinra treatment—6.9% in the control group versus 3.2% treated with anakinra. Overall, 85.9% of patients were co-administered dexamethasone, but anakinra still improved outcomes in this context. The results of the SAVE-MORE trial suggest that anakinra treatment guided by suPAR is a therapeutic strategy before progression into critical illness.<p>A trial including 454 patients randomized 1:1 to placebo or canakinumab, which blocks only IL-1β, did not reach significance for its primary outcome, which was survival without invasive mechanical ventilation at day 29 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 55" title="Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. JAMA 326, 230–239 (2021)." href=#ref-CR55 id=ref-link-section-d6748958e2817>55</a></sup>). Patients enrolled were hypoxic and hospitalized without the need for invasive mechanical ventilation. COVID-19-related mortality occurred in 11 out of 223 patients (4.9%) in the canakinumab group versus 16 out of 222 (7.2%) in the placebo group, with a rate difference of −2.3% (95% CI, −6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30–1.50).<p>For patients with hypoxemia and in need of oxygen therapy, anti-IL-6 strategies have been shown to be beneficial by the large-scale platforms RECOVERY<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 56" title="Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021)." href=#ref-CR56 id=ref-link-section-d6748958e2825>56</a></sup> and REMAP-CAP<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 57" title="Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N. Engl. J. Med. 384, 1491–1502 (2021)." href=#ref-CR57 id=ref-link-section-d6748958e2829>57</a></sup>. In the open-label, randomized RECOVERY trial, which predominantly included patients who were not critically ill, 2,094 patients received usual care, and 2,022 patients received the IL-6 inhibitor tocilizumab. Mortality was decreased from 35% in the usual care arm to 31% in the tocilizumab arm (<i>P</i> = 0.0028)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 56" title="Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 1637–1645 (2021)." href=#ref-CR56 id=ref-link-section-d6748958e2836>56</a></sup>. The REMAP-CAP trial included 2,274 critically ill participants, with 972 participants receiving tocilizumab, 485 randomized to sarilumab, 378 to anakinra, and 418 to control. Tocilizumab and sarilumab were both effective, when compared with control, and likely to be equivalent in terms of improving survival and release from organ support. However, anakinra was not effective in this population. Median organ-support-free days were 7 (interquartile range (IQR) –1, 16), 9 (IQR –1, 17), 0 (IQR –1, 15) and 0 (IQR –1, 15) for tocilizumab, sarilumab, anakinra, and control, respectively. Median adjusted odds ratios for hospital survival were 1.42 (95% CrI 1.05, 1.93), 1.51 (95% CrI 1.06, 2.20) and 0.97 (95% CrI 0.66, 1.40) for tocilizumab, sarilumab, and anakinra, respectively, compared with control<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 57" title="Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N. Engl. J. Med. 384, 1491–1502 (2021)." href=#ref-CR57 id=ref-link-section-d6748958e2840>57</a></sup>. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group published a prospective meta-analysis of clinical trials of patients hospitalized for COVID-19 that showed an association with lower 28-day all-cause mortality in patients treated with IL-6 antagonists compared with patients that received usual care or placebo<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 58" title="Domingo, P. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA 326, 499–518 (2021)." href=#ref-CR58 id=ref-link-section-d6748958e2845>58</a></sup>. Collectively, these data support the use of blocking IL-6 in patients with COVID-19 who are hospitalized and in need of oxygen supplementation.<p>Other proinflammatory cytokines besides those in the IL-1–IL-6 axis are also involved in COVID-19-mediated inflammation; one attractive approach is to inhibit neutrophil recruitment in the lung through inhibition of GM–CSF. In the double-blind randomized trial OSCAR, patients with respiratory distress were randomized to receive one infusion of the monoclonal anti-GM–CSF otilimab (<i>n</i> = 395) or placebo (<i>n</i> = 398). The primary study endpoint was the rate of patients being alive and free of respiratory failure by day 28: this was 71% in the placebo group and 67% in the otilimab group (<i>P</i> = 0.09). However, in the group of patients aged 70 years or older, there was a significant effect of otilimab on the primary endpoint, namely 66% in the placebo compared with 46% in the group that received otilimab (<i>P</i> = 0.009)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 59" title="Patel, J. et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). Preprint at medRxiv 
                  https://doi.org/10.1101/2021.04.14.21255475
                  
                 (2021)." href=#ref-CR59 id=ref-link-section-d6748958e2864>59</a></sup>, which provides the rationale to further explore otilimab in patients aged 70 years or more. Nonetheless, one should be cautious with such age-dependent interpretations, as they may imply opposite negative effects in the younger patients. Other cytokine-targeted therapies, such as anti-TNF, are currently being studied (<a href=https://clinicaltrials.gov/ct2/show/NCT04705844>NCT04705844</a>). Cytokine-targeted treatment strategies for COVID-19 seem to be an attractive approach and might benefit from biomarker-based precision RCTs that help identify which patients are likely to benefit the most.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec9>Anti-complement therapies: anti-C5a</h4><p>Complement activation seems to contribute to the pathophysiology of severe COVID-19. Autopsies of patients with severe COVID-19 showed widespread complement activation in the lung and kidney<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 60" title="Diao, B. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat. Commun. 12, 2506 (2021)." href=#ref-CR60 id=ref-link-section-d6748958e2885>60</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 61" title="Schurink, B. et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1, e290–e299 (2020)." href=#ref-CR61 id=ref-link-section-d6748958e2888>61</a></sup>. The potent anaphylatoxin C5a increases adherence and migration of neutrophils and monocytes to blood vessel walls; this causes tissue damage by oxidative radical formation and enzyme release, but also induces release of tissue factor from endothelial cells and neutrophils, thereby activating the coagulation system<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Seshan, S. V. et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 114, 1675–1683 (2009)." href=#ref-CR62 id=ref-link-section-d6748958e2892>62</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Kambas, K. et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J. Immunol. 180, 7368–7375 (2008)." href=#ref-CR63 id=ref-link-section-d6748958e2892_1>63</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 64" title="Ritis, K. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794–4802 (2006)." href=#ref-CR64 id=ref-link-section-d6748958e2895>64</a></sup>. In patients with severe COVID-19, high concentrations of C5a are associated with poor outcomes<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 65" title="de Bruin, S. et al. Clinical features and prognostic factors in COVID-19: a prospective cohort study. EBioMedicine 67, 103378 (2021)." href=#ref-CR65 id=ref-link-section-d6748958e2899>65</a></sup>. On the basis of these observations, anti-complement therapies have been investigated in severe COVID-19. One randomized phase 2 open-label trial (<i>n</i> = 30) investigated blockade of C5a using a chimeric monoclonal IgG4 antibody (vilobelimab) that specifically binds with high affinity to the soluble form of human C5a and was shown to be safe in patients with severe COVID-19. In this study, infections considered as serious adverse events were reported in three (20%) patients receiving direct C5a inhibition, versus five (33%) patients in the control group<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 66" title="Vlaar, A. P. J. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 
                  https://doi.org/10.1016/S2665-9913(20)30341-6
                  
                 (2020)." href=#ref-CR66 id=ref-link-section-d6748958e2906>66</a></sup>. The secondary outcomes, including severe pulmonary embolism and mortality, were in favor of anti-C5a treatment. A phase 3 trial (<a href=https://clinicaltrials.gov/ct2/show/NCT04333420>NCT04333420</a>) that aims to enroll 360 patients with severe COVID-19 and use28-day mortality as the primary endpoint is ongoing.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec10>Stimulators of antiviral defense: interferons</h4><p>Type I IFNs are crucial for antiviral host responses, and they have previously been used with partial success against severe acute respiratory syndrome (SARS)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 67" title="Cinatl, J. et al. Treatment of SARS with human interferons. Lancet 362, 293–294 (2003)." href=#ref-CR67 id=ref-link-section-d6748958e2926>67</a></sup>. Daily inhalations with IFNβ-1a for 14 days versus placebo was investigated in a double-blind RCT in 101 patients with COVID-19 in the United Kingdom. Patients receiving inhaled IFNβ-1a had greater odds of improvement (odds ratio 2.32; 95% CI 1.07–5.04; <i>P</i> = 0.033) on day 15 or 16, and were more likely to recover during treatment (hazard ratio 2.19; 95% CI 1.03–4.69; <i>P</i> = 0.043)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 68" title="Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, e764–e773 (2021)." href=#ref-CR68 id=ref-link-section-d6748958e2936>68</a></sup>. In a multicenter, prospective, open-label, randomized, phase 2 trial in China, 127 patients received either triple antiviral therapy (lopinavir, ritonavir and ribavirin) and 3 doses of 8 million international units of IFNβ-1b on alternate days (<i>n</i> = 86) or lopinavir and ritonavir (<i>n</i> = 41). Again, triple antiviral therapy plus IFNβ-1b resulted in shorter viral shedding and faster clinical improvement compared to lopinavir–ritonavir alone in patients with mild to moderate COVID-19 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 69" title="Hung, I. F. N. et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395, 1695–1704 (2020)." href=#ref-CR69 id=ref-link-section-d6748958e2947>69</a></sup>). By contrast, in the WHO Solidarity trial, in which IFNβ-1a was given subcutaneously and intravenously for 6 days, death occurred in 243 out of 2,050 patients receiving IFNβ-1a and in 216 out of 2,050 receiving its control (rate ratio, 1.16; 95% CI, 0.96–1.39; <i>P</i> = 0.11)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 70" title="Pan, H. et al. Repurposed antiviral drugs for COVID-19 — interim WHO Solidarity Trial results. N. Engl. J. Med. 384, 497–511 (2021)." href=#ref-CR70 id=ref-link-section-d6748958e2954>70</a></sup>. An important note is that half of the patients in the Solidarity trial received corticosteroids that might affect interferon signaling, but the clinical relevance of this is uncertain.<p>Interferon-gamma (IFNγ) is a type II interferon that has an important role in boosting the innate host defense and might therefore act as an immunostimulatory agent. In a case series of five patients with persistent high viral loads and poor clinical condition with secondary infectious complications, recombinant IFNγ showed viral culture conversion from positive to negative and rapid decrease in viral load by PCR without subsequent signs of hyperinflammation<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 71" title="van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med (N Y.) 2, 1163–1170 (2021)." href=#ref-CR71 id=ref-link-section-d6748958e2961>71</a></sup>. In another report with six non-immunocompromised patients with ventilator-associated pneumonia, IFNγ treatment led to a fast increase in HLA-DR<sup>hi</sup> monocytes in all but one patient, and was well tolerated<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 72" title="Nguyen, L. S., Ait Hamou, Z., Gastli, N., Chapuis, N. &amp; Pène, F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Intensive Care Med. 47, 619–621 (2021)." href=#ref-CR72 id=ref-link-section-d6748958e2967>72</a></sup>. IFNγ might represent an immunostimulatory agent that could help to clear viral infection and be beneficial in the setting of secondary infections in critically ill patients with COVID-19. Other strategies to boost the immune system are checkpoint inhibitors or recombinant IL-7, and these are currently under investigation (<a href=https://clinicaltrials.gov/ct2/show/NCT04335305>NCT04335305</a>, <a href=https://clinicaltrials.gov/ct2/show/NCT04379076>NCT04379076</a>)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 73" title="Laterre, P. F. et al. Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19). JAMA Netw. Open 3, 3–7 (2020)." href=#ref-CR73 id=ref-link-section-d6748958e2986>73</a></sup>.<div class=c-article-box data-expandable-box-container=true><div class=c-article-box__container data-expandable-box=true aria-hidden=true id=box-Sec11 style=height:95px><h3 class="c-article-box__container-title u-h3 js-expandable-title" id=Sec11>Box 1. The role of biomarker-driven immunotherapy in COVID-19</h3><div class=c-article-box__content><p>The emergence of SARS-CoV-2 infection has been associated with a flurry of studies investigating biomarkers associated with disease severity and outcome. Many inflammatory biomarkers, from the number of subpopulations of immune cells (for example, lymphopenia and the neutrophil-to-lymphocyte ratio), to circulating cytokines (such as IL-6 and chemokines) or acute-phase proteins (such as CRP and ferritin), to biomarkers of endothelial cell activation (such as suPAR) or complement, are associated with development of severe COVID-19. Unfortunately, a large gap persists between the use of these biomarkers for predicting disease severity and for patient stratification to improve host-directed (immune-based) therapies. In addition, more work needs to be done to understand the variability of various immunological biomarkers in time, which may also influence treatment approaches. Although the readily available anti-COVID-19 immunotherapies (such as steroids and anti-IL-6 therapies) have already been explored, the next steps for optimizing immunotherapy will require identification of patient subgroups that would benefit from specific approaches: for example, immune-modulating approaches in patients with hyperinflammation versus immune-stimulatory therapies in those with immune paralysis. A blueprint for biomarker-guided therapies is provided by the use of suPAR to guide anakinra treatment in the subgroup of patients with COVID-19 with lung hyperinflammation<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 54" title="Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021)." href=#ref-CR54 id=ref-link-section-d6748958e2999 tabindex=-1>54</a></sup>, or the use of HLA-DR expression to guide IFNγ treatment<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 106" title="Döcke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678–681 (1997)." href=#ref-CR106 id=ref-link-section-d6748958e3003 tabindex=-1>106</a></sup>. Intense biomarker research focusing on patient stratification is warranted; in addition, biomarkers to enable the monitoring of the effects of immune-based therapies are also needed.</p></div></div><div class=c-article-box__controls><div class=c-article-box__fade></div><button aria-expanded=false aria-describedby=Sec11><span class=c-article-box__button-text data-expandable-label>Show more</span></button></div></div><h3 class=c-article__sub-heading id=Sec12>Immunotherapies that target effector pathways</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec13>Inhibitors of local pulmonary edema: kallikrein–kinin system</h4><p>Timely inhibition of the kallikrein–kinin system in patients with COVID-19 is proposed to counteract pulmonary edema and suppress thromboinflammation<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 74" title="Shatzel, J. J. et al. The contact activation system as a potential therapeutic target in patients with COVID‐19. Res. Pract. Thromb. Haemost. 4, 500–505 (2020)." href=#ref-CR74 id=ref-link-section-d6748958e3020>74</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 75" title="van de Veerdonk, F. L. et al. Kallikrein–kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9, 57555 (2020)." href=#ref-CR75 id=ref-link-section-d6748958e3023>75</a></sup>, thereby limiting disease severity. In a case–control study of 9 patients with COVID-19 treated with icatibant (bradykinin B2 receptor antagonist) and 18 matched controls, icatibant showed promising results compared to SoC treatment<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 76" title="van de Veerdonk, F. L. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw. Open 3, e2017708 (2020)." href=#ref-CR76 id=ref-link-section-d6748958e3027>76</a></sup>. Directly after treatment with 3 doses of 30 mg of icatibant, a reduction in oxygen supplementation of 3 l min<sup>−</sup><sup>1</sup> or greater was observed in 89% of patients in the intervention group compared with 17% of patients in the control group. Another case–control study investigating the effects of icatibant and an inhibitor of C1-esterase/kallikrein in 30 patients found no significant effect on clinical outcome, but found that both drugs were safe and had beneficial effects on lung CT severity scores and blood eosinophil counts<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 77" title="Mansour, E. et al. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials 22, 1–13 (2021)." href=#ref-CR77 id=ref-link-section-d6748958e3034>77</a></sup>. Disease severity and timing of treatment may be important factors determining the efficacy of icatibant as a COVID-19 treatment. Several other drugs that modulate the kallikrein–kinin system are currently under investigation.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec14>Modulation of immune–thrombotic complications</h4><p>Damage to the vascular endothelium induced by the inflammatory reaction, together with activation of platelets and the coagulation system, are key pathophysiological features of COVID-19 (refs. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 78" title="Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319–329 (2021)." href=#ref-CR78 id=ref-link-section-d6748958e3046>78</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 79" title="Talasaz, A. H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19. J. Am. Coll. Cardiol. 77, 1903–1921 (2021)." href=#ref-CR79 id=ref-link-section-d6748958e3049>79</a></sup>). These host response aberrations have been implicated in the high occurrence of venous thromboembolic disease or arterial thrombosis in COVID-19 despite conventional thromboprophylaxis<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 80" title="Muñoz-Rivas, N. et al. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: a retrospective study. Thromb. Res. 199, 132–142 (2021)." href=#ref-CR80 id=ref-link-section-d6748958e3053>80</a></sup>. Consequently, many clinicians and scientific societies proposed the use of thromboprophylaxis medication at higher doses than usual in clinical practice, and over 75 RCTs related to antithrombotic therapy in hospitalized patients with COVID-19 have been initiated<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 79" title="Talasaz, A. H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19. J. Am. Coll. Cardiol. 77, 1903–1921 (2021)." href=#ref-CR79 id=ref-link-section-d6748958e3057>79</a></sup>.<p>In a multicenter RCT conducted in Iran, encompassing 562 ICU patients with COVID-19, intermediate-dose prophylactic anticoagulation (enoxaparin 1 mg kg<sup>−</sup><sup>1</sup>) compared with standard-dose prophylactic anticoagulation (enoxaparin 40 mg) did not impact the primary outcome, which was a composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or mortality<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 81" title="Mazloomzadeh, S. et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. JAMA 325, 1620–1630 (2021)." href=#ref-CR81 id=ref-link-section-d6748958e3067>81</a></sup>. In a multicenter RCT in Brazil in 615 hospitalized patients, of whom 94% were considered clinically stable, anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 82" title="Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 397, 2253–2263 (2021)." href=#ref-CR82 id=ref-link-section-d6748958e3071>82</a></sup>.<p>By contrast, two open-label adaptive multiplatform RCTs evaluating the use of therapeutic-dose anticoagulation with heparin in hospitalized non-critically ill<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 83" title="ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N. Engl. J. Med. 385, 790–802 (2021)." href=#ref-CR83 id=ref-link-section-d6748958e3078>83</a></sup> and critically ill patients with COVID-19 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 84" title="REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N. Engl. J. Med. 385, 777–789 (2021)." href=#ref-CR84 id=ref-link-section-d6748958e3082>84</a></sup>) were performed. The primary outcome of these RCTs was organ-support-free days, an ordinal scale composed of survival to hospital discharge and—in survivors—the number of days free of organ support to day 21. Among the 2,219 non-critically ill patients, the probability that therapeutic anticoagulation increased organ-support-free days compared with standard thromboprophylaxis was 98.6% (adjusted odds ratio 1.27, 95% CrI 1.03–1.58)<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 83" title="ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N. Engl. J. Med. 385, 790–802 (2021)." href=#ref-CR83 id=ref-link-section-d6748958e3086>83</a></sup>. Major bleeding occurred in 1.9% of patients treated with therapeutic heparin and 0.9% of patients treated with standard thromboprophylaxis<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 83" title="ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N. Engl. J. Med. 385, 790–802 (2021)." href=#ref-CR83 id=ref-link-section-d6748958e3090>83</a></sup>. By contrast, in critically ill patients (<i>n</i> = 1,098) therapeutic anticoagulation with heparin did not improve survival or days free of organ support<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 84" title="REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N. Engl. J. Med. 385, 777–789 (2021)." href=#ref-CR84 id=ref-link-section-d6748958e3098>84</a></sup>. Major bleeding occurred in 3.8% of patients assigned to therapeutic anticoagulation versus 2.3% of patients on standard thromboprophylaxis<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 84" title="REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N. Engl. J. Med. 385, 777–789 (2021)." href=#ref-CR84 id=ref-link-section-d6748958e3102>84</a></sup>.<p>Collectively, the results of these first RCTs suggest that therapeutic dose heparin might be beneficial in hospitalized non-ICU patients with COVID-19, whereas therapeutic dose oral anticoagulants are not. In addition, therapeutic dose heparin does not improve the outcome of critically ill patients with COVID-19 and likely is associated with harm. A mechanistic explanation for these observations is currently not known and the results are counterintuitive from the coagulation point of view. This is most likely due to the use of a pleiotropic drug (heparin) in a heterogeneous disease (COVID-19), underscoring the importance of patient stratification—that is, precision medicine. It is tempting to speculate that these differences are explained by heterologous effects on immune effector pathways, but this remains to be demonstrated. Other antithrombic drugs under investigation in RCTs in hospitalized patients with COVID-19 include tissue type plasminogen activator (a profibrinolytic agent), several antiplatelet drugs (dipyramidole, aspirin, clopidogrel) and nafamostat (a serine protease inhibitor and a short-acting anticoagulant). Moreover, several trials have been initiated to evaluate the effect of thromboprophylaxis in patients with COVID-19 following hospital discharge<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 79" title="Talasaz, A. H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19. J. Am. Coll. Cardiol. 77, 1903–1921 (2021)." href=#ref-CR79 id=ref-link-section-d6748958e3109>79</a></sup>.<h4 class="c-article__sub-heading c-article__sub-heading--small" id=Sec15>Antifibrotic therapies in COVID-19</h4><p>Development of fibrosis may be related to organizing pneumonia following acute lung injury or the abnormal immune response in the lung, as pulmonary compartmentalization of hyperinflammation is present in patients with COVID-19 (ref. <sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 4" title="Jouan, Y., Baranek, T., Si-Tahar, M., Paget, C. &amp; Guillon, A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. Crit. Care 25, 120 (2021)." href=#ref-CR4 id=ref-link-section-d6748958e3121>4</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 85" title="Bendib, I. et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. Crit. Care 25, 23 (2021)." href=#ref-CR85 id=ref-link-section-d6748958e3124>85</a></sup>). It is not known why some may recover from this insult, whereas others respond with an unchecked cellular proliferation, including accumulation of fibroblasts and myofibroblasts, and deposition of collagen to result in pulmonary fibrosis. For these latter patients with COVID-19, available antifibrotic therapies may be beneficial. Apart from steroids, new compounds, mainly tyrosine kinase inhibitors, have demonstrated efficacy in patients with idiopathic pulmonary fibrosis<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 86" title="Richeldi, L. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365, 1079–1087 (2011)." href=#ref-CR86 id=ref-link-section-d6748958e3128>86</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 87" title="Richeldi, L. et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm. Med. 20, 3 (2020)." href=#ref-CR87 id=ref-link-section-d6748958e3131>87</a></sup>. In addition, preclinical data suggest beneficial effects of inhibitors of Janus kinase–signal transducer and activator of transcription (JAK–STAT) in preventing pulmonary fibrosis<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 88" title="Menshawey, R., Menshawey, E., Alserr, A. H. K. &amp; Abdelmassih, A. F. JAK out of the box; the rationale behind Janus kinase inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovasc. Endocrinol. Metab. 10, 80–88 (2021)." href=#ref-CR88 id=ref-link-section-d6748958e3135>88</a></sup>. However, there are currently no data on antifibrotic treatment in COVID-19 and severalclinical trials are ongoing.</p></div></div></section><section data-title="The immunotherapeutic approach in the clinic"><div class=c-article-section id=Sec16-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Sec16>The immunotherapeutic approach in the clinic</h2><div class=c-article-section__content id=Sec16-content><p>The large number of trials performed since the beginning of the pandemic have provided an unprecedented amount of knowledge for a disease that has been known for such a short time, but this also raises the challenge of discerning the best path for a systematic and rational treatment of the patient with COVID-19. The first important step in approaching the patient with COVID-19 is to determine the severity of the disease, which is one of the most important criteria for patient stratification. Many clinical trials have used the criterion of severity when investigating different approaches of immunotherapy in hospitalized patients outside of the ICU (patients with moderate to severe disease), or in the ICU (severe to critically ill patients). It is important to note that immunotherapy in COVID-19 is dynamic and in constant development. Therefore, we aim to provide guidance on immunotherapeutic strategies that are supported in expert guidelines, such as anti-IL-6R blockade and corticosteroids; however, we will augment this guidance with possible treatment options for when patients fail to respond and there is a clear clinical rationale for an alternative therapy, even if not yet formally tested in large RCTs.<h3 class=c-article__sub-heading id=Sec17>The patient with moderate disease at high risk of worsening</h3><p>From the perspective of patient stratification based on severity, the first major group of patients with COVID-19 are those with moderate disease admitted to general medicine wards. The aim of immunotherapy in these patients would be to prevent worsening of the disease, and potentially reducing the duration of hospitalization. The patients with mild disease that do not need hospitalization are believed to be able to recover without the need of immunotherapy, and no studies have been conducted on host-directed therapy in this subgroup.<p>For patients admitted to general medicine wards, several immunotherapeutic approaches have been proposed (Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig2>2</a>). First, the data available on anticoagulant therapy suggest that therapeutic-dose heparin might be beneficial in these non-ICU patients with COVID-19 (but not patients in the ICU). Second, the serological status of the patient should be assessed; if the patient is seronegative, passive immunization with antibody cocktails should be considered. Third, if the patients are seropositive and the addition of antibody cocktails is not expected to be useful, additional steps need to be taken if the patient displays signs of worsening. If the patient needs oxygen supplementation, treatment with dexamethasone should be initiated. Moreover, the initiation of anti-IL-6 therapy (tocilizumab, sarilumab) is advised if the patient needs oxygen therapy and CRP is higher than 50 (this limit differs in the guidelines of various countries). Furthermore, treatment with the kinase inhibitor baricitinib has been shown to improve outcome in patients with high-flow oxygen therapy and noninvasive ventilation<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 45" title="Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med. 384, 795–807 (2021)." href=#ref-CR45 id=ref-link-section-d6748958e3162>45</a></sup>. If the patient does not need oxygen therapy but biomarkers indicate worsening inflammation—for example, suPAR higher than 6 ng ml<sup>−</sup><sup>1</sup>, or the presence of the surrogate markers CRP (more than 50 mg l<sup>−1</sup>) and ferritin (higher than 700 mg l<sup>−1</sup>)—then administration of the IL-1 receptor blocker anakinra should be considered<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 54" title="Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752–1760 (2021)." href=#ref-CR54 id=ref-link-section-d6748958e3174>54</a></sup>.<h3 class=c-article__sub-heading id=Sec18>The ICU patient</h3><p>Monoclonal antibodies against COVID-19 are a possible option in patients that have no seroconversion during infection or after vaccination. Treatment with corticosteroids and anti-IL-6 should be initiated within 48 hours of admission to the ICU. When a patient is transferred from the ward and has not yet received dexamethasone or tocilizumab, it is still an option to start corticosteroids and anti-IL-6 treatment.<p>Difficult therapeutic decisions on patients with severe COVID-19 may need to be made if severe complications develop during the ICU stay. When signs of immunoparalysis are present, reflected by lymphopenia, low HLA-DR expression on monocytes, opportunistic infections (for example, aspergillosis or herpes infections) or a persistent high SARS-CoV-2 load, then stimulatory immunotherapy would be a rational step—but this has not been formally tested in RCTs. From a pathophysiological point of view, and based on small case-series, one might consider immunostimulatory treatments such as recombinant IFNγ. Similar approaches boosting adaptive immune responses are currently under investigation in clinical trials, such as with recombinant IL-7 and checkpoint inhibitors. Targeting pulmonary fibrosis is another challenge and might benefit from biomarker-directed therapy, although there are currently no data on this in COVID-19. High-dose steroids have been proposed, with evidence coming from trials in the ICU before the pandemic. An overview of the potential approach to immunotherapy in the ICU patient with COVID-19 is presented in Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig3>3</a>.<div class="c-article-section__figure js-c-reading-companion-figures-item" data-test=figure data-container-section=figure id=figure-3 data-title="Treatment guide for critical illness due to COVID-19."><figure><figcaption><b id=Fig3 class=c-article-section__figure-caption data-test=figure-caption-text>Fig. 3: Treatment guide for critical illness due to COVID-19.</b></figcaption><div class=c-article-section__figure-content><div class=c-article-section__figure-item><a class=c-article-section__figure-link data-test=img-link data-track=click data-track-label=image data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/3 rel=nofollow><picture><img aria-describedby=Fig3 src="data:image/webp;base64,UklGRgheAABXRUJQVlA4IPxdAACwOAGdASqtAqsBPjEYikOiIaESOW04IAMEs7dwuZdD+x8QRYqQ/2D+v7ouZ/b/8P+3+lnzf4SfRdQy5D7iyX+pHmI+cH/B/ab3Kf1H/HewF+rPnt+rX90fUL+1H7se8B/xf2u91n9a/3v5AfIP/UP8Z6uf/E/8nuUf2H/Vf+v3Cf5n/ef/h67n7n/+/5Sv7v/0v3S+BP9x////yPcA///qAf/TrX+mv8a/DrzM/mf9A/uf62f2v/5f5T2l/Ffkf6d/bf2B/qX/v/1PwM/un5Eeez0P+R/wn+G9Rv4z9Svpn9S/xn+Z/sf7j/dX9f/rv9p/ZH+3ekfwN/cfyx/rXyC/jn8c/p/9r/ZX+2fur7mv+V23Wmf6H/FfmB8Avqn8o/vX9o/xv+1/uX7bewh+q/4j9h/7x///kn8q/oP9t/uH7Gf4T///gB/Fv5D/dv7J/iv9l/d//9/yvrn/Tf8vx+/q/+W/63+g+AL+V/03/W/3D/Mf9r/B//////iX+5/7X/B/6D/v/47////v4rfmn9z/3n+M/0//1/xf///Af+V/0P/Rf3H/I/93/E////4/d9///cT+4v//91n9oP/5/0CamiYO6RMHc08brhpSQHczYaH06oF4wV7iXzm3TGtoFRMAIgtxD4H7Kl9oePHW/r76/ISXPPBKd2XStKF+ZdLD5v17fRwX7ivvXv57pEwd0iYO6RMHdImDsKTFBZ9we7Kbqv3WRXaJEYUVwMn7VUt4p2I+hla6cm12hyX/NycU8Olp7TopDMju1lGO690SSHz6V2hD2lvk5qR6U3jeoAgIABdaHqC+Yimyl0jZS6RspdI2UukOO/idWzoKf5jlyZfhW63tM2pCQKcLz19VAQjuL/FEMoFj8uMgE3jzlBqEV4tcXCyAvM0y6r8PAQo7t4s4WvQqr8WXBqD1ikRWHT4vpKJ0+g3nukTB3SJg7pEwd0iYK7HfNKmpqampoyO1Am0TfhISEgVi+41Q/If0U2UukbKXSNlLpGyl0jZS1JCgg0TB3SJg7pEwd0iYO6RMHdImDrJ/jQ0NCtN/jTqQcNjXKmb8bTWBTHSNlLpGyl0jZS6RspbIm/spXUV0AqODay0rL5AImqn0FaCYJ6IL9PdImDukTB3SJg7pEwd0iKxeSOXWP6WZVqSct1YOkPJkm/EfXS2rApUywnHoX2dLJzRMHdImDukTB3SJg7pEwdze3LRZzbnOVVMoaGMT8xb+Veeai4IwWy6RspdI2UukbKXSNlLpGylookoW4miQj4+BuoVPn+FJ5PCfS6RspdI2UukbKXSNlLpGyl0jY+hndImDukTB3SJg7pEuWCTpAVI8oku6Df9X5DEaPFtAgIB/yxD3kThihyUiCLlQ8XN3N1e6tZwi+vr6+vr6+vr6+vr6+sXEq04aUmjKmyl0jR9ZqQg3J9ImDukTB3Mw/NEfp7pEwd0iMa7ZMll0B46K0EBAP+cSONLEd7g9F5eXfY1r+OUi4Lz8/Pz8+OlEtkF9rJcx8fHx8fB2oXtoKGgpp8bfn2Ns6tkERIujo6OiJzFsfxF9Y6KQGSZXalfFOOKPR6ymnuSzKqHfVSiK9+03Dl6DE7/JWtIoP+EvskZQ/HIK8NAPcA5QLkEFL+YeZnubeulh8dNV05jcdpBe2Lgvu1++FDVGy/+c/c9WSWxdbD+G/g8ZXZ632SOE+Sm5FCEy3jIuaJRT5AZml57HJZ8TJcWEjCBFMtPuiUYI/p4xqf1wPqXZL5u4tOJwhTjnTmAw+TcOnKm43zCobVea0/9fDqCyuvSfkkHWrlmpDQMSr8+ESwEqLhSkE4KSV/rMp9ZBn5JRBUPfZfI0uR/Ydgzvb+Zjig2pRu+zYwNVDGw8tQ1KKNnLnx4qLu/WDKDGnPR+XPUc1hOew02qYSn6OU5RotD2heO2ASsiJoKKj6OJ3DMF4CMVHwWqCbi6K4Y5f9TXT84wNJX/PuB6sIh+TE5GlPn57x6SJIuWLaEors+38lEVY9KsLYYb1V+EJALjacTIwUVoWRreBF5fcdIHSXmTz6iL1wXFoPtPbqYT2SomkOlLbaJKgZdMv9nWoMhbZTHKxDk4K+g5hznINEFdkBjxIp2DJrJIMvijD6AWXxWxYGRb3R/+igjLICwCn7COk/oppGb5kryoTjvMxDhXmtGGe5eaSJqLU4H7z3t2ztFBT4PcwQecj9MRbJlm82SBy2QCeqiVThmhSQzcjYnAjqRUsG2I/Le0CbaBLPu0sQjtmaFdv1LdaMno3jHmna/EQyP8YQ3tNyTF6usDYU2BNxHzwL6EDhNmzswBYk6Vm1xb9n++m21kPR3SJgwz2Y4nIdktzO9Ps7V6k1VX/l0RYSM5kDq889Aa/mILWDnawvkhfJDStwFLrmdhU4vbk94LfIH+dwlq8P/CKhZYg9bABzEXKXt0elLdn6OkBhwsWW6Ok+V8JwfbDrFjORkwjfwI3AWFyDyQ/opo+qhoOUukaNVS3YaS5CQkJBlWCQ9zHp6enp6eXXrnFjy5D1M0W6rsKQDusHBM0hISbUuf1jpQbz3SJ07aT+S/E2U1gUx0mdoUuJZeujZRebZ9s3uYCKc/3090iYO6RAhqEpmgLBQpg7pEwd0gUo8C0TEZ05A7n8Yji1qSpp64U1hgRvHl/w1dq5zqhP5iTMBS+l4MH5BoxfMHW+JC/Ls/hLiYxCVMCgv4OmomcLko1z1P6azjXLrH8uWB3VeM8Q4pBwY9m1VNEO2yqJ1neV+6HHIqQalNNbvdU48uVJnF8sONw5jSW41tWauPc2VINIylYOKvBVYXraOf+RAd8l0vepu+5DkJPj6dsx3h5PF0WFjvA4GaH9CvOEuU5A0DCatqgagGVAOblRrENOYpf/BltVHB5PKKISNjg8GtOJ+msaXFQdGsx5Q5A2DpIl69sRtWREhVaSDIeY5vq6hR7p9bW9hOeUyh3pMa6rpac5vgJKIPOsAb+HkgpNuG0Ics67cqQjIUOn/+9q/CIVLSyhBYE+55NsnNvlhTWyFSmImJu94Hch/SlNENyAkbKMET5tz+RPc4i6R+MjJKnHTW8idH0qXRISwlBoGaEHDK1++npaFHi/XL5KZEuWQt0gnx8fHx8PvP3IGDuZvXHArGSR3IDvaLTEPkAvxxIFgdrzOPVqHDMvlGb3oHt4S297c7CnmjySsUdjMky5B4cJZ6qCcEi4Y/uViMCbDV6WVOyk5WfSnkOX8ZtXou2YO6O69puGaGOwYNKTN24Mvx5B8pL8gPyDwUMRTZS6RspdATA8t+GVDpdx/r2rmk6U8rdyNjzJbGnY8xVhHwM3IRguLA/TvwrJJpMaeJg7pEwd5kAAD+/szgTAfbFwttV29WjfAGO4sVhsgEQr9oGQ723ugTHFhL44BprSX99bVDrgpLe3NiqR3GkqWdvg8jHyRkGzdwXzbkeVKeK802jX/Yo1RzOHssE7dr4cgTkm9MO1Wbb1tU2U/3H1FzBbyx08UR8vt6MJHQA8HV3t/Wjs3AEvDyBBQVtkmQmEAMnGHYhof0yYPqDwoVw08c9eulHy6iqQGjeO1mZK/H353oc6Kr/2guyVpwTj9Nznq9mexkmgxJ9qS30jlgjPMDophEJXZ34xnxHVtObNxf51WobCAe7rylf5tXlkDJmjpRYLGbLMxTMozTrpItmfiE/QlOEYawcYGqrDtDHOQ+dVKDQ7jFePytSwQuyz/UXIIpCnr3fOIGAbqCOo/SRUIZFjTnO1heZv9MbB7Q9Xqdk5Iqzd33/1lmM0i43bHn3Nk8Aaqgv8VXbwK7Zub4nNbpCOyFvzFW9UPc1/eDv7A94pygEtIrlYrOghJYwuNvr5zCuIsNQ6OSZ18xfz/H5WW1wqC3hqdv2LHaxR60KsKlHqCH4Rt1biEaCZr8T1Cc0NmYM9VPnZJ63PqTHD4cE3bipdZlwA5UYJ6dN4q6g8JrE6VOp8G9E4cuRJXoSEVwQq6AxpL0792cjJhbK6pSfKfIKrrFcNwgDbey62hWNCAK1neymRtVM1a/R2QvIRszudmLCeYDX22O/3vv0/SZvZ7VYnlqozaQ69p9mR1iM8GLqSYesRzO2bEUQ4has9U8/EzIMdlAnI5zEWDV2zSsUv21zI2PzZOl5pgug/Oq7OjVtUat0UyZ4Lpvo2XGqSPkJT7FQO4uo9jkqcAALD21ekF1gJtnxRtvWVdbOvUER+I/sCCwdeTbsoUvnwwyaJJ94LYVhfUPba+rVNABJitnrfdXcXvWNmP2reV/AMobNiE5TeOMetvhUpFo3xxhu8thpXLI61woDJ7Opmjign74/P4+Hy5IUuJKSrwxbk2vHd/warjRA199CMbZR+Bo/VQMnVhkLG8teI6nJc6cJtp6IwRrf+NVr0wJf855D1IqorfHKd6b4cntEiOFo9LefRLJohC61IAXSWIh41reD3EZHTaxYsBmVUP5PHaC4svCvIcLAZmP9e7L8dpcMHP/pZny9N32tkHORHqeCL5+HLBaN/yJ/cSXgONVrY2DG179UzjcqeRFy0TdKSSucX3bIMx2ihROYSXVeuU/sLLSvK8bFSjdYf0mY+ppODpWW5sUdu8OQmaIUqvF4CCjEbuQmppu0NCh7EZDcx8ARy/xZI1VlpL1LxQbjqGj0VM4QP6NtfoEiuiRRs3WshSvRMs5EWxjrlTCs0RkTcQ5LLsnTvyhJYXDFgefvOUiX44elBCBEbJHts9qeOkm3ILVr+eExtWQersuey0BCKqt0aeAjmwodwtEATC5yldAoFRO8XjuJvGKDEJBTyYTVIfBvQ3F8uO5HpXrMxC6lk7yRV2hQ9OJx5i1/Npj8zOx2201xgQwIdLCJYIQ5On3xCdAFXtJZ5OEkOe3O0YIjohp6Qe3UqHzeDF/j5eKdstjLVEepAjG1dOrsxWt773+yyawX8Iuq4gtYUEFSIEVwNSV+hYP4D18b5X703ljqMWyliDZSalPTSy8Pz0myfAADe/1qgvdTZqULSuvpMP1ctGIsiecI4qsk6Uzd+rLNgkSchFk39iY84o3AIdQkLCYNzsLnNiK8HuAhYXTX4SykxyrApRstQTm40fEg8cMt51MiMrRHnA+6p4MAQw0Fb9ouwtEZ3VnP3HpmYvEC/40npxwMtpAW3SzUpiHIyoA/M3SW9P2nVq549DZ+Ue/nRnvfWJ7BKdJXxu+VQrlp2vOhVOdi0e+ffKCrsAA0YTCJ+IWen0wPNwqGffen8/2x9elCQ2T14kw022HFSuKVr1awDGCUfkG3mQsIye1ZfSBC4GglGrU3Fv0y+EfzkwTKW1htcCvoPzeU5wxoI0WoR2m7qTZgDvhHQoQGeOC5Ev/No9VGpfLcf/rdxMqcvXoiFi9xHcW907aYDJ46/xVgW/tV91J1ylv8iD6+ThSjAttvLIHtjJBFruLgQJbDbgxArj5jJXGTqMnkgAATx17ls9UZ7MB1DOq/vYIlqIo61bARHGOpbCjJfqLX0dmCZ6dsb4/FQ8sZ6Ylq3hBUYu0mgW31+w4AAwQLk7NQPvFgKDqcjtsxgYt5GghaclyMBU0ICKUrfmyBb5AsLcQujSadLLdkEmaB+m3X/FWLM9lmn6yQ9kh/9tbtuWkPfSOmkZi1UCJSAC5tcs08XbkcLzi043WWjoZhQP1E/lktu/AYSvWzx60NMYqlxI94vtMz+if852ALYBn4zEC30Df+P2Rj5P53kt66ZMiIJNISdgMTDFDAR/ZbeW2Al+40SvQueXLyMs2hl56CoZtqS94Gv014TCIC3PQ47xd5Fo++PVKjklLPr51CYwhyX2ag1E5bGgAYYB2GSz6uUpMiWpsUB3NbLZf9kLgfcxHvXF34mKdWVA5WB4S3evhr3aa5Z0zJ6FDmpH1CH1fKYAufR6ppdm0twK80w7Zzd7lMsk7h/tNB80jVnrPyivw/5zP5RaR/eDjWENKgOQDQPZ9DkBTn8y97HV5L1dfjIKDqVCNIDHQ1GOrpLisSUJWtH11XjkWge6s40uXqV4f4fPt1DaORqNDJ1T3HW9p+IH14bQb0JEWYt76KH4HY1hHRb7ggNtQuODRW4YaWjNj0OngyDWQMgq9om+SyCkNfKlLCex4OSbrO2IQXxyb1zVcLNXluqD0SOIMwNRCw7+/CMB6A2kAu4jkwE3UUiN4IsdPWREIXj5le/Whu8iymts6XDt7MBEF3M+Xs6phWfvHBntQPkEUmXxyr/t6J0UqtadAxVJowLKqYaIwAToAYwN8dSnZfh+TBP1UEtWApyNm7upcU2fZdTp2JMbZUsla3tw5Dl7TzmxvAv4jyaGlKfIZBx9jJvC/o4slud4v19npkVZWSydJhMSorZrtoV9jxqtM8GwayjxJ6zQgzayl2ZpKKjjcYxz0FC13Pb36ciZIlHbx7Yua7kvNTK0UUshYvcF3mSK6PVs8/ahFnbfwlSdR8f8rxD0soIdy+OtOYgZklDDgFYoAxY6E6zqPLFikq95kqNqsIMCfYv8cUQeUk03Z6AkBGBX8vSsJ3BP6VG3to988VrDa5z/xyap3uHbb6fHli0mL+yzUMoz+HmMAutcVV0QUlppVBG0tmbtewUbplOrdolcydjt6rYrYyIDPuksBDuz9OGpxDmp9kkbU84VYCbJZE8I9yb1Vz9aYzsoEPYNL3gDMnjxqGca7O6IDpjV0psdxdYmUAxVRh2+SH2V/0aLinQ57pKiznCHM4/HQ2LG9KQEKURASZYB7bZO7d6SUbyo6rLyQOFqbNIPXuTs6L447b9SVsLYvoVQIYlhh1IX0K+sMTTUnpljR+nfRpOla2xXBIg9Aq5CqPz6LKGpy6CJBsSSxizsB7qv+YBPhTTKoNnuzJzFqL5NFcGRkbSL1xdR20AGk0F/WnYgV/onsRfCnDzKkR9QcW8eVw0u0/SBhq9sYfzAk0MRRxm+vgos6ocT7v7z2m4QTtFQAABAFowLHsren/E8xXFPdFw71MMNt2KbL4O9j8fy0j32S91qrJkrKOGS5B2t1y/jF7yQAAFmcU7+BC3AFZWSF9CGWbgTv9PP9+E0KBd1Hcs9a8LpTYGmljTNcELC92QOPe4VVa9+vQSc5UlHhRRlzOHwDUm3Gw4jyyvl9pVCtwJmiWUhKb6ONCXac+Z9yxrr7FfclHh5R8LIk98ibzEAACM2T6iwrsXFdDXUyhdNbdYQmBcZQ5KPCS+d4DapvAqO9hEz9gBEmlNoeyc1MH4ZF3LWUyQwzZVL1zIKqNuQ1Zl/lmFcWAlzgoN3xi0yZNNonZz1Vuro0gp3SzmQE0NA71sHoLG69guuipgspyJ2n4+5xfZGwVJheJLfELIe6OB4wOhY6v9UdCp2ceNsg0vUSt82epjvX2wi3EeC3e9V+54QwFnCwN81oBHLTDWU6MpdTVPwTYwQub+MIsorEVC/oj5ABnuf5XoriJ3PTFceLYwkr5BVDaEoXHmsbB9DLjI6hHQUT3H98OHJp4m3tphjopIHAFoqWTkhJfO3X6DR0tbt8sKSY14Yi9QSAedAU4rC07Py8kvmbn3ZNCSPtjMVghPIx+VdeIyfDtWwwdM7uEgI//3l5rG0MC7aW2UGksHIjuLOzFQGURGFJ5ZWm1FFHp9wsPckwW4xgqwes8lpGVNAIp1xjiG9VkNZ7WZW1Wsbf9ehsXhEhhsY4aWwdLxpDYeWbjRfYyRJz9JsB8RbDQERP+5i36dltIdtexUSJJ0GsuH7ZdFHqCd5x6emPqyqGT4F6IzZcrNlARGdxym4cAAND8CEFML9E9cp24r1WH+u6l2TsP/ur1wfruX0scdFOf+pL49TBdeIW+/PIExFOZou4dUgrNNjQpVlVWiTosdKVaWe5Lico4X6ZF5Mb+0k3pndjyOZqX6ZzTbfvH2Q1Z4+tkOuspfYjVSEjeikMDbVDIswkDb7EytPkJXzAmpRDl79By/YDIIFXEiT0MMRHCWHivn+nCZ7mCD0xsAFxTKaTa5np/6Bp5rRc5lBQAxzlSB2ZItMqy08DkwTPpqalAvRLM7k5oDiKfTWlJy7T09QbivhidfiXPdQK1w14AfyZxNIndwEAXfnKJf9UkfMj/ZG23twq/CUSmSurIgRuQZyEsPLT8Nhw5SVxlEBtmtIUZxMMa2OBSZJrikMIL4jPb2+iYHzey/WUHNjG4KUdEeyDDRWkRCpVcLqMt8IcT5ZX0+9lQ4J+gphWqfK/AxMNll8A8TtK0LcRpAmjf7lUUJ+dEszO3cH0vw8SMLYssgJmenXC83YLOmMblNv3pY6cf8yfteczxLaeLrBKT8UB2ao2SGm67RzhwtJ+h3n+8bcAZu7gKnXQGylDxRGe9MeLp3nr20SONydu3j1Qa5GUuXs8bqta3dgeKDoHbsM45fIlXqZIVsIABndSl927kDbTsapdinebPDCx+2FZ1eBBjHfYnr9T7LV3I1oFS2ZmuqQCRPfKKlMLNQ1PzOeZd3+yVJ9bBfecJD+Gy/rasFYt4IhSCqUanqDGEBrevl4KD9s0LIy7weUdJxfb/ch2q24uB3C3O7BCC5BWGm1Yfd0tn7pEn3vpGo3r/NowSia9MByN/jcQW8XpM4kx3bt3bPz7hDEQfSE+lVPyzAz06hvDsNJ9vO6z2FHaZ+WTh+E6ZdYG15AV+MzWt6jjz1VSWkF8fYpzlXpJ/Xj8RNLIXDQOXhiWtEulzeCNGVE8zOg4IjtYaiL9mRHqCFwnYDl2zhWlvX4hdMcasTp84jtVo1MrORoLnEk5stEA0iHvbWaJ/krlIRME6XGbyIX8j91d9cpUNTVrtjXLdZ5XP9wTYJEQACuzJ2R0T2lkBbaemCf8yrPhmfe4WBvHw/ErezEkHcP+h8eu38WnaEZFWuwMroBzAb/eMiU+BWNDF2t7mGmUR1vHwNmWF4n6GfIi9E68AAAAACN8pw3pD8wm3gmjOpnGtgk+hFBgBlD7IRfkU75tI3pBJeij/m868icSGOUdkRq3rdp2Wrf/7S0rCier2e2hmd/ZpgLCgp8pBjOR4A6w2f5VB1DhIDkxurEfDzzVRmyMawBHVwzBMAMK+v5Al5r9SNhpvXdNxhGIewzj1VqVsRag4GJFacD7LPfF3SasFDMSvjxZE/vz3Tl3h0SLc3VblQdjMTUiHs+o7KURrAAyPGbUAlSCuMOJXdiVl6mUCyAGlVx0yQ//65LCdS9Umqf04zCOaXPuA2D4brwI4aShb1lPAjbrMCC7IkcSPdp1h1nZs1dXqLGuGJ3jvpOflCWynCL+ADiIboGrCwJxyxAWXChMAN910vqGPG6JEnTkrDOvN4rcVx+HSZLQjp/GizrPmFFlevoj6iYrmYP/UaBIbtQOr6G96lymc0zWugqXFAP2tEZ4P7ZLbMEzUFkQkhY7+Y1BiT/ZaWtYWw4aIFUi0x30s71Csyvw6QtEvmMsRzbVG44ISI/EgoR1Qimn8QWEokQC173z9Qx8TzSouulEcDfrB8EM9HUyiAhtJvNaLZOT9WtzVxJ18L6MYUBcmhRTvK8TlxHThAgyKmI5mqVyXhxUlRzu7lA87ratLSSXDbRuNwzyg89d7PoAAp5RyQ4jkww8f2SzlP4BS1GNwatzGCSqBvQlkwK7zkl/FAC8wbzVa8yO9/b31zfjK/R1/vBMX28RCVym0bn6XawcV6QyaEUtTJM6uHYlsfumghtsG9gLQcEE01tI0n7FR9loCcT5zu3lbByRivBHKMBePScneCzuOOr6ZP0DdOE1VTssiRFWfMHMAPZVikJU+wh9huPi2ajGg+ZQ5lwY6oOzB+/mVWInm3scmxA5p9F1xAfo0henUnRossjasjEuVPHi7kZ6a8V0xv8poKgnmCWo7xcQFlo2apfnWPQzmJeAWjMN6eVWEHR2h+yPhNZ10dvDOO5wieNIbOTLt+pvRtnO5j/hu4657MZgawG4uuMe9JrtPRPz5YqOWyOx1L/59fuZdbkfzHJ6y39ztxfriNMmUEa1+l8PsOkkmT5VT4xQ0IqtS7s5oZN4CAXk2IDbah/tdmi1snlULnsmk6eAvwWk7RFnVdG8xtTd/GItayJ2rEHoWQ5UN7ZO85Bj8H597jzcauAa6gWmssLOfIXEYivnE00s4bi7Bi34Ht3pNeqp6OF1+aflFs7OdTEhYxFxyTNFbKlHZT4dU14cqvvhc4f2oZgcEGiibGn0iibJw9Hw0O91Y4tBWxrXaVO/tiI9C8r4hxi4pVVFbydYb7VB3/3fL/gP+KKytattA2kJLVcx+mZXE98KKwibZ1rXwvBE4UwXCQt1OLjk8MfpQo/rJ2Tj517e80RJJ9oXU9HtRStZGRMQJhqa1Qez4meIjKTXTimdN5jpjyZJIQpQmUTJvQJLvpCJKgro7L6GTUBDB4aSkjO3Ehs1u42Vmt/2YHLBcIoEexoQ9VbAg8Qd1czDDaTHD/M06W7ncR4RzpnZWUo3P1hllzWzDqPXkW1UwNx5o1u8R4x+qRK1WDXXfxm+M58T2jtcoPQzrXysgZpAA89Dmr7aEW3v8vZFH7IKNVRtHtpmif0Aw+WiNufqzTDoof3jcdCHAq1hQ8EQzTjRidUkQMk8DG07pQ9K4yVX0O9ddljcY2sdj0oCtX6zEn3KZ+A4ZS3yWM85d79A7wHYJFzsvptxagIM4aVOYhxVcedsjqRs3kUQdMlZaOUbNeEWUJqHKmlNS/MWpe9a066u2vhAjmoMlcanfSYJkAoY58QCsdJ2cUxCTEw1qM8g9Ln+GZ0pUYonnU0OEVg+0OlCm3lVdYmx2czqk8C8pmq2s0sqb6APdVF5iuUSnaaf3/EufNQTWe7Evv0g0eMi9IbbN5gKS8Gy9b83w74DAoq77IRQxVZIFtfwzGFUwVcrBOXALpNH/qjCpcOU+oVsvNs5CxRucdf4srp5HynzWG9cm+9DKxwUoclMNqEsmKjhvdaTDSgIi4fTBr7oN5nvNY8LZ/jEZu0nhcMsutlNn211uEWypY5V9bLZdpoCsaBi0+Qh+VTv6gWPN24vrxK84FfJ04T7qXePHfIq6qASJkNKbwVSF0YYgGvnEi9OewNTKNBNXJJBGZngaUsd+Ulc0nI7Ndxc7KtiMm83OuwW2TJnWSfDKfQLaM3kxBqVl2i2qbB6vUR7bRKQXHp71oayvUZneeyRwk3U/ca+VkA4TuhX8eH9heVR+49/CRaccXPhluETt2TOhP4GlOwizoQJdTi2S9DG5ddeOVSW2IbqHQTGfviDy69FVefPbz332Tm5jyr+apwDXmkEJ7kTS5Km/fpY/1e8JtkuQH/67xP/ZGZHmrhKlwN5/PWIjso+XIm3ym5djGG3xHnDn4zmSC8oKS7O9GNldA6PavFCinUvig46L8vqsvoqAgIzpFMbpxkzkWh8crKRc0IohlTlYqCXEOBX3egghIJSrBaTcywqtoizaClwjxNcbcplJs6SkSUtvy69PBlamib/auwp8dXber0oAu/OtYHiRmfFetZOwoCPFvZ+nVSlIYA673bLbi1Iq6ncgvRTImb7rQMr9rQ6Fh2FTfbI1COobWO2T373wP1GfoPtoie6zuYB5LzZhJrN/JKEveCuVNBA0omCENkMac2gFCVVU41BjvUE+px0JrF6oty/Ge/kj5SrwFh80j8oOkZw5kbjYfAm6B4gqrnsqAoWFuvrqqkNxmPxDV4/Tn72/jq8a6tTOYrjTYNqh3fo6V+v8XiHd+wfriAFTL3Y3p9WB7HYo8rg+cJ/pTdBliyJZIeT30CY2QTkrFW+SIwLM5K2teQwOfmbKGU4NGk2qLs3I8vmhrcCO8F/ltvKIug8YSwTDL1TLmFqU0fgJrMdX/ufp+NjEMo+0TiKXtRBH4wbJX9eQxBV07yL+8hZR5cfNxI4bnahKNLK+YRckxDJleyZYzMKJQs8EtyKeYCgaPfAkIuixQ7BOxuOUhVZwqBwguiOKpqdmIS/I7JM815cO65eeZ5w9FCqeMVmCDlXcVpfsl6Dq1HWYmuk8SkJOIpc+Jw7c+MhLyZrD9ADZhPbJ1rx08vP1V+beAAS7hUm88YRKhrNaiSQ4uwRPtriUQEteMuTB52oxodEUGUO2KWUxOteb7M+H4u/N0VBV+ZnQD4fnmUkI1rnrKVZzsEwyP4/+I+ZJOqESDApmuldZ24tmQKcPDE6iVGKj1MP4weivPyyB6cntmb4hA6lVwKK/JPO2YoDtNL4aVp+/aSForAzFWgp7yr3ersKU9MW7qEZilJfHzqSgIhFYUmQvDNFFv5Gubr/gFluKpVovvmLngjTQRIN0CxtvwkK2iBtdyRbN7uLioBAjFlyIUuaN7YVrdZeVeWHt83tmRNfv5vix7eYkvqh8RYgdmzucT7IPpmFhgsQRzCmEWNRFlPy/0MCZRQkehmP95IejvDrX1a34KEtJ/rPogv+IVpmjRTHZOkm5INd1dofA30prpytaZvr1peMP6eqBrYqL+TKAnHeXeMK9nHlidx+hiZVUPDWMyIlu82dcVDDQo79XkFnCm1aA5XmJAAOluJxVBJSMZwEZN0UBAlAXfXupCB4jwxVxCziS/h9Hy8Yc2s64UCc3kE1fZVc+2h6gBW8V189b69P2WgGsVigPmY6ouI18dyP+rb558vdV1XQtV/HFNAhVsVGImkCi8HA7EtyyjqiqlLBuR9wzHXONgaUeHquFtoMkBJkDwRA4QEeM51BI2Mr3zJF7jYuf59I2H8w/rtCrYve5qxTjNiJkSYQ4XPElnJ6h3jqXcvbIBD8qWQp+XIRT5ZY1wS1RY3t+spEjyc525H7E8k/qlSrlBIFFD4zqCJXYME5NyISLinKOKGm+1Qg025bM2QNZ0nmLcCRSnPYJjOk4pw2FydnzcFDt0N7jwcs1IkrJ2tqCgqhh5yn6zd9NY/VG1nwfNEXJ+IoZ9LbyW0oGUa/WD9eNecU0mQtwvvqjRLt9qmosTdsEUv6M9AUIxM5YVfRlP0O4zaO+LBecvH0vlHsu3TQCaySgTG2M4vfAUKvCvbcfzMqMWMKTy5c4Q05c12Frvi5K19IRlypK4BO5zQH+QIuQ7eccgDxQsz5Gt6SWChM/hvWOnYZZxw4R/OukQerwaSnCgshVpRHwo3/WuC0zQO0fNHw85KuSingmHb/NaF/tycRFI25GAJ2ItWv0TaAgdX6pu6DyeMK/woWuJJ8IxaBsMnKksrqGDdiiNLTkB4DCQaHV825854Yb/TcIiXgaZbNsQqlELmsbTISP3SA/FPtS65WfOs4lO4jBDe1fIUBA+7hKjaOVE8wF45C06zncYtyi+4N9sW6FAgrZdoCmQqwu+3GCayd+doU7ythjaDWYJ8EKeRmhLX9YfVI4Im/5YNisnjwn80qJ6HSB90yU5TNzz6s1OfbgdVNhQzzBmilGX7sx5L9WDO87KDXCfA0qC/u+T6/GZvGmb7IxUFY3ilaVqfI/TYQhqFwTAmYOh4XxmvYNzrCWB0BaNeiha483j/kaMQj5EVhSrnvo47LyDcfuYLwBtHl5AQdWE62+YI6XN4i8AfpbuuKdu612Yo9+kgp4reM9SlpAsY6s99VhbReSr90LTIdvb7cNgUYE9vBlsf+9G37MPjXu4ElXKNkhCJ49iNlgGSpIjm/28RiQhdaz/H72ZLK3H7VMXdBxiMZgNyuHR6cE+qfzjHGSt1KgpPq2ZBwv4gl4NSNRNefJ+FSt0jfebI3zBbL60lPjQY+7BEZBO/V62q7pDzpldUXfA9S5cn74pc+FATlRB/MH1dBBv84e4AGtJG2croALTH8LmrUQ02UEAAscGt7RUV7KFJwNhTe2ailj3IR7ibsiiXI0INeCHvpQfWpWSIt3I+hd4phP6Na40kPF/p/ArkExHtvS2FmVSVxT/r6KVExKX63GwFIpdhxyZ36Ltz0Qt0Dju+RvpJVLMnsEbhj+JqmDnVDsW6ibCSyoYMU/rFOTDkR5Y0mGoLmt1SSdYGZvNSgipJoMcvPmGNe3a2QjO5EHD1797Uv5vABjr6vYI3YwgcnjxP136tLP9rLRjQT8ZXo/eupNY09YVrw6Fzqk5JETXyr0hUPycUQojnw3dksXe9YGFO7mCl2Ua35EKCUXNtu8o/Y5qFGJXwEGPUWIy4fHPJGBmqeEb/3JOHgmRqGO9/vkSXK73t8yDENsElEpH3kDmsEzqW1Qh3er4ZuRslzaa1Xs3Km/koQ1E5oPZg8jU4ydmv3tz/tVA0VGhTX9tZrv57J1BgSdXqo2+1OimVXjT+4qjkqNkmfTgRG/z0reGAqnoDo45Xx+IUMedN+zm1i5oUoyJC+eRUa9jXLia1jOu8zLRO7mKvaeo3XGtsPQhjYovRY/kcZHpgLeQDW+CLa2OYCPcIrQDHbZN5HKU4guhN875d3GDxMOyNggHbC1O+7BFB9g8YTKRhGjexgoZ9FAr8lWve7OMK18nGev1eNHtASqr8ZCvX2dPYx5bSvmj/+PNhNNeBnFC1tCZ1l1Gb//nF0+pzglRLWDyM7tSxsC7eGv1vXbPqTonrbCbESb4RjBANzMqPgYDPjx/yRIkTm/bpJ5SwYt1JJa/kJPX48q9vvWq0BowxV8hdAfr5LUHL/wkmHtXou2mEhX0u/rACeuKE9V7M5vLO0JyvMeL9g9PyeuEiRXTUcy40dEW12+Iyc+Ceugrb5dyR9/0TvU/HgMtaWy59zKgwxwvzphyKBczzMTpibgtI/P3cj+w1i7uTM3gmjACcEHdtbDXMnNofZBVTl0ptDPngksjOfV1pkWB9uEk5S9zwsw23pJy+Hn/j4cpw3ZhNY+Scb36zJtYgGA6puXi8E1Qi5GA2iivhOQO4q/GhKoVWpVePXE8tbnGanEmxScL6q9wpRPdbKIUwfqAeP2N8wrvSKS4hDZybimcw10vEYQPW5MntXi8PTzIyyPK+gOsN/vuDaEACdnFV2fIas/f17VHQKj3IKzP3YlQJWCoAyTz1vG4AFYNxcMVXzyo+Werhtcd+r41Amh5C+BC0og5p0tC3ncnqp7omZ+UJVeRj91M3D7zqrgNSrXyo1FiEmvDKO5quZ2GU9ykIDu+26/V7qmx9SPRvYaEehA83tMcfMxaGEDIx1tHweqUWeCfJFiMApRcQmf25URuW30OguEN8gOsre9qVMwna5mhQCI5TCN9Zu4Cz7utWSMLFtIBlYzSzOENPEj4VLJxY8B2QburDt1+UYB3NOD4cSm1QIHcj0wLA6DjoEvY99Ao8HBiTIiPP2OZiqTHIdAVKFyD0naodZ8h91/tib0uDoCEy+igvcobrFAc4aP37ah56jjyMTiatjnD4VkIBv5s5ePSBe8ZyNhsYwHZiixSvdkNYtSyGJT6fWwRqFpg1Bwtbnlo8UbX9Y1qMch73Q1dlod8WIkwkeWsVFWUGXVmSW7Z5b8QpUPrWVjqGQHxMp48S2geVcrrgFdPno3rBwuLkIL7jqSLhKGUApNQ11YMPtCRV1WkwD3E65aiHajFvyBQp3TynBRnvCTjflQrL1tCq1nI5qepiOIKLI5sWw4HQ8W5F5d0jn6E8TNmfmONdWdb2HqrAgQErT2588pjExSBRZEwscobGdZsmlb2uYdQVwSiILnpEZCuqS3f04QtlPTIMfbgfpgYQjKVf+AQ4b2W2rpuusKHD8MQqFC6KbA0CFPbono6PS/JXYWZe21MD/G8lLZSVK7KSaHkMyorWZZv0kFdBzDhLAGIE3RxGsuPqUDXY9eANczIczJNviRoRY8VENw7BvsHd6GQyd8b00z5ApIruMBHsh1tTssASyk0XUffI8f7o9Ot5h7lchB29IwmvSxYiXC2U4mRR/qI8ERsWy2D1R70gTDuuYS0KKzDmked2GYvG8JK0m7G8bIRnW+guKWMSKiwSfhHMVliKsZeClAYHZyTVKCBZAMGIwQzhRRVuWAuRqQaRJhJmgrjGyJVW5PaDaSI2GfM3BxYYqMJaibPoftOugYFQSEPFCuZl3D9nE4tJ+yFh4wLIbYWjXeTvLi92ROqcj4/OAqPlAOniLoSLSZGF7NoMofn+bDT8fueLybUvMze75+IKeO8Gur+23VniJUspdTsy41QeeWu8Zo7UG/TPKWUhxpY2WgOaXZKf1tbzSaIJTA1Lyul8ac0sDJzyxwCHh9GpDFjqEmlhZzZK20irDxpm83AV74TB1wlJVTaLtl4TCUAbfs1NcmNTav9jnd0QK88mYKgGPvrN5QWHiALNmMJDDeVUBm3BrnrO/GxM18e7RZhkdkUqpzUCPgCU2dVAEi4ekw1wRPNy3J990Pv0VslU6ZwHJ5JqCrDmjCRiQmVvjJZwOh5+TwrapfWgWnVxX3iPlPtjDZSrlC0+hroNZjT8nyUOY4Lg23entWaEe+sH6G18UFrSgjU/b262hxEE/calt9RZ2EXYSsxMLbhIaB1mSiQ7AALl7ZdmLr1h6ZMlyGZsGMuj/iH7w57zRlW5J01+3u0vsGzmq6vFLzKcfTc1SOWUphDtuXeB6tei33La1dW6GovTxjBfF9oE8dPCVs77dMPM0BritwAPtLAF3YZIXF0kFyashl/+X0JPH5kUYgPSoNsKf8h5UH9xptYEcwKsDE1ohEgH0oiiwEoBaV4jlEGiXCplrbt7rpMWIC/lN8P6tzZkyFgMVoHwg8k41869ANn63QCU0gVgbyQcx9D9S8qwfoyq610BYlgsuKzD8zn50Nx1bqyErzLo3807sWzm4EAUWbdvVOmzW1RAlsiUsYsWA7YII7dT8mCYLZ7cMxp66LcqekQSxyRqojdL40jLDflDemvTxZuUub3n587pN/2xSL+Ia+EsK+s06B2VJMnKzz29HWcDUxbY2uG9ZepFy1k6yqwTvnHwmzMA/BdV+jFilcEFMVEVvMGNN6V8j1Db+YU/r+tArk8fC8Kg9kI7p4G4SpDg2FtjQgknpTv6WNliBF2knsjsHHP1bQrDxrJlBmHD3lKAcOF+wAAQ0kVIQRyhipB0YSZwxEloGhHAvoY8rEBTRdq+Kvfv+Jxv9B78Tm7o/5mzJuc6UJav2sMdy/gawysZvpFPY+5Pwod0p3xuLn+z8FrDVwRgWnCUqwZ85EGgb8Rch8nBAKPQt/SLmjzgp2n18Qffb6pmtH48hPO54WyAXgZkJ+GEUUHlKboVQq5cD3jMMOIAWeYb8FtW8XKgznEwfEYm94rxQ3L+8r7SXym9do0lxgSTx1dTO9BGDkGw0O79FcfDqdj3sdBgpo84PgQjA1lxPets7aZFDod5EadCADEfoPVW1LP7OJVI7z7gbWekE5SZ0a+0GAa9E0kgsuGdfDxeiO2IDflJ0oLaHSDDisctRf1BEYQYw+S01GsKMNYfNFa2BxJLW/za2mOE0Nh/pPf9RZzxH7uP5CS/RIgeBGftUjzy8eZ4icz4OV6QdtKYxxQQpY0Oa+Yat0UpdDxSabju7cgJ1gVM4MgPxY2IiJKbdMDb26bePkvd6VDz7rWtpn2Brx8to4y6zBnW/058IO+jw3Lsdezok2LZnm8lLg3hiKIK0cRGu7Gb84GW0s1bd/SWX6pwV9ZUzbsY8QDBUFHXTVb0cSzdnBEvTGjgmBuVYGajLehltML65oIFZhoG/DI+Bedw/Q/ypCrphgNmfg+HuiSPbZNaILiAlGQWTw3FZEheDwg9z32TOqYZVwhOk6iNs9M4yCndFFg395JAMzbo1CxJhcGpT/E+CTa5xPGRrn5S4j933rNTmRdJ81Mk8VFSp+5h07anVhSP4e5Gwz5V1jIp9cG5E9VnNUOB1+PzW90CADInSQWmSoNXYSWYrlNXrD6fTzSMulfFVN3S396+OeOCSXH6bBzRCXir5zGhPW828nyZM+Cv1r1n2q5qvHW0y8hdfI/D4VPsyePJmgy7VOd75K5MMs2wTeRHZmGkls7kaOqvnSQTcdo2RMK+hIeyrPsVT5keVG/Zi/X29kLcuQdp/xcdLAxfL1CQUHNqSL4YMt1Jn9rlnaRI4464ma+CyQKrbwL3Mi9q2akeMz50nHQmfut2xVk1u8pUUJhP+/A+W0Fy++3eZffYTaoFZEHNN/y61/MyMgIlqS941NVLW2tK08MT+K2q/72hrxoGkTI6nUysD9Tj9jrtOP8LG46E+FUfzBmTLZnFbBG0/COVeIW67nvnS4lmA1eurMf2lhBWLQHnu397LFlRw+2qzhbbg+p+w3ZKgmiwsWfZ/VPSdbfHBa9gKq+hccOnauQtfCIphQaI8kUjOZ0ckAIo1eSC7UrrWfhP3pCNDnNZ17CVpZdDEWFoNen5a4PNPFwu+PV0X1Y/RdFHT8wTAOgrHcVVYQOwRB/BWZjWHmZAyABST9sgW59AHII0RM3Zv61waHzDw+6NNLqR33g7X5VNRjzvV+KYyXsKvjM7Gw7oquKfQMJdROyFReh/QOQr//xI6ck+5boLFPmSh0F0SgafOsslBhgi1OUtab96VSHXpQre9sBkzv7vRZcMsvWu4HKat0Q2rfU3eg+sv7od69JCc1coVIbpsvwYQfK/NtI06mpCia6KgkN5HNBsrYVgP1DTWAkkrq1YHezHAWOeDt8CEN48KWzG2ZOepGGXzCmJ/QKd1i/+yqHLDgbQEYl10b1cjjvUmlV93WHWWB8JU/bq1RW0idcBJyxjs+OSm1uEWbTfb5EXMDrQU8xgIHlQeg+uFza8xlDCnrKUs/VPTS1QeykOjrpiXL8zK03nYHnP76jbOmiH1N3kz+KPA/ZZf6g7eoJA8Rm055wdLhkOzATgXDm4ShoasKk1VSEnvfm8F+JsRtYsGUT7Yagu9lKqlGDLvaiO9a6VyFmu7Jc86q4+RzQIvUaM0tKuUnze/nykXKonhb0dzImAaoewGIwNnZal8WvwO6qw626a0bciSeAiASgoVcV+zQhh/8q9pxVdburodSxo98Si1si7LcYgsJK06/0UQoC14k6ru1JlWv0/SvFVsRrLMqhrKoMIV3BfB+orIxSc1e/6Nnz/aMOUFZohmIWvY7WKqZDOkJraOh+aX9Wqn5veTmgrOCLI/S2ePJkogcFrfgKZcHtXWEZ4xouQhyee89U0W+/tossKy6L1AFAOptPNEecchaoU3MQ5MEUPuZX4ZPzI0DcPjnE4tf3cspodmW3H04nFx3hW91LiIW+GEtAUUQALjZGtoCKbK8cCG03yIDbDmnyBBBcxBEiJXikJZEWlZpu9OUJOcmnuGf9UJ5NTPBIMnxaUc9j+Xx5bR8B7wtfKwApNqXXkdU3u9Zm2loqdU7r55cVBYGAiGcBHa4CpS6gIwljA33TlsVAzraICpRYGBgRnD3H83hgs+2vL3hO0bvFIjhdsx3ljSOHw1wy993wF6dKfHnRHxFejmbxDaUvqfjH1XwqzKdz082Qt/Ij6hj26fGhBn+WTWG4EWRK+w6RL3lh6+2JNzF40YwTG/tkz/HsZPOFc/y5HhxGBAN13P1JpgwgqrIppJpdL3M0VnSwKBGbDLQyJlQUGFM61KeYP/8Gdf/O4nz2/evoIqT4pFu4M0QfKCYwp6hVqV7+mvgYpSqFV8EXqkPJ8+b60ptwj9NEAG/mgB4xJrZD1lg84YHdPzv90xXYcafegmR3o0pHv2n+bT+i2hee6SI4O0tjt+4ow5SRpoSJmSffC4mX7YlotI3CR4ZOXjUsWKezG6iW/jxqtSlC1h++UjtY5p3Wbk2iwi2asku/p2YPPG1uux6MGtrV9txiKXuRXV1EczmmeeSZoUm7lZ1yi7ABKxKhhTJHOE15YN+E8M1Z3qI+ufpOqlQzIdJdBj+MK1HFC8d57HJhXqyyIX/5PS+UkVcw/FlyDb+D/yUR+sy4Akeb7vts2raezSFjx5d8RzQ3MowgjvKfj4pu/cRm34tlqBCS3GgYUh6/PscRHGf3myObloJP9J7jo1UYbkjH3fBAnjeruxcPS8fSB6RyrF85dr35E3LrT8OKio0cAAycPDH2AGo2+wf8tqCNH+zltSpaDXEcxDEIgfsfALb7fNbYFY/g9kf0Kb8WFQNXjQM0xmfamalpKIudOKbuSIt+sUdZWSnx8aMASQwbNJCS1xRuC6SwrprztREzVdUztI6rRjGBQUyNlq1jLTqAreyfjbmKDQ9t+tL3a/ZagnDoZhWVMfLzAWmYQCxm+0EDtq2H3OglLm5Q6VuCO1Ik4gp9c889DhDDOA/UQl+V0L/0xgxHes1ToBWxJu4IbgjqBOq3T0gzpTWwoROYquMFP8ImmwTrWFCVlSvT1r8S+22czyCWUeGGvXKP4U9DifupL2/hnFRmrd6inB3VO4e6uHj+GjI1Ac/2b+fhlufTHIzxOa0sNc+9KAxJuwre/9eUnP3XlWVEupnjHwnvlml3uFZk+7CnfwGqSBQvd/mEYMgWBT9F6q41BCsMhRONNKTdJEJQRlo6xh0vg0GjRpL3WJAojGBoYTobAi9aeycTkjc8lT+PW5GDotRcN2F23xKZ7Tw6vZKsfmEIlBKnFWo1rXn+stoz7NcvZ/cNPd/fh5dai8Kdb81tgVCZd8u+GRBvTITQNREuFfFvYlnX62cSjTBcCw0l96bSoivMi8uFTe2lkXGMUz2dh2D1ue0hG/KL9Bb+1+hwFWBTGI5a1pKD0FmN/EZnA14mjMi+TkOlWK3OIrnwMWfCSkBlHozT1Iclz+qTnKcJiKK+1Jvw27l6uHVCKasCz4WmDUQFLOj0vPyYWGJ7w7efp2J+nQWCB7rXlr2zaplIkdojN5tqcO1tAMdApXA+tz3gm7T/WxmjHR8Qx53p/iCSOobc3nZg72suPdM03Le7ibBeqnDwdv1Fa5Yg8q4C3q3pa4o2FkkLJpeV+8TS5yZSlNrZ6ptJFv1DsW+o5KfihRAN/gHQEScFqCeqY9OdgAG0Rzc64td+iprR0ezWfSTuLNXIXz7il8z5BpKkYE8gAOBi4CLXGLYqL3xmEkNXqbQUN1U1aIDW74sj9QVErmYpKgLf2kQ7w5qx8839s9Kpdd4xs6IrnpsbMvCPhEehGSi0+5mTHttCXEy6sFmeE5H0yxvhUWso+UzpBQuD3VU/eMdF9GmcuE7c1mg66bUz1JEcjQWbgvl1xsPlgYMDY/MPXrCtfgUAKy2bcQKmMhNuXOx0TuuITEa4IbFcSIxo+X8SeOOW4hBkk0lROxQ97WC4t7Q0RFuF8L5APSBTHK8a6pUQDYTQH0gNhnX/JNIEg2GPJuYJzuneYrJ2ZDihAYN0ki86CrfPJHZNU0iF0fikL6IR/bmDPuD1puYZu/La2FRi4xTcYwfRCCNc+9gZz+2qetkz+DvTien/THUPqHgpQ5DRstr1gE8L5K8O8V2Q6lRCrp9ybxZjRKbaaVa3v4AXquqz7wMdaEm1LKS48Bxykk5a+ZviIBnRGd5seqilkp/ZkuYQwOtS7u9rxoZDOmYlgOg4I2GqGzP6Nxp680f9kALKRiPE6j4M6+YPjzmOTtxHkZx4xD8Ij/H5BMelmfdlLJLrk8IOS+K8yN8q6Y3beeXTlbgs3PBj398ZLzG1qBxSjQjqMr9gEX2V13bB8suKdLD1S5rdx2G2NGyXzzm0/uJW7Yys+XAKobUP9q4AVmGFeodBo9bhDJzrbL0wk2Ch5/TmGY0K01zh34XJaYTjjtO2Y2F/T7L5F+z/Tx+m2PLJQcEJCZgUjomMxon/yDMoDt1M62bZxjTi4PheBZxk/UnCPMQyseLgbijRZUMVMx40MNkUgspojqkPDVPsS8Gzs2CYHbtrU1ONK11rdgu9cYAkxs6y11W5tQR3r1gPuQxlKu79m3sk50ly4HfV7maltV2oZvNKvI7QAneGRXbVPClePm5ioYa80MFiT0VE8Ps+jbNlnzSH2I4R0Qs6QUSGIzqi6RJXlRdU4dPnTCZCNulgHJQol93L/baRu7NgjvDG9GTeGOuaGUvz+uy6i2Oa0oVrsDx3IweBi34SQu5H1NouLNS0Cqy0RdboZHtx4ecBjLPfKGp3X+2QABGAAkFEd3A6Avjb5C0vNpsmjeHkKtt61xzub2B7ZJb+s0z837RtsakbAcYhpcm8wHL1B+dSP9/HfSZaKAcpH12WZveP5BI91tEE9+K2uti/bm2zD3YJTUkByvJ1EESXsjmLjwcKQ7NSrhIHjgos75pQzvFFOfnUyIpoLIjA93DzBhjiiKHt5gabiGUnYdDvIewQJbXXm4n/oMdKx6c0Y8bYwEtKHX+pLWYW/rhYIrCcvlvqUGDwcjm2/2QAM5KI+pvx7n9oN8DGU3bmqKMInLPqMWOi/B8SlKHLGzGJEdkl6JIAuP7vNa6DEPqdxSNyeGNQN9ARLgNKlbyQ7U9WSQneuZY9ZanhCZcEUpgNbFEPQEKaDFvGeGDbdle7PNVVo1SB1dcPQgb4WiOBIBddsycAxmXIGOMehqDytiN1xcOLsBH3NDgV+GGKhMWQZG568AxEiB1EkkkQgcJJqO5j1K+Qbh7KbZ0J77HJ7jVdLCIBvzFEiagBTxthPmfFEuh4So7u8w43EYoyjt386w9Z5sKaunswn8Cn3X5rAMQh1DiAIiWkWaC8GcA4pQu+tib8gLj33e2o8JDJ7AQlyXYWg+6eUSc+WJ5lEEE0cADid/qsRU5y+G54U5tRSlA1e3UI8ajMg/yWlMenaHJLhjyZzPg8IE9me5MCO8YjoHyRY8mFkuUqERyBq6cZ/sPCZQXqAjQ1abkjJY5EtHK1xj32F3Hf47bksKBXn5s3JGJ7gqM/aO97Am3560AFSOWxS3D3FngcDaTMcNzL/fyPRo4kn17FWCVj3TlSx86f/xW1F0U+hcRiOb337Fbz1tWkN/n8g4RuuTyqtPXcIGtcG6VcASeal/MZUTvqY53ryIWSkx+u50fJehAe6N9oHCWPpiqNO3ve5sRQ3eArJiWC5gbQjWlxOiSwkr4j02UKIpXJ8NhXzB9PWv6zcI9cWo15nCgxE8dM7NCca6FJw5+IpwE7ZeRty/Cdg4uNzic636eT3G3IVXfaOs7mhAIH8IVjvvOsqJtJ4dWEUdWeaw0qIVz7EcyZfArw/VDfN79M6sHpAiH0CcdkOlmTtUEchsvZxSgTTS79niWXvaUDhwZ319jlpHtfCLx2K/v3Tym4jEc4Hc1RecwndTm7xaacezLb5uJWw/D1+MNxNBbd8QQ2wEqX05oMLLYrn8xD1XWxf83dHa+eE6evGsYKgTVhKVk4JrPt6mVWzpJb6ebj05FEWcgdyGfNRQw2lyGu0Mx3FgqORvwbCffolZDUdsWu7LM3U/Y6digWTnRxqq2YlPH+c59/quNgt9BPal+9+MbE9B+95fghB46MS4yZbKO+DBeFuqrhXC/sf4XNsGMtJMT/+/5D5u8PNY5E6lLYZdbU5KLq1z2H3rkOCLZAjIIvNKXp2BL1tyc4s+mbORxUuj2Jc355TL5IWXOnFp1Ir/1w1wUJkpemGGf6pJ2k6bUKXBIBfplfVx7uZHblt57bSadUQMVg6ynNrlZyF7qVEsrZBiiwLLcJl5Sse66gTSR8/JO3wRC7FWMOZRC2ZYm6dvYzXiSSY0tQuXvgO3+eAH37Q9/8fhbzPnq55AMAeg+D/VZyFv4lG5qs8XZMCS2Ao3nYJ6jKol3Jf4gUo0r9YGuLQYxfWYWvsiyst51KmBSJWGH7jZZaxo1/Jkq/90xQ9h6vLYuouEr9mu8q/zF8wAAsslasvOC6LY41WIlu9zvZgv/kV4r5xCP/+SzlmltCmBXAABDc+PAsxzdYTx6H8X/WzNHkVKUxEUHv/AAACbfO4HbCge0XvT+FPf/Jt3kwPDYLCeX1pDngoiwutAYf8xnY7HWCq+ntP1hiF4J/f5/aAbqaULW1FsYUiOeUVIBOVC/VtXS659m4ljn2Y050AEvUAFiC89T0okLB0ABhb9TtGD+sv8zrc1Qw1nru77oziwCGI4EPef1ZnnzjPREfAYhfX83PUvVQCpLqk5yVzW0QnpMpw7RkowlUWLX43lGeQkEyY98QMvpE9JsBiEVc6ISoCFJH7IpDhP9ygAA5xA2Fwkxe+j6wvgAQkaxx7tmnL8DZEmrdE4zqSBySIXj/w6JxTxBUxRtsdAsXac13Whxq3H7J3/+OHd7N8Ut5zPh6nQdJ3lVSq6HNEgllx65OjFKeW8UmF1EX9T0RwY/Hp6+WBmJIbNvNpwpjB22TG06xCRRKRerPb9SAIAjtFq/GnhqGj/iDVrgoBVosC9aLB+mLL9Ir87HZhCYngublIwWZXXTW3b+awsukjUdw/JFByaquMAyY51kTlazumptWXMoW2TLRI83S89x4M5wL4x3XD873XzIQy8whdS3eO0YOdUFc8XRuY2PucEqTMRWCldNHgI4sfGFkNun5rjwRlL7t8Kg8xTmoGYWT/qToeGRt6Ao0zLdDiB7iuOVr92nYj8Ifwq2MnqFSwTjNUVejWRT5tL0eGI+dov0SK5ubrAyd/dl6FSO+ijFUDKY0YDeiHghet2vobVSFL7WwAqJgq/dxi7hxaEVRfhsa2CRqjC8PIbkCp8zUUezLCXcCymIvL2vyBSHwY85wEabZoCLzqfZOkLDC2YnzF6iSpTxqT5CYuqD5GLBS24wEoDHgeiJtTn0r5wqnX4u6+aSvuGhUACAjVuqkPQqRLDLJGMuNmqsFlSNoAI90wmGlaKZlACXvv3nRRI4Gf3N23IClzHCrbTx1Dqe7rLgGSYJEDDWURBiNmrQ3j5yaIr/+LjQHTIAWHf8KYF5tE3uW8kl6XXZMRcxy8ZMR/CQlmPUFWxt5o1BcG2pRhsycWGANcNhs555h4OStWI8YWlPV+PxpADiw7KrOkFvsQ9B5ZAEgKc8QxX47vUyCZDE5KRHUKY9zfWFhpjzibstaceRGOZAuWYRK358THyJVg5FXZMrzf7x1aEAa+3klz+Cc+fG2Q3DXJNyMtOFENySDmzTe2piZXXbhpG5S0+fxWiPE27r1NeS7UvUcankncQrwqMk/40FRvZlXecBykvEWg0R9SJfa/TaVlBhBfky0EUoTZupgTpDnJgnb8jGc7n/UqO628CJsMoWv384fS4cPZZxiUnfjTmW0azibXn5RFo0tqQCTZuZdLC6+GLkHoHTo7NndjyDuzM5WPqkQ5Z91z+22uavNOyscCu91Ljz54WnEK8XDxrg+4LIYiWZPxiCXnBQkL9hcUZlMQE+2juYcNFeQHxfBh65KtICpNDVseGIB96I1n8SfmqHf1jMbYtSt0Nx8o15xW1MnWfhdeQjKxpaskb6U05jrgnEzmokai/ZjGbomJQ1EbMny+Hg4ftJ82ZmBDYbwXIG77aFBhFeqf5j4Br5BLoidcnQMQ4m5FEroM8KLryDC0MaPH7X2RnKNNG5mqXBstlovcf6wSUfiaQcYqhtbT0ujqob3WxvcsSBLGg+pwYMbYplImu3G9TKWhy6jrQqKMz2J4Fp4frFmAc97ONAC+t8YTLzRLw0mufjY2mBPAJ+1Y0ielTdMdHZ9R/qSPE+D5KwsfCeMk099MW1kzovTkByJeTIEAk8wm99JvXd9vgFGMD/wdrOK3Ipe127QZJpJ5HmEQZeW2/U9EgmmqwP2FKbZRmtYG8/Ak6zOLHMr2JhGxWRLpHgHezQsJqKwZoNKisARByb54wjz4neaQtNcCdJqjM47QSIj8xaJpHS0cEYmLa40jcebYeetTyJhqzO4jR3M8jCOcZ9DwZl8mBVmLO7u4EswWFsM/zqSZlRROcvrX6GQLzoRiEjTJBosiGuOQyG2FqY5KdolYfTjvGckXBS9as8Zoi1vP/c2VnO1f3rFvvakO7N4T9d3/SYR4OvlWBqPHD6ebrbIk1tFPNQ9Rk2yRK7L8WOutisRer1ne9vN21vRgm9enfcouoAQrWdYNeDoGW+Aolo2KdISbsD+TXE93x+MOo1Udy2KFfMS1argq/jxeP0ST1ige/GDXsS+Q+7hTit4p99ILXNFBcRzQv4dBvkTwRvxeNzTdSiMnjluB3mOOvaEepurxvKU2YuDeSLzUE1rZOltX1B0YntbptryZET0JirdrOuL/Rr+pAzX5Pfo2Ih7lFpx4xp5vjIDYxavfucSDWhapIqHQiAkNwpHlaQ1H2ZmF8K2hV4AIfzuLjZLTOq1EZJSmnVLecrSNioajLnsiFOR0Z/7LP8SxrnP2oIa5kysPAiC4watWzMq1GYDkBEaTYQ70QXa5ef4pUhimm2sQ7jCRyz0ZPnvuT9VK3QMFV95IXhJu3osrL+ZzCQ40WKezLrN40Vr8SUvMdfxEoCTjkf6+HrjsMGkuyLwgCZfSecUMsLHXFnFBbaIdKfrtjBIL+aXBYGpftb4VtMbuFphNlnSHiQpjvfZrAAH1pdRzHei9Pa/HT1K8SH5c79S5JtArGDNfGO+GUssD8y/1rrAci9KbdEGbaZc7qZmxC/ovmSksn9kAVYNWGoSVJx9cWqmPQ8uScD3QFgeGK1dhAEi5p8zCChmMZB+Gy2rwFsgNHda2F4BgSkN4HHLcGoHTwREJ3Wz4qqg0E4KhsCPhEV5kS04avFLwkeSGLLpdKcBTnG9XTKEH/Br/ET4bOYzNVNMlBj6X6AYTwFKIXYMIyVR5Nyp6VxeHxRgzIYr3PdTAsJUZlEzl5VcibtQonW0J2gPJwmwgUhuyMtRy3LXAZJ1eZx1r9839gFKwwtPvuP7/uFGgbP5wUOTTrsfrJnNHtjgvW7AQgV8zFxF5lHhI0Z26UUWmki5IyTwpK2uUfO/I1CWbTEzK76SanEQ48hFIAQZZUjdB9/6WlHAwGo1Fzne3BvTrl4SCnBGSvtFwP4aeJe7SCGeY0ennT6yp3PQc8l9uPVBA8qPgLY5Fek3NyxKj+p0WlgwdgFpnliaxfMw7EH1ZtVgnxb9Svb2c+s/PE6xHGJOPoDS+23t6dGRia99tnyeKDPlKKaEThhYGfN1zpBU3i745hllmzS6tetA5qX8bAgIHp2U4iTZ1Z/yvmvzcGrHrWlKK5yChsK0xxqlP+NEAL4fTxlGbkJWG6NYT0UDmHf/XDvPXttu9z4lq7mgbNPEfC/rv0DxGoSlFlEU4QYLlIcV7GmnJgiBzSIpt8TexQcifoN+81yJrrM4v022Tp0FCP+OK05IIEBpKE3ID0t8/qE+ZQe2CRV2xKegfpbcwlQJp7ndfdItwHEavPKFztgS+b8GP9IMZsY6BPLJnc/sqCHCat7K18qpIaKz23rV/xjQ79gKpsieuEs3gdwQ4+IU3FaiFB1vZwYSNNBqx+RrhNBQZ0+9s/+QhxONzA/sknUhgU7JBiSidkkMEN8msRZ9zBmUrkkKnhdwuANlwV4CP5VL2+AnPpEKdiYoLY4hgbi4iEQJXpJJfYZcucUFUu2LLmSZzt6NJc+Fi8Exn3QoVynRlSxq/c+k9GB4hrZ3kH7j0W4rlj/rWK0M3b2EsONbasOu0wpVRqYuej3HtKPLUwo/RCPB3pCJijqi5EhBIvyjR/aeUWM0cGb4dYBln+vaWr2ST8hZ+vU5Ywf0Wzv2H9CFi9fkj+bAxplvomC6bPqWBZsOUZ0eZcSlJLwzU/zlZur6kIEN8fbGtoZFLgk4wvS6SOCi8YX3Q6LFbsnlB7iisAZxUHA6tN7xLPcebKYfpy1U8TjE8iAa9A78sD+fNF4L4SguxZOr+dDx8C4rDrzcZzaSj8S3A2GFDfQnu5BTmBSHCP+MPzBGIjD9ALjFwR2n1Doo6KpnAYohESoWITYT38R/9aT91YNQXPUqRI6coRBTz6D3FHB3sNqlwhIkW0VN6Nfs9411qw7tlRBRbs9QQfD7on/XryP/BCII35f2oWA6VYQ6IPcMV6CEfMHQwONMQwTz/woaI7PPY82twmdQW1n6FwJHCpIQLDEqZlXaYdl4Y2Gr1DRBAcKXhtiIN8xDhHefRX+sujSq9MmI+2P9sjsNf91WMR73eJ7fal77fDCLLCCPh8gA1R3fhMlx1N+hVt0T1gWdUwpAnV4RqPwh1U7EZ5+3npyy6bcmsOSr+Lbs53ZgviOHAVF/mLLZHfrb4jAjR0UuN3KBsaxngrP8d/k2p1c3yuPJROXkM4ktwStG3uMP640O9fl7reoFlj+0S5ZI9TMZnhN9nIU+4kkSiMX587jMnWTFKKUicigCQS98/XhZEDBPQTUL1ofBXKYKxoxK/q1NlCsxsIz1do/V/yJk5cUV7TfTIuOKnAmWKjIp96GMmd6ziVd8fjaChN4BMUFBbPMogxWNUhSMbe3vBazahf5fOL+LS4z9YvsVrw/Oq/No+s5f0ilxkkhnFrrBXYmb924AguW/T3OEWE9o0fpYMfdqC7u374hkZ+9P1zzJXNxDCH4FNMd0yKdLluj2LS0gDvq49rgbAAiSQ5vWNy0ilMfKwumrttfqaC/Fe4d6S0gq2B8x1x1d2VBSw5zD3w0hgiAfocH+vw9uF5fjm+/XkgR1wY/dT8HBqQ1jUVSWM4q9ErPUERJpaADB7+hNhuIbVwcVeWWAg0pDI/EVm3UOHuuwxyh1KdcS5QwapNPmPoFfIujcwXrk7sYNCWKuzeFDGTe2oqArHmKStAw0IRB67tzzQC0HkESUEj4q6+lfAlar6yeMlYdPYZ/kGA79n+tSUDQK6oiv/TS3l0aPwdp89IZioGro0fYtClUHigZTTqr1ZLwZDwA7fNQqt6rx6EAfpqmu2ADsTd1HFFpbqNnP6m7VAf5jAkZMGnsEJoJ0EaqGyCFBO324sUeDy/KnTWIbZETp+IcI6A7oheE/hKi9sk+zffFvjCVFDXZ+o/M9J1JWxY8XxP+HGSC6pL0jf+0LdKtXoM8J0ABftSVH0f8si6n8ZyP5K4jrX2TdWM+hQ8ajME1HQp48B3hUjJ91M9sOSwu61UYI0REjuodeakTCAYae6SvjKT3hnYREbnHhF+3rEERS//MAKzpdw2PFrLE3pZVU/41C1fyQh9JoqvdV8wRCfyBQcuFn6ZC3czMCWTrxC/GiQaUi6KgcPUQ9Yrjj8sLJ74Wtuc9FFgZLnt2hVWDmvstxB5+Q8Hd51MMedwCDqjik4gPdCydCx8S8JEocSJR8Oc/H4F3WS53Uxa2iy4kP6EZ+61juLIpnkQla7UEuM4f4A5g+b7YldpbKLOEMGbR4plhqHjm2vYUK1Olh492d+GmPIv0fkAGf63Z7bPb+mf+prWNO65xeHCY84b8HwSYggb+HDyqq+FN8RJoxTSFv201mcdOKrP67xILZpop9bBIFuz/8cvVhIU/baPaz1hYQAtUJ9FfcIShmleiHy5kThK0HHD9IU6P2ng4u1S5EiGTg11SghJs0ebFxa/jTYpDYWzW2UevkHQh8r1t7Ogm83mQjRub8yqO6ksQgAkkBoWnM2liMzfPJRZnIbFK9780fJx/BQobRPTdnQf5aRfA537aAHjJEMu4jQqGF2l6EHl6/zqluuSEgn7dg+m5+pDo3Fkx1CTmTfWxP/yp4qMMWAJRW2ajsutQqYyDfmO2pgfhVDnHCNMPRN4/BXTR339BvPigYASY2qN+0Unzh7bIgam82M4tC6BkuoC6B8xjauyDgeASUmSZNohoa3+ZNGeKrnCLyqeBhDUyLPE3rr3n52yjetJAnAnIFNevCoTHQzgs/lcTmiKLq3FsTi+e1oeH0ahm3uG9ZJxRbfVrku7esmmRBWbI9zw22xI3jJ6mFie5ZyKeoKAf7pSYbFCXJ14IedsnhfjqP4VuA3rAhlsnZJL/fSGI9oWghuefHK5c/n7ydAoVQf9+s+/lyeiua9G3v1p3XJjrrtriOsCbt964/0QyRZe7+fQSL2v/U5ovi5xdYjYNioSE915kYm/EGaWZwjlUfFQgWK3afNpW0VBqHls7PXWkrT4urz1pykQhWJd5YfQrWyBeUI7SnCwi8ut603MHf5WVbZ0ZO6C7Qg6CTJZbLirUuXxWU7MCPR35KuO6ep7vj5cDdsme9MJ8F7/JyUymeaPkf/b3mLtD462Liv/aUyforbU6HgJM9q/Pqf57sBcSKx5f5+3h+eHdSSnjljHlDtZLhyT950S8ykgxIy/VmLoj05GV/Z6L6wIbJ0keoTn6yaS6aB1Xn2YnlImtydjBFn52fpod+l8BmRuIoDgUEosTO9lE473LD/LmcwllXZc+d6eNBudIT4dYnesvgNjRMODRT6bqDini/iu1CTFepVFQUGyom1gk+y42pCNONR7VaIisZss8we2YyyApN2bo3y3SAvuep7pyc5Qi9UH3QqkprnOxFXgFm5K22I/MPYLcGCDuZRW7erW4zHx0u+Jmq91yE1K5CUcrT/vuWxZ6foHvJav4ICRUio5YDjPhfhQzr9zX8UlaE/8uDENi2hNgmPWZCImk7yJQ3o0dkJteR+eSZI7VjdNSuYBiLFC2KeGXcbl9/EWuFgNQPSd4tWCQU15Vi5PUp/eW7a81NF/r/xoo/XGqNDswu3jf79W52rr0Nigw0c6O+/lq2MKX8XDZio/AvsxjpI/sFcuk+hJ92Teiq0OiwLj6giNK66KhJjzJflx3tRjEpLUqiKAgaC0u/eHMnEThOSPiBCzTvUGLGOcdwWgmJnK9TAbDNNXz/mLzhR2skQtb4DjwHuTF8JhJxIiVCWkHOBRFKMVUqjJIeiD02cPzvlLaNzxsisYvG+0RaDaYNuk/9rIv5TNb4qTdneTZxteysR+iZE49NH59aG7ak+2RiR97+xptaW/bew94o5DbKCutU17u4IdBfvpNEi4JDreMoXU0AzLNK6mjDHLAmAeCXE4A9pKDdV6oaI2wO2ZjtEQ8thwBXt8CSjrweNXNe6UvPceMDTKj2HHb7eAQIN7LJIaZez82h9PmmHptQmWcuwiAMLiqRYWA7scN0PfUN71FdIHRaRrv23zKjyIefGw2BQhnVActgQ2qcLp9Wmh3JqK5t9oCcSF99EPsqy0oXPCdgtsd0YBzxPfL7HeDak1ONWzt1VygrdUBATribJ/PAa/gR1aLo+fXDes6wWRy8O23lnKRfnigOPitlX7i3VEW+9CHrjl3DEkAnIl8T0By59XxvgvnRxIFZypu0WcKIrAVH3QMSGVVAl7M8QdMM6vzpkQNELEiEXSYhR8oEJBh4f3yW9F57bnFHsNwcXrUbOq65OuSb0kRBGgmJm/J2cw8npKZh32XT+lNyGdSuGQy2bxOTweWJiWa/D/Jx6vWVKWHB7HQx4ftcBdPBl59zmX7iHufREACBlJ3mv6gNQmhnUFj2VBzVQq4bwctUU9bP9PG4Mqz16zp4V4JZ2OWLg2Nw91ZETC1iLLNRM8rvpj7MlTbNU3+XeWvi8zz0IuQUJMm8qTnYalWg5v4CvM7MRVLReLdkZgVOl5j3pIyHWKhD5I3AIQPSE1KZUQGZkMM5QMKHgQwGUDjgZzkrA+6VQCzTlBNxcK0K3C/mvNGC/kA/BTTAAAQC+w6mRa+XpFyEnG22Dwr4XwtSV0EGJ26lKGGBOTPnZvwgKWhieE5Gb6upV+WlWG1Xrmzaue8u7PAsWcX8p1/np5VUDNbQyIaVuToX+H/nFLGPz8oe7KsgCvzmh/rOy3lMAx3wnC33GnOoh2E1sNAEiQu4yY+BKIVldICdryp71mglUEFhU7iSkJC3c8bVDIwl3Igbbp0Hgr9JGj9R+/BX+Jtd/T4rWwb2JM1I9F8O0N2UPFoi1RFr6BzIwUTDnaDbgHGrECveDoC31Sif6oiolhb9Coz/CBRphR3uRe9VR9iDdihmb0V0L8r9Db6tru3Qz8RaBzNkiF+/VDpI3A95ribbyjv++5/w18zW5YdPP4w3IktrLUuUHt+oc5eN3y8WXa5/jT4SEkXaiaGv6QnDEOt20GlUjuJmj2tzrE6LDGDZZYfRwntrmzv5rHqidxvm17FsCDaAxV7fr5Zx6t2YDdz4/Keb5mJKICtru8oe6BBFUZ6IjtQQgTzv6McIOTlkKAoir0oWXSDngN8XwQLbCOTPsC+Qmz8uxCkmWtFzY6KUpukCpSRlbZyT73Nwbte2OmXv92N8DhZ0NkmO8oW36USa+ceJmxTC0G3i7yO/CBRphSVMrT+UxYaReDjVWZBwJJEsPJuCS7HJn7/f+XfzN8yTPaWRhVhfCtR65eN3TWXnxaQBAAAAA=" alt="figure 3" loading=lazy srcset sizes width=685 height=427></picture></a></div><div class=c-article-section__figure-description data-test=bottom-caption id=figure-3-desc><p>A decision-making chart for immunotherapy of patients with critical illness due to COVID-19. Solid boxes depict treatment advice supported by phase 3 clinical trials, whereas boxes in dashed lines depict treatments suggested on the basis of observational and case-series studies alone. Asterisks depict treatments that could be considered, but have not been yet tested. HLA-DR, human leukocyte antigen DR-isotype; ICU, intensive care unit; IL-6, interleukin-6; Igs, immunoglobulins; rIFNy, recombinant interferon-gamma; rIL-7, recombinant interleukin-7.</p></div></div><div class="u-text-right u-hide-print"><a class=c-article__pill-button data-test=article-link data-track=click data-track-label=button data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/3 data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel=nofollow><span>Full size image</span><svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-chevron-right></use></svg></a></div></figure></div><h3 class=c-article__sub-heading id=Sec19>The patient with multisystem inflammatory syndrome: MIS-C and MIS-A</h3><p>Early in the pandemic, children were seen to present with diverse COVID-19 symptoms, such as persistent fever, headache, fatigue, abdominal pain, vomiting, conjunctival injection, myocarditis and rash, usually 2–6 weeks after mild COVID-19; this condition was named multisystem inflammatory syndromes in children (MIS-C). A similar syndrome has been described in adults (MIS-A). Some of the children with MIS-C developed multiorgan failure and shock or coronary aneurysms.<p>The American College of Rheumatology treatment guideline recommends intravenous immunoglobulin (IVIG) and/or high-dose glucocorticoids as first-line therapies in MIS-C<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 89" title="Henderson, L. A. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV‐2 and hyperinflammation in pediatric COVID‐19: version 1. Arthritis Rheumatol. 72, 1791–1805 (2020)." href=#ref-CR89 id=ref-link-section-d6748958e3222>89</a></sup>. Approximately 30–80% of patients do not respond to IVIG and may require adjunctive immunomodulatory therapy<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Pouletty, M. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann. Rheum. Dis. 79, 999–1006 (2020)." href=#ref-CR90 id=ref-link-section-d6748958e3226>90</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383, 334–346 (2020)." href=#ref-CR91 id=ref-link-section-d6748958e3226_1>91</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. Brit. Med. J. 369, m2094 (2020)." href=#ref-CR92 id=ref-link-section-d6748958e3226_2>92</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Cheung, E. W. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 324, 294 (2020)." href=#ref-CR93 id=ref-link-section-d6748958e3226_3>93</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Ramcharan, T. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. Pediatr. Cardiol. 41, 1391–1401 (2020)." href=#ref-CR94 id=ref-link-section-d6748958e3226_4>94</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 95" title="Nakra, N., Blumberg, D., Herrera-Guerra, A. &amp; Lakshminrusimha, S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children 7, 69 (2020)." href=#ref-CR95 id=ref-link-section-d6748958e3229>95</a></sup>. Pulse methylprednisolone, additional dosing of IVIG, anakinra, tocilizumab and infliximab have all been used as escalation therapies<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 92" title="Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. Brit. Med. J. 369, m2094 (2020)." href=#ref-CR92 id=ref-link-section-d6748958e3233>92</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Lee, P. Y. et al. Distinct clinical and immunological features of SARS-CoV-2–induced multisystem inflammatory syndrome in children. J. Clin. Invest. 130, 5942–5950 (2020)." href=#ref-CR96 id=ref-link-section-d6748958e3236>96</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259–269 (2020)." href=#ref-CR97 id=ref-link-section-d6748958e3236_1>97</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Riollano‐Cruz, M. et al. Multisystem inflammatory syndrome in children related to COVID‐19: A New York City experience. J. Med. Virol. 93, 424–433 (2021)." href=#ref-CR98 id=ref-link-section-d6748958e3236_2>98</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 99" title="Ruscitti, P. et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front. Immunol. 11, 1130 (2020)." href=#ref-CR99 id=ref-link-section-d6748958e3239>99</a></sup> in MIS-C. Far fewer cases of MIS-A have been reported in the literature<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Morris, S. B. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. MMWR. Morb. Mortal. Wkly. Rep. 69, 1450–1456 (2020)." href=#ref-CR100 id=ref-link-section-d6748958e3243>100</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref title="Bastug, A. et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. Rheumatol. Int. 41, 993–1008 (2021)." href=#ref-CR101 id=ref-link-section-d6748958e3243_1>101</a>,<a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 102" title="Uwaydah, A. K., Hassan, N. M. M., Abu Ghoush, M. S. &amp; Shahin, K. M. M. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. BMJ Case Rep. 14, e242060 (2021)." href=#ref-CR102 id=ref-link-section-d6748958e3246>102</a></sup>. These adult patients were treated with glucocorticoids, with or without IVIG, and anticoagulants with mostly favorable outcomes.<p>In two large observational cohort studies, the effects of different treatment strategies on short-term outcome were compared, with propensity score adjustments for confounding. The Overcoming COVID consortium reported a lower risk of cardiovascular dysfunction and a lower need for vasopressors and adjunctive therapy in initial treatment with IVIG plus glucocorticoids compared with IVIG monotherapy<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 103" title="Son, M. B. F. et al. Multisystem inflammatory syndrome in children — initial therapy and outcomes. N. Engl. J. Med. 385, 11–22 (2021)." href=#ref-CR103 id=ref-link-section-d6748958e3253>103</a></sup>. Yet, in the Best Available Treatment Study (BATS), treatment with IVIG, IVIG plus glucocorticoids, or glucocorticoid monotherapy did not yield statistically significant differences for endpoints of ventilation, inotropic support or death, or for improvement on an ordinal clinical severity scale<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 104" title="McArdle, A. J. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 385, 11–22 (2021)." href=#ref-CR104 id=ref-link-section-d6748958e3257>104</a></sup>. Both studies reported reduced risks for escalation therapy in patients treated with IVIG plus glucocorticoids compared with IVIG monotherapy, which corroborates the findings from a smaller French study<sup><a data-track=click data-track-action="reference anchor" data-track-label=link data-test=citation-ref aria-label="Reference 105" title="Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855–864 (2021)." href=#ref-CR105 id=ref-link-section-d6748958e3261>105</a></sup>; however, glucocorticoid monotherapy and IVIG monotherapy were equally effective.<p>Differences in study results could result from genetic differences between study populations, differences in viral-strain-dependent hyperimmune responses, and, of course, suboptimal adjustments for all potential confounders, in particular confounding by indication. Therefore, randomized controlled trials are needed to determine the optimal therapy for MIS-C and MIS-A. At present, there is one recruiting RCT comparing infliximab, glucocorticoids or anakinra as escalation therapy after IVIG monotherapy (<a href=https://clinicaltrials.gov/ct2/show/NCT04898231>NCT04898231</a>). In addition, treatment with mesenchymal stromal cells is currently being evaluated in open-label studies (<a href=https://clinicaltrials.gov/ct2/show/NCT04549285>NCT04549285</a>, <a href=https://clinicaltrials.gov/ct2/show/NCT04456439>NCT04456439</a>).</p></div></div></section><section data-title="Future outlook and conclusions"><div class=c-article-section id=Sec20-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Sec20>Future outlook and conclusions</h2><div class=c-article-section__content id=Sec20-content><p>The immunotherapy of COVID-19 has reached important milestones, being the first severe acute infectious disease in which a strong level of evidence permits recommendation of immunotherapy, as detailed above. However, major quandaries remain in the day-to-day clinical practice, and they should be addressed as a matter of urgency.<p>One major quandary with which we are confronted is the treatment of the patient with COVID-19 who does not improve, despite treatment with immunotherapeutic agents such as dexamethasone and anti-IL-6 therapy. Some of these patients remain strongly hyperinflammatory, and no formal RCTs of follow-up immunotherapy have been performed to help to guide our decision; this is a substantial unmet need. However, such studies will be more challenging to perform than earlier trials, and until such data are available, one can rationally argue that the addition of alternative immunotherapies should be considered (Table <a data-track=click data-track-label=link data-track-action="table anchor" href=#Tab1>1</a>).<p>It will thus be very important to pursue further clinical studies to identify novel immunotherapies that could improve the outcome of severe cases. If the patient is still not improving despite the available combinations, other immunomodulatory drugs could be an option to further dampen the hyperactive immune status, such as blocking C5a, anti-GM–CSF, or anti-TNF. However, the level of evidence for anti-cytokine therapies in the ICU patients beyond anti-IL-6 is very low. Furthermore, an increased risk of secondary infections can be anticipated when blocking more components of the immune system. Therefore, escalation of immunosuppressive treatment is currently not advocated outside of clinical trials. An overview of novel potential therapies that need to be formally tested in future clinical trials is presented in Fig. <a data-track=click data-track-label=link data-track-action="figure anchor" href=#Fig4>4</a>.<div class="c-article-section__figure js-c-reading-companion-figures-item" data-test=figure data-container-section=figure id=figure-4 data-title="An overview of the options for immunotherapy in patients with COVID-19, depending on the stage of the disease (based on the WHO Clinical Progression Score)."><figure><figcaption><b id=Fig4 class=c-article-section__figure-caption data-test=figure-caption-text>Fig. 4: An overview of the options for immunotherapy in patients with COVID-19, depending on the stage of the disease (based on the WHO Clinical Progression Score).</b></figcaption><div class=c-article-section__figure-content><div class=c-article-section__figure-item><a class=c-article-section__figure-link data-test=img-link data-track=click data-track-label=image data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/4 rel=nofollow><picture><img aria-describedby=Fig4 src=data:image/webp;base64,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 alt="figure 4" loading=lazy srcset sizes width=685 height=322></picture></a></div><div class=c-article-section__figure-description data-test=bottom-caption id=figure-4-desc><p>The treatments based on high-quality randomized trials are presented in dark blue, while the more speculative treatments based on observational or small case-series studies are presented in light blue. FiO<sub>2</sub>, fraction of inspired oxygen; GM–CSF, granulocyte–macrophage colony stimulating factor; IL-1/6, interleukin-1/6; JAK, Janus kinase; NIV, noninvasive ventilation; pO<sub>2</sub>, partial pressure of oxygen; SpO<sub>2</sub>, oxygen saturation; TNF, tumor necrosis factor.</p></div></div><div class="u-text-right u-hide-print"><a class=c-article__pill-button data-test=article-link data-track=click data-track-label=button data-track-action="view figure" href=https://www.nature.com/articles/s41591-021-01643-9/figures/4 data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel=nofollow><span>Full size image</span><svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-chevron-right></use></svg></a></div></figure></div><p>A second quandary that has only been superficially addressed until now is represented by the pathophysiological heterogeneity of COVID-19. Several interventions proven to be effective work by modulating the host’s immune response, or cascades downstream of the immune response. However, the host response to SARS-CoV-2 is complex, characterized by a plethora of pathways that can be both beneficial and deleterious. Not surprisingly, agents that modify these pathways can be beneficial for some patients and ineffective or even harmful in others. Further complexity arises when one considers that the agents themselves can have additive, multiplying, or negative effects when used in combination. These variable treatment effects, dependent on a patient’s particular immune state, the disease course, and on the use of co-interventions, likely explain some of the disparate findings from some clinical trials. The weaving together of findings from these experiments into an overarching conceptual model is a largely theoretical exercise at this point. Consequently, the current evidence-based guidelines appear somewhat simplistic and lacking in nuance for the individualized treatments that many clinicians likely wish to prescribe. Nevertheless, preliminary data suggest that defined subgroups of patients (based on their inflammatory response) may benefit more, or less, from certain immunomodulatory therapies. The way forward is to perform trials based on robust biomarkers, so that patients that are more likely to benefit from a given treatment will receive it.<p>There are two broad barriers to the generation of robust experimental evidence supporting individualized treatment algorithms. First, the underlying heterogeneity in pathophysiology that likely drives differential treatment responses may often be clinically invisible: two clinically similar patients may have diverse immune states. Second, traditional trial designs are not well-suited for efficient evaluation of differential treatment effects in different patient groups. The good news is that much of the evidence supporting best treatment has come from adaptive platform trials, such as RECOVERY or REMAP-CAP. These designs are more flexible for the evaluation of combinations of therapies and evaluation of effects across different subgroups. And, indeed, one can argue that adaptive platform trials have been the dominant source of robust clinical evidence for COVID-19, perhaps ushering in a new paradigm for clinical research. Nonetheless, these trials have thus far still used relatively simple approaches for the assessment of subgroup effects and heterogeneity of treatment effects. Although they can provide clinical rationale and explore more personalized options when common approaches are not working, smaller trials often lack statistical power to confirm clinical efficacy. Therefore, immunotherapy in COVID-19 needs to be further explored through RCTs ito consolidate knowledge and experience and to determine the optimal biomarker-driven host-directed strategies.<p>One final quandary that must be addressed in the future is the availability of immunotherapy. Although the approaches described here can be incorporated in standard-of-care protocols of high-income countries, these treatments are often not available in many low- or middle-income countries. Efforts should be made to increase the availability of the current medications but also explore cheaper but equally effective alternatives. Only by ensuring equal therapeutic opportunities for all our patients can we fulfil our mission of optimal treatment of COVID-19.</p></div></div></section>
 
 <div id=MagazineFulltextArticleBodySuffix><section aria-labelledby=Bib1 data-title=References><div class=c-article-section id=Bib1-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Bib1>References</h2><div class=c-article-section__content id=Bib1-content><div data-container-section=references><ol class=c-article-references><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=1.><p class=c-article-references__text id=ref-CR1>Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. <i>Cell</i> <b>181</b>, 281–292.e6 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXkvVejsLk%3D aria-label="CAS reference 1">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32155444" aria-label="PubMed reference 1">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102599 aria-label="PubMed Central reference 1">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Structure%2C%20function%2C%20and%20antigenicity%20of%20the%20SARS-CoV-2%20spike%20glycoprotein&amp;journal=Cell&amp;volume=181&amp;pages=281-292.e6&amp;publication_year=2020&amp;author=Walls%2CAC">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=2.><p class=c-article-references__text id=ref-CR2>Hoffmann, M. et al. SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. <i>Cell</i> <b>181</b>, 271–280 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=3.><p class=c-article-references__text id=ref-CR3>Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. <i>Cell</i> <b>182</b>, 429–446.e14 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFGhtrbI aria-label="CAS reference 3">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=7250779" aria-label="PubMed reference 3">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250779 aria-label="PubMed Central reference 3">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=SARS-CoV-2%20reverse%20genetics%20reveals%20a%20variable%20infection%20gradient%20in%20the%20respiratory%20tract&amp;journal=Cell&amp;volume=182&amp;pages=429-446.e14&amp;publication_year=2020&amp;author=Hou%2CYJ">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=4.><p class=c-article-references__text id=ref-CR4>Jouan, Y., Baranek, T., Si-Tahar, M., Paget, C. &amp; Guillon, A. Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS. <i>Crit. Care</i> <b>25</b>, 120 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33761985" aria-label="PubMed reference 4">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988241 aria-label="PubMed Central reference 4">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Lung%20compartmentalization%20of%20inflammatory%20biomarkers%20in%20COVID-19-related%20ARDS&amp;journal=Crit.%20Care&amp;volume=25&amp;publication_year=2021&amp;author=Jouan%2CY&amp;author=Baranek%2CT&amp;author=Si-Tahar%2CM&amp;author=Paget%2CC&amp;author=Guillon%2CA">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=5.><p class=c-article-references__text id=ref-CR5>Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. <i>Cell Host Microbe</i> <b>27</b>, 992–1000.e3 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnvFehsb4%3D aria-label="CAS reference 5">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32320677" aria-label="PubMed reference 5">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172841 aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Complex%20immune%20dysregulation%20in%20COVID-19%20patients%20with%20severe%20respiratory%20failure&amp;journal=Cell%20Host%20Microbe&amp;volume=27&amp;pages=992-1000.e3&amp;publication_year=2020&amp;author=Giamarellos-Bourboulis%2CEJ">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=6.><p class=c-article-references__text id=ref-CR6>Chen, X. et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. <i>Clin. Infect. Dis.</i> <b>71</b>, 1937–1942 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisVWhtb%2FI aria-label="CAS reference 6">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32301997" aria-label="PubMed reference 6">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Detectable%20serum%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20viral%20load%20%28RNAemia%29%20is%20closely%20correlated%20with%20drastically%20elevated%20interleukin%206%20level%20in%20critically%20ill%20patients%20with%20coronavirus%20disease%202019&amp;journal=Clin.%20Infect.%20Dis.&amp;volume=71&amp;pages=1937-1942&amp;publication_year=2020&amp;author=Chen%2CX">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=7.><p class=c-article-references__text id=ref-CR7>Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. <i>J. Clin. Invest.</i> <b>130</b>, 2620–2629 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXpt12ks78%3D aria-label="CAS reference 7">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32217835" aria-label="PubMed reference 7">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190990 aria-label="PubMed Central reference 7">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20and%20immunological%20features%20of%20severe%20and%20moderate%20coronavirus%20disease%202019&amp;journal=J.%20Clin.%20Invest.&amp;volume=130&amp;pages=2620-2629&amp;publication_year=2020&amp;author=Chen%2CG">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=8.><p class=c-article-references__text id=ref-CR8>Payen, D. et al. A longitudinal study of immune cells in severe COVID-19 patients. <i>Front. Immunol.</i> <b>11</b>, 580250 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitVClu7s%3D aria-label="CAS reference 8">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33178207" aria-label="PubMed reference 8">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597438 aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20longitudinal%20study%20of%20immune%20cells%20in%20severe%20COVID-19%20patients&amp;journal=Front.%20Immunol.&amp;volume=11&amp;publication_year=2020&amp;author=Payen%2CD">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=9.><p class=c-article-references__text id=ref-CR9>Huang, I. &amp; Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. <i>J. Intensive Care</i> <b>8</b>, 1–10 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Lymphopenia%20in%20severe%20coronavirus%20disease-2019%20%28COVID-19%29%3A%20systematic%20review%20and%20meta-analysis&amp;journal=J.%20Intensive%20Care&amp;volume=8&amp;pages=1-10&amp;publication_year=2020&amp;author=Huang%2CI&amp;author=Pranata%2CR">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=10.><p class=c-article-references__text id=ref-CR10>Iskander, K. N. et al. Sepsis: multiple abnormalities, heteroge-neous responses, and evolving understanding. <i>Physiol. Rev.</i> <b>93</b>, 1247–1288 (2013).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsVekurfF aria-label="CAS reference 10">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23899564" aria-label="PubMed reference 10">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962548 aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Sepsis%3A%20multiple%20abnormalities%2C%20heteroge-neous%20responses%2C%20and%20evolving%20understanding&amp;journal=Physiol.%20Rev.&amp;volume=93&amp;pages=1247-1288&amp;publication_year=2013&amp;author=Iskander%2CKN">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=11.><p class=c-article-references__text id=ref-CR11>Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV- 2: a prospective cohort study. <i>Eur. Respir. J</i>. <b>55</b>, 2000524 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=12.><p class=c-article-references__text id=ref-CR12>Janssen, N. A. F. et al. Dysregulated innate and adaptive immune responses discriminate disease severity in COVID-19. <i>J. Infect. Dis.</i> <b>223</b>, 1322–1333 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFGjurrL aria-label="CAS reference 12">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33524124" aria-label="PubMed reference 12">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Dysregulated%20innate%20and%20adaptive%20immune%20responses%20discriminate%20disease%20severity%20in%20COVID-19&amp;journal=J.%20Infect.%20Dis.&amp;volume=223&amp;pages=1322-1333&amp;publication_year=2021&amp;author=Janssen%2CNAF">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=13.><p class=c-article-references__text id=ref-CR13>Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. <i>Nat. Med.</i> <b>26</b>, 1623–1635 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1Wru77N aria-label="CAS reference 13">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32807934" aria-label="PubMed reference 13">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC32807934 aria-label="PubMed Central reference 13">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20dynamic%20COVID-19%20immune%20signature%20includes%20associations%20with%20poor%20prognosis&amp;journal=Nat.%20Med.&amp;volume=26&amp;pages=1623-1635&amp;publication_year=2020&amp;author=Laing%2CAG">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=14.><p class=c-article-references__text id=ref-CR14>Kreutmair, S. et al. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. <i>Immunity</i> <b>54</b>, 1578–1593.e5 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtFymt7%2FF aria-label="CAS reference 14">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34051147" aria-label="PubMed reference 14">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106882 aria-label="PubMed Central reference 14">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Distinct%20immunological%20signatures%20discriminate%20severe%20COVID-19%20from%20non-SARS-CoV-2-driven%20critical%20pneumonia&amp;journal=Immunity&amp;volume=54&amp;pages=1578-1593.e5&amp;publication_year=2021&amp;author=Kreutmair%2CS">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=15.><p class=c-article-references__text id=ref-CR15>Bost, P. et al. Deciphering the state of immune silence in fatal COVID-19 patients. <i>Nat. Commun.</i> <b>12</b>, 1–15 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Deciphering%20the%20state%20of%20immune%20silence%20in%20fatal%20COVID-19%20patients&amp;journal=Nat.%20Commun.&amp;volume=12&amp;pages=1-15&amp;publication_year=2021&amp;author=Bost%2CP">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=16.><p class=c-article-references__text id=ref-CR16>Obi, A. T., Barnes, G. D., Napolitano, L. M., Henke, P. K. &amp; Wakefield, T. W. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. <i>J. Vasc. Surg. Venous Lymphat. Disord.</i> <b>9</b>, 23–35 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32916371" aria-label="PubMed reference 16">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Venous%20thrombosis%20epidemiology%2C%20pathophysiology%2C%20and%20anticoagulant%20therapies%20and%20trials%20in%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection&amp;journal=J.%20Vasc.%20Surg.%20Venous%20Lymphat.%20Disord.&amp;volume=9&amp;pages=23-35&amp;publication_year=2021&amp;author=Obi%2CAT&amp;author=Barnes%2CGD&amp;author=Napolitano%2CLM&amp;author=Henke%2CPK&amp;author=Wakefield%2CTW">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=17.><p class=c-article-references__text id=ref-CR17>Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. <i>Lancet</i> <b>395</b>, 1054–1062 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXkvVGktL8%3D aria-label="CAS reference 17">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32171076" aria-label="PubMed reference 17">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC32171076 aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan%2C%20China%3A%20a%20retrospective%20cohort%20study&amp;journal=Lancet&amp;volume=395&amp;pages=1054-1062&amp;publication_year=2020&amp;author=Zhou%2CF">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=18.><p class=c-article-references__text id=ref-CR18>Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. <i>Brit. Med. J.</i> <b>368</b>, m1295 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20characteristics%20of%20113%20deceased%20patients%20with%20coronavirus%20disease%202019%3A%20Retrospective%20study&amp;journal=Brit.%20Med.%20J.&amp;volume=368&amp;publication_year=2020&amp;author=Chen%2CT">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=19.><p class=c-article-references__text id=ref-CR19>Goyal, P. et al. Clinical Characteristics of Covid-19 in New York City. <i>N. Engl. J. Med.</i> <b>382</b>, 2372–2374 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32302078" aria-label="PubMed reference 19">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20Characteristics%20of%20Covid-19%20in%20New%20York%20City&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=382&amp;pages=2372-2374&amp;publication_year=2020&amp;author=Goyal%2CP">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=20.><p class=c-article-references__text id=ref-CR20>Mandal, S. et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. <i>Thorax</i> <b>76</b>, 396–398 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=21.><p class=c-article-references__text id=ref-CR21>Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. <i>J. Clin. Invest.</i> <b>130</b>, 2757–2765 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFCkt7%2FI aria-label="CAS reference 21">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32254064" aria-label="PubMed reference 21">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259988 aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Deployment%20of%20convalescent%20plasma%20for%20the%20prevention%20and%20treatment%20of%20COVID-19&amp;journal=J.%20Clin.%20Invest.&amp;volume=130&amp;pages=2757-2765&amp;publication_year=2020&amp;author=Bloch%2CEM">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=22.><p class=c-article-references__text id=ref-CR22>Shankar-Hari, M., Spencer, J., Sewell, W. A., Rowan, K. M. &amp; Singer, M. Bench-to-bedside review: Immunoglobulin therapy for sepsis — biological plausibility from a critical care perspective. <i>Crit. Care</i> <b>16</b>, 206 (2012).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=23.><p class=c-article-references__text id=ref-CR23>Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. <i>JCI Insight</i> <b>4</b>, e123158 (2019).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=24.><p class=c-article-references__text id=ref-CR24>Bournazos, S., Gupta, A. &amp; Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. <i>Nat. Rev. Immunol.</i> <b>20</b>, 633–643 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsFOlsb%2FN aria-label="CAS reference 24">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32782358" aria-label="PubMed reference 24">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20role%20of%20IgG%20Fc%20receptors%20in%20antibody-dependent%20enhancement&amp;journal=Nat.%20Rev.%20Immunol.&amp;volume=20&amp;pages=633-643&amp;publication_year=2020&amp;author=Bournazos%2CS&amp;author=Gupta%2CA&amp;author=Ravetch%2CJV">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=25.><p class=c-article-references__text id=ref-CR25>Zinsser H., Batchelder A. P. Studies on Mexican typhus fever. <i>I. J. Exp. Med.</i> <b>51</b>, 847–858 (1930).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=26.><p class=c-article-references__text id=ref-CR26>O’Donnell, M. R. et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. <i>J. Clin. Invest.</i> <b>131</b>, e150646 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245169 aria-label="PubMed Central reference 26">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20randomized%20double-blind%20controlled%20trial%20of%20convalescent%20plasma%20in%20adults%20with%20severe%20COVID-19&amp;journal=J.%20Clin.%20Invest.&amp;volume=131&amp;publication_year=2021&amp;author=O%E2%80%99Donnell%2CMR">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=27.><p class=c-article-references__text id=ref-CR27>Arnold Egloff, S. A. et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. <i>J. Clin. Invest</i>. <b>131</b>, e151788 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=28.><p class=c-article-references__text id=ref-CR28>Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. <i>Transfusion</i> <b>61</b>, 2503–2511 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsV2jsrrF aria-label="CAS reference 28">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34036587" aria-label="PubMed reference 28">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Use%20of%20convalescent%20plasma%20in%20COVID-19%20patients%20with%20immunosuppression&amp;journal=Transfusion&amp;volume=61&amp;pages=2503-2511&amp;publication_year=2021&amp;author=Senefeld%2CJW">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=29.><p class=c-article-references__text id=ref-CR29>Piechotta, V. et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>Cochrane Database Syst. Rev.</i> <b>7</b>, 1–293 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Convalescent%20plasma%20or%20hyperimmune%20immunoglobulin%20for%20people%20with%20COVID-19%3A%20a%20living%20systematic%20review&amp;journal=Cochrane%20Database%20Syst.%20Rev.&amp;volume=7&amp;pages=1-293&amp;publication_year=2020&amp;author=Piechotta%2CV">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=30.><p class=c-article-references__text id=ref-CR30>Abani, O. et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet</i> <b>397</b>, 2049–2059 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Convalescent%20plasma%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;volume=397&amp;pages=2049-2059&amp;publication_year=2021&amp;author=Abani%2CO">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=31.><p class=c-article-references__text id=ref-CR31>Writing Committee for the REMAP-CAP Investigators et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. <i>JAMA</i> <b>326</b>, 1690–1702 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=32.><p class=c-article-references__text id=ref-CR32>Aiello, A. et al. Immunosenescence and Its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. <i>Front. Immunol.</i> <b>10</b>, 2247 (2019).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFyhsb0%3D aria-label="CAS reference 32">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31608061" aria-label="PubMed reference 32">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773825 aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Immunosenescence%20and%20Its%20hallmarks%3A%20how%20to%20oppose%20aging%20strategically%3F%20A%20review%20of%20potential%20options%20for%20therapeutic%20intervention&amp;journal=Front.%20Immunol.&amp;volume=10&amp;publication_year=2019&amp;author=Aiello%2CA">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=33.><p class=c-article-references__text id=ref-CR33>Libster, R. et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. <i>N. Engl. J. Med.</i> <b>384</b>, 610–618 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=34.><p class=c-article-references__text id=ref-CR34>Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. <i>JAMA</i> <b>325</b>, 632–644 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=35.><p class=c-article-references__text id=ref-CR35>RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to 4 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Preprint at medRxiv <a href=https://doi.org/10.1101/2021.06.15.21258542>https://doi.org/10.1101/2021.06.15.21258542</a> (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=36.><p class=c-article-references__text id=ref-CR36>Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> <b>369</b>, eabc8511 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslCltrnF aria-label="CAS reference 36">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32669297" aria-label="PubMed reference 36">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402624 aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Deep%20immune%20profiling%20of%20COVID-19%20patients%20reveals%20distinct%20immunotypes%20with%20therapeutic%20implications&amp;journal=Science&amp;volume=369&amp;publication_year=2020&amp;author=Mathew%2CD">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=37.><p class=c-article-references__text id=ref-CR37>Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. <i>JAMA Intern. Med</i>. <b>180</b>, 934–943 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=38.><p class=c-article-references__text id=ref-CR38>Horby, P. et al. Dexamethasone in hospitalized patients with COVID-19. <i>N. Engl. J. Med.</i> <b>384</b>, 693–704 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXlt1Kgsbo%3D aria-label="CAS reference 38">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32678530" aria-label="PubMed reference 38">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC32678530 aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Dexamethasone%20in%20hospitalized%20patients%20with%20COVID-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=384&amp;pages=693-704&amp;publication_year=2021&amp;author=Horby%2CP">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=39.><p class=c-article-references__text id=ref-CR39>Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. <i>JAMA</i> <b>324</b>, 1330–1341 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32876694" aria-label="PubMed reference 39">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20hydrocortisone%20on%20mortality%20and%20organ%20support%20in%20patients%20with%20severe%20COVID-19&amp;journal=JAMA&amp;volume=324&amp;pages=1330-41&amp;publication_year=2020&amp;author=Angus%2CDC">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=40.><p class=c-article-references__text id=ref-CR40>Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. <i>JAMA</i> <b>324</b>, 1307–1316 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=41.><p class=c-article-references__text id=ref-CR41>Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. <i>JAMA</i> <b>324</b>, 1330–1341 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=42.><p class=c-article-references__text id=ref-CR42>Rochwerg, B. et al. A living WHO guideline on drugs for COVID-19. <i>Brit. Med. J.</i> <b>370</b>, m3379 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=43.><p class=c-article-references__text id=ref-CR43>Ferguson, F. M. &amp; Gray, N. S. Kinase inhibitors: the road ahead. <i>Nat. Rev. Drug Discov.</i> <b>17</b>, 353–377 (2018).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXks12ktbg%3D aria-label="CAS reference 43">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29545548" aria-label="PubMed reference 43">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Kinase%20inhibitors%3A%20the%20road%20ahead&amp;journal=Nat.%20Rev.%20Drug%20Discov.&amp;volume=17&amp;pages=353-377&amp;publication_year=2018&amp;author=Ferguson%2CFM&amp;author=Gray%2CNS">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=44.><p class=c-article-references__text id=ref-CR44>Jacobs, C. F., Eldering, E. &amp; Kater, A. P. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. <i>Blood Adv</i>. <b>5</b>, 913–925 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=45.><p class=c-article-references__text id=ref-CR45>Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. <i>N. Engl. J. Med.</i> <b>384</b>, 795–807 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFCksrw%3D aria-label="CAS reference 45">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33306283" aria-label="PubMed reference 45">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Baricitinib%20plus%20remdesivir%20for%20hospitalized%20adults%20with%20COVID-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=384&amp;pages=795-807&amp;publication_year=2021&amp;author=Kalil%2CAC">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=46.><p class=c-article-references__text id=ref-CR46>Marconi, V. C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. <i>Lancet Respir. Med.</i> <b>19</b>, 1–12 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20and%20safety%20of%20baricitinib%20for%20the%20treatment%20of%20hospitalised%20adults%20with%20COVID-19%20%28COV-BARRIER%29%3A%20a%20randomised%2C%20double-blind%2C%20parallel-group%2C%20placebo-controlled%20phase%203%20trial&amp;journal=Lancet%20Respir.%20Med.&amp;volume=19&amp;pages=1-12&amp;publication_year=2021&amp;author=Marconi%2CVC">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=47.><p class=c-article-references__text id=ref-CR47>Aman, J. et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Respir. Med</i>. <b>9</b>, 957–968 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=48.><p class=c-article-references__text id=ref-CR48>Guimarães, P. O. et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. <i>N. Engl. J. Med.</i> <b>385</b>, 406–415 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=49.><p class=c-article-references__text id=ref-CR49>Tharaux, P.-L. et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respir. Med</i>. <b>9</b>, 295–304 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=50.><p class=c-article-references__text id=ref-CR50>The REMAP-CAP Investigators. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. Preprint at medRxiv <a href=https://doi.org/10.1101/2021.06.18.21259133>https://doi.org/10.1101/2021.06.18.21259133</a> (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=51.><p class=c-article-references__text id=ref-CR51>Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. <i>Crit. Care</i> <b>24</b>, 187 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=52.><p class=c-article-references__text id=ref-CR52>Azam, T. U. et al. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. <i>J. Am. Soc. Nephrol.</i> <b>31</b>, 2725–2735 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXltFOkuw%3D%3D aria-label="CAS reference 52">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32963090" aria-label="PubMed reference 52">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608953 aria-label="PubMed Central reference 52">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Soluble%20urokinase%20receptor%20%28SuPAR%29%20in%20COVID-19-related%20AKI&amp;journal=J.%20Am.%20Soc.%20Nephrol.&amp;volume=31&amp;pages=2725-2735&amp;publication_year=2020&amp;author=Azam%2CTU">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=53.><p class=c-article-references__text id=ref-CR53>Kyriazopoulou, E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. <i>eLife</i> <b>10</b>, e66125 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=54.><p class=c-article-references__text id=ref-CR54>Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nat. Med</i>. <b>27</b>, 1752–1760 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=55.><p class=c-article-references__text id=ref-CR55>Caricchio, R. et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. <i>JAMA</i> <b>326</b>, 230–239 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=56.><p class=c-article-references__text id=ref-CR56>Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> <b>397</b>, 1637–1645 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Tocilizumab%20in%20patients%20admitted%20to%20hospital%20with%20COVID-19%20%28RECOVERY%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20platform%20trial&amp;journal=Lancet&amp;volume=397&amp;pages=1637-1645&amp;publication_year=2021&amp;author=Abani%2CO">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=57.><p class=c-article-references__text id=ref-CR57>Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. <i>N. Engl. J. Med.</i> <b>384</b>, 1491–1502 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33631065" aria-label="PubMed reference 57">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC33631065 aria-label="PubMed Central reference 57">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Interleukin-6%20receptor%20antagonists%20in%20critically%20ill%20patients%20with%20COVID-19&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=384&amp;pages=1491-1502&amp;publication_year=2021&amp;author=Gordon%2CAC">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=58.><p class=c-article-references__text id=ref-CR58>Domingo, P. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. <i>JAMA</i> <b>326</b>, 499–518 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=59.><p class=c-article-references__text id=ref-CR59>Patel, J. et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). Preprint at medRxiv <a href=https://doi.org/10.1101/2021.04.14.21255475>https://doi.org/10.1101/2021.04.14.21255475</a> (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=60.><p class=c-article-references__text id=ref-CR60>Diao, B. et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. <i>Nat. Commun.</i> <b>12</b>, 2506 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtVGltrrF aria-label="CAS reference 60">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33947851" aria-label="PubMed reference 60">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096808 aria-label="PubMed Central reference 60">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=Human%20kidney%20is%20a%20target%20for%20novel%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20infection&amp;journal=Nat.%20Commun.&amp;volume=12&amp;publication_year=2021&amp;author=Diao%2CB">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=61.><p class=c-article-references__text id=ref-CR61>Schurink, B. et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. <i>Lancet Microbe</i> <b>1</b>, e290–e299 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXisF2ksLvE aria-label="CAS reference 61">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33015653" aria-label="PubMed reference 61">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518879 aria-label="PubMed Central reference 61">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Viral%20presence%20and%20immunopathology%20in%20patients%20with%20lethal%20COVID-19%3A%20a%20prospective%20autopsy%20cohort%20study&amp;journal=Lancet%20Microbe&amp;volume=1&amp;pages=e290-e299&amp;publication_year=2020&amp;author=Schurink%2CB">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=62.><p class=c-article-references__text id=ref-CR62>Seshan, S. V. et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. <i>Blood</i> <b>114</b>, 1675–1683 (2009).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhtVyiurvN aria-label="CAS reference 62">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19535796" aria-label="PubMed reference 62">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927091 aria-label="PubMed Central reference 62">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Role%20of%20tissue%20factor%20in%20a%20mouse%20model%20of%20thrombotic%20microangiopathy%20induced%20by%20antiphospholipid%20antibodies&amp;journal=Blood&amp;volume=114&amp;pages=1675-1683&amp;publication_year=2009&amp;author=Seshan%2CSV">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=63.><p class=c-article-references__text id=ref-CR63>Kambas, K. et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. <i>J. Immunol</i>. <b>180</b>, 7368–7375 (2008).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=64.><p class=c-article-references__text id=ref-CR64>Ritis, K. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. <i>J. Immunol.</i> <b>177</b>, 4794–4802 (2006).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28Xps1Gns7s%3D aria-label="CAS reference 64">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16982920" aria-label="PubMed reference 64">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20novel%20C5a%20receptor-tissue%20factor%20cross-talk%20in%20neutrophils%20links%20innate%20immunity%20to%20coagulation%20pathways&amp;journal=J.%20Immunol.&amp;volume=177&amp;pages=4794-4802&amp;publication_year=2006&amp;author=Ritis%2CK">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=65.><p class=c-article-references__text id=ref-CR65>de Bruin, S. et al. Clinical features and prognostic factors in COVID-19: a prospective cohort study. <i>EBioMedicine</i> <b>67</b>, 103378 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34000622" aria-label="PubMed reference 65">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118723 aria-label="PubMed Central reference 65">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20features%20and%20prognostic%20factors%20in%20COVID-19%3A%20a%20prospective%20cohort%20study&amp;journal=EBioMedicine&amp;volume=67&amp;publication_year=2021&amp;author=Bruin%2CS">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=66.><p class=c-article-references__text id=ref-CR66>Vlaar, A. P. J. et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. <i>Lancet Rheumatol</i>. <a href=https://doi.org/10.1016/S2665-9913(20)30341-6>https://doi.org/10.1016/S2665-9913(20)30341-6</a> (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=67.><p class=c-article-references__text id=ref-CR67>Cinatl, J. et al. Treatment of SARS with human interferons. <i>Lancet</i> <b>362</b>, 293–294 (2003).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=68.><p class=c-article-references__text id=ref-CR68>Monk, P. D. <i>et al</i>. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respir. Med</i>. <b>9</b>, e764–e773 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=69.><p class=c-article-references__text id=ref-CR69>Hung, I. F. N. et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. <i>Lancet</i> <b>395</b>, 1695–1704 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXovFOjsr0%3D aria-label="CAS reference 69">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32401715" aria-label="PubMed reference 69">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC32401715 aria-label="PubMed Central reference 69">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Triple%20combination%20of%20interferon%20beta-1b%2C%20lopinavir%E2%80%93ritonavir%2C%20and%20ribavirin%20in%20the%20treatment%20of%20patients%20admitted%20to%20hospital%20with%20COVID-19%3A%20an%20open-label%2C%20randomised%2C%20phase%202%20trial&amp;journal=Lancet&amp;volume=395&amp;pages=1695-1704&amp;publication_year=2020&amp;author=Hung%2CIFN">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=70.><p class=c-article-references__text id=ref-CR70>Pan, H. et al. Repurposed antiviral drugs for COVID-19 — interim WHO Solidarity Trial results. <i>N. Engl. J. Med.</i> <b>384</b>, 497–511 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXjvFSmsbg%3D aria-label="CAS reference 70">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33264556" aria-label="PubMed reference 70">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Repurposed%20antiviral%20drugs%20for%20COVID-19%20%E2%80%94%20interim%20WHO%20Solidarity%20Trial%20results&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=384&amp;pages=497-511&amp;publication_year=2021&amp;author=Pan%2CH">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=71.><p class=c-article-references__text id=ref-CR71>van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. <i>Med (N Y.)</i> <b>2</b>, 1163–1170 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=72.><p class=c-article-references__text id=ref-CR72>Nguyen, L. S., Ait Hamou, Z., Gastli, N., Chapuis, N. &amp; Pène, F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. <i>Intensive Care Med.</i> <b>47</b>, 619–621 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXms12jur8%3D aria-label="CAS reference 72">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33688993" aria-label="PubMed reference 72">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 72" href="http://scholar.google.com/scholar_lookup?&amp;title=Potential%20role%20for%20interferon%20gamma%20in%20the%20treatment%20of%20recurrent%20ventilator-acquired%20pneumonia%20in%20patients%20with%20COVID-19%3A%20a%20hypothesis&amp;journal=Intensive%20Care%20Med.&amp;volume=47&amp;pages=619-621&amp;publication_year=2021&amp;author=Nguyen%2CLS&amp;author=Ait%20Hamou%2CZ&amp;author=Gastli%2CN&amp;author=Chapuis%2CN&amp;author=P%C3%A8ne%2CF">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=73.><p class=c-article-references__text id=ref-CR73>Laterre, P. F. et al. Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19). <i>JAMA Netw. Open</i> <b>3</b>, 3–7 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 73" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20of%20interleukin%207%20immunotherapy%20with%20lymphocyte%20counts%20among%20patients%20with%20severe%20coronavirus%20disease%202019%20%28COVID-19%29&amp;journal=JAMA%20Netw.%20Open&amp;volume=3&amp;pages=3-7&amp;publication_year=2020&amp;author=Laterre%2CPF">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=74.><p class=c-article-references__text id=ref-CR74>Shatzel, J. J. et al. The contact activation system as a potential therapeutic target in patients with COVID‐19. <i>Res. Pract. Thromb. Haemost.</i> <b>4</b>, 500–505 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtFOjsLbF aria-label="CAS reference 74">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32542210" aria-label="PubMed reference 74">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264624 aria-label="PubMed Central reference 74">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 74" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20contact%20activation%20system%20as%20a%20potential%20therapeutic%20target%20in%20patients%20with%20COVID%E2%80%9019&amp;journal=Res.%20Pract.%20Thromb.%20Haemost.&amp;volume=4&amp;pages=500-505&amp;publication_year=2020&amp;author=Shatzel%2CJJ">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=75.><p class=c-article-references__text id=ref-CR75>van de Veerdonk, F. L. et al. Kallikrein–kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. <i>eLife</i> <b>9</b>, 57555 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 75" href="http://scholar.google.com/scholar_lookup?&amp;title=Kallikrein%E2%80%93kinin%20blockade%20in%20patients%20with%20COVID-19%20to%20prevent%20acute%20respiratory%20distress%20syndrome&amp;journal=eLife&amp;volume=9&amp;publication_year=2020&amp;author=Veerdonk%2CFL">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=76.><p class=c-article-references__text id=ref-CR76>van de Veerdonk, F. L. et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. <i>JAMA Netw. Open</i> <b>3</b>, e2017708 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32789513" aria-label="PubMed reference 76">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426743 aria-label="PubMed Central reference 76">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 76" href="http://scholar.google.com/scholar_lookup?&amp;title=Outcomes%20associated%20with%20use%20of%20a%20kinin%20B2%20receptor%20antagonist%20among%20patients%20with%20COVID-19&amp;journal=JAMA%20Netw.%20Open&amp;volume=3&amp;publication_year=2020&amp;author=Veerdonk%2CFL">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=77.><p class=c-article-references__text id=ref-CR77>Mansour, E. et al. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. <i>Trials</i> <b>22</b>, 1–13 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 77" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20the%20efficacy%20and%20safety%20of%20icatibant%20and%20C1%20esterase%2Fkallikrein%20inhibitor%20in%20severe%20COVID-19%3A%20study%20protocol%20for%20a%20three-armed%20randomized%20controlled%20trial&amp;journal=Trials&amp;volume=22&amp;pages=1-13&amp;publication_year=2021&amp;author=Mansour%2CE">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=78.><p class=c-article-references__text id=ref-CR78>Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nat. Rev. Immunol.</i> <b>21</b>, 319–329 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFejs7w%3D aria-label="CAS reference 78">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33824483" aria-label="PubMed reference 78">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 78" href="http://scholar.google.com/scholar_lookup?&amp;title=Endothelial%20dysfunction%20and%20immunothrombosis%20as%20key%20pathogenic%20mechanisms%20in%20COVID-19&amp;journal=Nat.%20Rev.%20Immunol.&amp;volume=21&amp;pages=319-329&amp;publication_year=2021&amp;author=Bonaventura%2CA">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=79.><p class=c-article-references__text id=ref-CR79>Talasaz, A. H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19. <i>J. Am. Coll. Cardiol.</i> <b>77</b>, 1903–1921 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXntFOht7k%3D aria-label="CAS reference 79">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33741176" aria-label="PubMed reference 79">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963001 aria-label="PubMed Central reference 79">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 79" href="http://scholar.google.com/scholar_lookup?&amp;title=Recent%20randomized%20trials%20of%20antithrombotic%20therapy%20for%20patients%20with%20COVID-19&amp;journal=J.%20Am.%20Coll.%20Cardiol.&amp;volume=77&amp;pages=1903-1921&amp;publication_year=2021&amp;author=Talasaz%2CAH">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=80.><p class=c-article-references__text id=ref-CR80>Muñoz-Rivas, N. et al. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: a retrospective study. <i>Thromb. Res.</i> <b>199</b>, 132–142 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33503547" aria-label="PubMed reference 80">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787910 aria-label="PubMed Central reference 80">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 80" href="http://scholar.google.com/scholar_lookup?&amp;title=Systemic%20thrombosis%20in%20a%20large%20cohort%20of%20COVID-19%20patients%20despite%20thromboprophylaxis%3A%20a%20retrospective%20study&amp;journal=Thromb.%20Res.&amp;volume=199&amp;pages=132-142&amp;publication_year=2021&amp;author=Mu%C3%B1oz-Rivas%2CN">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=81.><p class=c-article-references__text id=ref-CR81>Mazloomzadeh, S. et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. <i>JAMA</i> <b>325</b>, 1620–1630 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=82.><p class=c-article-references__text id=ref-CR82>Lopes, R. D. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet</i> <b>397</b>, 2253–2263 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=83.><p class=c-article-references__text id=ref-CR83>ATTACC Investigators et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. <i>N. Engl. J. Med</i>. <b>385</b>, 790–802 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=84.><p class=c-article-references__text id=ref-CR84>REMAP-CAP Investigators et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. <i>N. Engl. J. Med</i>. <b>385</b>, 777–789 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=85.><p class=c-article-references__text id=ref-CR85>Bendib, I. et al. Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS. <i>Crit. Care</i> <b>25</b>, 23 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=86.><p class=c-article-references__text id=ref-CR86>Richeldi, L. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. <i>N. Engl. J. Med.</i> <b>365</b>, 1079–1087 (2011).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=87.><p class=c-article-references__text id=ref-CR87>Richeldi, L. et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. <i>BMC Pulm. Med</i>. <b>20</b>, 3 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=88.><p class=c-article-references__text id=ref-CR88>Menshawey, R., Menshawey, E., Alserr, A. H. K. &amp; Abdelmassih, A. F. JAK out of the box; the rationale behind Janus kinase inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. <i>Cardiovasc. Endocrinol. Metab</i>. <b>10</b>, 80–88 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=89.><p class=c-article-references__text id=ref-CR89>Henderson, L. A. et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV‐2 and hyperinflammation in pediatric COVID‐19: version 1. <i>Arthritis Rheumatol</i>. <b>72</b>, 1791–1805 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=90.><p class=c-article-references__text id=ref-CR90>Pouletty, M. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. <i>Ann. Rheum. Dis</i>. <b>79</b>, 999–1006 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=91.><p class=c-article-references__text id=ref-CR91>Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. <i>N. Engl. J. Med.</i> <b>383</b>, 334–346 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsFWrs7jI aria-label="CAS reference 91">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32598831" aria-label="PubMed reference 91">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 91" href="http://scholar.google.com/scholar_lookup?&amp;title=Multisystem%20inflammatory%20syndrome%20in%20U.S.%20children%20and%20adolescents&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=383&amp;pages=334-346&amp;publication_year=2020&amp;author=Feldstein%2CLR">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=92.><p class=c-article-references__text id=ref-CR92>Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. <i>Brit. Med. J.</i> <b>369</b>, m2094 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=93.><p class=c-article-references__text id=ref-CR93>Cheung, E. W. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. <i>JAMA</i> <b>324</b>, 294 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsFWksbfJ aria-label="CAS reference 93">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32511676" aria-label="PubMed reference 93">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 93" href="http://scholar.google.com/scholar_lookup?&amp;title=Multisystem%20inflammatory%20syndrome%20related%20to%20COVID-19%20in%20previously%20healthy%20children%20and%20adolescents%20in%20New%20York%20City&amp;journal=JAMA&amp;volume=324&amp;publication_year=2020&amp;author=Cheung%2CEW">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=94.><p class=c-article-references__text id=ref-CR94>Ramcharan, T. et al. Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK Tertiary Paediatric Hospital. <i>Pediatr. Cardiol</i>. <b>41</b>, 1391–1401 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=95.><p class=c-article-references__text id=ref-CR95>Nakra, N., Blumberg, D., Herrera-Guerra, A. &amp; Lakshminrusimha, S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. <i>Children</i> <b>7</b>, 69 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=96.><p class=c-article-references__text id=ref-CR96>Lee, P. Y. et al. Distinct clinical and immunological features of SARS-CoV-2–induced multisystem inflammatory syndrome in children. <i>J. Clin. Invest.</i> <b>130</b>, 5942–5950 (2020).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitlSnt7jN aria-label="CAS reference 96">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32701511" aria-label="PubMed reference 96">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598077 aria-label="PubMed Central reference 96">PubMed Central</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 96" href="http://scholar.google.com/scholar_lookup?&amp;title=Distinct%20clinical%20and%20immunological%20features%20of%20SARS-CoV-2%E2%80%93induced%20multisystem%20inflammatory%20syndrome%20in%20children&amp;journal=J.%20Clin.%20Invest.&amp;volume=130&amp;pages=5942-5950&amp;publication_year=2020&amp;author=Lee%2CPY">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=97.><p class=c-article-references__text id=ref-CR97>Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. <i>JAMA</i> <b>324</b>, 259–269 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=98.><p class=c-article-references__text id=ref-CR98>Riollano‐Cruz, M. et al. Multisystem inflammatory syndrome in children related to COVID‐19: A New York City experience. <i>J. Med. Virol.</i> <b>93</b>, 424–433 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32584487" aria-label="PubMed reference 98">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 98" href="http://scholar.google.com/scholar_lookup?&amp;title=Multisystem%20inflammatory%20syndrome%20in%20children%20related%20to%20COVID%E2%80%9019%3A%20A%20New%20York%20City%20experience&amp;journal=J.%20Med.%20Virol.&amp;volume=93&amp;pages=424-433&amp;publication_year=2021&amp;author=Riollano%E2%80%90Cruz%2CM">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=99.><p class=c-article-references__text id=ref-CR99>Ruscitti, P. et al. Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. <i>Front. Immunol</i>. <b>11</b>, 1130 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=100.><p class=c-article-references__text id=ref-CR100>Morris, S. B. et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection — United Kingdom and United States, March–August 2020. <i>MMWR. Morb. Mortal. Wkly. Rep</i>. <b>69</b>, 1450–1456 (2020).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=101.><p class=c-article-references__text id=ref-CR101>Bastug, A. et al. Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent. <i>Rheumatol. Int</i>. <b>41</b>, 993–1008 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=102.><p class=c-article-references__text id=ref-CR102>Uwaydah, A. K., Hassan, N. M. M., Abu Ghoush, M. S. &amp; Shahin, K. M. M. Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination. <i>BMJ Case Rep</i>. <b>14</b>, e242060 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=103.><p class=c-article-references__text id=ref-CR103>Son, M. B. F. et al. Multisystem inflammatory syndrome in children — initial therapy and outcomes. <i>N. Engl. J. Med.</i> <b>385</b>, 11–22 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 103" href="http://scholar.google.com/scholar_lookup?&amp;title=Multisystem%20inflammatory%20syndrome%20in%20children%20%E2%80%94%20initial%20therapy%20and%20outcomes&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=385&amp;pages=11-22&amp;publication_year=2021&amp;author=Son%2CMBF">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=104.><p class=c-article-references__text id=ref-CR104>McArdle, A. J. et al. Treatment of multisystem inflammatory syndrome in children. <i>N. Engl. J. Med.</i> <b>385</b>, 11–22 (2021).<p class="c-article-references__links u-hide-print"><a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href=https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhsFWgsLjL aria-label="CAS reference 104">CAS</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34133854" aria-label="PubMed reference 104">PubMed</a>&nbsp;
 <a data-track=click data-track-action="outbound reference" data-track-label=link rel="nofollow noopener" aria-label="Google Scholar reference 104" href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20of%20multisystem%20inflammatory%20syndrome%20in%20children&amp;journal=N.%20Engl.%20J.%20Med.&amp;volume=385&amp;pages=11-22&amp;publication_year=2021&amp;author=McArdle%2CAJ">
 Google Scholar</a>&nbsp;
 </p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=105.><p class=c-article-references__text id=ref-CR105>Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. <i>JAMA</i> <b>325</b>, 855–864 (2021).</p><li class="c-article-references__item js-c-reading-companion-references-item" data-counter=106.><p class=c-article-references__text id=ref-CR106>Döcke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. <i>Nat. Med.</i> <b>3</b>, 678–681 (1997).</p></ol><p class="c-article-references__download u-hide-print"><a data-track=click data-track-action="download citation references" data-track-label=link href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01643-9?format=refman&amp;flavour=references">Download references<svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-download></use></svg></a></p></div></div></div></section></div><section data-title=Acknowledgements><div class=c-article-section id=Ack1-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=Ack1>Acknowledgements</h2><div class=c-article-section__content id=Ack1-content><p>F.L.v.d.V. gratefully acknowledges financial support from the Netherlands Organization for Scientific Research (Vidi grant from ZonMW &amp; ZonMW project nr 10430012010010).M.G.N. was supported by a Spinoza grant of the Netherlands Association for Scientific Research.</p></div></div></section><section aria-labelledby=author-information data-title="Author information"><div class=c-article-section id=author-information-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=author-information>Author information</h2><div class=c-article-section__content id=author-information-content><h3 class=c-article__sub-heading id=affiliations>Authors and Affiliations</h3><ol class=c-article-author-affiliation__list><li id=Aff1><p class=c-article-author-affiliation__address>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands<p class=c-article-author-affiliation__authors-list>Frank L. van de Veerdonk,&nbsp;Reinout van Crevel,&nbsp;Job J. Engel,&nbsp;Jos W. M. van der Meer&nbsp;&amp;&nbsp;Mihai G. Netea</p><li id=Aff2><p class=c-article-author-affiliation__address>Department of Infectious Diseases, Attikon Hospital, University of Athens, Athens, Greece<p class=c-article-author-affiliation__authors-list>Evangelos Giamarellos-Bourboulis</p><li id=Aff3><p class=c-article-author-affiliation__address>Department of Intensive Care Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands<p class=c-article-author-affiliation__authors-list>Peter Pickkers</p><li id=Aff4><p class=c-article-author-affiliation__address>Department of Intensive Care, University Medical Center Utrecht, Utrecht, the Netherlands<p class=c-article-author-affiliation__authors-list>Lennie Derde</p><li id=Aff5><p class=c-article-author-affiliation__address>Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands<p class=c-article-author-affiliation__authors-list>Helen Leavis</p><li id=Aff6><p class=c-article-author-affiliation__address>Division of Infectious Diseases, Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands<p class=c-article-author-affiliation__authors-list>W. Joost Wiersinga&nbsp;&amp;&nbsp;Tom van der Poll</p><li id=Aff7><p class=c-article-author-affiliation__address>Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care Medicine and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands<p class=c-article-author-affiliation__authors-list>Alexander P. J. Vlaar</p><li id=Aff8><p class=c-article-author-affiliation__address>School of Immunobiology and Microbial Sciences, King’s College London, London, UK<p class=c-article-author-affiliation__authors-list>Manu Shankar-Hari</p><li id=Aff9><p class=c-article-author-affiliation__address>Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands<p class=c-article-author-affiliation__authors-list>Lennie Derde&nbsp;&amp;&nbsp;Marc Bonten</p><li id=Aff10><p class=c-article-author-affiliation__address>UPMC and University of Pittsburgh, Pittsburgh, PA, United States<p class=c-article-author-affiliation__authors-list>Derek C. Angus</p><li id=Aff11><p class=c-article-author-affiliation__address>Department of Immunology and Metabolism, Life &amp; Medical Sciences Institute, University of Bonn, Bonn, Germany<p class=c-article-author-affiliation__authors-list>Mihai G. Netea</p></ol><div class="u-js-hide u-hide-print sf-hidden" data-test=author-info></div><h3 class=c-article__sub-heading id=corresponding-author>Corresponding authors</h3><p id=corresponding-author-list>Correspondence to
 <a id=corresp-c1 href=mailto:frank.vandeveerdonk@radboudumc.nl>Frank L. van de Veerdonk</a> or <a id=corresp-c2 href=mailto:mihai.netea@radboudumc.nl>Mihai G. Netea</a>.</p></div></div></section><section data-title="Ethics declarations"><div class=c-article-section id=ethics-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=ethics>Ethics declarations</h2><div class=c-article-section__content id=ethics-content>
 
 <h3 class=c-article__sub-heading id=FPar2>Competing interests</h3>
 <p>The authors declare no competing interests.</p>
 
 </div></div></section><section data-title="Peer review"><div class=c-article-section id=peer-review-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=peer-review>Peer review</h2><div class=c-article-section__content id=peer-review-content>
 
 
 <h3 class=c-article__sub-heading id=FPar1>Peer review information</h3>
 <p><i>Nature Medicine</i> thanks Michael Joyner and Vincenzo Bronte for their contribution to the peer review of this work. Karen O’Leary was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p>
 
 </div></div></section><section data-title="Additional information"><div class=c-article-section id=additional-information-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=additional-information>Additional information</h2><div class=c-article-section__content id=additional-information-content><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Rights and permissions"><div class=c-article-section id=rightslink-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=rightslink>Rights and permissions</h2><div class=c-article-section__content id=rightslink-content><p class=c-article-rights><a data-track=click data-track-action="view rights and permissions" data-track-label=link href="https://s100.copyright.com/AppDispatchServlet?title=A%20guide%20to%20immunotherapy%20for%20COVID-19&amp;author=Frank%20L.%20van%20de%20Veerdonk%20et%20al&amp;contentID=10.1038%2Fs41591-021-01643-9&amp;copyright=Springer%20Nature%20America%2C%20Inc.&amp;publication=1078-8956&amp;publicationDate=2022-01-21&amp;publisherName=SpringerNature&amp;orderBeanReset=true">Reprints and Permissions</a></p></div></div></section><section aria-labelledby=article-info data-title="About this article"><div class=c-article-section id=article-info-section><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id=article-info>About this article</h2><div class=c-article-section__content id=article-info-content><div class=c-bibliographic-information><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark=10.1038/s41591-021-01643-9 target=_blank rel=noopener href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01643-9" data-track=click data-track-action="Click Crossmark" data-track-label=link data-test=crossmark><img alt="Verify currency and authenticity via CrossMark" src=data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg> width=57 height=81></a></div><div class=c-bibliographic-information__column><h3 class=c-article__sub-heading id=citeas>Cite this article</h3><p class=c-bibliographic-information__citation>van de Veerdonk, F.L., Giamarellos-Bourboulis, E., Pickkers, P. <i>et al.</i> A guide to immunotherapy for COVID-19.
 <i>Nat Med</i> <b>28, </b>39–50 (2022). https://doi.org/10.1038/s41591-021-01643-9<p class="c-bibliographic-information__download-citation u-hide-print"><a data-test=citation-link data-track=click data-track-action="download article citation" data-track-label=link data-track-external href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01643-9?format=refman&amp;flavour=citation">Download citation<svg width=16 height=16 focusable=false role=img aria-hidden=true class=u-icon><use xmlns:xlink=http://www.w3.org/1999/xlink xlink:href=#global-icon-download></use></svg></a><ul class=c-bibliographic-information__list data-test=publication-history><li class=c-bibliographic-information__list-item><p>Received<span class="u-hide sf-hidden">: </span><span class=c-bibliographic-information__value><time datetime=2021-08-25>25 August 2021</time></span></p><li class=c-bibliographic-information__list-item><p>Accepted<span class="u-hide sf-hidden">: </span><span class=c-bibliographic-information__value><time datetime=2021-11-24>24 November 2021</time></span></p><li class=c-bibliographic-information__list-item><p>Published<span class="u-hide sf-hidden">: </span><span class=c-bibliographic-information__value><time datetime=2022-01-21>21 January 2022</time></span></p><li class=c-bibliographic-information__list-item><p>Issue Date<span class="u-hide sf-hidden">: </span><span class=c-bibliographic-information__value><time datetime=2022-01>January 2022</time></span></p><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--doi"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide sf-hidden">: </span><span class=c-bibliographic-information__value>https://doi.org/10.1038/s41591-021-01643-9</span></p></ul><div data-component=share-box><div class="c-article-share-box u-display-inline"><h3 class=c-article__sub-heading>Share this article</h3><p class=c-article-share-box__description>Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" id=get-share-url data-track=click data-track-label=button data-track-external data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none sf-hidden" hidden></div><div class="js-share-url-container u-display-none sf-hidden" hidden></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
 Provided by the Springer Nature SharedIt content-sharing initiative
 </p></div></div><div data-component=article-info-list>
 <h3 class=c-article__sub-heading>Subjects</h3>
 <ul class=c-article-subject-list>
 <li class=c-article-subject-list__subject><a href=https://www.nature.com/subjects/immunology data-track=click data-track-action="view subject" data-track-label=link>Immunology</a><li class=c-article-subject-list__subject><a href=https://www.nature.com/subjects/immunotherapy data-track=click data-track-action="view subject" data-track-label=link>Immunotherapy</a></li>
 </ul>
 </div></div></div></div></div></section>
 
 
 <span data-recommended=jobs></span>
</div>
</article>
</main>
<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion data-container-type=reading-companion data-track-component="reading companion">
 <div class=js-context-bar-sticky-point-desktop>
 
 
 
 
 
 <div class="c-pdf-download u-clear-both js-pdf-download">
 <a href=https://www.nature.com/articles/s41591-021-01643-9.pdf class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf=true data-readcube-pdf-url=true data-test=download-pdf data-draft-ignore=true data-track=click data-track-action="download pdf" data-track-label=link data-track-external>
 <span class=c-pdf-download__text>Download PDF</span>
 <svg aria-hidden=true focusable=false width=16 height=16 class=u-icon><use xlink:href=#global-icon-download></use></svg>
 </a>
 </div>
 
 
 
 </div>
 
 
 
 
 
 <div class=c-reading-companion>
 <div class=c-reading-companion__sticky data-component=reading-companion-sticky data-test=reading-companion-sticky style=top:40px>
 <ul class=c-reading-companion__tabs role=tablist><li role=presentation><button data-tab-target=sections role=tab id=tab-sections aria-controls=tabpanel-sections aria-selected=true class="c-reading-companion__tab c-reading-companion__tab--active" data-track=click data-track-action="sections tab" data-track-label=tab>Sections</button><li role=presentation><button data-tab-target=figures role=tab id=tab-figures aria-controls=tabpanel-figures aria-selected=false tabindex=-1 class=c-reading-companion__tab data-track=click data-track-action="figures tab" data-track-label=tab>Figures</button><li role=presentation><button data-tab-target=references role=tab id=tab-references aria-controls=tabpanel-references aria-selected=false tabindex=-1 class=c-reading-companion__tab data-track=click data-track-action="references tab" data-track-label=tab>References</button></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id=tabpanel-sections aria-labelledby=tab-sections role=tabpanel><div class=c-reading-companion__scroll-pane style=max-height:none><ul class=c-reading-companion__sections-list><li id=rc-sec-Abs1 class="c-reading-companion__section-item c-reading-companion__section-item--active"><a href=#Abs1 data-track=click data-track-action="section anchor" data-track-label=link:Abstract>Abstract</a><li id=rc-sec-Sec1 class=c-reading-companion__section-item><a href=#Sec1 data-track=click data-track-action="section anchor" data-track-label=link:Main>Main</a><li id=rc-sec-Sec2 class=c-reading-companion__section-item><a href=#Sec2 data-track=click data-track-action="section anchor" data-track-label="link:Immune pathophysiology of COVID19">Immune pathophysiology of COVID-19</a><li id=rc-sec-Sec3 class=c-reading-companion__section-item><a href=#Sec3 data-track=click data-track-action="section anchor" data-track-label="link:Immunotherapy for COVID19">Immunotherapy for COVID-19</a><li id=rc-sec-Sec16 class=c-reading-companion__section-item><a href=#Sec16 data-track=click data-track-action="section anchor" data-track-label="link:The immunotherapeutic approach in the clinic">The immunotherapeutic approach in the clinic</a><li id=rc-sec-Sec20 class=c-reading-companion__section-item><a href=#Sec20 data-track=click data-track-action="section anchor" data-track-label="link:Future outlook and conclusions">Future outlook and conclusions</a><li id=rc-sec-Bib1 class=c-reading-companion__section-item><a href=#Bib1 data-track=click data-track-action="section anchor" data-track-label=link:References>References</a><li id=rc-sec-Ack1 class=c-reading-companion__section-item><a href=#Ack1 data-track=click data-track-action="section anchor" data-track-label=link:Acknowledgements>Acknowledgements</a><li id=rc-sec-author-information class=c-reading-companion__section-item><a href=#author-information data-track=click data-track-action="section anchor" data-track-label="link:Author information">Author information</a><li id=rc-sec-ethics class=c-reading-companion__section-item><a href=#ethics data-track=click data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a><li id=rc-sec-peer-review class=c-reading-companion__section-item><a href=#peer-review data-track=click data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a><li id=rc-sec-additional-information class=c-reading-companion__section-item><a href=#additional-information data-track=click data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a><li id=rc-sec-rightslink class=c-reading-companion__section-item><a href=#rightslink data-track=click data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a><li id=rc-sec-article-info class=c-reading-companion__section-item><a href=#article-info data-track=click data-track-action="section anchor" data-track-label="link:About this article">About this article</a></ul></div>
 <div class=u-mt-16 data-component-mpu>
 <div class="c-ad c-ad--300x250">
 <div class=c-ad__inner>
 <p class=c-ad__label>Advertisement</p>
 
 <div id=div-gpt-ad-right-2 class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type=right data-pa11y-ignore data-gpt data-gpt-unitpath=/285/medicine.nature.com/article data-gpt-sizes=300x250 data-gpt-targeting="type=article;pos=right;artid=s41591-021-01643-9;doi=10.1038/s41591-021-01643-9;subjmeta=250,251,631;kwrd=Immunology,Immunotherapy">
 <noscript class=sf-hidden>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1206851530&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01643-9%26doi%3D10.1038/s41591-021-01643-9%26subjmeta%3D250,251,631%26kwrd%3DImmunology,Immunotherapy">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=1206851530&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01643-9%26doi%3D10.1038/s41591-021-01643-9%26subjmeta%3D250,251,631%26kwrd%3DImmunology,Immunotherapy"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
 </div>
 </div>
 </div>
 </div>
 </div>
 <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width sf-hidden" id=tabpanel-figures aria-labelledby=tab-figures role=tabpanel><div class="c-reading-companion__scroll-pane sf-hidden"><ul class="c-reading-companion__figures-list sf-hidden"><li class="c-reading-companion__figure-item sf-hidden"><figure class=sf-hidden><picture class=sf-hidden><source type=image/webp data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig1_HTML.png?as=webp"></picture></figure><li class="c-reading-companion__figure-item sf-hidden"><figure class=sf-hidden><picture class=sf-hidden><source type=image/webp data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig2_HTML.png?as=webp"></picture></figure><li class="c-reading-companion__figure-item sf-hidden"><figure class=sf-hidden><picture class=sf-hidden><source type=image/webp data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig3_HTML.png?as=webp"></picture></figure><li class="c-reading-companion__figure-item sf-hidden"><figure class=sf-hidden><picture class=sf-hidden><source type=image/webp data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01643-9/MediaObjects/41591_2021_1643_Fig4_HTML.png?as=webp"></picture></figure></ul></div></div>
 <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width sf-hidden" id=tabpanel-references aria-labelledby=tab-references role=tabpanel></div>
 </div>
 </div>
</aside>
</div>
 
 
 
 
 
 
 
 
 
 
 
<footer class=composite-layer itemscope itemtype=http://schema.org/Periodical>
 
 
 <div class="u-mt-16 u-mb-16">
 <div class=u-container>
 <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
 
 <p class="c-meta u-ma-0 u-flex-shrink">
 <span class=c-meta__item>
 Nature Medicine (<i>Nat Med</i>)
 </span>
 
 
 <span class=c-meta__item>
 <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop=onlineIssn>1546-170X</span> (online)
 </span>
 
 
 
 <span class=c-meta__item>
 <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop=printIssn>1078-8956</span> (print)
 </span>
 
 </p>
 </div>
 </div>
</div>
 <div>
 <div class=c-footer>
 <div class=u-container>
 <div class=u-hide-print data-track-component=footer>
 <h2 class=u-visually-hidden>nature.com sitemap</h2>
 <div class=c-footer__header>
 <div class=c-footer__logo>
 <img alt="Nature portfolio" src="data:image/svg+xml;base64,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" loading=lazy width=200 height=31>
 </div>
 <ul class="c-menu c-menu--inherit u-mr-32">
 <li class=c-menu__item><a class=c-menu__link href=https://www.nature.com/npg_/company_info/index.html data-track=click data-track-action="about us" data-track-label=link>About us</a></li>
 <li class=c-menu__item><a class=c-menu__link href=https://www.nature.com/npg_/press_room/press_releases.html data-track=click data-track-action="press releases" data-track-label=link>Press releases</a></li>
 <li class=c-menu__item><a class=c-menu__link href=https://press.nature.com/ data-track=click data-track-action="press office" data-track-label=link>Press office</a></li>
 <li class=c-menu__item><a class=c-menu__link href=https://support.nature.com/support/home data-track=click data-track-action="contact us" data-track-label=link>Contact us</a></li>
 </ul>
 <ul class="c-menu c-menu--inherit">
 <li class=c-menu__item>
 <a class=c-menu__link href=https://www.facebook.com/NaturePortfolioJournals/ aria-label=Facebook data-track=click data-track-action=facebook data-track-label=link>
 <svg class=u-icon role=img aria-hidden=true focusable=false xmlns=http://www.w3.org/2000/svg width=16 height=16 viewBox="0 0 20 20"><path d="M2.5 20C1.1 20 0 18.9 0 17.5v-15C0 1.1 1.1 0 2.5 0h15C18.9 0 20 1.1 20 2.5v15c0 1.4-1.1 2.5-2.5 2.5h-3.7v-7.7h2.6l.4-3h-3v-2c0-.9.2-1.5 1.5-1.5h1.6V3.1c-.3 0-1.2-.1-2.3-.1-2.3 0-3.9 1.4-3.9 4v2.2H8.1v3h2.6V20H2.5z"></path></svg>
 </a>
 </li>
 <li class=c-menu__item>
 <a class=c-menu__link href="https://twitter.com/NaturePortfolio?lang=en" aria-label=Twitter data-track=click data-track-action=twitter data-track-label=link>
 <svg class=u-icon role=img aria-hidden=true focusable=false xmlns=http://www.w3.org/2000/svg width=20 height=20 viewBox="0 0 20 20"><path d="M17.6 4.1c.8-.5 1.5-1.4 1.8-2.4-.8.5-1.7.9-2.6 1-.7-.8-1.8-1.4-3-1.4-2.3 0-4.1 1.9-4.1 4.3 0 .3 0 .7.1 1-3.4 0-6.4-1.8-8.4-4.4C1 2.9.8 3.6.8 4.4c0 1.5.7 2.8 1.8 3.6C2 8 1.4 7.8.8 7.5v.1c0 2.1 1.4 3.8 3.3 4.2-.3.1-.7.2-1.1.2-.3 0-.5 0-.8-.1.5 1.7 2 3 3.8 3-1.3 1.1-3.1 1.8-5 1.8-.3 0-.7 0-1-.1 1.8 1.2 4 1.9 6.3 1.9C13.8 18.6 18 12 18 6.3v-.6c.8-.6 1.5-1.4 2-2.2-.7.3-1.5.5-2.4.6z"></path></svg>
 </a>
 </li>
 <li class=c-menu__item>
 <a class=c-menu__link href=https://www.youtube.com/channel/UCvCLdSgYdSTpWcOgEJgi-ng aria-label=YouTube data-track=click data-track-action=youtube data-track-label=link>
 <svg class=u-icon role=img aria-hidden=true focusable=false xmlns=http://www.w3.org/2000/svg width=20 height=20 viewBox="0 0 20 20"><path d="M7.9 12.6V6.9l5.4 2.8c0 .1-5.4 2.9-5.4 2.9zM19.8 6s-.2-1.4-.8-2c-.8-.8-1.6-.8-2-.9-2.8-.2-7-.2-7-.2s-4.2 0-7 .2c-.4 0-1.2 0-2 .9-.6.6-.8 2-.8 2S0 7.6 0 9.2v1.5c0 1.7.2 3.3.2 3.3s.2 1.4.8 2c.8.8 1.8.8 2.2.9 1.6.1 6.8.2 6.8.2s4.2 0 7-.2c.4 0 1.2-.1 2-.9.6-.6.8-2 .8-2s.2-1.6.2-3.3V9.2c0-1.6-.2-3.2-.2-3.2z"></path></svg>
 </a>
 </li>
 </ul>
 </div>
 <div class=c-footer__grid>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Discover content</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/siteindex data-track=click data-track-action="journals a-z" data-track-label=link>Journals A-Z</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/subjects/ data-track=click data-track-action="article by subject" data-track-label=link>Articles by subject</a></li>
 <li class=c-footer__item><a href=https://nano.nature.com/ data-track=click data-track-action=nano data-track-label=link>Nano</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/protocolexchange/ data-track=click data-track-action="protocol exchange" data-track-label=link>Protocol Exchange</a></li>
 <li class=c-footer__item><a href=https://www.natureindex.com/ data-track=click data-track-action="nature index" data-track-label=link>Nature Index</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Publishing policies</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/authors/editorial_policies/ data-track=click data-track-action="Nature portfolio policies" data-track-label=link>Nature portfolio policies</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/nature-research/open-access data-track=click data-track-action="open access" data-track-label=link>Open access</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Author &amp; Researcher services</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/reprints/ data-track=click data-track-action="reprints and permissions" data-track-label=link>Reprints &amp; permissions</a></li>
 <li class=c-footer__item><a href=https://www.springernature.com/gp/authors/research-data data-track=click data-track-action="data research service" data-track-label=link>Research data</a></li>
 <li class=c-footer__item><a href=https://authorservices.springernature.com/go/nr data-track=click data-track-action="language editing" data-track-label=link>Language editing</a></li>
 <li class=c-footer__item><a href=https://authorservices.springernature.com/scientific-editing/ data-track=click data-track-action="scientific editing" data-track-label=link>Scientific editing</a></li>
 <li class=c-footer__item><a href=https://masterclasses.nature.com/ data-track=click data-track-action="nature masterclasses" data-track-label=link>Nature Masterclasses</a></li>
 <li class=c-footer__item><a href=https://partnerships.nature.com/product/researcher-training/ data-track=click data-track-action="nature research academies" data-track-label=link>Nature Research Academies</a></li>
 <li class=c-footer__item><a href=https://solutions.springernature.com/ data-track=click data-track-action="research solutions" data-track-label=link>Research Solutions</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Libraries &amp; institutions</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.springernature.com/gp/librarians/tools-services data-track=click data-track-action="librarian service and tools" data-track-label=link>Librarian service &amp; tools</a></li>
 <li class=c-footer__item><a href=https://www.springernature.com/gp/librarians/manage-your-account/librarianportal data-track=click data-track-action="librarian portal" data-track-label=link>Librarian portal</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/openresearch/about-open-access/information-for-institutions/ data-track=click data-track-action="open research" data-track-label=link>Open research</a></li>
 <li class=c-footer__item><a href=https://www.springernature.com/gp/librarians/recommend-to-your-library data-track=click data-track-action="Recommend to library" data-track-label=link>Recommend to library</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Advertising &amp; partnerships</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://partnerships.nature.com/product/digital-advertising/ data-track=click data-track-action=advertising data-track-label=link>Advertising</a></li>
 <li class=c-footer__item><a href=https://partnerships.nature.com/ data-track=click data-track-action="partnerships and services" data-track-label=link>Partnerships &amp; Services</a></li>
 <li class=c-footer__item><a href=https://partnerships.nature.com/media-kits/ data-track=click data-track-action="media kits" data-track-label=link>Media kits</a></li>
 <li class=c-footer__item><a href=https://partnerships.nature.com/product/branded-content-native-advertising/ data-track-action="branded content" data-track-label=link>Branded content</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Career development</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/naturecareers data-track=click data-track-action="nature careers" data-track-label=link>Nature Careers</a></li>
 <li class=c-footer__item><a href=https://conferences.nature.com/ data-track=click data-track-action="nature conferences" data-track-label=link>Nature<span class=u-visually-hidden> </span> Conferences</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/natureevents/ data-track=click data-track-action="nature events" data-track-label=link>Nature<span class=u-visually-hidden> </span> events</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Regional websites</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/natafrica data-track=click data-track-action="nature africa" data-track-label=link>Nature Africa</a></li>
 <li class=c-footer__item><a href=http://www.naturechina.com/ data-track=click data-track-action="nature china" data-track-label=link>Nature China</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/nindia data-track=click data-track-action="nature india" data-track-label=link>Nature India</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/natitaly data-track=click data-track-action="nature Italy" data-track-label=link>Nature Italy</a></li>
 <li class=c-footer__item><a href=https://www.natureasia.com/ja-jp/ data-track=click data-track-action="nature japan" data-track-label=link>Nature Japan</a></li>
 <li class=c-footer__item><a href=https://www.natureasia.com/ko-kr/ data-track=click data-track-action="nature korea" data-track-label=link>Nature Korea</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/nmiddleeast/ data-track=click data-track-action="nature middle east" data-track-label=link>Nature Middle East</a></li>
 </ul>
 </div>
 <div class=c-footer__group>
 <h3 class=c-footer__heading>Legal &amp; Privacy</h3>
 <ul class=c-footer__list>
 <li class=c-footer__item><a href=https://www.nature.com/info/privacy data-track=click data-track-action="privacy policy" data-track-label=link>Privacy Policy</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/info/cookies data-track=click data-track-action="use of cookies" data-track-label=link>Use of cookies</a></li>
 <li class=c-footer__item><a class=optanon-toggle-display href=https://www.nature.com/articles/s41591-021-01643-9 data-cc-action=preferences data-track=click data-track-action="manage cookies" data-track-label=link>Manage cookies/Do not sell my data</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/info/legal-notice data-track=click data-track-action="legal notice" data-track-label=link>Legal notice</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/info/accessibility-statement data-track=click data-track-action="accessibility statement" data-track-label=link>Accessibility statement</a></li>
 <li class=c-footer__item><a href=https://www.nature.com/info/terms-and-conditions data-track=click data-track-action="terms and conditions" data-track-label=link>Terms &amp; Conditions</a></li>
 <li class=c-footer__item><a href=https://www.springernature.com/ccpa data-track=click data-track-action="california privacy statement" data-track-label=link>California Privacy Statement</a></li>
 
 <li class=c-footer__item><a href=https://support.nature.com/de/support/solutions/articles/6000255911-k%C3%BCndigungsformular>Cancel contracts here</a></li>
 
 </ul>
 </div>
 </div>
</div>
 </div>
 </div>
 </div>
 <div class=c-corporate-footer>
 <div class=u-container>
 <img src="data:image/svg+xml;base64,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" alt="Springer Nature" loading=lazy width=140 height=14>
 <p class=c-corporate-footer__legal data-test=copyright>© 2022 Springer Nature Limited</p>
 </div>
</div>
 
 <svg class="u-hide hide">
 <symbol id=global-icon-chevron-right viewBox="0 0 16 16">
 <path d="M7.782 7L5.3 4.518c-.393-.392-.4-1.022-.02-1.403a1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L7.782 9l1.013-.998z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=global-icon-download viewBox="0 0 16 16">
 <path d="M2 14c0-.556.449-1 1.002-1h9.996a.999.999 0 110 2H3.002A1.006 1.006 0 012 14zM9 2v6.8l2.482-2.482c.392-.392 1.022-.4 1.403-.02a1.001 1.001 0 010 1.417l-4.177 4.177a1.001 1.001 0 01-1.416 0L3.115 7.715a.991.991 0 01-.016-1.4 1 1 0 011.42.003L7 8.8V2c0-.55.444-.996 1-.996.552 0 1 .445 1 .996z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=global-icon-email viewBox="0 0 18 18">
 <path d="M1.995 2h14.01A2 2 0 0118 4.006v9.988A2 2 0 0116.005 16H1.995A2 2 0 010 13.994V4.006A2 2 0 011.995 2zM1 13.994A1 1 0 001.995 15h14.01A1 1 0 0017 13.994V4.006A1 1 0 0016.005 3H1.995A1 1 0 001 4.006zM9 11L2 7V5.557l7 4 7-4V7z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=global-icon-institution viewBox="0 0 18 18">
 <path d="M14 8a1 1 0 011 1v6h1.5a.5.5 0 01.5.5v.5h.5a.5.5 0 01.5.5V18H0v-1.5a.5.5 0 01.5-.5H1v-.5a.5.5 0 01.5-.5H3V9a1 1 0 112 0v6h8V9a1 1 0 011-1zM6 8l2 1v4l-2 1zm6 0v6l-2-1V9zM9.573.401l7.036 4.925A.92.92 0 0116.081 7H1.92a.92.92 0 01-.528-1.674L8.427.401a1 1 0 011.146 0zM9 2.441L5.345 5h7.31z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=global-icon-search viewBox="0 0 22 22">
 <path fill-rule=evenodd d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z"></path>
 </symbol>
 <symbol id=icon-info viewBox="0 0 18 18">
 <path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-success viewBox="0 0 18 18">
 <path d="M9 0a9 9 0 110 18A9 9 0 019 0zm3.486 4.982l-4.718 5.506L5.14 8.465a.991.991 0 00-1.423.133 1.06 1.06 0 00.13 1.463l3.407 2.733a1 1 0 001.387-.133l5.385-6.334a1.06 1.06 0 00-.116-1.464.991.991 0 00-1.424.119z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-chevron-down viewBox="0 0 16 16">
 <path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule=evenodd transform="matrix(0 1 -1 0 11 1)"></path>
 </symbol>
 <symbol id=icon-warning viewBox="0 0 18 18">
 <path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-plus viewBox="0 0 16 16">
 <path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-minus viewBox="0 0 16 16">
 <path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-error viewBox="0 0 18 18">
 <path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill=currentColor fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-springer-arrow-left>
 <path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path>
 </symbol>
 <symbol id=icon-springer-arrow-right>
 <path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path>
 </symbol>
 <symbol id=icon-arrow-up viewBox="0 0 16 16">
 <path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule=evenodd></path>
 </symbol>
 <symbol id=icon-tick viewBox="0 0 24 24">
 <path d="M12,24 C5.372583,24 0,18.627417 0,12 C0,5.372583 5.372583,0 12,0 C18.627417,0 24,5.372583 24,12 C24,18.627417 18.627417,24 12,24 Z M7.657,10.79 C7.45285634,10.6137568 7.18569967,10.5283283 6.91717333,10.5534259 C6.648647,10.5785236 6.40194824,10.7119794 6.234,10.923 C5.87705269,11.3666969 5.93445559,12.0131419 6.364,12.387 L10.261,15.754 C10.6765468,16.112859 11.3037113,16.0695601 11.666,15.657 L17.759,8.713 C18.120307,8.27302248 18.0695334,7.62621189 17.644,7.248 C17.4414817,7.06995024 17.1751516,6.9821166 16.9064461,7.00476032 C16.6377406,7.02740404 16.3898655,7.15856958 16.22,7.368 L10.768,13.489 L7.657,10.79 Z"></path>
 </symbol>
 </svg>
</footer>
 
 
<div class="c-site-messages message u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif" data-component-id=nature-briefing-banner data-component-expirydays=30 data-component-trigger-scroll-percentage=15 data-track=in-view data-track-action=in-view data-track-category="nature briefing" data-track-label="redesign banner visible">
 
 <div class=c-site-messages__banner-large>
 
<div class=c-site-messages__close-container>
 <button class=c-site-messages__close data-track=click data-track-category="nature briefing" data-track-label="redesign banner dismiss">
 <svg width=25px height=25px focusable=false aria-hidden=true viewBox="0 0 25 25" version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink>
 <title>Close banner</title>
 <defs></defs>
 <g stroke=none stroke-width=1 fill=none fill-rule=evenodd>
 <rect opacity=0 x=0 y=0 width=25 height=25></rect>
 <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill=#ffffff></path>
 </g>
 </svg>
 <span class=visually-hidden>Close</span>
 </button>
</div>
 <div class=c-site-messages__form-container>
 <div class="grid grid-12 last">
 <div class="grid grid-4">
 <img alt="Nature Briefing" src="data:image/svg+xml;base64,PHN2ZyBlbmFibGUtYmFja2dyb3VuZD0ibmV3IDAgMCAyNDkgMzkuNiIgaGVpZ2h0PSIzOS42IiB2aWV3Qm94PSIwIDAgMjQ5IDM5LjYiIHdpZHRoPSIyNDkiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PGcgZmlsbD0iI2ZmZiIgZmlsbC1ydWxlPSJldmVub2RkIj48cGF0aCBkPSJtNy4xIDkuMi4xIDQuN2guMWMxLTIuNiAzLjMtNC44IDYuOC00LjggNC41IDAgNS44IDIuMiA1LjggNi41djguNGMwIDIuNi4yIDUuMi44IDcuMmgtNy4yYy42LTEuOS43LTQuMi43LTd2LThjMC0yLS44LTIuOS0yLjktMi45LTEuNiAwLTIuOS40LTMuOCAxLjN2OS42YzAgMi44LjEgNS4xLjcgN2gtNy40Yy42LTIgLjgtNC42LjgtNy4ydi03LjhjMC0yLjEtLjgtNC0xLjYtNXoiLz48cGF0aCBkPSJtMzAuOCA5LjFjNS42IDAgNy43IDIuMiA3LjcgNi44djkuNmMwIDEuNy43IDIuMiAyIDIuMi4yIDAgLjktLjEgMS4yLS4zLS4xLjYtLjIgMS0uNCAxLjQtLjYgMS44LTEuOCAzLTQuMiAzLTIuOCAwLTQuMi0xLjktNC4yLTRoLS4xYy0uOSAyLjgtMi43IDQtNS42IDQtMy41IDAtNS43LTIuMS01LjctNS40IDAtMy40IDMuMS00LjkgNi40LTYuMiAzLjEtMS4yIDQuOC0yLjEgNC44LTQuM3YtLjRjMC0yLjQtLjgtMy43LTMtMy43LTEuNCAwLTIgLjYtMi4zIDItLjQgMi4xLTEuMyAyLjgtMi43IDIuOC0xLjIgMC0yLjQtLjgtMi40LTIuNCAwLTMgNC4yLTUuMSA4LjUtNS4xem0xLjkgMTh2LTcuOGMtLjQuNi0xIDEtMi42IDEuOC0yIDEtMi44IDIuMS0yLjggNC40IDAgMS45IDEgMy4xIDIuNyAzLjEgMS43LS4xIDIuMi0uNyAyLjctMS41eiIvPjxwYXRoIGQ9Im01NC4yIDI4LjljLS44IDEuNy0yLjYgMi44LTUuMiAyLjgtNC40IDAtNi4yLTIuMi02LjItNi4zdi0xMi44aC0yLjF2LS4ybDcuOC04aC4xdjVoNS41bC0uNiAzaC01djExLjhjMCAyLjMgMSAzLjIgMyAzLjIgMS42IDAgMi40LS4yIDMuMS0uNi0uMSAxLS4yIDEuNC0uNCAyLjF6Ii8+PHBhdGggZD0ibTYxLjYgOS40djE1YzAgMi4yLjkgMy41IDMgMy41IDEuOCAwIDMuMi0uNiA0LTEuNnYtMTAuMmMwLTIuMi0uMi00LjEtLjktNmw2LjctLjd2MTUuM2MwIDMuNC40IDQuOS45IDYuNWgtNi41di00LjNoLS4xYy0uOSAyLjgtMi43IDQuOC02LjQgNC44LTQuNyAwLTYuNC0yLjgtNi40LTcuMXYtOC41YzAtMi4yLS4yLTQuMS0uOS02eiIvPjxwYXRoIGQ9Im04My42IDE0LjdjMS00IDIuOC01LjYgNS4yLTUuNiAyLjIgMCAzLjQgMS4yIDMuNCAzIDAgMS43LS45IDMtMi43IDMtMSAwLTEuNi0uNC0yLS45LS41LS40LS44LS45LTEuMy0uOS0xLjIgMC0yLjQgMS45LTIuNCA1LjJ2NS40YzAgMi43LjIgNS4zLjcgNy4zaC03LjJjLjYtMiAuOC00LjYuOC03LjJ2LTcuOGMwLTIuMS0uOC00LTEuNi01bDcuMS0yaC4xeiIvPjxwYXRoIGQ9Im0xMDEuNyAzMS43Yy01LjUgMC0xMC4xLTMuNy0xMC4xLTEwLjcgMC03LjIgNC40LTExLjkgMTAuMi0xMS45IDUuNiAwIDguMiAzLjYgOC4yIDEwLjJoLTEyLjd2LjdjMCA1LjQgMi44IDcuNSA2LjYgNy41IDMuNCAwIDUtMS40IDYtMi40bC4xLjRjLS45IDMuMi0zLjUgNi4yLTguMyA2LjJ6bS00LjMtMTMuOSA3LjItLjZjLS4xLTMuNC0uNi01LjUtMy01LjVzLTMuOCAyLTQuMiA2LjF6Ii8+PHBhdGggZD0ibTEyMy42IDEzLjdjLjgtMi4xIDMuNi00LjYgNi45LTQuNiA0LjUgMCA3LjcgMy4yIDcuNyAxMC41IDAgNi40LTMuMyAxMi4xLTExLjIgMTIuMS0zLjggMC02LjgtLjktOS4xLTJ2LTIyLjRjMC0yLjgtLjctNC4zLTEuNS01LjRsNy40LTJoLjFsLS4yIDUuN3Y4LjF6bTMuNCAxNS4zYzMuNiAwIDQuOS0zLjMgNC45LTguNiAwLTUuMi0xLjItNy40LTQuNC03LjQtMS41IDAtMy4yLjgtMy44IDEuN3YxMy4yYy45LjcgMi4xIDEuMSAzLjMgMS4xeiIvPjxwYXRoIGQ9Im0xNDYuMyAxNC43YzEtNCAyLjgtNS42IDUuMi01LjYgMi4yIDAgMy40IDEuMiAzLjQgMyAwIDEuNy0uOSAzLTIuNyAzLTEgMC0xLjYtLjQtMi0uOS0uNS0uNC0uOC0uOS0xLjMtLjktMS4yIDAtMi40IDEuOS0yLjQgNS4ydjUuNGMwIDIuNy4yIDUuMy43IDcuM2gtNy4yYy42LTIgLjgtNC42LjgtNy4ydi03LjhjMC0yLjEtLjgtNC0xLjYtNWw3LjEtMmguMXoiLz48cGF0aCBkPSJtMTYyLjQgMjRjMCAyLjYuMiA1LjIuOCA3LjJoLTcuNGMuNi0yIC44LTQuNi44LTcuMnYtNy44YzAtMi4xLS44LTQtMS42LTVsNy41LTJoLjFsLS4yIDUuNHptLTYuNi0xOS42YzAtMS45IDEuNC0zLjQgMy41LTMuNHMzLjUgMS41IDMuNSAzLjQtMS40IDMuNC0zLjUgMy40Yy0yLjEuMS0zLjUtMS41LTMuNS0zLjR6Ii8+PHBhdGggZD0ibTE3NSAzMS43Yy01LjUgMC0xMC4xLTMuNy0xMC4xLTEwLjcgMC03LjIgNC40LTExLjkgMTAuMi0xMS45IDUuNiAwIDguMiAzLjYgOC4yIDEwLjJoLTEyLjd2LjdjMCA1LjQgMi44IDcuNSA2LjYgNy41IDMuNCAwIDUtMS40IDYtMi40bC4xLjRjLS45IDMuMi0zLjUgNi4yLTguMyA2LjJ6bS00LjMtMTMuOSA3LjItLjZjLS4xLTMuNC0uNi01LjUtMy01LjVzLTMuOSAyLTQuMiA2LjF6Ii8+PHBhdGggZD0ibTIwMy4yIDI0YzAgMi42LjIgNS4yLjggNy4yaC03LjRjLjYtMiAuOC00LjYuOC03LjJ2LTljMC0uOCAwLTEuNi0uMS0yLjNoLTUuNXYxMS4zYzAgMi44LjMgNS40LjkgNy4zaC03LjRjLjYtMiAuOC00LjYuOC03LjJ2LTExLjVoLTIuNHYtLjJsMi40LTIuNnYtMS4yYzAtNS45IDQuNC04LjYgOC44LTguNiA1LjYgMCA3LjYgMS45IDcuNiA0LjMgMCAxLjctMSAyLjgtMi45IDIuOC0xLjcgMC0yLjgtLjktMy4yLTIuNS0uMy0xLjQtLjctMi4yLTItMi4yLTEuNSAwLTIuNiAxLTIuNiAzLjh2My40aDQuOWw2LjYtLjRoLjFsLS4yIDUuNHoiLz48cGF0aCBkPSJtMjExLjggOS4yLjEgNC43aC4xYzEtMi42IDMuMy00LjggNi44LTQuOCA0LjUgMCA1LjggMi4yIDUuOCA2LjV2OC40YzAgMi42LjIgNS4yLjggNy4yaC03LjJjLjYtMS45LjctNC4yLjctN3YtOGMwLTItLjgtMi45LTIuOS0yLjktMS42IDAtMi45LjQtMy44IDEuM3Y5LjZjMCAyLjguMSA1LjEuNyA3aC03LjJjLjYtMiAuOC00LjYuOC03LjJ2LTcuOGMwLTIuMS0uOC00LTEuNi01eiIvPjxwYXRoIGQ9Im0yNDEuNSAxMC45aC4xYzEtMS45IDMtMi44IDQuMi0yLjggMS45IDAgMy4xIDEgMy4xIDIuNSAwIDEuNC0uNyAyLjYtMi4yIDIuNi0xLjEgMC0xLjYtLjYtMS45LTEuMS0uNC0uNC0uNy0uOS0xLjUtLjktLjQgMC0uNy4xLTEgLjMgMS4yIDEuNCAyIDMuMSAyIDQuOCAwIDUuMS00LjIgNy44LTguOCA3LjgtMS4yIDAtMi41LS4yLTMuNy0uNi0uNi40LS45IDEtLjkgMS43IDAgLjguNiAxLjUgMiAxLjUgMi42IDAgNi41LS4yIDktLjIgMy42IDAgNS43IDEuNSA1LjcgNSAwIDUuMi00LjcgOC4xLTEyLjEgOC4xLTYuOSAwLTkuOC0xLjktOS44LTQuMiAwLTIgMi41LTMgNS41LTMuNHYtLjFjLTIuMS0uNC00LTIuMS00LTQuNHMxLjYtMy43IDMuOC00LjN2LS4yYy0yLjUtMS4xLTQuNC0zLjItNC40LTYuMiAwLTUuMSA0LjItNy44IDguOC03LjggMi4zLjEgNC42LjcgNi4xIDEuOXptLTYgMjYuM2M1LjUgMCA3LjgtMS43IDcuOC0zLjUgMC0xLjMtLjgtMS44LTIuNi0xLjgtMi4zIDAtNy42LjItOC42LjQtMSAuMS0xLjYgMS4xLTEuNiAyLS4xIDEuOCAxLjQgMi45IDUgMi45em0zLjQtMjAuOGMwLTMuMi0xLjQtNC44LTMuNS00LjgtMi4yIDAtMy40IDEuNS0zLjQgNS4yIDAgMy4yIDEuNCA0LjggMy41IDQuOCAyLjIgMCAzLjQtMS41IDMuNC01LjJ6Ii8+PC9nPjwvc3ZnPg==" width=250 height=40>
 <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
 </div>
 <div class="grid grid-8 last">
 <form action=/briefing/signup/formfeedback method=post data-location=banner data-track=submit data-track-action=transmit-form>
 
 
 <label class=nature-briefing-banner__email-label for=banner-EmailAddressInput>Email address</label>
 <div class=nature-briefing-banner__email-wrapper>
 <input class="nature-briefing-banner__email-input box-sizing text14" type=email id=banner-EmailAddressInput name=email value placeholder="e.g. jo.smith@university.ac.uk" required data-test-element=briefing-emailbanner-email-input>
 <button type=submit class="nature-briefing-banner__submit-button box-sizing text14" data-test-element=briefing-emailbanner-signup-button>Sign up</button>
 </div>
 <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
 <input class=nature-briefing-banner__checkbox-checkbox id=gdpr-briefing-banner-checkbox type=checkbox name=gdpr value=1 data-test-element=briefing-emailbanner-gdpr-checkbox required>
 <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for=gdpr-briefing-banner-checkbox>I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href=https://www.nature.com/info/privacy>Privacy Policy</a>.</label>
 </div>
 </form>
 </div>
 </div>
 </div>
 </div>
 
 <div class="c-site-messages__banner-small sf-hidden">
 
 
 </div>
</div>
 
 
 <noscript class=sf-hidden>
        <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
    </noscript>
 
<img src="data:*/*;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR4nGP6zwAAAgcBApocMXEAAAAASUVORK5CYII=" alt class=u-visually-hidden width=1 height=1>
<noscript class=sf-hidden><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1229240860577415&amp;ev=PageView&amp;noscript=1"></noscript>
<div id=ZN_0CcSRG9GrqrxATc></div>
<div style=width:0px;height:0px;display:none;visibility:hidden id=batBeacon292704527445></div><div id=criteo-tags-div style=display:none></div><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1><img src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" style=display:none width=1 height=1>
<div style=animation-name:expand class="view-pdf-widget expanded"><span class="view-pdf-arrows expanded"></span><a class=view-pdf-text target=_blank href="moz-extension://428f36e2-626f-4ea4-8a69-56f690c7228f/enhanced-reader.html?openApp&amp;pdf=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-021-01643-9.pdf">View PDF</a></div>